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Abstract 
Sepsis is a deadly condition that develops when the host immune system is ill equipped to 
respond to infection. Delays in the appropriate identification and management of sepsis in 
health care facilities can lead to organ failure, which is associated with high mortality 
rates (40-70%). Current therapies of sepsis provide support and target the source of 
infection, but do not address the inflammatory pathways that have shown to contribute to 
increased disease severity. As such, there is an urgent need for an effective adjunct 
therapy for sepsis.  
There is increasing evidence for the use of low-dose aspirin as an adjunct therapy in 
sepsis. Aspirin offers a cost-effective alternative to other adjunct therapies currently under 
investigation, and at low-doses the proposed mechanism of action includes the production 
of specialised pro-resolving mediators; including aspirin-triggered lipoxins (ATL), that 
mediate the resolution of inflammation by inhibiting the activation of NFκB, which has 
been shown to improve outcomes in other inflammatory conditions. The purpose of this 
study was therefore to investigate the anti-inflammatory effects of aspirin in clinical 
sepsis, as well as experimentally in mouse models of gram-positive sepsis, using ATL 
and NFκB as primary read out parameters and device-related biofilm infection. 
Chapter 3 of this thesis investigated of the mechanisms of aspirin-therapy in participants 
with sepsis enrolled into the Mechanism of Aspirin Therapy in Sepsis (MATHS) 
randomised control trial. In keeping with the hypothesis, low-dose aspirin therapy  
(100 mg/day) was shown to induce the increased production of ATL in plasma, and 
inhibition of NFκB in PBMC (not previously shown with this dose). Aspirin therapy did 
not appear to significantly reduce the production of previously reported pro-inflammatory 
cytokines, but did impact the proportion of circulating innate and adaptive immune cell 
subsets. While these results were encouraging, it remained unclear whether these effects 
extended beyond circulation. In order to address this question, a mouse model of systemic 
bloodstream infection was established.  
As Staphylococcus aureus is the most frequent source of sepsis, Chapter 4 of this thesis 
investigated the effect of aspirin therapy in a wild-type mouse model of staphylococcal-
induced sepsis. The model was designed following the preliminary analysis of data from 
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the MATHS trial. Further, this study permitted analysis of target organs that tend to be 
damaged in the early development of sepsis. Unlike the participants in the trial, aspirin at 
an equivalent low-dose (1 mg/kg/day) over two days did not significantly impact ATL 
and NFκB in mice. Nevertheless, low-dose aspirin-treated mice did demonstrate a 
complete clearance of bacteria from all target organs within 24 h of the second aspirin 
dose, and showed considerable improvements in clinical outcomes; in the absence of 
supportive antibiotic therapy. Redevelopment of the model timeline in future studies hope 
to provide a more accurate comparison with human trial subjects. 
Contamination of indwelling medical devices can lead to the formation complex biofilms 
on device surfaces, which are difficult to treat. Further, replacement of contaminated 
devices can result in spread of bacteria to other sites in the body, leading to the 
development of sepsis. Aspirin and its major metabolite Salicylic acid (SA) have been 
shown to diminish biofilm formation in vitro in a number of pathogens, however the 
exact mechanism of action against staphylococcal biofilm formation is poorly understood. 
Chapter 5 in this study aimed to elucidate the mechanisms of SA inhibition on growing 
staphylococcal biofilms, both in vitro and in an in vivo mouse model of device-related 
biofilm infection. Results from in vitro studies revealed that SA treatment significantly 
diminishes two key mechanisms of biofilm formation including: reducing the amount of 
biomass produced and extracellular DNA (eDNA) released, reducing the structural 
integrity of biofilm. This combined effect suggests weakened biofilms have an increased 
susceptibility to both immune attack and antimicrobial therapies.  
Of the studies investigating novel therapies of device-related biofilm in vivo, none thus 
far have investigated the potential therapeutic benefit of low-dose aspirin. In this study, 
low-dose aspirin (1 mg/kg/day) over five days lead to the reduction of surface biofilm in 
stainless steel implanted mice, however this wasn’t seen with catheter implants. Aspirin-
treated mice, regardless of implant type appeared to have accelerated wound healing as 
shown by reduced epithelial thickness compared with non aspirin-treated counterparts, 
and in some cases an increased local presence of CD11b+ cells. This suggested that the 
inhibitory effect of aspirin in vivo is inducing CD11b+ cell-mediated clearance of 
biofilms; however further investigation is required to confirm this.  
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In summary, this thesis has contributed to the understanding of immunological pathways 
activated following localised and systemic infection, leading to the early development of 
sepsis. Further, this study has elucidated a potential role for low-dose aspirin (100 mg/ 
day or equivalent in animal studies) as an adjunct pro-resolution therapy in both  
device-related biofilm infection and sepsis. Completion of the MATHs clinical trial will 
be required to provide definitive evidence to support advancing to a prospective trial in 
septic patients. Further research is required in to develop animal models that will more 
accurately represent human disease. 
 
	
	 
 
  
Chapter 1 
Introduction  
and review of the literature 
1.  
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1.1. General introduction 
Sepsis is the leading cause of infection-related death worldwide, with one death occurring 
every 3-4 seconds [1]. Despite every effort in the last two decades to improve outcomes 
in critically ill patients, mortality rates of sepsis continue to rise [2]. The significance of 
this severe inflammatory condition is often under-reported, due to limited available data 
from the developing world. As symptoms of this condition are non-specific, it is difficult 
for clinicians to clearly distinguish sepsis. This often results in a delay in correct 
diagnosis and contributes to increased mortality rates of sepsis. Following infection, the 
host immune response triggers a series of pro-inflammatory and anti-inflammatory 
responses. Sepsis is characterised by uncontrolled immune response and occurs when 
infection fails to clear; resulting in widespread inflammation, organ failure and death [3]. 
The predominant causative pathogen of sepsis has changed in the past fifteen years there 
has been from gram-negative bacteria, to gram-positive bacteria; with increasing 
incidence of Staphylococcus aureus (S. aureus) infections causing sepsis [4]. 
S. aureus is a well-recognised nosocomial pathogen. This bacterium is commonly the 
cause of a number of deep-seated invasive infections including endocarditis [5] and 
device-related biofilm infections [6]. These infections are a frequent source of sepsis, as 
transiently bound bacteria detaching from local sites of infection, disseminate into the 
bloodstream and other sites of the body. The increasing prevalence of sepsis due to 
antibiotic-resistant strains of S. aureus is becoming a cause for concern, with a need for 
novel adjunct therapies.  
Early identification and intervention provides the best potential for limiting progression 
of sepsis. Considerable interest has surrounded the use of biomarkers for rapid 
recognition and diagnosis of sepsis, permitting early intervention and potentially reducing 
the risk of death [7]. While many have been proposed, no individual biomarker has 
shown to be useful in diagnosis of sepsis. It has been suggested however, that the use of 
several biomarkers in combination (targeting both pro-inflammatory and anti-
inflammatory factors) could be more successful [8, 9].  
There is little evidence to suggest that currently employed therapies of sepsis (bundled 
therapies comprising of fluid resuscitation, oxygen delivery; achieving target acid-base 
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levels and empiric antibiotic delivery) have the capacity to reduce mortality rates alone 
[10, 11], thus the search for an alternative adjunct therapy to improve outcomes in sepsis 
continues. To be considered suitable, novel adjunct therapies should be cost-effective and 
aim to address the uncontrolled inflammatory response in sepsis. While many 
therapeutics avenues have been investigated, none have proved successful in reducing 
absolute levels of mortality. Other anti-inflammatory therapies previously suggested for 
sepsis target the inflammatory pathways via complete inhibition, which can delay the 
natural resolution of inflammatory pathways; associated with worsened outcomes [12].  
More recently it has been determined that “resolution” of inflammation, via the synthesis 
of specialized “pro-resolution” lipid mediators (SPMs) including lipoxins, resolvins, 
protectins and maresins [13-15] leads to improved outcomes. Following the selective 
inhibition of pro-inflammatory mediators, rapid activation of “pro-resolving” pathways 
leads to a return to homeostasis as shown in both animal models [16-18] and clinical 
studies [12, 19-21] of inflammation.  
Increasing evidence suggests there may be a potential role for low-dose aspirin in the 
adjunct treatment of sepsis. Not only is aspirin a cost effective therapeutic with multiple 
applications, low-dose aspirin therapy was shown to trigger the enhanced biosynthesis of 
these SPMs [14, 15]. The central hypothesis for the studies described in this thesis is that 
low-dose aspirin therapy produces immuno-modulatory effects in inflammation in both 
clinical and animal models of sepsis, as well as device-related biofilm infections. The 
rationale for this study is described further in the following review of the literature.  
	  
Chapter 1 
	
	 Page 7 
1.2. Sepsis 
1.2.1. Defining sepsis 
Sepsis is described as the interaction between the pathogen responsible for the infection 
and the host immune response; including but not limited to innate/adaptive immune 
systems, inflammatory and coagulation responses [3].  
Traditional consensus definitions of sepsis include: the presence of at least two signs of 
systemic inflammatory response syndrome (SIRS), and a suspected or known source of 
infection. This was determined in 1992, by the American College of Chest Physicians 
(ACCP) and the Society for Critical Care Medicine (SCCM) conference panel [22]. The 
pathway from sepsis to severe sepsis (sepsis with hypotension and evidence of organ 
dysfunction) arises when the host immune system is ill equipped to respond to the 
infection resulting in uncontrolled inflammation [23]. Septic shock is a most severe form 
of sepsis often accompanied by multiple-organ dysfunction syndrome (MODS). Patients 
presenting with septic shock and MODS have increased mortality rates of 40-70% [24]. 
In 2001, the consensus panel reconvened to evaluate the relevance of these definitions. It 
was concluded that the criteria for SIRS were still not specific enough for clinicians to 
distinctly identify the syndrome [25]. Clinicians continue use a range of different criteria 
to identify sepsis in the Intensive Care Unit (ICU) of hospitals, including patient 
demographics, source of infection, symptoms present, Acute Physiology and Chronic 
Health Evaluation (APACHE II or III) and Sequential Organ Failure Assessment (SOFA) 
physiological scoring systems and hospital mortality [26].   
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Table 1.1: Consensus conference definitions of sepsis, severe sepsis and septic shock. 
Adapted and reproduced with permission from the American College of Chest Physicians 
(ACCP) and the Society for Critical Care Medicine (SCCM) [22]. 
	
	 	
Disease Definition 
Systemic 
inflammatory 
response 
syndrome 
(SIRS) 
Systemic inflammatory response syndrome may or may not be the result of 
infection. Clinical manifestation includes two or more of the following 
conditions: 
§ Temperature >38˚C or <36˚C 
§ Heart rate >90 beats/min 
§ Respiratory rate >20 breaths/min OR PaCO2 <32 mm Hg 
§ White blood cell count >12,000/mm3 OR <4,000/mm3 OR >10% immature 
(band) forms 
Sepsis 
The systemic inflammatory response to infection*. Clinical manifestations as 
described above. 
Severe Sepsis 
Sepsis and organ dysfunction, hypoperfusion OR hypotension. Manifestations 
of hypoperfusion may include but are not limited to: 
§ Lactic acidosis 
§ Oliguria 
§ Acute alterations in mental status 
Septic shock 
Sepsis induced hypotension, persisting despite adequate fluid resuscitation, and 
the manifestations as described above** 
Multiple 
Organ 
Dysfunction 
Syndrome 
(MODS) 
Presence of altered organ functions in an acutely ill patient such that 
homeostasis cannot be maintained without intervention. 
* Inflammatory response to the presence of microbes or invasion of normally sterile tissues by 
these organisms; ** Patients receiving inotropic or vasopressor agents may no longer be 
hypotensive by the time they manifest hypoperfusion abnormalities or organ dysfunction, yet they 
would still be considered to have septic shock; PaCO2, Partial pressure of carbon dioxide. 
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1.2.2. Epidemiology of sepsis 
An estimated 28% of fatalities occurring in the United States (US) alone are due to severe 
sepsis. As a result, sepsis is now the leading cause of infection-related death worldwide 
[3]. For clinicians, often the consensus definitions are not specific enough to clearly 
identify a patient as being septic. As a result, data records for the number of sepsis cases 
are generally lower than estimated figures predict [27]. A US National Hospital 
Discharge Survey data brief in 2008 noted that the rate of hospitalisations associated with 
sepsis had more than doubled since 2000 (as shown in Figure 1.1). 
 
 
 
 
 
 
 
Figure 1.1: Increase in rates of sepsis reported in the US between 2000 and 2008. 
Documented hospitalisation rates per 10,000 people in the US with or as a result of 
septicaemia or sepsis. Blue line indicates the rate of hospitalisation for patients with 
septicaemia or sepsis (as a first-listed, principal, or secondary diagnosis, including: 
patients hospitalised for septicaemia or sepsis, patients hospitalized for another diagnosis 
but also had septicaemia or sepsis at the time they were admitted, and those who acquired 
septicaemia or sepsis during their hospital stay); Green line indicates patients who were 
hospitalised for septicaemia or sepsis (as a first-listed or principal diagnosis only). Figure 
reproduced, with permission from [28]. 
This rising incidence of sepsis in the US is attributed to the continuously ageing 
population, and increased prevalence of co-morbidities such as cancer, diabetes and the 
human immunodeficiency virus (HIV) [1, 4, 26, 29]. A study by the Centre for Disease 
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Control and Prevention (CDC) showed that the likelihood of hospitalisations associated 
with sepsis were higher in those older than 65 years of age, with patients 85 years and 
above approximately 30 times more likely to be hospitalised [28]. Similar with the CDC 
studies, other retrospective studies have shown the highest mortalities associated with 
those above 80 years of age [1, 26, 29, 30]. Other factors contributing to the likelihood of 
development and severity of sepsis include the site and source of initial infection. 
Finfer et al. conducted a study in Australian and New Zealand, showing that pulmonary 
(50.3%) and the abdomen (19.3%) were the most common sites in sepsis patients [30]. 
The average age of the participants was 55.9 years, and majority of the patients were 
male. Alongside this study, a more focused study on sepsis in the state of Victoria showed 
that of those admitted to ICU, again the majority of patients identified as having sepsis 
were male, and the predominant systems where organ dysfunction occurred were 
respiratory (41.9%), renal (41.5%) and cardiovascular systems (37.4%), respectively [29]. 
The association between race/ethnicity and likelihood of sepsis development has also 
been studied, with increased incidence of sepsis observed in minority groups, however 
this does not always translate to higher mortality rates [4, 31, 32]. Two recent Australian 
studies also showed in tropical regions of Australia, that indigenous populations had a 
higher prevalence of infectious and chronic diseases, and an increased likelihood of 
developing sepsis, but again mortality rate was not affected [33, 34]. It has also been 
shown, that when identified the most common source of infection was bacterial. Prior to 
1987, gram-negative bacterial infections were the majority cause of sepsis. Since then, the 
incidence gram-positive bacterial infection has risen rapidly to represent the primary 
cause of sepsis. There has also been a dramatic increase in the proportion of sepsis cases 
caused by fungal infections [26, 29, 30]. 
1.2.3. Sepsis pathophysiology 
Infections caused by pathogenic bacteria initiate the activation of the innate and adaptive 
immune responses. These immune responses collectively are aimed at controlling 
microbial growth in order to protect the host [35]. The involvement of both the innate and 
adaptive immune systems has been illustrated in both human trials and experimental 
animal models. An understanding of immunological contributions in regard to severe 
sepsis and septic shock is still yet to be fully elucidated [36]. 
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Figure 1.2: Immune response to bacterial infection, including communication 
between innate and adaptive immune cell types. Following ingestion of bacteria, 
Macrophages produce pro-inflammatory cytokines via activation of NFκB. Activation of 
NFkB will also induce activation of cyclooxygenase-2 (COX-2), which metabolises 
arachidonic acid to yield pro-inflammatory lipid derivatives, which contribute to 
vasoconstriction/ vasodilation of endothelial tissues. Macrophages also secrete IL-12 to 
activate CD4+ T lymphocytes, which also contributes to cytokine production. Bacteria 
also affect activation of neutrophils and platelets contributing to exacerbation of 
endothelial inflammation. Excessive damage to the endothelium results in bacterial and 
neutrophil spread to tissues, leading to tissue damage, organ dysfunction and death. 
Figure adapted and reproduced with permission from [3], Copyright Massachusetts 
Medical Society.  
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1.2.3.1. Innate immune response in sepsis 
The mechanism by which the inflammatory cascade is instigated by the innate immune 
system has been studied extensively. The cell subsets of the innate immune system 
comprise monocytes (such as macrophages and dendritic cells), granulocytes (such as 
neutrophils), and large granular lymphocytes (such as natural killer cells) [23].  
Activated endothelial cells also release cyclooxygenase (COX) and inducible nitric oxide 
synthase (iNOS), which contribute to septic shock by dilating blood vessels and eliciting 
a strong cardio-depressive effect [37]. COX enzymes convert essential fatty acids into 
pro-inflammatory eicosanoids such as prostaglandins, prostacyclin and thromboxane 
(shown in Figure 1.8A) [38]. Two isoforms of COX exist; COX-1, which is constitutively 
expressed in most tissues, and COX-2; whose activation is reliant on external pro-
inflammatory stimuli [39]. Production of cytokines during the sepsis inflammatory 
cascade leads to the activation of COX-2 and the production of prostanoids, resulting in 
vasoconstriction and/or vasodilation and platelet aggregation [40]. Further, cytokine 
production induces synthesis of nitric oxide (NO), via iNOS in endothelial cells, as well 
as activated macrophages and neutrophils. This leads to the increased formation of 
reactive oxygen and nitrogen species like hydrogen peroxide (H2O2) and peroxynitrite 
(ONOO-), which leads to stress-induced organ damage (shown in Figure 1.3) [41].  
The activation of these pathways in sepsis can result in the development of MODS, 
resulting in mortality rate increase of up to 90% (with failure of 4 or more organs), 
irrespective of treatment methods used [24]. In addition to initiating the inflammatory 
response, innate immune cells also have functions in phagocytosis of pathogens, as well 
as antigen presentation to initiate the adaptive immune response [42]. The roles of innate 
immune cells are discussed in more detail below. 
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Figure 1.3: Generation of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) in stimulated macrophages, neutrophils and endothelial cells. 
Following pro-inflammatory stimulus (lipopolysaccharide, peptidoglycan, and cytokines) 
macrophages, neutrophils and endothelial cells convert L-arginine into nitric oxide (NO) 
by inducing nitric oxide synthase (iNOS) activation. Pro-inflammatory stimuli also 
activate nicotinamide adenine dinucleotide phosphate (NADPH) production of 
superoxide radicals (O2-). The presence of these radicals and water molecules generates 
ROS such as hydrogen peroxide (H2O2), likewise presence of oxygen radicals and NO 
results in production of RNS such as peroxynitrite (ONOO-). Production of ROS and 
RNS leads to DNA, protein and lipid damage contributing to mitochondrial dysfunction 
and stress-induced organ damage. Figure adapted, with permission from [43]. 
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1.2.3.2. The role of platelets in sepsis  
Platelets are essential components in homeostasis and one of the first responding cell 
types in systemic infections. Bacteria, such as streptococci and staphylococci mediate the 
activation of platelets by binding plasma proteins such as von Willebrand factor (vWF) 
[44, 45]. Platelet activation leads to increased surface expression of platelet (P-) selectin 
in patients with sepsis, and increases in plasma levels of soluble factors including soluble 
P-selectin (sP-selectin), following cleavage from activated platelet surfaces [46, 47]. 
Soluble P-selectin triggers signalling via receptors present on myeloid cells and can result 
in disseminated intravascular coagulation (DIC) events [48, 49].  
Activated platelets intrinsically interact with a number of other immune cells during 
sepsis, including peripheral blood mononuclear cells (PBMC). Platelet interactions have 
been shown to induce the activation of B and T lymphocytes as well as monocytes  
in vitro [50]. An increase in formation platelet-neutrophil aggregates has also been shown 
in sepsis, with activated complexes showing a greater ability to phagocytose bacteria [51, 
52]. On the other hand, production of pro-inflammatory cytokines from this complex can 
be deleterious leading to increased inflammation [53, 54]. In contrast, complexes formed 
between platelets and macrophages inhibit the production of pro-inflammatory mediators 
during sepsis, preventing development of septic shock in a COX-dependent manner [55].  
Platelets have also been investigated as prognostic markers in sepsis. The study 
conducted by Aydemir et al. in 2015 evaluated whether the kinetics of platelet counts and 
mean platelet volumes (MVP) differed in adult patients with nosocomial sepsis [56]. 
Patients admitted to ICU had platelet count and MPV measured daily, over a 5 day 
period. A significant reduction in platelet count (<150,000/mm3) was noted for the first  
3 days in patients with gram-positive sepsis, 4 days in patients with gram-negative sepsis 
and 5 days in patients with fungal sepsis. These decreases in platelet count were also 
associated with an increase in MPV (defined as MPV of >10.4/fL), in the first 3 days in 
patients with gram-positive sepsis, and 5 days in patients with fungal sepsis. The study 
concluded that fungal sepsis induced a more significant effect on platelet count and 
function.  
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Decreased platelet count in septic patients are associated with higher mortality rates of up 
to 40%, compared with those with higher platelet count (~10%) [57]. Decreased platelet 
count is also associated with activation of coagulation pathways, with complications 
including DIC events and development of MODS [48]. A recent study by de Stoppelaar  
et al. (2014), showed similar results in a mouse model of pneumonia-induced gram-
negative sepsis [58]. When intranasally infected with 104 colony-forming units (CFU) of 
Klebsiella pneumoniae, platelet-depleted C57BL/6 mice showed a significantly higher 
level of bacterial burden in primary sites of infection (lung), blood and other distant 
organs (spleen and liver), compared with control mice. Further, evidence of haemorrhage 
at the primary site of infection was seen in platelet-depleted mice, as well as a significant 
increase in pro-inflammatory cytokines released (TNF-α and IL-6), both in vivo and when 
further stimulated in vitro. Combined, these complications lead to impaired survival in  
platelet-depleted mice, suggesting that decreased platelet count contributes to increased 
sepsis mortality [58]. 
Excess accumulations and aggregation of platelets are also shown to be key contributing 
factors to the development of acute lung injury (ALI) [59] and acute kidney injury (AKI) 
[60]; organ damage syndromes resulting from severe sepsis. As such, platelet count is 
often used as an independent predictor of mortality in ICU clinical settings [48].  
Inhibition of platelet activation and function in sepsis patients appears to be important in 
the modulation of the host immune response to systemic infection. Several animal and 
clinical studies appear promising, supporting the potential for anti-platelet therapies 
improving outcomes in sepsis [61-64], which will be discussed further in section 1.4.2. 
1.2.3.3.  The role of monocytes/macrophages in sepsis 
Monocytes and macrophages are an essential part of the innate immune response, and 
along with neutrophils, provide the first line of defence against infection (see Figure 1.2). 
Produced from hemopoietic stem cells in the bone marrow, monocytes enter the 
bloodstream and then differentiate into macrophages or dendritic cells, with functions in 
phagocytosis [65] and antigen presentation [66]. In contrast with what has been described 
for lymphocyte subsets, sepsis does not appear to affect levels of monocyte/macrophage 
populations, further suggesting that these cells are key drivers in regulating immune 
responses in sepsis. 
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Monocyte and macrophage populations are thought to play a dual role in sepsis [67]. 
Following infection, pattern-recognition receptors such as Toll-like receptors (TLRs) are 
expressed on these innate immune cell surfaces and activate the inflammatory cascade 
upon interaction with pathogenic microorganisms. Toll Like Receptor-2 (TLR-2) is one 
of the most studied receptors in the recognition of gram-positive specific molecular 
patterns. Peptidoglycan (PGN) and Lipotechoic acid (LTA) from the cell wall of bacteria 
such as S. aureus are recognised by TLR-2 on circulating monocyte/macrophages. This 
initiates signalling cascade via the activation of nuclear factor κB (NFκB), leading to the 
production of both pro-inflammatory (such as tumour necrosis factor α (TNF-α), 
macrophage migration inhibitory factor (MIF) interleukin-1β (IL-1β) and interleukin-6 
(IL-6)), and anti-inflammatory cytokines (such as interleukin-10 (IL-10); shown in Figure 
1.2). As a result, levels of pro-inflammatory cytokine release (TNFα and IL-6) increase, 
contributing to destruction of tissues and promoting organ failure [68].  
Monocyte/macrophage cells were also shown to be key regulators of systemic 
coagulation and inflammatory pathways in a mouse model of abdominal sepsis [69]. Mice 
were depleted of monocytes and then abdominal sepsis was induced via CLP, following 
which plasma and lung levels of inflammatory and coagulation markers were determined. 
As a result of monocyte/macrophage depletion, there were notable decreases in levels of 
plasma prothrombin, and coagulation factors x and v. Further, depletion of 
monocyte/macrophages lead to a decrease in plasma levels of IL-6 and CXC chemokines, 
which in control CLP sepsis mice were increased as expected, due to inflammation. 
Together these decreases in pro-inflammatory and coagulation pathways resulted in 
reduced kidney injury and further understand the role of monocytes/macrophages in 
pathology of sepsis, however it is unclear if this also extends to clinical sepsis [69]. 
Activated macrophages (stimulated by Interferon-γ (IFNγ)) also accumulate in and 
around infected tissues, and increase in number as inflammation progresses [70].  
When infected with 107 colony-forming units (CFU) S. aureus, mice with septic arthritis 
with depleted peripheral blood monocytes showed impaired pro-inflammatory cytokine 
production. This affected recruitment of leukocytes to tissues resulting in increased 
weight loss and likelihood of mortality [67]. Further, a lack of phagocytosing 
monocyte/macrophage population resulted in increased bacterial infiltration into organs 
[67] contributing to development of sepsis and organ failure. This was also similarly 
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shown in the recent study by Ngo et al. (2013) [71], in mice infected with 105 CFU of 
Candida albicans, following depletion of monocytes. Compared with the control mice, 
monocyte-depleted mice had significantly increased fungal burden in kidneys, and 
histological analysis showed abscess development in kidney tissues; containing 
neutrophils and cellular debris. Additionally, adoptive transfer of monocytes to depleted 
mice in this study restored some antifungal phagocytic responses. Macrophages also play 
a role in the NO synthesis; reacting with superoxide (produced by activated neutrophils) 
to form peroxynitrite, with cytotoxic and bactericidal effects [72] (Figure 1.3).  
1.2.3.4.  The role of neutrophils in sepsis  
Neutrophils are another important part of the innate immune response against infection, 
and are the first innate immune cell to arrive at sites of inflammation. Derived from 
haemopoetic stem cells in bone marrow in a similar manner to monocyte/macrophages, 
neutrophils also have functions in regulating inflammation via phagocytosis [73]. It is 
reported that the human body produces 1011 neutrophils daily, and that this number 
increases ten-fold with inflammatory stimuli such as cytokines or bacterial surface 
components [74]. Neutrophils are central to the sepsis inflammatory cascade, however 
there is continued debate in the effect on neutrophil phagocytosis of bacteria during 
sepsis; some studies reported no change [75, 76] others showing increased phagocytosis 
[77-80], or decreased phagocytosis [81-85].  
Maturation of neutrophils is a multi-stage process progressing from myeloblast, 
promyelocyte, myelocyte, metamyelocyte, band cell, to mature polymorphonuclear 
(segmented) cells [86]. One of the criteria for identifying sepsis is the presence of 
immature neutrophils (band cells) [22]. These are prematurely released from bone 
marrow in response to severe infections and have impaired phagocytosing ability 
compared to mature counterparts in both sepsis infected and healthy individuals [87]. 
Increased numbers of immature neutrophils were shown in a recent clinical trial in 
patients with sepsis, compared with SIRS patients and healthy volunteers [88]. While 
these cells are not considered to be fully functional, it was argued in another study that 
this did not negatively affect the phagocytic abilities of immature neutrophils in septic 
patients, when compared with healthy controls [89]. 
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While the host employs neutrophils in a protective role, in the presence of pro-
inflammatory cytokines and pathogenic stimuli these innate immune cells contribute to 
exacerbation of inflammation [90] (Figure 1.2), by binding endothelium and interfering 
with coagulation and fibrinolysis pathways (as shown in Figure 1.4), and migrate to other 
sites of inflammation. Recruitment of activated leukocytes to the vascular endothelium 
for migration to tissues occurs via a regulated multi-step cascade, including capture, 
rolling and firm adhesion [91]; mediated by surface molecules. Mature neutrophils 
express a number of surface markers following stimulation including CD66b; a 
carcinoembryonic antigen [92], and CD11b; also known as integrin alpha M (ITGAM) 
[93]. The study by Schmidt et al. (2015) recently showed that human peripheral 
neutrophils in whole blood became dysfunctional when exposed to S. aureus components 
in vitro, with reduced phagocytic ability and subsequently decreased anti-bacterial 
activity [94]. The study also noted a decrease in surface expression complement factor 
c5a, accompanied by an overexpression of CD66b and CD11b on the neutrophil surfaces 
and elevated aggregate formation, which contributed to the dysregulated phenotype of 
neutrophils. These activation markers, in conjunction with other cell surface molecules 
like selectins mediate the rolling and firm adhesion of neutrophils to the endothelial 
surfaces. 
Leukocyte (L-) selectin is the most ubiquitously expressed selectin subtypes, present on 
the cell surface of macrophages, neutrophils and T lymphocytes, with the primary role of 
trafficking leukocytes to local sites of acute inflammation [95]. During sepsis, L-selectin 
is often prematurely shed from neutrophil surfaces to reduce the level of injury at local 
sites [96]. Another adhesion molecule involved in migration of leukocytes is P-selectin 
glycoprotein ligand-1 (PSGL-1). PSGL-1 is a well-described ligand of L-selectin [97], 
and an integral surface adhesion molecule for recruitment of neutrophils to tissues [98]. 
Inflammation is generally resolved by way of apoptosis; as neutrophils are generally 
considered constitutively apoptotic [99], however during sepsis stimulatory signals inhibit 
apoptosis of neutrophils. A study by Taneja et al. [100] confirmed this, showing that only 
6.2% of neutrophils extracted from whole blood from critically ill patients with sepsis 
became apoptotic after 24 hours. Delayed apoptosis of neutrophils leads to exacerbated 
inflammation, which is a key-contributing factor for organ failure.  
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None of the current therapies for sepsis target the delayed apoptosis of neutrophils. In a 
recent study, neutrophils extracted from humans were cultured in the presence of serum 
amyloid A (an acute-phase protein that is increased during inflammation; SAA). Serum 
amyloid A binds to the formyl peptide receptor-like 1/lipoxin A4 (LxA4) receptor (ALX) 
on the surface of neutrophils, leading to suppressed apoptotic signalling pathways and 
prolonged neutrophil survival. However, incubation with pro-resolving lipid mediator  
15-epi-lipoxin A4 (15-epi-LxA4; 2 µmol/L) prior to incubation with SAA, resulted in 
restored neutrophil apoptosis by re-instating signalling pathways [101]. The implications 
of this study are that induction of pro-resolving mediators such as lipoxins may also be 
beneficial in sepsis (discussed further in section 1.4.6). 
1.2.3.5. Adaptive immune response in sepsis 
Sepsis also affects a number of key adaptive immune cell sub-populations, including  
B and T lymphocytes [23]. Sepsis causes a decrease in the proportion of B lymphocytes 
and both CD4+ and CD8+ T lymphocytes, proposed to be in conjunction with an increase 
in CD4+ CD25+ Regulatory T lymphocytes [102]. The combined effects of sepsis on the 
adaptive immune response are discussed below. 
1.2.3.6.  The role of B lymphocytes in sepsis 
B lymphocytes are an integral component of the adaptive immune system. They are the 
only cell type that produces the immunoglobulins (Ig), which recognise antigens of 
pathogenic microorganisms such as bacteria and facilitate the delivery of these antigens 
to neutrophils and natural killer cells for bacterial degradation [103, 104]. Two recent 
studies have highlighted a potential role for a newly identified subset of B-lymphocytes 
named innate response activator (IRA) B lymphocytes, which in mice were shown to 
protect against sepsis and septic shock [105, 106].  
The 2012 study by Rauch et al. noted an increase in both mortality rate and overall 
number of fatalities in B lymphocyte and GM-CSF deficient mice (GM/µMT-/-), when 
subjected to CLP to induce sepsis [105]. These deficiencies resulted in pronounced 
inflammation characterised by increased presence of neutrophils, as well as elevated 
levels of IL-1β, IL-6 and TNF-α in both the peritoneum and in serum, leading to severe 
bacteraemia and development sepsis before MODS, and death. In contrast, GM-CSF 
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produced by IRA B lymphocytes limited infection and inflammation, which was 
associated with improved outcomes. Following this, another study determined the 
mechanism of protection by B lymphocyte derived GM-CSF in a mouse model of 
pneumonia [106]. It was shown in vitro that wild type B-1a B lymphocytes produced IgM 
in response to IRA B lymphocyte-derived GM-CSF, leading to speculation that IgM 
recognises bacterial components, targeting them for phagocyte-mediated elimination, 
reducing the probability of uncontrolled inflammatory response. The study also showed 
that B lymphocytes migrate from the pleural space into the lung in order to protect against 
Escherichia coli and Streptococcus pneumoniae-induced pneumonia. Mice with  
B lymphocyte and GM-CSF deficiencies had increased bacterial burden and subsequent 
increased mortality rate, in a similar fashion to that of the Rauch et al. study [105]. 
Apoptosis of B lymphocytes during sepsis can lead to a state of immunosuppression. In a 
recent clinical study, septic patients demonstrated a significant loss of B lymphocytes in 
spleen (via immuno-histological and flow cytometry analysis), compared to non-infected 
trauma patients [107]. This was similarly shown in a mouse study, where caecal ligation 
and puncture (CLP) was performed to induce polymicrobial sepsis in B lymphocyte 
deficient µMT-/- mice. B lymphocyte deficient µMT-/- mice were not able to generate a 
sufficient inflammatory cytokine/chemokine response for bacterial clearance, leading to 
increased mortality compared with wild-type mice. Survival rates could be partially 
restored by transferring wild-type serum containing B lymphocytes [103]. In the same 
study, decreased Type-1 interferon-induced chemokine production was seen in µMT-/- 
mice, contributing to increased severity of disease. This suggests a role for  
B lymphocytes in regulation of early immune responses by way of Type-1 interferon 
signalling. 
1.2.3.7.  The role of T lymphocytes in sepsis  
Cytotoxic T lymphocytes (CD8+) are not generally considered to be of importance in 
acute sepsis; however one study did note an initial increase in CD8+ T lymphocytes in 
septic patients compared with trauma patients [107]. In contrast with other chronic 
infection and inflammatory states, sepsis is an acute inflammatory condition. As such, it 
has been debated as to whether subsets of Helper T lymphocytes (CD4+) are directly 
involved in early sepsis development. A number of studies have suggested that CD4+  
Chapter 1 
	
	 Page 21 
T lymphocytes mediate innate immune responses in animal models of sepsis. In these 
studies, CD4-deficient mice had reduced capacity to clear bacteria, and decreased 
neutrophil activity compared with wild-type mice, which contributed to an increased 
likelihood of mortality [108, 109]. Conversely, one study argued that CD4+ T 
lymphocytes do not impact inflammatory pathways in sepsis [110]. Depletion of CD4 
from wild-type mice in this study had no significant effect on bacterial load, pro-
inflammatory cytokine production or overall survival; contradicting what was shown in 
the above two studies.  
Similar to B lymphocytes, the main impact of sepsis on T lymphocytes is induced 
apoptosis (in lymphatic tissues), causing impaired antimicrobial responses and 
immunosuppression. Surviving CD4+ and CD8+ T lymphocytes in circulation either 
switch to anti-inflammatory (Th2) phenotypes [111], or become “exhausted” [112].  
T lymphocyte exhaustion is characterised by decreased cytokine production and reduced 
T lymphocyte receptor diversity, resulting in increased apoptosis [113]. Extended 
“paralysis” of the adaptive immune system contributes to increased mortality rates in 
sepsis. 
Upon activation, naïve CD4+ T lymphocytes differentiate into one of: Th1, Th2, Th17 and 
induced regulatory T lymphocytes (iTreg) populations. Treg are also derived directly 
from the thymus naturally (nTreg) [114]. Regulatory T lymphocytes (CD4+CD25+ Treg) 
have a number of proposed roles in regulation of both adaptive and innate immune 
responses in sepsis [115, 116]. One such function is in mediating immunosuppression, by 
inhibiting effector responses mediated by both CD4+ and CD8+ T lymphocytes and the 
innate immune response. Initially observed in trauma patients [117], decreases in 
CD4+CD25- cells were accompanied with an increase in CD4+CD25+ Treg. This has also 
been shown in patients with sepsis and septic shock [102], and in a mouse model of 
polymicrobial sepsis [118]. Given that an immunosuppressive role of Tregs has been 
shown in sepsis, a recent review proposed that inhibition of Tregs could potentially 
restore immune function in sepsis [119].  
As sepsis can result in immunosuppression via apoptosis of B and T lymphocytes (via the 
suppressive activity of Tregs), it is of both interest and importance that novel potential 
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therapies of sepsis aim to restore the activity of these cells for improved immune 
responses. 
1.2.4. Biomarkers as predictors of sepsis 
A number of biomarkers have been proposed in the identification of sepsis, as well as 
prognosis, however debate continues over their usefulness. Novel potential biomarkers 
should provide information that is additional to standard clinical assessments and 
investigations [7]. Optimally, detection of biomarkers could be done in a rapid and cost-
effective manner, and determine between the different pathogenic sources of sepsis and 
non-infective SIRS.  
C-reactive Protein (CRP) and Pre Calcitonin (PCT) are currently the two most frequently 
used biomarkers in the clinical diagnosis of sepsis. CRP is an acute-phase reactant 
produced in the liver, stimulated by IL-6 [120]. The exact role of CRP in inflammation is 
unclear, however in critically ill patients in Australia CRP was shown to be a reliable 
marker of bloodstream infection [121]. The assay to detect CRP is inexpensive and easy 
to perform. PCT is the precursor to calcitonin hormone synthesised in serum in low 
levels, with increased levels peaking early in inflammation (8-24 hours vs. 36 hours for 
CRP) potentially allowing for more rapid identification. While PCT is more specific and 
more sensitive (88% sensitive compared with 75% sensitivity for CRP) in determining 
bacterial sepsis [122]. Levels of PCT are more stable than CRP, and the assays to detect 
have a short turn-around time of 2 hours, however PCT does not accurately differentiate 
between other non-bacterial sources of sepsis and non-infectious inflammatory states (i.e. 
trauma, surgery) [123]. Thus, the best use for PCT is in ruling out bacterial infection, in 
order to reduce unnecessary administration of antibiotics. 
Early response cytokines such as TNF-α, IL-1β and IL-6 have also been proposed as 
biomarkers for identification of sepsis. These cytokines are released predominantly by 
macrophages and lymphocytes that have been activated by inflammatory stimuli, and 
rapidly increase following onset of sepsis (see Figure 1.2) [124]. Both TNF-α and IL-1β 
activate cells of the vascular endothelium, resulting in the recruitment of neutrophils to 
the site, continuing to perpetuate inflammation. Further, the release of TNF-α and IL-1β 
activates coagulation pathways and initiates the sepsis inflammatory cascade that leads to 
the production of other pro-inflammatory cytokines (like IL-6 and IL-8), lipid mediators, 
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and ROS and RNS; contributing to organ damage [24]. As levels of TNF-α were not 
significantly altered in clinical studies following anti-TNF therapy [125] and the role for 
IL-1β in sepsis has been debated, neither have been considered a suitable biomarker for 
sepsis diagnosis, however as increased levels are associated with poor outcomes, they 
could be useful as prognostic markers of sepsis.  
IL-6 is similarly produced by a wide variety of immune cells (in response to TNF-α and 
IL-1β), and is elevated in a wide variety of acute inflammatory conditions. A number of 
biological functions have been described for IL-6 in sepsis including the activation of B 
and T lymphocytes [126]. Other key functions of IL-6 include the induction of fever and 
loss of appetite, as well as increased production of acute-phase reactants (like CRP) in the 
liver, and signalling the release of immature neutrophils (hallmark of SIRS and sepsis). 
IL-6 appears to be a more reliable prognostic marker for sepsis than TNF and IL-1β, as 
elevated levels of plasma IL-6 are more stable (allowing for detection). Further, elevated 
IL-6 levels in sepsis are associated with highest mortality rates [127], and recent evidence 
suggests that low-dose aspirin therapy could potentially reduce IL-6 levels [128]. As 
such, an intervention study has been initiated (discussed in section 1.4.2), to investigate 
the effect of low-dose aspirin therapy with primary read-out parameters including levels 
of IL-6, measured over a 48 hour time frame. 
Activation markers on the surface of innate immune cell populations (in particular 
neutrophils and macrophages) have also been proposed as potential biomarkers of sepsis. 
CD64 expression was shown to be elevated on the surface of neutrophils in the presence 
of bacterial infection [129, 130], and has The expression of CD64 was shown in one 
study to have a higher specificity (95%) and sensitivity (96%) in detecting sepsis 
compared with PCT (70% and 94%, respectively) [130]. However, another concurrent 
study disputed the usefulness of CD64, as expression cannot distinguish between viral 
and bacterial infections reliably, nor could it distinguish between localised infection and 
systemic inflammation [131]. Further, a recent cross-sectional study by Gámez-Díaz et al. 
showed that CD64 expression on neutrophils were not significantly specific or sensitive 
enough to diagnose sepsis in patients admitted to the emergency department (cohort of 
631 patients) [132]. CD11b is expressed on macrophages and neutrophils, and facilitates 
binding to intracellular and vascular adhesion molecules (ICAM-1 and VCAM-1) on the 
endothelium, for recruitment to inflamed tissues, and one study therefore suggested that 
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the combined use of CD64 and CD11b could be beneficial biomarkers in diagnosing 
sepsis [133].  
The generation of ROS and RNS and the downstream pathways of apoptosis and organ 
damage have also recently become a point of interest as potential prognostic biomarkers 
of sepsis [134]. Markers of extrinsic apoptosis pathways such as cell surface death 
receptor Fas and their ligands (like FasL), were shown in a number of studies to correlate 
with the development of sepsis and high clinical scores (SOFA and APACHE II) [135, 
136]. The 2012 study by Huttenen et al. evaluated the prognostic value of soluble Fas 
(sFas), FasL and sFas/FasL ratio in the plasma patients with bacteraemia [137]. Patients 
presenting with systemic S. aureus, S. pneumoniae, beta-haemolytic streptococci or  
E. coli infections, were enrolled and plasma was taken over 4 days, following positive 
bacteraemia identification. The study showed that patients with increased concentration 
of sFas (ng/mL) and sFas/FasL ratio, and a decrease in FasL were associated with a 
higher SOFA score. Additionally, increased concentration of sFas (ng/mL) and sFas/FasL 
ratio were also indicative of hypotension, however these values did not predict 14- or 28-
day mortality. Similarly, the 2015 study by Mikić et al. evaluated the predictive value of 
sFas on APACHE II scores in patients with sepsis, severe sepsis and septic shock [135]. 
The study showed that sFas concentrations in plasma were elevated in 54.4% of all 
patients enrolled (with 76.9% of this being patients with MODS and 84.6% of mortalities) 
and this was correlated with higher APACHE II scores. The study concluded that in 
combination, sFas and APACHE II score could be used to predict poor outcomes in 
sepsis.  
To date, no individual biomarker has been successful in the identification of sepsis, 
however many have been useful as prognostic markers, allowing for precise monitoring 
and treatment. It has been suggested that a panel of useful biomarkers (both pro- and anti-
inflammatory) could serve as a better diagnostic tool for identification or potential 
development of sepsis [8, 9].  
Although microbiological confirmation of infection is required for sepsis diagnosis, the 
use of modern molecular technologies (such as amplified molecular methods, and whole 
blood assays) for rapid identification of causative organism are now also being 
considered, alongside a panel of biomarkers. In combination, these novel diagnostic 
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approaches would decrease turn-around time for positive identification, permitting more 
rapid therapeutic intervention [138]. The LightCycler SeptiFast test is a multiplex real-
time PCR assay, that can positively identify up to 25 of the most common sepsis-causing 
pathogens (10 different bacteria identified to species level, other bacteria to genus level, 
and 5 Candida species) produced by Roche Molecular Systems (USA), and has 
previously been evaluated in patients with endocarditis and suspected sepsis [139-141]. 
The basis for this technique is fluorescently labelled probes, which target the internal 
transcribed spacer (ITS) region, specific for each bacterium. The study by Wallet and 
colleagues evaluated the SeptiFast test in patients with suspected sepsis over a 6-month 
period [140], with the test producing reliable results; with increased specificity (93.5%) 
and sensitivity (85%) up to 57 hours sooner than conventional blood cultures. Some 
limitations reported with the assay; chiefly relating to some unreliability in accurate 
detection of pathogens in the system database, and that the test does not allow for 
identification of organisms not in the database. Further, as this method does not rely on 
growth prior to amplification, there is no discriminating between amplification of dead 
organisms, and like other highly sensitive molecular methods there is the possibility of 
contamination, and false positive results. 
These newer advancements in modern molecular detection methods have also allowed for 
identification of diagnostic and prognostic biomarkers of sepsis including microRNAs 
(miRNA). These small endogenously produced RNAs (approximately 22 nucleotides) 
were shown to be important in targeting mRNA for translational repression or cleavage 
[142]. The study by Wang and colleagues in 2012, highlighted 6 serum miRNAs with 
potential prognostic value in sepsis [143]. Using Next-generation Solexa sequencing 
techniques, which had similarly been useful in identifying biomarkers in patients with 
other conditions like cancer [144, 145], the miRNA expression profiles in sera of 
surviving and non-surviving patients of sepsis were screened. Quantitative RT-PCR was 
then used to confirm that 6 miRNAs were differentially expressed in non-survivors (miR-
223, miR-15a, miR-16, miR-122, miR- 193*, and miR-483-5p). Further, when combined 
with sepsis stage, APACHE II and SOFA scores, these seven variables were strongly 
associated with sepsis mortality, were not useful from a diagnostic perspective. These 
approaches are yet to be evaluated in multi-center trials.  
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There is recent interest in the pro-inflammatory marker NFκB and anti-inflammatory lipid 
mediators such as lipoxins, as levels of both markers are shown to rapidly increase 
following onset of inflammation (within 8 hours) [146, 147]. Not only could these 
markers be useful in rapid identification of inflammation, both NFκB and Lipoxin A4 
pathways are impacted by low-dose aspirin therapy with therapeutic benefit seen in other 
conditions (discussed further in section 1.4.3). A majority focus of studies in this thesis is 
the production of NFκB and Lipoxin A4, as potential surrogate markers of sepsis. As well 
as this, the potential therapeutic benefit of low-dose aspirin therapy will be determined by 
measurable levels of these markers in both patients with sepsis (Chapter 3) and in a 
murine model of staphylococcal-induced sepsis (Chapter 4).  
1.2.5. Treatments of sepsis 
Current guidelines for sepsis therapy suggest that a successful therapy should be directed 
towards rapid identification and effective clearance of infectious foci [2]. Following this, 
the delivery of appropriate antimicrobial therapy and symptomatic organ support (via 
fluid resuscitation and vasopressor support) should be instigated (as outlined in Table 
1.2). However, these therapies do not target the uncontrolled inflammatory response by 
the host immune system, contributing to sepsis mortality. Since 1982, over 60 phase 2 
(P2) or phase 3 (P3) randomised control trials of potential therapeutic targets for sepsis 
have been initiated [148]. Despite this, no significant advance has been made in reducing 
the mortality rates associated with sepsis. The following treatments represent some of the 
most notable current and potential target therapies that have been investigated extensively 
for their use against sepsis. 
1.2.5.1. Early goal directed therapy  
Early goal directed therapy (EGDT) was pioneered in a study conducted by Rivers et al. 
in 2001, following a randomised single-centre clinical trial [149]. The rationale for the 
study was that oxygen delivery would improve outcomes in sepsis. Patients were enrolled 
following admission to the emergency department (ED) or ICU, with severe sepsis as 
well as decreased systolic blood pressure (less than 90 mmHg) or blood lactate 
concentration equal to or greater than 4 mmol/L. Patients randomly assigned to EGDT, 
had central venous catheter measurements for levels of oxygen saturation (SVCO2) taken, 
following which “goal directed” treatment protocol was employed.  
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The trial was initially deemed a success with an absolute reduction in sepsis mortality of 
16%. Although some groups adopted the EGDT protocol; conducting similar single and 
multi-centre trials [150-153], other studies have argued that the major limitation of the 
study (data analysed were from a single centre study), imply the results were not 
indicative of an absolute mortality rate that was comparable with a broader subset of 
patients [11, 154]. An investigation conducted by the Australasian Resuscitation in Sepsis 
Evaluation (ARISE) Investigators and the Australian and New Zealand Intensive Care 
Society (ANZICS) Adult Patient Database (APD) Management Committee was initiated 
in 2007, questioning the validity of EGDT, following the success of the pilot study [11, 
149]. This study showed, although the incidence of sepsis continued to increase over a 9 
year period, associated mortality rates decreased from an estimated 36% in 1997 to 21.2% 
in 2005 [11]. Similar declines in hospital mortality were shown in a concurrent 
epidemiological study in the US by Martin et al., with a 9.9% reduction in mortality over 
a 22 year period [4]. This drop in mortality rates over time were not taken account in the 
design of the EGDT pilot study [155]. As a result, further research is currently underway 
to permit evidence-based decisions on the therapeutic benefit of EGDT in sepsis. 
1.2.5.2. Antimicrobial therapies 
1.2.5.2.1. Source control and empirical antibiotic therapy 
Identification of causative pathogens of sepsis is usually made via blood culturing, which 
has a turn-around time of 24-28 hours. Empirical therapy employs broad-spectrum 
antibiotics, targeting a variety of both gram-positive and gram-negative organisms [156]. 
During the first “golden” hours in sepsis identification, empiric antibiotic therapy is 
administered along with fluid resuscitation, to treat the unknown infection, while blood 
culture results are pending (Table 1.2) [157]. Patients are assessed according to the 
guidelines for early empiric-antibiotic delivery based on parameters including: recent 
antibiotic therapy, previous infection or colonisation with antibiotic resistant organisms, 
potential harm of antibiotic treatment, polymicrobial infection, organ failure status, risk 
of antibiotic resistant infection and recent surgeries (that may contribute to risk of 
infection) [158]. Once this information is determined, patients are then assessed for 
neutrophil counts (as this is a key indicator of infection severity), in which case a separate 
set of guidelines is consulted before antibiotics can be prescribed.  
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Table 1.2: Initial treatment regimen for septic patients, according to the 2012 
Surviving Sepsis Campaign guidelines, reproduced with permission from [2]. 
Strong recommendations* Suggestions* 
Initial resuscitation (first 6 hours) 
Begin Resuscitation immediately if hypotension or 
arterial lactate > 4 mmol/L  
Resuscitation Goals: 
• CVP 8-12 mmHg 
• MAP ≥ 65 mmHg 
• Urine Output ≥ 0.5 mL/kg/h 
• SVCO2 ≥ 70% or mixed venous saturation ≥ 
65% 
If venous saturation target not achieved: 
• Consider increasing fluids 
• Transfuse packed red blood cells to 
maintain haematocrit ≥ 30% and/or 
• Begin dobutamine infusion (maximum 
20 µg/kg/min) 
Diagnosis 
Obtain appropriate cultures before antibiotic 
delivery (including blood cultures and other sites 
as clinically indicated, consider candidiasis) 
 
Antibiotic therapy 
Begin broad spectrum intravenous antibiotics 
within 1 hour 
Consider combination therapy if 
Pseudomonas spp. infection is suspected or 
if patient is neutropenic 
Re-assess antimicrobial regimen daily Combination therapy for 3-5 days, then  de-escalation 
Limit therapy to 7-10 days unless patient is 
immunosuppressed or has undrainable focus  
Initiation of antiviral therapy as quickly as 
possible if suspected viral origin  
Antimicrobial therapy should not be used in 
patients with severe inflammation of non-
infectious cause 
 
Source identification and control 
A specific source of infection should be rapidly 
identified  
Formally evaluate patient for infection focus 
amenable to source control measures (i.e. 
drainage, debridement) 
 
Remove intravascular devices if infected  
* Recommendations are classified according to GRADE of evidence system [172, 173].  
CVP: central venous pressure; MAP: mean arterial pressure; SVCO2: superior vena cava 
saturation. 
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Debate continues as to whether this type of therapy does in fact have any impact on the 
reduction of mortality in patients with severe sepsis and/or septic shock. Several studies 
have demonstrated that treatment with adequate empirical antibiotics within the first few 
hours following identification lead to lower mortality rates (Table 1.2) [10, 159, 160], 
however this was excluding patients who have been transferred from a non-hospital 
setting who may have been taking antibiotics previously. 
1.2.5.3. Recombinant human activated protein C  
Human activated protein C (hAPC) is an endogenous plasma protein activated in the 
presence of thrombin/thrombomodulin complex to form a serine protease, and is involved 
in modulating coagulation and inflammation; interfering with thrombotic signalling (as 
shown in Figure 1.4) [161, 162]. The pilot study of recombinant hAPC (rhAPC) in sepsis 
(PROWESS trial) was conducted in 2001 [163]; showing a 6.1% absolute reduction in 
mortality compared with placebo-treated patients, as well as improved cardiovascular and 
respiratory function. Following this, rhAPC became the first pharmacological therapeutic 
approved for use in over two decades in the treatment severe sepsis in the US [164] 
between 2002 and 2010. The use of rhAPC was included as a recommended therapeutic 
for critically ill sepsis patients with a high risk of death in the first edition of the 
Surviving Sepsis Campaign guidelines in 2004 [162, 165].  
Not only has debate arisen over the costs associated with rhAPC; with short-term 
treatment estimated to be AUD$15,000 per 4 day course [166], treatment with rhAPC 
was also associated with increased bleeding (especially in patients with low risk of death) 
[163, 164, 167-169]. The efficacy of rhAPC was questioned after other randomized trials 
failed to reproduce outcomes seen in the initial study [168-170]. In 2011, the Cochrane 
collaboration reviewed five of the largest clinical trials involving treatment with rhAPC 
against severe sepsis [171]. The study concluded that rhAPC showed no significant 
beneficial effect on the 28-day mortality in sepsis patients compared to the placebo group; 
leading to the withdrawal of rhAPC from the market in October 2011, as it was not a 
reliable therapeutic against severe sepsis and septic shock [170, 171]. 
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Figure 1.4: Systemic inflammatory, pro-coagulant, and fimbrinolytic pathways and 
the proposed mechanisms of action by Recombinant Human Activated Protein C 
(rhAPC). Following recognition of pathogens in circulation, monocyte/macrophages 
produce cytokines and chemokines to induce inflammatory response. The uncontrolled 
inflammatory response (due to reactive oxygen species produced by neutrophils) results 
in local cellular damage of the vascular endothelium and development of coagulopathy. 
TNF and IL-1 induce monocyte production of tissue factor leading to thrombin formation 
and formation of a fibrin clot. Both cytokine production and thrombin induces release of 
plasminogen-activation inhibitor 1 (PAI-1), interfering with fibrinolysis resulting in 
oedema; contributing to diffuse endovascular injury, micro-vascular thrombosis, organ 
ischemia, development of MODS, and death. RhAPC treatment was shown to intervene at 
multiple within the vascular endothelium, reducing inflammation. While these pathways 
were impacted with RhAPC treatment, no significant therapeutic benefit has been 
observed in clinical outcomes of sepsis patients. Figure reproduced with permission from 
[163], Copyright Massachusetts Medical Society.  
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1.2.5.4. Novel anti-complement therapies for sepsis 
Of the complement factors that drive innate immune responses in sepsis, C5 is becoming 
of significant interest. Cleavage of this complement factor leads to the production of C5a; 
a powerful anaphylatoxin that triggers the pro-inflammatory responses, contributing to 
MODS and septic shock [174]. The other products of the cleavage of C5 include C5b, 
which is then converted to C5b-9 (by the C5 convertase enzyme), forming the membrane 
attack complex (MAC), which lyses gram-negative bacteria [175, 176]. As complement 
pathways are activated rapidly following onset of sepsis, investigations in targeting 
complement pathways have shown potential for neutralising antibodies as adjunct therapy 
for sepsis.  
The use of anti-C5 therapy was also shown to have benefits in other terminal illnesses 
which interfere with the complement system such as paroxysmal nocturnal 
haemoglobinuria (PNH) [177, 178] and atypical haemolytic uraemic syndrome (aHUS) 
[179]. In both of these conditions, administration of a humanised monoclonal anti-c5 
antibody (Soliris: Eculizumab marketed by Alexion Pharmaceuticals) was found to be 
safe and effective in reducing the number of thrombotic events and intravascular 
hemolysis [180]. There are some limitations that have been noted with this therapy in 
patients with aHUS. Once given, this therapy is life-long, making it the most expensive 
drug currently on the market (€430,000 annual spend in Europe, $409,500 USD/year) 
[181]. Also, adverse side effects including minor headaches, nausea and anaemia have 
been reported, however most concerning was the increased risk of developing sepsis, 
shown in aHUS patients treated with anti-C5 therapies [182]. Further, use of anti-
complement pathways to inhibit C5a, and in particular C5b-9 MAC could result in 
unfavourable outcomes, due to the impairment of other general immuno-protective 
mechanisms provided by the complement system.  
Recent studies in animal models of sepsis have also shown therapeutic benefit of anti-C5 
antibody therapies, both alone and in combination inhibiting other markers of 
inflammatory responses in sepsis [183, 184]. Investigations into anti-complement 
therapies in sepsis do in fact date back as far as the 1980’s; where septic monkeys treated 
with anti-C5 antibody, showed attenuation of E. coli-induced septic shock and had 
decreased presence of acute respiratory distress syndrome (ARDS) [185, 186]. The 2015 
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study by Huber-Lang and colleagues, showed that by blocking both C5 and CD14 (a Toll-
like receptor family protein that recognises LPS of gram-negative bacteria) with 
neutralising antibody therapy, reduced morbidity and mortality mice with CLP-induced 
sepsis [184]. More recently, a phase 2 randomised-control human-intervention trial has 
just been completed at the Paul-Erlich Institut, Germany (Trial ID: NCT02246595), to 
further evaluate the safety and efficacy of anti-C5 therapies in patients with early or 
newly developing sepsis. Data from this trial may show whether or not the potential seen 
in animal models are translated into a human therapeutic potential. 
1.2.5.5. Corticosteroids in sepsis therapy 
Corticosteroids are synthetic hormone drugs related to cortisol, a classically produced 
hormone in the adrenal gland [187]. The most recognised corticosteroids with known 
anti-inflammatory properties class are Glucocorticoids (GC) [188]. Therapeutic benefit of 
GC therapy have been demonstrated in both infectious and non-infectious sources of 
inflammation [189], bronchial inflammation (e.g. asthma) [190], inflammatory bowel 
diseases [191] and traumatic brain injuries [192]. Schumer et al. first noted success in the 
treatment of sepsis with corticosteroids in 1976, with significant decrease in mortality 
observed in patients treated with dexamethasone or methylprednisolone compared with 
placebo treated patients [193]. Studies following this failed to reproduce the effect seen in 
the preliminary study, with the exception of reversal of symptoms in cases of septic shock 
[194-198]. Also noted, in non-life threatening cases, administration of corticosteroids was 
more harmful than beneficial, resulting in increased risk of hyperglycaemia (85% of 
patients) or super-infection (33% of patients) [199]. Currently corticosteroid therapy is 
only recommended for use (as a last resort) in sepsis patients with a high risk of death and 
is used in conjunction with other antimicrobial therapies 
1.2.5.6. Acetaminophen (Paracetamol) 
Hyperthermia is one of the key markers in identifying severe infection. It was suggested 
in one study that targeting the internal body temperature with anti-pyretic therapy could 
potentially improve mortality rates [200]. Paracetamol (acetaminophen) is a widely used 
over-the-counter analgesic and anti-pyretic agent. Initial studies in children with viral 
illnesses supported the use of paracetamol treatment in a randomised study [201], leading 
to a number of intervention trials with adults and other inflammatory states. One study 
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showed the use of paracetamol in febrile patients (650 mg every 6 hours), lead to a 
significantly higher mortality rate [202]. Differences in mortality rates were so extreme 
that the study was terminated following completion of the first preliminary analysis. This 
was consistent with other studies showing increased risk in mortality in infected patients 
with suppressed fever, due to anti-pyretic medication [203, 204]. Currently a multi-centre 
randomised study is underway in Australia and New Zealand called the HEAT trial 
(permissive HyperthErmia Through Avoidance of paracetamol in known or suspected 
infection in the ICU) [205]. The outcomes of which are to determine the safe and 
effective use of paracetamol in treating fever in sepsis patients within ICU. 
1.2.5.7. Non-steroidal anti-inflammatory drugs (NSAIDs) 
As the name suggests, NSAIDs are non-steroid based drugs that provide analgesic and 
anti-pyretic effects and at higher doses also confer anti-inflammatory effects. The main 
mechanisms of action are by inhibition of COX-1 and COX-2, which reduces synthesis of 
pro-inflammatory eicosanoids (prostaglandins and thromboxane). There are a number of 
family groups of NSAIDs classified on their structure including: salicylates (including 
aspirin and salicylic acid), propionic acid derivatives (including Ibuprofen), acetic acid 
derivatives (including indomethacin and diclofenac), among others (reviewed in [206]). 
There have been several studies elucidating the potential for NSAID treatment of sepsis, 
the most widely studied being ibuprofen and aspirin as discussed below. Some research 
into indomethacin has been done, however only in an animal model of sepsis [207]. 
1.2.5.7.1. Ibuprofen 
Ibuprofen (from isobutylphenylpropanoic acid) is a NSAID derived from propionic acid, 
commonly prescribed for use as an analgesic, with anti-pyretic and anti-inflammatory 
effects [208]. The mechanism of action of ibuprofen is similar to other NSAID therapies 
via the non-selective inhibition of both COX-1 and COX-2, blocking pro-inflammatory 
prostanoid synthesis (i.e. prostaglandin, thromboxane). Initial investigations of ibuprofen 
treatment showed promise against severe inflammatory conditions, however sample sizes 
in these studies were not large enough to confer significance [40, 209, 210]. A larger 
study was conducted in 1997 to determine what the effects of ibuprofen intervention 
against sepsis [211] finding that in patients treated with ibuprofen did in fact have 
reduced levels of pro-inflammatory lipid mediators and decreased fever, but did not 
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prevent the development of shock or respiratory distress. Further, the study was 
underpowered, showing that ibuprofen therapy did not significantly impact mortality rates 
of septic patients, with only 3% of patients showing any improvement.  
In contrast with aspirin, a recent study also showed that ibuprofen therapy in healthy 
volunteers with induced inflammation also suppressed leukotriene responses, leading to 
reduced lipoxygenase (LOX) activity [12]. Impairment of these pathways results in 
diminished production of pro-resolution lipid mediators such as lipoxins, resolvins and 
protectins (discussed further in section 1.4.6), and failure to resolve inflammation is 
associated with poor outcomes. Given that sepsis is characterised by uncontrolled 
inflammation, and resolution of inflammation, returning to homeostasis are key pathways 
for improved outcomes, it is not surprising that ibuprofen therapy did not appear to confer 
any therapeutic advantage.  
1.2.5.7.2. Aspirin 
Aspirin is a salicylate-derived NSAID with analgesic, anti-pyretic and anti-inflammatory 
properties. Similar to Ibuprofen, the mechanisms of aspirin’s anti-inflammatory effects 
are by COX inhibition (previously described in section 1.1.3.1), leading to inhibition of 
platelet aggregation and reduced prostaglandin synthesis [212]. Unlike other NSAIDs, 
aspirin at low-doses not only inhibits COX-1, but also acetylates COX-2, activating a 
biosynthetic pathway triggering the epimeric production of anti-inflammatory lipid 
mediators including lipoxins, resolvins and protectins. These lipid mediators have “pro-
resolving” characteristics, which contribute to resolution of inflammation and return to 
homeostasis (discussed further in section 1.4.6) [19, 20]. Evidence for the potential 
benefit of aspirin as an adjunct therapeutic of sepsis is increasing, with a number of 
animal studies [16-18, 213, 214] and clinical studies [20, 61, 101, 215-220] showing 
support for this hypothesis. In addition to being cost-effective, aspirin therapy triggers 
resolution of inflammatory pathways (at low-doses), and recently it has been suggested 
that aspirin directly impacts bacteria such as S. aureus [221]; the most frequent source of 
sepsis. The significance of aspirin and its potential as a therapeutic agent for sepsis is 
further discussed in section 1.4.3. 
	  
Chapter 1 
	
	 Page 35 
1.2.6. Animal models of sepsis 
One of the major obstacles in the development of novel adjunct therapies of sepsis is the 
lack of animal models that are a true representation of the clinical syndrome. The most 
popular animals used for pre-clinical studies of sepsis are mice, as inbred strains (such as 
C57BL/6 and BALB/c), largely because of the availability of reagents, markers and 
knockout strains. A recent review on animal models of sepsis remarked that of the 
pharmacological agents that show promise in animal models, none have shown 
significant therapeutic benefit in human clinical sepsis [148]. This has become a 
significant discussion point, with continued debate over the usefulness of animal models 
for this syndrome. In 2013, a meta-analysis performed by Seok et al. [222] comparing 
transcription profiles of inflammatory genes in PBMC found a poor correlation between 
mouse models and human systemic inflammation. The authors stated that on this basis, 
mouse models were not useful for investigating sepsis. More recently, another group 
analysing the same subset of data via different methods found the opposite conclusion, 
with high correlations observed between the two models of infection [223]. A closer look 
at the design of these analyses, raised questions about the assumptions made and what 
constituted an equivalent study; as “blood from an inbred mouse, 4 hours after 
staphylococcal infection compared with uninfected control mice” is not a valid 
comparison to “whole blood from patients with sepsis as a result of community-acquired 
infection compared with healthy controls”. This question was also raised in a recently 
published letter by Shay et al. [224]. As such, the use of and limitations of animal models 
of sepsis and human clinical sepsis remain controversial.  
There are a number of established animal models of systemic infection and sepsis 
including; Lipopolysaccharide (LPS) stimulation by intravenous injection; to mirror 
gram-negative endotoxin infection [225-228], caecal ligation and puncture (CLP) [229-
232]; to induce polymicrobial infection, or direct intravenous infection with either gram-
negative [17] or gram-positive bacteria [233]; to induce bloodstream infection and 
development of sepsis. 
In contrast with what has been described for human sepsis, the clinical definitions for 
sepsis in veterinary medicine has not been well defined. Parameters commonly measured 
in rodent animal models of sepsis are based on responses seen in human sepsis, and 
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include changes in physical appearance, weight loss/gain, measurable clinical signs; such 
as temperature, cardiac or respiratory rate change, and unprovoked/stimulated 
behavioural responses [234-236]. However, not all of these responses are seen in in vivo 
models of sepsis, and response can depend on the dose administered. A 2005 study by 
Copeland et al. compared the responses to endotoxemia in humans and in a mouse model. 
Human subjects injected with 2 ng/kg of endotoxin derived from E. coli were monitored 
for physiological changes every 2 hours for 24 hours, demonstrating elevated 
temperature, heart rate, and blood pressure. In contrast physiological changes were not 
seen in C57BL/6 mice, even with a higher dose (500 ng/kg) of endotoxin [237]. Indeed, 
mice have been shown to be significantly more resistant to infection, requiring doses 
1,000 to 10,000-fold greater than doses inducing severe symptoms of human 
inflammation [238]. At these high doses, intravenous bacterial infection in mice can also 
lead to rapid cardiovascular collapse and death (in a matter of hours), which is not 
commonly seen in human sepsis.  
Other measurable parameters used in animal models of sepsis include the analysis of 
immunological responses. Aside from the lack of physiological responses seen in mice in 
the Copeland et al. study, similar immunological responses were seen; in changes to the 
proportions of circulating neutrophils and lymphocytes in both humans and mice over a 
24 hour period; and peak response times for increases in plasma IL-6 and TNF-α 
similarly seen in humans and mice within 2 hours of infection; signifying in this model, 
that immunological responses in mice were a valid representation of human inflammatory 
disease [237].   
Coinciding with the increased prevalence of gram-positive sepsis, there has been an 
increase in the number established mouse models of gram-positive sepsis [67, 239-241]. 
A recent study by von Köckritz-Blickwede et al. showed differences in the levels of 
susceptibility to bloodstream infection with S. aureus in a variety of inbred mouse strains 
including C57BL/6, C57BL/10, C3H/HeN, CBA, BALB/c, DBA/2, and A/J mice [241]. 
Mice were infected with 4 × 107 CFU S. aureus, and monitored survival over a 14 day 
period. Over this time, C57BL/6 mice appeared more resistant to infection and had higher 
survival rates (15% mortality rate) compared with BALB/c, DBA/2 and A/J mice, all of 
which showing 100% mortality within 7 days of infection. This was similarly shown in 
other studies of staphylococcal sepsis [242, 243]. Additionally, C57BL/6 mice limited 
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bacterial growth more effectively in target organs within 24 hours of infection, with no 
histological sign of tissue damage observed in these organs [241]. As such, C57BL/6 
mice could provide a robust mouse model for the extended study of sepsis development. 
Although mouse models of systemic staphylococcal infection have been established, 
comparative studies of responses of mice in parallel studies of human sepsis are limited.  
A major consideration is the variations in responses observed in clinical infections (due to 
previous or current infection or colonisation), compared to the inbred species of 
laboratory animals that have not previously been exposed to systemic infection [148].  
Sepsis is a complex inflammatory condition that has proved difficult to replicate in 
animal models, to address this a number of considerations should be made when 
designing animal models of sepsis studies: 
i. The animal model should aim to mirror the timelines of infection with that of 
human clinical sepsis (days not hours) 
ii. Measurement of the same parameters where possible during infection in animal 
models to determine whether similarities/differences are observed in the 
mechanism of immune responses with human clinical sepsis.  
iii. Animals of both genders in wild-type strains, and in more susceptible strains of 
mice (including immuno-deficient/transgenic mice) should be investigated to 
model patients with comorbidities with increased risk of mortality in sepsis. 
The study described in Chapter 4 of this thesis represents a preliminary investigation into 
the response of C57BL/6 wild-type mice to staphylococcal-induced sepsis as well as the 
potential of low-dose aspirin therapy to resolve inflammatory states, in parallel with the 
clinical study outlined in Chapter 3. The C57BL/6 mouse strain was selected on the basis 
of previous studies showing increased resistance to staphylococcal infection; in order to 
facilitate the measurement of clinical parameters during the onset of early sepsis 
following bloodstream infection, and permitted analysis of target organs. Additionally, 
this model took into consideration the humane endpoints required for approval by the 
institutional ethics committee, as death as an endpoint was not permissible. 
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Parameters indicating development of sepsis seen in clinical patients will also be 
determined in mice: including activation of NFκB and production of specialised pro-
resolving mediators, as well as effects to innate and adaptive immune systems. The 
design of the study included similar timeline of infection, and permitted a detailed 
analysis of the mouse model as an accurate representation of human clinical sepsis. 
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1.3. Staphylococcus aureus 
Discussed below are general characteristics of S. aureus as an important nosocomial 
pathogen and the virulence and pathogenicity factors involved in the development of 
invasive staphylococcal infections (e.g. endocarditis and device-related biofilm 
infections). These invasive infections are a frequent source of bloodstream infections 
leading to the development of sepsis. 
1.3.1. General classification and characteristics 
Staphylococcus species were first identified in the early 1880’s by Scottish surgeon Sir 
Alexander Ogston [244]. Initial classification of staphylococci was given within the 
common genus of Micrococcus, but was later reclassified as Staphylococcus with species 
determined according to colony colour with S. aureus (from the Latin word for gold) 
compared with S. epidermidis to signify its consistent colonisation on human skin.  
S. aureus is differentiated from other bacterial species on the basis of biochemical testing 
for catalase and coagulase production, mannitol fermentation, and acid production of  
D-trehalose [245]. Catalase production also distinguishes S. aureus from other 
Enterococcus and Streptococcus species, and majority (but not all) of S. aureus isolates 
will produce coagulase, which clots blood plasma of the host [246]. Those staphylococcal 
species that are not coagulase-positive are classified as Coagulase Negative 
Staphylococci (CoNS). Traditional bacterial identification methodology carries the 
disadvantage of the prolonged time required for a definitive result. As this contributes to 
the delay in diagnosis and severity of sepsis, rapid identification of causative organisms 
potentially improve response time for targeted antibacterial therapy. Since the 1970’s, 
advancement in identification methods have improved the detection time of S. aureus by 
molecular methods such as PCR [247] and semi-automated systems like Vitek and 
matrix-assisted laser desorption/ionisation time of flight of mass spectrometry 
(MALDITOF-MS) [248]. However as these methods still rely on growth of colonies from 
blood cultures, reductions in the detection time remain at approximately 8 hours. 
 
 
Chapter 1 
	
	 Page 40 
1.3.2. Emergence of methicillin-resistant S. aureus (MRSA)  
Records of penicillin and methicillin resistant variants of S. aureus date as far back as 
1948 and 1961, respectively [249, 250]. The introduction of these antibiotics into the 
routine treatment of infections, gives bacteria the pressure to adapt in order to survive. 
Initial resistance to penicillin by staphylococci was due to the production β-lactamases 
that could hydrolyse β-lactam. Methicillin was synthesised with modifications to resist 
the hydrolysis of β-lactam. Methicillin resistance is attributed not to β-lactamase 
production, but to the expression of an additional penicillin binding protein (PBP2a) 
encoded by the gene conferring methicillin resistance (mecA), acquired from another 
species [251]. 
Initially the epidemiology of MRSA was limited to the hospital-acquired infections (HA-
MRSA), however in the last decade the incidence of skin and soft tissue infections due to 
community-acquired MRSA (CA-MRSA) have risen dramatically [252]. Molecular 
typing studies conducted in both Australia and the US have shown that CA-MRSA 
infections are more strongly associated with strains carrying the Panton-Valentine 
leukocidin (PVL) virulence factor and the presence of SCCmec type IV allele, and appear 
more susceptible to some non- β-lactam antibiotics than HA-MRSA strains [253]. Of 
interest HA-MRSA infections did not appear to posses PVL and were usually related to 
other SCCmec alleles [253, 254]. The persistent increase in these multi-drug resistant 
strains and their spread from hospital environment into the community had increased the 
likelihood of a potentially serious infection to the general public. 
Vancomycin is the last resort for antibiotic treatment of MRSA the emergence of such 
strains is of great concern for global health, with increases in the number of strains of 
MRSA with reduced susceptibility to vancomycin being reported [255, 256]. Strains of 
vancomycin-intermediate S. aureus (VISA) were first reported in 1997 in Japan, with 
moderate increases in resistance to glycopeptide therapy [255]. Further, there are  
S. aureus strains reported to have a vancomycin minimum inhibitory concentration (MIC) 
within a susceptible range, however upon more detailed investigation (by either 
prolonged incubation or higher incoculum) show a resistant subpopulation with an 
increased MIC [257]. These strains are now referred to as heterologous-VISA (hVISA).  
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These vancomycin intermediate strains are more commonly associated with HA-MRSA, 
and can result in vancomycin treatment failure; contributing to extended hospitalisation, 
due to prolonged infection [258]. Although VISA and hVISA strains are not typically 
associated with high mortality rates, infections with these strains are difficult to treat. As 
vancomycin is at present a last resort, antibiotic resistance poses a significant challenge 
for treatment of complex infections. The use of alternative therapies have been suggested 
in the treatment of complex VISA and hVISA infections such as endocarditis and joint 
infections, with aspirin and major metabolite salicylic acid showing potential benefit 
(discussed further in section 1.4.3).  
1.3.3. Epidemiology of staphylococcal disease 
1.3.3.1. Colonisation and infection 
While colonisation rates of S. aureus vary, approximately 20% of the general population 
consistently carry at least one strain of S. aureus [259, 260]. Epidemiological studies have 
shown general carriage rates among the general population are similar to that of hospital 
staff and other patients (both on admission and already hospitalized) [261]. Patients 
already colonised with S. aureus are at also a higher risk of developing infections, by 
transmission via contact with hospital staff that are transiently colonised with a different 
strain. The rise in antibiotic resistant strains of S. aureus (MRSA) within the hospital and 
community settings also increases the risk of spread to other patients. 
There are several known risk factors for infection with S. aureus. Individuals who are 
immuno-compromised (including infants, the elderly and those with previous infections 
or pre-existing conditions such as diabetes, patients on haemodialysis and intravenous 
drug users) presented with higher carriage rates than healthy counterparts [259, 262, 263]. 
High carriage rates in immuno-compromised patients are also associated with increased 
risk of developing infection. Patients who had previously had surgery or indwelling 
catheters other medical devices (such as pacemakers and artificial joints) inserted are also 
high potential risk factors for hospital-acquired infection [264-266].  
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1.3.4. Pathogenesis of staphylococcal disease 
In order to initiate infection, S. aureus enters the bloodstream or other adjacent tissues 
following damage to skin or mucosal barriers. With a host of virulence factors, and the 
ability to avoid the innate immune response [267], S. aureus infection can cause result in 
the destruction of host lymphocytes and serious inflammation, giving rise to a 
symptomatic response. Figure 1.5 illustrates the mechanisms of staphylococcal 
pathogenesis. The virulence factors and associated bacterial genes that play a role in 
staphylococcal pathogenesis are also summarised in Table 1.3; the most significant 
virulence and pathogenicity factors for this study are discussed below. 
1.3.4.1. Adhesins as virulence factors 
Adhesion is the first step in initiation of S. aureus infection. Adhesins are molecules 
produced in order to facilitate bacterial attachment to a variety of host substrates 
including epithelial and endothelial cells, and other host protein surfaces. Adhesins may 
be anchored to the surface of staphylococci like the family of proteins known as 
Microbial Surface Recognising Adhesive Matrix Molecules (MSCRAMMs) [268], or 
secreted adhesins known as Secretable Expanded Repertoire Adhesive Molecules 
(SERAMs) [269]. Both of these types of adhesins are proteinaceous, however 
polysaccharide intercellular adhesin (PIA) [270] and techoic acids [271] have also been 
shown to behave as adhesins.  
Major MSCRAMMs of S. aureus include clumping factors (ClfA and ClfB), fibronectin-
binding proteins (FnBPA and FnBPB), and collagen-binding protein (Cna). These 
proteins represent the largest class of cell wall anchored (CWA) proteins [272]. FnBPs 
initiate a bond between fibronectin from the host and the surface of the bacteria, allowing 
attachment to host integrins via the extracellular matrix proteins [273]. ClfA binds 
fibrinogen on the surface of implanted medical devices to promote biofilm formation 
[274], and also interferes with complement pathways [275]. Both ClfA and ClfB are 
involved in platelet aggregation by binding host fibrinogen [276]. ClfB on the other hand 
is also involved in the attachment of staphylococci to desquamated epithelial cells by 
binding to cytokeratin-8 [277]. Attachment to host collagen by staphylococci is mediated 
by Cna, facilitating deeper invasion into the tissues [278]. Further, Cna behaves as a 
virulence factor in experimental models of endocarditis [279] and arthritis [280].  
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1.3.4.2. Staphylococcal protein A  
An important virulence factor of S. aureus is staphylococcal protein A (SpA), with 
significant roles in including inflammation in lung infection, development of abscess 
formation and severe sepsis [234, 281, 282]. This 45-kDa secreted and cell-anchored 
protein is present in majority of clinical isolates and is unique in its N-terminal structure; 
unlike other proteins its signal sequence is comprised of five adjoining immunoglobulin 
G (IgG) binding domains that fold into repeated triple helical bundles [283, 284]. Another 
noted function of SpA is in facilitating staphylococcal evasion of phagocytosis by 
polymorphonuclear leukocytes (PMN) [285]. By binding this the Fc region of non-
specific IgG, SpA interferes with the signalling cascade; preventing recognition of  
S. aureus by PMN, avoiding opsonisation and Fc-mediated phagocytosis [286, 287]. 
Surface-anchored SpA also instigates B lymphocyte proliferation and apoptosis, in a  
T lymphocyte independent manner, by increasing B lymphocyte sensitivity to allow  
cell-wall binding of staphylococcal LPS to TLR-2 [288]. Soluble SpA (sSpA) has also 
been suggested to be involved B lymphocyte activation, in the presence of  
T lymphocytes, as well as behaving as a T-cell mitogen [289, 290]. Its also been shown 
that SpA mediates bacterial binding to human vWF [291], interfering with platelet-
binding at sights of endothelial damage further promoting endovascular infection [292]. 
Moreover, SpA was shown to activate TNF-α by binding its receptor (TNFR1), 
contributing to inflammation, in a mouse model of S. aureus-induced pneumonia [293].  
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Figure 1.5: Pathogenesis of staphylococcal invasion of tissue (sequence beginning left 
to right). Staphylococci bind damaged vascular cells via MSCRAMM-mediated 
mechanisms or bind endothelial cells directly by either adhesion-receptor or ligand 
bridging interactions. Heparin sulfate proteoglycan on the surface of the extracellular 
matrix (ECM) facilitates the staphylococcal attachment and increases susceptibility of 
endothelial cells to infection [294]. In order to facilitate spread of infection, staphylococci 
excrete proteolytic enzymes and translocate to the bloodstream to infect adjoining tissues. 
The inflammatory response triggered by infection in sub-epithelial tissues results in 
abscess formation, which can increase pathogenesis of endocarditis in the cardiac 
endothelium. Inflammatory cytokines are released by tissue-based macrophages and 
circulating monocytes, triggering the recruitment of T lymphocytes. Interferon-γ (IFN-γ) 
released by T lymphocytes activates neighbouring macrophages. The continued release of 
inflammatory cytokines contributes to symptoms of systemic staphylococcal infection 
and severe sepsis. PMN denotes polymorphonuclear leukocytes. Figure reproduced with 
permission from [295], Copyright Massachusetts Medical Society. 
. 
	
Chapter 1 
	
	 Page 45 
1.3.4.3. Evading host defences 
S. aureus adheres to host lymphocytes and can also invade, in order to initiate infection. 
Once S. aureus enters host tissues deeper than the mucosal layer, secretable proteins 
interact with local tissues and trigger the host immune response. These exoproteins 
include cytolytic toxins and other pathogenicity factors that protect the bacteria from 
elimination (Table 1.3). Of these, PVL is an important virulence factor for S. aureus, 
frequently responsible for necrotic lesions found in infected skin of patients [296]. PVL is 
only produced in 2-3% of strains, however of those strains producing PVL, the majority 
are MRSA isolates [297]. The two subunits of the toxin assemble in the membrane of 
monocytes, macrophages and lymphocytes, forming a pore [298]. In contrast with pvl-
negative staphylococci, the release of PVL from pvl-positive staphylococci lead to rapid 
cell death in both human and rabbit PMN, with greater implications in staphylococcal 
pathogenesis [299].  
1.3.4.3.1. Interaction of S. aureus with Toll-like receptors 
The role of TLRs in the innate immune system has previously been discussed in the 
context of sepsis and similarly applies in regards to staphylococcal infection. Recognition 
of S. aureus LTA by TLR2/TLR6 complexes, results in a signalling cascade and the 
activation of pro-inflammatory mediators, such as NFκB. This promotes the production of 
inflammatory cytokines and chemokines in order to initiate phagocytosis by PMNs [300].  
1.3.4.3.2.  Inhibition of neutrophil chemotaxis 
S. aureus can persist within epithelial cells, endothelial cells and macrophages, however 
neutrophils provide a challenge for S. aureus survival [301]. Patients with severe 
neutrophil dysfunction disorders (such as Leukocyte Adhesion Deficiency and Chronic 
Granulomatous Disease) have increased susceptibility to S. aureus infection, further 
confirming the importance of neutrophils in the clearance of staphylococcal infection 
[302, 303]. In order to evade neutrophil killing, S. aureus secretes two molecules: 
Chemotaxis Inhibitory Protein (CHIP) and Extracellular adherence protein (Eap). Sixty 
percent of S. aureus strains secrete CHIP, which binds to both the formyl peptide receptor 
(FPR) and the C5a receptor (C5aR), blocking ligand binding and signal transduction of 
neutrophils [304]. Likewise, Eap directly interacts with intracellular adhesion molecule 1 
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(ICAM-1), fibrinogen or vitronectin, effectively disrupting β2-integrin mediated adhesion 
and migration of neutrophils to the infected tissues [305]. 
Table 1.3: Pathogenicity factors associated with S. aureus infection and biofilm 
formation. 
	
	
Virulence Factor Function Genes  Reference 
Fibronectin binding protein 
(FnBPA/FnBPB) Fibronectin binding fnbA, fnbB [45] 
Clumping factor A/ B 
(ClfA/ClfB) 
Fibrinogen binding  
clfA, clfB [276] 
Collagen Binding protein 
(Cna) cna [280] 
Extracellular cellular matrix 
binding protein (ECM) Extracellular matrix binding ebh [306] 
Extracellular adherence 
protein (Eap) Extracellular adherence eap [305] 
Protein A 
Evasion of opsonisation and 
phagocytosis 
spa [282] 
Capsular polysaccharide type 
1, 5 & 8 
cap1, cap5, 
cap8 [307] 
Aureolysin Metalloproteinase involved in complement inactivation aur [308] 
Staphylokinase Enzyme involved in complement inactivation sak [309] 
α-haemolysin 
Haemolytic toxins 
hla 
[310] 
β-haemolysin hlb 
γ-haemolysin hlg 
δ-haemolysin hld 
Panton-Valentine Leukocidin 
(PVL) β-pore forming cytotoxin lukF, lukS [311] 
Polysaccharide intracellular 
adhesin (PIA) Non-proteinaceous factors 
including pro-inflammatory cell 
wall components 
ica  [312] 
Lipoteichoic acid,  
Cell wall tecihoic acid ltaS, wta [313] 
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1.3.5. Staphylococcal infections in humans 
1.3.5.1. Skin-related infections 
Any minor breach of mucosal barriers or the skin gives staphylococci the opportunity to 
invade local and adjacent tissues. As an abscess forms with a core of pus containing a 
combination of bacteria, macrophage and PMN influx [314]. Skin-related infections 
including, carbuncles, cellulitis, folliculitis, furuncles, impetigo, keratitis, mastitis and 
psoriasis are often caused by S. aureus. Localised infections like these have the potential 
to become life-threatening infections and inflammatory diseases including bacteraemia, 
sepsis, endocarditis, pneumonia and device-related biofilm infections. The significance of 
these invasive infections is discussed in more detail below. 
1.3.5.2.  Bacteraemia and sepsis 
As blood is generally considered sterile the presence of the bacteria is considered 
abnormal and serious, as often there is no symptomatic response. S. aureus is the most 
frequent source of bacteraemia, with nosocomial causes including the use of indwelling 
medical devices such as pacemakers and catheters. A recent study by the Australian 
Institute of Health and Welfare reported moderate decreases in hospital-associated 
staphylococcal bacteraemia cases between 2010 and 2013; coinciding with implemented 
MRSA screening and early identification of bacteraemia-like infections [315]. What this 
study did not take into consideration was the S. aureus bacteraemia events occurring as a 
result of indwelling medical devices prior to hospitalisation, thereby underestimating the 
total number of cases of bacteraemia, and the seriousness of infection. Untreated 
bacteraemia can result in an uncontrolled inflammatory response, leading to the 
development of severe sepsis; associated with a high mortality rate and gross economic 
burden (discussed in section 1.2.2).  
The relationship between staphylococcal disease and sepsis has been studied since the 
early 1880’s, with the initial identification of S. aureus from an abscess that had become 
septic [244]. Over the last two decades, the incidence of S. aureus-related sepsis has 
risen; now the majority cause of severe bloodstream infections, with the high associated 
mortality rates [4]. With this in mind, invasive staphylococcal infections known to be a 
frequent source of sepsis are discussed below. 
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1.3.5.3. Persistent complex infections (Biofilms) 
In nature, biofilms tend to contain complex communities of different bacterial and/or 
fungal species. The history and significance of biofilm forming organisms dates back to 
Van Leeuwenhoek’s observation of dental plaque formation by various microbes [316]. 
Following this, it has been shown that biofilm-forming organisms form multi-dimensional 
structures [317], and changes in phenotype (from planktonic to biofilm-forming) can 
result in a change in gene expression and growth patterns [318]. The stages of biofilm 
formation by staphylococci are outlined in Figure 1.6. 
1.3.5.3.1.  Components of the biofilm 
The composition of biofilm consists of multiple biopolymers, termed extracellular 
polymeric substances (EPS). Originally thought to be comprised solely of polysaccharide 
matter, EPS also includes peptides (such as pili and flagella peptides in the case of motile 
bacteria including Pseudomonas aeruginosa, Salmonella species and Escherichia coli 
[319, 320]); nucleic acids (extracellular DNA), which were shown to be integral to 
staphylococcal biofilms [321, 322]; lipids, and other non-cellular components (such as 
blood or water), depending on the environment. 
A number of general functions have been determined for the EPS matrix of 
staphylococcal biofilms. EPS allows quorum sensing (signalling between adjacent cells) 
by immobilising the cells closely next to one another [323-325]. The matrix also recycles 
lysed components of dead microbial cells such as extracellular DNA, for horizontal gene 
transfer and EPS degradation [326]. This regulated lysis process also provides an 
alternative source of nutrition for remaining biofilm cells [327-330]. 
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Maturation Detachment   
Attachment 
To polymer surface: 
Surface hydrophobicity, 
autolysins and  
techoic acids 
To host matrix 
proteins: 
MSCRAMMs 
Host matrix proteins provide a  
“conditioning film” 
Adhesive Factors: 
PIA, eDNA, Aap and 
other proteins 
Disruptive factors: 
PSMs, proteases and 
nucleases 
CidA, CcpA and other 
regulatory genes (agr, sarA, 
sigB) for biofilm formation 
 
Figure 1.6: Stages of biofilm formation by S. aureus. Attachment represents the 
initiation of the biofilm and there are multiple factors to consider. Microbes will often 
bind preferentially to an interface between the surface and an aqueous medium. 
Following attachment, microbes further adapt to growth within a biofilm environment, 
increasing the production of extracellular polymeric substances (EPS), this is known as 
biofilm maturation. This results in increased structural integrity of biofilm (via 
crosslinking of extracellular DNA and polypeptides the EPS matrix), leading to increased 
resistance to antibiotic therapy. Dispersal of the biofilm is the final stage of its 
development. Cells begin to detach from the biofilm, then disseminate to a new site, 
initiating attachment to a new surface; perpetuating infection. Figure reproduced and 
adapted with permission from [331]. 
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1.3.5.3.2. Quorum sensing 
Quorum sensing also commonly known as intracellular signalling is an important 
regulatory aspect of staphylococcal biofilm production. This mechanism is also seen in 
biofilms of Pseudomonas aeruginosa [332-334] and Streptococcus mutans [335, 336], for 
example. Quorum sensing in S. aureus is mediated by the protein encoded by accessory 
gene regulator (agr) locus [337, 338]. The agr locus consists of two operons (P2 and P3) 
that are governed by separate promoters. These operons encode the RNAII and RNAIII 
regulatory molecules, which then are responsible for the transcription and translation of 
various staphylococcal virulence factors. Agr-mediated signalling is regulated by the 
Staphylococcal accessory regulator (SarA) [339, 340], which increases cellular 
concentrations of RNAII and RNAIII. This signalling mechanism is critical to the 
generation and enhanced survival of staphylococcal biofilms, and impairment in 
signalling can result in reduced capacity to form biofilms.  
1.3.5.3.3. Extracellular DNA in staphylococcal biofilms  
S. aureus produces extracellular DNA (eDNA) in excess in both standard broth culture 
and biofilm via autolysis [341]. When produced within a staphylococcal biofilm, eDNA 
is what provides the integral and structural support. When bound to bacterial cells, eDNA 
provided a more viscous and adhesive surface enabling the enhanced attachment to 
hydrophobic substrata (such as plastic/glass/metal surfaces) [342]. Crosslinking of eDNA 
within the EPS matrix provides strength and stability to the biofilm, contributing to 
increased resistance to antimicrobial therapies and phagocytosis by macrophages. Cell 
lysis is a is tightly regulated process by which eDNA is produced, released into the 
environment [343]; facilitated by autolysins from Cid (positive regulators) and Lrg 
(negative regulators) operons [328, 329]. These operons are regulated by quorum sensing 
molecules agr and SarA, thus impairment to quorum sensing could impact regulation of 
autolysis [344]. Reduced eDNA production impacts structural integrity of staphylococcal 
biofilms, potentially increasing susceptibility of weakened biofilms to immune attack 
(phagocytosis) [345]. 
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1.3.5.3.4. Biofilms as a source of infection 
The clinical relevance of staphylococcal biofilms is becoming more apparent with the 
increased incidence of complex infection associated with the use of indwelling medical 
devices and observed increases antimicrobial resistance within the last 15 years [346, 
347]. Discussed below are a range of infectious diseases that can develop following 
staphylococcal biofilm formation.  
Periodontitis is the inflammation of bone and ligaments that surround teeth bones. While 
not commonly caused by S. aureus, the formation of staphylococcal biofilms on teeth will 
then promote a host of other oral infections [348]. Similarly, Osteomyelitis is the 
presence of bacterial infection in bone and surrounding tissues. At present, S. aureus is 
the leading cause of bone infections, commonly introduced following surgery or trauma, 
bloodstream infection or as a result of other underlying conditions or infections [349]. 
Bacterial stimulation of host adhesive matrix proteins (fibronectin, fibrinogen, collagen), 
facilitates bacterial attachment to the damaged or dead bone [350]. As the host cannot 
resorb dead bone, the severity of infection of bone becomes more difficult to treat, with 
debridement required to resolve infection [351]. Mature staphylococcal biofilms are 
resistant to PMN-mediated phagocytosis, interfering with PMN motility. Evasion of 
phagocytosis leads to extended tissue damage and provides a perfect niche for continued 
bacterial attachment and survival. Intervention during early stages of biofilm formation, 
can result in effective clearance of biofilms by phagocytosis [352]. 
Patients with indwelling medical devices such as catheters [6, 353, 354], pacemakers 
[265] medical prostheses [355] and those patients requiring haemodialysis are at an 
increased risk for development of a biofilm infection. Breaks in mucosal membranes 
provide opportunities for nosocomial bacteria like S. aureus to migrate across impaired 
mucosal membranes, attach to the device surface and form biofilms. In both osteomyelitis 
and infective endocarditis (discussed in section 1.3.5.4), persistence of biofilms are 
dependent on the recruitment of host matrix proteins; providing an optimal surface for 
attachment [274]. Complex vegetations formed on the surface of indwelling devices, 
comprise of both host matrix proteins and biofilm components, and demonstrate 
enhanced antimicrobial resistance.  
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1.3.5.3.4.1. Animal models of device-related biofilm infections 
While in vitro models of biofilm-infections provide useful information on the 
characteristics of biofilm development, their usefulness is limited, as they do not allow 
the investigation of the complex strategies employed by biofilms to evade host immune 
responses in vivo [356, 357]. Animal models have allowed researchers to bridge the gap, 
replicating biofilm and device-related infections in humans; with rodents (such as rats and 
mice) and rabbits being popular choices for pre-clinical and comparative animal model 
studies (as similarly described in section 1.2.6) [358, 359]. Discussed below are the 
advantages and disadvantages of animal-models of biofilm-related infections, including 
sub-cutaneous implant infections and prosthetic-joint infections, which were investigated 
in Chapter 5 of this study. 
The association between intravascular- and urinary-catheter insertion, biofilm growth and 
subsequent development of bloodstream infection have been examined in a number of  
in vivo animal models [323, 360-362]. The sub-cutaneous infection model in this study 
(Chapter 5) represents a static infection, allowing the investigation of both biofilm 
development and local immune response, following insertion of the contaminated or 
infected foreign body implant. An intravascular venous catheter-model first developed by 
Rupp et al. in 1999 is one of the most popular models, used to investigate colonisation 
and infection with 106-108 CFU S. epidermidis in rats [360]. This model has been 
successfully used to identify the important bacterial components that contribute to 
establishment of biofilm, and in more recent studies elucidated the effects of complex 
biofilm-related infections on the innate immune system [357, 360, 363]. Sub-cutaneous 
catheter models of biofilm-related infection are often employed to investigate the 
potential of novel anti-bacterial compounds (such as anti-microbial coatings), to reduce or 
prevent adhesion of biofilm formation, or as a pre-clinical model prior to trials or 
application in clinical setting [364, 365]. As similarly discussed in section 1.2.6, these 
studies do have the capacity to identify promising compounds that can reduce bacterial 
attachment, biofilm formation or reduced inflammation, however these benefits are not 
always seen in clinical biofilm-related infections [366].  
The connection between human orthopaedic devices and joint-implants with biofilm 
formation was made in the clinical setting, following the use of rabbit models to study a 
foreign body inserted in the tibia [367-369]. In this model, a number of different materials 
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such as stainless-steel (s/s), titanium, other metals and plastics have been used to study  
in vivo biofilm formation (reviewed in [370]). The most recently reported models use 
contaminated pins, which are then inserted into a mouse tibia [356]. This model similarly 
allows for visual investigation by imaging, as well as bacterial enumeration and 
histological analysis. It has been debated whether this model is suitable for determining 
antimicrobial activity, or pharmacokinetics of a potential therapy or investigating immune 
responses. However the study by Prabhakara et al. (2011) did in fact show that an 
adaptive immune response of Th2/Treg cells were protective against a chronic S. aureus 
implant infection [356]. Further, antibiotic-coated implants have been developed as a 
preventative measure against biofilm attachment and formation, with promising results in 
both an animal model and in humans [371, 372].  
As similarly described for other human infections (section 1.2.6), there are considerations 
that must be made when developing models for device-related biofilm infections. While 
these models have provided researchers with valuable information, a major concern 
remains, with the promising results shown in both in vitro and in vivo models of device-
related infection, have not translated to any therapeutic/prophylactic benefit in clinical 
trials [366, 373]. This is often due to the limitations of in vivo models themselves. As 
similarly described in section 1.2.6, there are differences between human and murine in 
responses to infection (for example the response to different concentrations of LPS) that 
can influence conclusions made in these models [374].  Moreover, as so many in vivo 
models of device-related biofilm infections have been developed; investigating different 
surface characteristics of implants, or novel therapeutic/preventative approaches, there is 
no standard model to allow reliable comparisons to be made between different device-
related infection studies. Other suggestions have been made in an effort to improve 
animal models of device-related infections. These include, consideration of the effects of 
environmental factors that could affect outcomes in infection [375], and the study of 
polymicrobial biofilms, to more accurately represent the infections seen in clinical setting 
[376]. With these considerations in mind, development of novel in vivo models of device-
related biofilm infection will allow for a more reliable representation of human infection, 
and further our understanding of the complex nature of biofilm infections.  
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1.3.5.4. Endocarditis 
Endocarditis is described as the inflammation of the endocardium (the inner surface) of 
the heart, more commonly affecting the heart valves. Host matrix proteins (such as fibrin 
and fibrinogen) and platelets bind to damaged valves to form non-infective thrombotic 
endocarditis. Extracellular matrix growth provides a perfect environment for bacterial 
colonisation. Infective endocarditis (IE) occurs when bacteria adhere to damaged heart 
valves, via interactions with fibrin; inducing platelet-aggregation, leading to enhanced 
complex vegetation growth. While infective endocarditis is ordinarily uncommon,  
S. aureus is the majority source of surgical treated IE, with high associated mortality rates 
[377, 378]. Increased incidence of S. aureus-induced IE is due to clinical risk factors such 
as indwelling medical devices, invasive diagnostic or therapeutic procedures and 
intravenous drug use [379].  
Treatment of S. aureus-induced IE relies on long-term intravenous antibiotics at high-
doses. As complex vegetations on heart valves have limited blood supply, antibiotic 
therapy is not always effective and more severe vegetations require surgical removal, 
which often leads to secondary infection [380]. Untreated vegetations carry an increased 
risk in complications such as congestive heart failure (CHF) and systemic embolism (SE) 
which contribute to a higher likelihood of death [381]. SE is the most commonly reported 
complication of IE, with majority of effects observed in neurological systems [382], 
however emboli may also affect major arteries and organs with large vascular supplies 
such as lungs, spleen and liver. Transiently colonised bacteria on the surface of emboli 
also present a complication with dissemination through the bloodstream often resulting in 
sepsis [383]. 
Studies in animal models of S. aureus-induced IE have shown that aspirin in various 
doses had the capacity to reduce bacterial vegetation size [384]. Further, retrospective 
analysis showed a decreased incidence of S. aureus-induced IE and reduced requirement 
for valve replacement, in patients on long-term aspirin therapy [385]. Additional 
supporting evidence for the potential use of aspirin as an adjunct therapy against 
staphylococcal-based infections is discussed further in the next sub-chapter. 
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1.4. Aspirin 
Aspirin is a salicylate derived NSAID. The active natural form; salicylic acid (SA), found 
in the bark of willow and myrtle tree species have documented medicinal uses dating as 
far back as 3000 BCE, in some Ancient Egyptian communities [386]. While the credit for 
production of modern acetylated aspirin was given to chemist Dr Felix Hoffman (while 
working at Bayer Pharmaceuticals) in 1897, aspirin (by acetylating traditional SA) was 
first made by Charles Frederic Gerhardt 14 years earlier [387]. Since then, aspirin has 
risen to become the most regularly consumed medication globally. Clinical responses 
differ depending on the dose of aspirin administered, providing a wide variety of 
therapeutic applications, some of which are discussed below. 
1.4.1. Medical applications of aspirin 
1.4.1.1.  Aspirin as an analgesic and an anti-pyretic 
Aspirin and aspirin-like drugs are classed as weak analgesics (when compared to stronger 
narcotics like morphine), with effective action against clinical pain of low to moderate 
intensity such as some headache, postoperative pain, rheumatoid arthritis and 
osteoarthritis [388]. However, the preferred NSAID given for pain relief is ibuprofen. 
Ibuprofen is considered a safer alternative, to aspirin with no apparent side effects (like 
gastrointestinal bleeding) [389]. As previously outlined in section 1.1.5.6, all NSAIDs 
elicit their anti-inflammatory effects by binding and inhibiting COX-1 and COX-2, 
interfering with prostaglandin synthesis. Aspirin however is the only NSAID known to 
irreversibly acetylate and inhibit COX [390]. While this treatment has been well 
documented in adults, the use of aspirin has been strongly discouraged in combatting 
fever in children by medical societies and regulatory agencies. This is due to an increased 
risk of development of Reye’s syndrome) [391, 392]. 
1.4.1.2. Aspirin in the management of cardiovascular diseases 
General physician Lawrence Craven was the first to identify the anti-thrombotic effects of 
aspirin in 1953 [393]. At this time, the beneficial effects of aspirin therapy in preventing 
cardiovascular events such as myocardial infarction (MI) had not been described. Craven 
observed more bleeding in patients taking analgesic gum treated with aspirin following 
oral surgery, showing that aspirin prevented MI. Within 10 years of this initial discovery, 
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connections had been made between cardiovascular diseases including coronary 
atherosclerosis, thrombosis and acute MI [394], and evidence suggested that prevention 
of cardiovascular events in these diseases were due to anti-platelet effects of aspirin 
therapy [395]. 
The pilot study in the treatment of cardiovascular disease with aspirin was at a dosage of 
300 mg/day. At this dose of aspirin treatment, early maximum levels of platelet inhibition 
were also seen [396]. Initially the prescribed doses in a number of studies ranged between 
500 mg and 4000 mg daily, however these high-dose treatments over long periods of time 
resulted in a significant increase in adverse bleeding [397, 398]. In the last three decades, 
an increasing trend towards low-dose aspirin treatment for cardiovascular disease has 
been adopted. Inhibition of COX-1 and decreases in gastric prostaglandin levels have 
been observed in healthy subjects with doses as low as 30 mg/day [399]. Thromboxane 
production is persistently increased in patients with cardiovascular disease; therefore a 
minimum of 50 mg/day aspirin treatment is required for optimal inhibition [400, 401]. At 
present, the recommended dose of aspirin for the prevention of cardiovascular disease is 
between 75 mg and 150 mg daily.  
1.4.1.3. Aspirin in the prevention of cancer 
The initial link between aspirin and cancer prevention was made in the late 1980’s with 
one study reporting a 50% reduction of colorectal cancer risk in patients that regularly 
took aspirin-like drugs [402]. Early studies into the protective effects elicited by aspirin 
and other NSAIDs were supported by literature, experimentally observed in the reduction 
of tumour growth in animal model studies [403, 404]. Within the last decade however, 
debates have risen in the effectiveness of aspirin to prevent cancers, with one study 
showing no benefit of long-term aspirin (100 mg/day) in preventing total breast, 
colorectal or other cancers in healthy women [405].  In contrast, recent studies have 
shown support for the anti-cancer effects of aspirin, with modest decreases in the risk of 
developing colorectal [406-408], oesophageal [409, 410], stomach [411], prostate [412, 
413], breast [414, 415], pancreatic [416], skin melanomas [417], and ovarian cancers 
[418]. The mechanism of action of aspirin in its prevention of some cancers appears to be 
again the result of COX-2 inhibition and subsequent inhibition of prostaglandin 
production, which is often increased in a variety of cancer cell types [419, 420]. 
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1.4.2. Adverse effects of aspirin therapy 
The most commonly reported adverse effect of aspirin therapy is damage to the 
gastrointestinal (GI) tract [421-423]. Although administration of aspirin has been 
associated with GI injury, the level of damage observed depends on several factors 
including: dosage, term of administration, use of other medications, and pre-disposition 
from other conditions.  
The adverse GI symptoms induced by low-dose aspirin (<325 mg daily) that have been 
reported range from symptoms without mucosal lesions, to more serious GI toxicity (with 
prolonged use), including bleeding, ulceration, with rare instances of perforation, 
resulting in death [424]. Upper GI symptoms including gastro-oesophageal reflux 
(regurgitation or heartburn), and dyspepsia (including bloating, gastric discomfort and 
ingestion-related nausea) are most frequently seen in patients (up to 20%) on long-term 
aspirin therapy [425, 426]. Additionally, low-dose aspirin therapy over a long period of 
time can lead to small bowel bleeding and protein loss, which can contribute to iron-
deficiency, anaemia and hypoalbuminaemia (64.5% low-dose aspirin taking patients 
presenting with mucosal and ulcerated lesions) [427]. The exact mechanism of aspirin-
induced ulcer formation in intestines is not yet clear, however it is known that following 
aspirin-induced COX inhibition, the resulting decreases in prostanoid synthesis contribute 
to loss of cells from the gastric epithelium, causing superficial mucosal injury [428].  
The majority of studies reporting on gastric mucosal injury have only evaluated the effect  
low-dose aspirin therapy over a prolonged period of time. Although there is limited data 
available, there is some debate as to whether short-term administration may also cause 
minor mucosal inflammation. A 2009 pilot study in healthy volunteers (n=10 subjects) 
showed a higher incidence (30%) of mucosal injury in 100 mg aspirin-taking participants, 
compared with placebo control participants over a 2-week period, however this was not 
statistically significant [429]. It is still unclear whether the adverse effects described can 
also be expected to occur in patients treated with low-dose aspirin for a shorter period of 
time (100-325 mg daily dose, for less than 1 week). 
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1.4.3. Evidence for aspirin as an adjunct therapy in sepsis 
Low-dose aspirin therapy has been shown to impact inflammatory pathways in the 
inflammatory conditions described above prompting the question, could aspirin be a 
useful adjunct therapeutic in sepsis? 
As previously mentioned, evidence is accumulating for the potential of aspirin-therapy in 
sepsis, as shown in both animal models and clinical studies. Studies from mouse models 
of inflammation dating back to 2004 have proposed therapeutic benefits of aspirin 
therapy, via the triggered synthesis of aspirin-triggered lipoxins (ATL). In a mouse model 
of IL-1β induced inflammation, aspirin therapy (200 mg/kg) resulted in increased plasma 
ATL production, as well as decreased peritoneal influx of neutrophils and inhibition of 
leukocyte adherence, rolling and migration [18]. This was also seen in a rat model of 
myocardial inflammation. Rats stimulated with LPS showed decreased prostaglandin 
synthesis and increased myocardial ATL production, when pre-treated with 200 mg/kg 
aspirin [213]. In mouse models of both acute lung injury [16] and induced peritonitis 
[17], post-infection ATL therapy showed anti-inflammatory “pro-resolution” effects 
including reduction of pro-inflammatory cytokine and chemokine production, reduced 
influx of neutrophils. In conjunction with antibiotic therapy, ATL given to mice with  
E. coli induced peritonitis lead to decrease bacterial loads and improved survival [17]. 
While these data from animal studies are encouraging in supporting aspirin therapy in 
sepsis, comparisons between animal models of inflammation and human inflammation 
remain controversial (as discussed in section 1.2.6).   
More recently, a number of observational studies have investigated the potential 
therapeutic benefit of aspirin therapy in both healthy volunteers and clinical inflammatory 
states. The pro-resolving benefits of aspirin therapy were first seen in a randomised 
double-blind trial investigating the anti-inflammatory effects of aspirin at different doses 
(81, 325, and 650 mg) in healthy volunteers [20]. Levels of plasma ATL and 
thromboxane B2 were analysed both at baseline and after 8-weeks of aspirin therapy, with 
a daily dose of 81 mg significantly increasing ATL production with a subsequent 
decrease in production of thromboxane B2, suggestive of a pro-resolution anti-
inflammatory response. This was also shown in a study by Morris et al., investigating the 
effect of aspirin-therapy in healthy volunteers with inflammation by inducing skin blisters 
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[19]. In this study, low-doses of aspirin (75 mg daily) over 10 days not only increased the 
localised production of ATL and reduced thromboxane and prostaglandin levels within 
the blister, but also modulated the migration of PMN and macrophages site of 
inflammation. This effect was also shown in mice with zymosan-induced peritonitis, 
when treated with aspirin at daily doses of 2 mg/kg for the same period of time, in the 
same study. 
Both studies noted increases in ATL production and decreases in pro-inflammatory 
pathways. One study also suggested that because long-term aspirin therapy dampens 
inflammatory responses, this could contribute to the delay in diagnosis of sepsis and 
delivery of appropriate antibiotic therapy. However, this did not increase the risk of 
developing severe sepsis or septic shock [430]. Aside from this, recent cohort studies of 
ICU patients with SIRS and/or sepsis (with low-risk of active bleeding) have shown 
reduced mortality rates following low-dose aspirin therapy [61, 63]. Of these studies, the 
retrospective study by Eisen et al. in 2012 examined the differences in in-hospital 
mortality rates of patients with SIRS and/or sepsis in a single centre cohort from 2000 to 
2009, on the basis of previous aspirin therapy [61]. When compared with non-aspirin 
takers, aspirin-therapy reduced the likelihood of mortality by 6.2%, suggesting that 
aspirin could be a suitable adjunct therapy of sepsis. Likewise, in clinical studies of 
patients with community-acquired pneumonia, aspirin therapy was associated with 
shorter length of hospital stay [64], as well as reduced mortality rates [217].   
There is also increased evidence for the potential therapeutic benefit of aspirin in other 
inflammatory states including device-related infection. Patients previously taking aspirin 
had fewer incidences of both mitral valve regurgitation and congestive heart failure, 
resulting in a decreased requirement for early valve replacement surgery in a clinical 
study of S. aureus-induced IE [385]. This was also shown in an experimental rabbit 
model of S. aureus-induced IE, resulting in reduced vegetation, bacterial burden and 
embolic events in animals treated with 4-12 mg/kg aspirin [384]. Similarly aspirin use 
was shown to reduce the risk of S. aureus bacteraemia in patients undergoing 
haemodialysis with tunnelled catheters [218]. From these studies it has also been 
suggested that aspirin might have anti-bacterial action in infection (both directly and 
indirectly) [221, 431], with one study showing that aspirin and salicylic acid impacted  
S. aureus global regulatory pathways, affecting cell-signalling [221].  
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There has been limited experimental analysis of the immunological impact of aspirin 
therapy in clinical sepsis, however a number of clinical trials have been initiated to 
determine these effects worldwide including; Aspirin for Treatment of Severe Sepsis 
(currently recruiting patients, sponsored by the Federal University of São Paolo, Brazil 
Trial ID; NCT01784159), The PROTECTIN study (not yet recruiting, Austin Hospital, 
Australia; ACTRN12614001165673). The data presented within this study (see Chapter 
3) is in part contributing to a current ongoing clinical study from a single centre in 
Melbourne, Australia observing the Mechanism of Aspirin THerapy in Sepsis (The 
MATHS clinical trial; ACTRN12611000649910). This intervention study is currently 
recruiting, analysing immunological parameters over a 48 hour period in patients with 
SIRS and sepsis; randomized to 100 mg aspirin, 300 mg aspirin therapy or placebo 
therapy. 
1.4.4. Mechanisms of aspirin therapy in sepsis 
Aspirins anti-inflammatory induced mechanism of action has been previously elucidated 
in general [212] and for cardiovascular events and to some degree cancer prevention, via 
the inhibition of COX [403, 404], prostaglandin synthesis [38], and platelet inhibition 
[396]. The effects of aspirin within the context of systemic infection derived 
inflammation, have been hypothesised to occur via a number of mechanisms including; 
the inhibition of inflammatory pathways via the inhibition of NFκB [432, 433] and an 
increase the production of anti-inflammatory lipid mediators including lipoxins [14, 18, 
434], resolvins and protectins now grouped in a family of “specialised pro-resolving 
mediators” (SPMs) [13, 435]. 
1.4.5. Inhibition of NFκB signalling in inflammatory pathways 
An integral signalling molecule, transcription NFκB is known for its role in regulation of 
the inflammatory cascade and the exacerbation of severe symptoms of sepsis and other 
serious inflammatory conditions (as shown in Figure 1.7) [436, 437]. Under ordinary 
inflammatory conditions, NFκB is bound to Iκβ in the cytoplasm, Iκκα and Iκκβ (Iκκ 
complex) will migrate and bind to Iκβ, phosphorylating it and releasing NFκB to move 
into the nucleus and transcribe genes encoding pro-inflammatory cytokines and 
chemokines (Figure 1.7A) [438]. However in the presence of aspirin and other salicylate 
based drugs (1 mmol/L to 20 mmol/L concentrations), the active salicylic acid component 
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binds the Iκκ complex, preventing phosphorylation of Iκβ and subsequent activation of 
NFκB, outlined in Figure 1.7B [433]. The minimal dose for this effect has not yet been 
defined. 
 
 
Figure 1.7: Representation of the canonical NFκB activation pathway. A) Under 
normal inflammatory conditions. Pro-inflammatory stimulation will result in Iκκ 
complex phosphorylating Iκβ and the subsequent release of activated NFκB to enter the 
nucleus and further transcribe pro-inflammatory cytokines to prolong inflammatory 
states. B) Following treatment with aspirin and salicylates. The active metabolite 
salicylic acid binds the Iκκ complex preventing Iκβ phosphorylation and keeping NFκB 
bound and inactive, decreasing the transcription of pro-inflammatory cytokines and 
reducing inflammation, adapted and reproduced with permission from [437].  
 
 
A B 
Chapter 1 
	
	 Page 62 
1.4.6. Specialised pro-resolving mediators (SPMs) 
1.4.6.1. Production and role of lipoxins in inflammation 
The lipid mediator Lipoxin A4 (LxA4) is a well-known SPM with both synthesis and 
applications studied. Derived from the metabolism of arachidonic acid (AA), there are 
three biosynthetic pathways that result in lipoxin production. Platelet/leukocyte 
interactions trigger leukocyte 5-lipoxygenase (5-LOX) conversion of AA to epoxide 
Leukotriene A4 (LTA4). Leukotriene A4 is metabolised further generating LxA4 in 
leukocyte-adherent platelets [439]. Alternatively, 15-LOX catalyses the conversion of AA 
(on mucosal surfaces) generating 15S-hydroxyleicosatetraenoic acid (15S-HETE). 15S-
HETE is internalised by PMN and converted by 5-LOX to produce LxA4 (Figure 1.8A) 
[440, 441]. Low-dose aspirin therapy (75 mg daily) was recently shown to trigger the 
increased production of epimeric lipoxin isomers (15-epi-lipoxin A4 also termed aspirin-
triggered lipoxins (ATL), similar to the “classical” lipoxin biosynthesis pathways as 
described above (shown in figure 1.8B) [442].  
There is also evidence that statins including atorvastatin and pioglitazone can promote the 
production of ATL, via the S-nitrosylation of COX-2 in animal models of inflammation 
[443, 444]. Human studies of statin therapy also showed similar responses, however 
increases in ATL as a result of low-dose statin therapy over a 4-week period were much 
lower compared with increased levels shown with low-dose aspirin [445]. Not only can 
ATL can be induced by other pharmacological agents like statins, previous studies 
investigation ATL production showed detectible levels of this epimeric lipid mediator 
even in the absence of aspirin. Given this, the term “aspirin-triggered” and subsequent 
abbreviation of ATL do not give an accurate description, and for the remainder of this 
thesis will be referred to as 15-epi-lipoxin A4 (15-epi-LxA4). Both LxA4 and 15-epi-LxA4 
play important roles in improving innate immune responses and reducing inflammation as 
discussed below.[19]. 
Both LxA4 and 15-epi-LxA4 used in both in vitro studies and animal models of infection 
have showed therapeutic benefit. A 2011 in vitro study by Prescott & McKay showed that 
when stimulated with low-doses of 15-epi-LxA4 (100 nmol/L) over 6 hours, THP-1 
differentiated macrophages showed an enhanced capacity to phagocytose both 
fluorescently labelled beads (quantified by fluorescence microscopy), as well as non-
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pathogenic E.coli (quantified by the number of internalised bacteria) [446]. In 
conjunction with antibiotics, 15-epi-LxA4 therapy not only reduced systemic 
inflammation, but also prevented bacterial dissemination into organs, leading to improved 
survival mice with gram-negative sepsis [17]. Further, in a model of induced acute lung 
injury, post-treatment with 15-epi-LxA4 lead to decreased TNF-α and NO production in 
lungs, and histology showing a decrease in the proportion of neutrophils infiltrating into 
lungs, accompanied by reduced oedema, and alveolar injury. Combined, these effects lead 
to attenuated lung damage, as well as increased survival in 15-epi-LxA4 treated mice, 
compared with untreated mice [16]. 
The pro-resolution mechanisms of LxA4 and 15-epi-LxA4 include the inhibition of pro-
inflammatory cytokines (via inhibition of NFκB), and increased immune response (by 
inhibition of prostaglandin E2 and 5-LOX derived leukotrienes) similarly seen with anti-
inflammatory flavonoid compounds [230]. In both humans and mouse models,  
15-epi-LxA4 production impairs leukocyte migration (particularly neutrophils) measured 
as total cells in exudates in local inflammatory models, preventing progression of 
systemic inflammation [18, 19, 215]. Reduced or impaired lipoxin production (including 
15-epi-LxA4), can result in an uncontrolled inflammatory state; consistent with responses 
in severe sepsis [447]. These findings support the clinical relevance of LxA4 and  
15-epi-LxA4 and their potential as an adjunct therapeutic treatment. Clearance of 
inflammation is a complex process, and these effects have also been shown with other 
SPMS like resolvins and protectins [13, 448]. As such, it is more likely that resolution of 
inflammation is the combined action of lipoxins with other SPMs; resolvins, protectins 
and maresins [449]. 
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Figure 1.8: A) Simplified pathways of biosynthesis of pro- and anti-inflammatory 
lipid mediators from their parent polyunsaturated fatty acids (PUFA). Enzymatic 
hydrolysis of PUFA such as Arachidonic acid (AA), Eicosapentaenoic acid (EPA) and 
Docosahexaenoic acid (DHA) yields specialised pro-resolving lipid mediators with 
functions in clearance of infection and resolution of inflammation. B) Detailed pathways 
and effects of aspirin-triggered lipoxin synthesis. Aspirin acetylates and inhibits  
COX-2 derived from AA in epithelial, endothelial cells and monocytes. Remaining AA 
generates 15R-hydroxyleicosatetraenoic acid (15R-HETE), which is metabolised by 
leukocyte 5-lipoxygenase (5-LOX) to produce 15-epi-lipoxin A4 (15-epi-LxA4). Synthesis 
pathways of 15-epi-LxA4 mirror the pathway for classical lipoxin synthesis, with similar 
anti-inflammatory and pro-resolving functions, including the inhibition of plasma-derived 
growth factor (PDGF), epidermal growth factor (EGF) and leukotriene D4 (LTD4)-
mediated signaling in neutrophils and macrophages. Figure adapted and reproduced with 
permission from [450] and [451]. 
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1.4.6.2. The production role of other SPMs in inflammation 
Derived from polyunsaturated fatty acids (PUFA) eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), resolvins, protectins and newly identified lipid mediators 
termed maresins represent the other SPMs with proposed roles in resolution of 
inflammation (Figure 1.8A).   
E-series resolvin production occurs via a similar synthesis pathway to that of 15-epi-
LxA4. Following aspirin treatment or cytochrome P450 mono-oxygenase stimulation, 
acetylation of COX-2 leads to the conversion of EPA to 18R-hydro(per)oxy-EPE, which 
is reduced to form resolvin E2 (RvE2). Alternatively an intermediate by product of this 
18R-hydro(per)oxy-EPE (18R-HEPE), is converted to 5,6-epoxy fatty acid within human 
PMNs and resolvin E1 (RvE1) is produced via the 5-LOX pathway [452]. Recently a 
third E-series resolving was identified, produced via a novel alternative pathway of 18R-
HEPE conversions via 12/15-LOX [453]. E-series resolvin treatment in vivo in murine 
infection models resulted in increased bacterial clearance, a decrease in pro-inflammatory 
cytokine production, an decreased PMN infiltration due to inhibition of chemotaxis; 
improving survival in a model of bacterial induced lung injury [448, 453]. There was also 
an observed increased in PMN apoptosis, with enhanced macrophage efferocytosis in 
vitro with RvE1 exposure at concentrations as low as 1 nmol/L [454, 455]. 
Resolvin D series, protectins and maresins, are produced as a result of DHA metabolism. 
D-series resolvins are the product of two lipoxygenation steps. Firstly, conversion of 
DHA to 17S-hydro(pero)xy-DHA (17S-HpDHA), which is then metabolised to generate 
resolvin D1 (RvD1) or epimeric resolvin D2 (RvD1). At present, 6 D-series resolvins 
have been identified through natural biosynthetic pathways. Mice treated with RvD1 
showed suppressed NFκB activation, by impairing peroxisome proliferator-activated 
receptor γ (PPARγ) signalling pathways [456]; protecting against organ damage, leading 
to increased survival [13, 457]. Resolution of inflammation mediated by RvD2 is multi-
faceted; with roles in modulating leukocyte-endothelium interactions both directly and 
indirectly, similarly impacting cytokine production and promotion of bacterial clearance 
by phagocytosis [458]. Aspirin also triggers epimeric resolvin production similarly to  
15-epi-LxA4, resulting in AT-RvD1, AT-RvD2 and others; with similar pro-resolving 
functions as described above. 
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Protectins are another class SPMs produced in a number of human cell types and in 
murine skin and brain tissue and exudates [450]. These SPMs are synthesised in a similar 
manner to RvD1 and RvE3, as a result of DHA conversion via the 15-LOX pathway to 
17S-HpDHA. This is then converted once by an epoxide to form 16S, 17S-epoxy-
protectin and hydrolysed to form protectin D1 (PD1) also known as neuroprotectin D1 
(NPD1) when formed in the nervous system [459], with implications in Alzheimer’s 
disease (reviewed in [460]). The key described mechanism of action of protectins is in the 
reduction of PMN infiltration and enhanced efferocytosis of apoptotic neutrophils by 
macrophages [461]. Aspirin also able to trigger the epimeric synthesis of PD1/NPD1 
(AT-PD1/NPD1), which was shown to have more potent pro-resolution effects, compared 
to their naturally biosynthesised counterpart [15]. 
Maresins are the newest family of SPMs to be identified, produced exclusively by 
macrophages. Synthesised via DHA conversion to 14S-HpDHA via the 12-LOX pathway 
and then similarly to PD1, epoxidation and hydrolysis events yield maresin 1 (MaR1) 
[462]. Like other described SPMs, MaR1 is a potent inhibitor of PMN infiltration and 
stimulator of phagocytosis and efferocytosis by both human and mouse macrophages 
(with treatment as low as 0.1 ng per mouse in a zymosan induced model of peritonitis). In 
the same study, MaR1 was shown in Planaria to stimulate tissue repair (although the 
mechanism is unclear) and impairs pain recognition in mice, by inhibiting expression of 
transient receptor potential V1 (TRPV1) currents on the surface of sensory neurons [463]. 
The findings from this study proposed a potent analgesic role for MaR1, on the basis of 
resolution of inflammation and associated pain. 
In the case of critical inflammatory illnesses such as sepsis, it is unlikely that the actions 
of any of these SPMs are independently responsible for clearance of inflammation as 
production of these SPMs are intricately connected. Moreover, the proposed mechanism 
of combined action occurs over the course of inflammation; with a triggered “class 
switch” away from COX-derived pro-inflammatory mediators like prostaglandins and 
leukotrienes and to SPMs including lipoxins, resolvins, protectins and maresins (see 
figure 1.8A) [464], which in a number of studies was reported to be more potent 
following aspirin treatment [13, 15, 465]. 
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1.5. Summary 
Despite advances made in both medical and supportive care, we are no closer to reducing 
mortality rates associated with sepsis. Sepsis-related deaths occur more frequently than 
any other infection in clinical setting [1]. Reductions of mortality rates of sepsis rely 
heavily on the rapid identification of the condition and initiation of appropriate supportive 
therapies, which is difficult and often prolonged. Antibiotic therapy targets the pathogenic 
source of sepsis, with fluid resuscitation providing systemic organ support, however there 
is no approved adjunct therapy to target the uncontrolled inflammatory response that 
characterises the sepsis syndrome. Potential therapeutics identified in animal models of 
sepsis often fail to confer therapeutic benefit in human clinical trials; fuelling the debate 
over the validity of animal models as accurate comparisons of human inflammatory 
disease [148, 224]. A successful adjunct therapy should not only be cost-effective, the 
therapy should aim to target the previously described chaotic inflammatory responses, by 
resolving inflammation and promoting a return to homeostasis.  
Of the many therapeutics investigated for potential use in sepsis, support is increasing for 
aspirin therapy. Aspirin is already produced on a global scale for the vast number of other 
medical applications, meeting the criteria for a cost-effective therapeutic. Low-doses of 
aspirin were shown in a number of inflammatory states (infectious and non-infectious 
alike) to trigger the production of anti-inflammatory lipid mediators that mediate 
resolution of inflammation, resulting in improved outcomes in both animal models and 
human clinical studies [18, 19, 219, 434, 447].  
The present study will investigate the potential of low-dose aspirin therapy in critically ill 
patients with sepsis, as well as mouse models of staphylococcal-induced sepsis and 
device-related biofilm infection. It is hypothesised that low-dose aspirin therapy will 
produce immuno-modulatory effects in inflammation as seen in both clinical and animal 
models of sepsis, as well as device-related biofilm infections. 
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1.6. Statement of aims 
The central aims of this study were to: 
i. Analyse samples from the MATHS clinical study of low-dose aspirin in sepsis 
and to determine the impact on key surrogate measures of 15-epi-LxA4 and NFκB 
and the subsequent impact on inflammatory pathways 
ii. Establish a murine model for staphylococcal-induced sepsis and perform parallel 
analyses to the human into low-dose aspirin therapy in wild-type C57BL/6 mice, 
to permit extended analysis of organs and other systemic effects. 
iii. Investigate the effects of low-dose aspirin and its metabolite salicylic acid on 
staphylococcal biofilm formation in vitro and in an in vivo model of device-
related biofilm infection. 
	Chapter 2 
General Materials & Methods 
2.  
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2.1. General laboratory procedures 
Unless otherwise stated, all solutions were prepared with reverse osmosis double distilled 
water (MQH2O), obtained from the Millipore Milli-Q® water system (Millipore, USA). 
Chemicals used were analytical or molecular grade and stored at ambient temperature 
unless otherwise stated. Sterilisation of all media and glassware by autoclaving was 
performed at 121ºC (15 lbf/in2) for 20 min. 
2.2. Chemicals and media 
2.2.1. Bacterial media 
Media used in bacterial culture studies were Brain Heart Infusion broth (BHIB; Oxoid, 
UK) and Brain Heart Infusion agar (BHIA; Oxoid). BHIB was prepared by dissolving  
37 g dehydrated media in 1 L MQH2O; BHIA was prepared by dissolving 47 g 
dehydrated media in 1 L MQH2O. BHIB and BHIA were sterilised by autoclaving as 
described above. 
2.2.2. Aspirin and salicylic acid (SA) stock solutions 
Stock solutions of SA (1 mol/L) were prepared by dissolving lyophilised SA  
(Sigma-Aldrich, USA) in 70% (v/v) ethanol (Merck KGaA, Germany). Once dissolved, 
stock solutions were filter sterilised (Filtopur 0.22 µm, Sarstedt, Germany) and stored at 
RT for up to one year. 
Aspirin was prepared as follows: 0.2 mg/mL and 2 mg/mL solutions were prepared by 
dissolving 2 mg and 20 mg lyophilised aspirin (Sigma-Aldrich), respectively in a total of 
10 mL sterilised MQH2O containing 2% (w/v) sodium bicarbonate (NaHCO3; BDH, 
Germany). Once dissolved, stock solutions were filter sterilised as described above and 
stored at 4°C.  
2.2.3. Cell culture media and reagents for histology and flow cytometry  
Cells thawed at 4°C for flow cytometry analysis were resuspended in Dulbecco’s 
Modified Eagle Medium complete (DMEM; high glucose (4.5 g/L), GlutaMAX™  
(4 mmol/L); Life Technologies, USA), supplemented with 10% (v/v) heat-inactivated 
foetal calf serum (FCS; Bovogen Biologicals, Australia).  
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Phosphate Buffered Saline (PBS; Bioline, UK) for histological and flow cytometry wash 
steps was prepared by dissolving one PBS tablet in 1 L MQH2O, and sterilised by 
autoclaving as described. FACS wash buffer (PBS supplemented with 2% (v/v) FCS) was 
used for wash steps in flow cytometry procedures. FACS freeze media (heat-inactivated 
FCS supplemented with 5-10% (v/v) dimethyl sulfoxide (DMSO; Sigma-Aldrich) was 
used to freeze all immune cell aliquots for flow cytometry analysis. 
2.3. Bacteria 
2.3.1.  Bacterial strains 
All bacterial strains used in Chapter 4 and Chapter 5 of this study are listed in Table 2.1.  
Table 2.1: Bacterial strains used in this study. 
 
 
 
Bacteria Characteristics Chapter  
Staphylococcus aureus  
ATCC 25923 Methicillin sensitive 4 
Staphylococcus aureus Rosenbach 
ATCC-BAA 1680 
Methicillin resistant  
(Non-biofilm former) 5 
Staphylococcus aureus Rosenbach 
ATCC-BAA 1698 
Methicillin resistant  
(Biofilm former) 5 
Staphylococcus epidermidis  
ATCC 12228 
Methicillin sensitive 
(Non-biofilm former) 5 
Staphylococcus epidermidis RP62A; 
ATCC 35984 
Methicillin sensitive 
(Biofilm former) 5 
Staphylococcus aureus  
Clinical isolate #5 (UoM) 
Methicillin resistant  
(Non-biofilm former) 5 
Staphylococcus aureus  
Clinical isolate #6 (UoM) 
Methicillin resistant  
(Non-biofilm former) 5 
RMIT University Clinical isolate 
PM#2 
Methicillin sensitive  
from pacemaker (Biofilm former) 5 
RMIT University Clinical isolate 
JO#2 
Unknown staphylococcal isolate  
from wound (Biofilm former) 5 
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2.3.2. Bacterial growth conditions 
2.3.2.1. General culture conditions 
Strains of S. aureus and S. epidermidis frozen in glycerol stocks were plated onto BHIA 
plates and incubated at 37°C under aerobic conditions overnight. For preparation of broth 
cultures, a single bacterial colony was isolated from BHIA plates, resuspended in  
5 mL of BHIB and incubated at 37°C under aerobic conditions, either shaking for 4-6 h in 
a shaking incubator at 180 rpm, or static conditions overnight. To determine the growth 
phase, the absorbance of broth cultures were measured at a wavelength of 595 nm.  
Colony-forming units (CFU)/mL were determined by plating 10-fold serially diluted 
staphylococcal broth cultures on BHIA and incubating overnight at 37°C, under aerobic 
conditions. 
2.3.2.2. Growth in the presence or absence of SA 
Stock solutions of SA (1 mol/L prepared in 70% (v/v) ethanol; described in section 2.2.2) 
were diluted in appropriate volumes of BHIB to achieve a final concentration of  
1-20 mmol/L. Vehicle controls were prepared by diluting 70% (v/v) ethanol in 
appropriate volumes of BHIB to achieve equal concentrations described for SA. For 
biofilm growth experiments, broth cultures grown at 37°C overnight were diluted in 
BHIB/SA or BHIB/vehicle in a suspension of 105 CFU.   
2.4. Animal experiments 
2.4.1.  Mice 
All experiments involving animals were carried out with the approval of the RMIT 
Animal Ethics Committee (AEC Permit Number 1213; Chapter 4, or 1426; Chapter 5). 
Specific pathogen free, 6-8 week-old female C57BL/6 mice used in experiments were 
sourced from the Animal Resource Centre (ARC; Australia). Prior to experimentation, 
mice were acclimatised for a minimum of seven days within the RMIT Animal facility 
(RMIT University, Australia). A maximum of four mice were housed in a single housing 
unit; mice were fed standard rodent chow and had access to sterilised-water ad libitum. 
For the duration of experiments, infected mice were monitored for signs of weight loss, 
fatigue and behavioural abnormalities according to criteria as outlined in Table 2.2 
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(modified from [235]). These criteria were used to determine the progression of 
inflammation following infection in Chapter 4 and Chapter 5 studies.  
Table 2.2: Clinical parameters measured and expected scores for mice with local 
and systemic inflammation, modified from [235]. 
Score Variable Expected score 
 Body Weight Changes  
0 
1 
2 
3 
Normal 
<10% Weight loss 
10-15% Weight loss 
>15% Weight loss 
2 
 Physical Appearance  
0 
1 
2 
3 
Normal 
Lack of Grooming 
Rough Coat, Nasal/Ocular Discharge 
Very Rough Coat, Abnormal Posture, Enlarged Pupils 
1 
 Measurable Clinical Signs  
0 
1 
2 
 
3 
 
Normal 
Small changes of potential significance 
Temp change 1-2oC, cardiac & respiratory rates increased up to 
30% 
Temp change >2oC, cardiac & respiratory rates increased up to 
50%, or markedly reduced 
2 
 Unprovoked Behaviour  
0 
1 
2 
3 
 
Normal 
Minor Changes 
Abnormal/reduced mobility, decreased alertness, inactive 
Unsolicited vocalisations, self-mutilations either very restless or 
immobile 
2 
 Behavioural Responses to External Stimuli  
0 
1 
2 
3 
Normal 
Minor depression/exaggeration of response 
Moderately abnormal responses 
Violent reactions, or comatose 
2 
Total Score 9 
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Experimental designs of staphylococcal-induced sepsis and device-related biofilm 
implant models in mice are described in Chapter 4 and Chapter 5, respectively. Aspirin 
therapy (prepared as described in section 2.2.2) was administered by oral gavage at a dose 
of either 1 mg/kg (equivalent to 100 mg daily dose; Chapter 4 and Chapter 5) or 10 mg/kg 
(equivalent to 1000 mg daily dose; Chapter 4). 
At the end of each experiment, mice were euthanised via CO2 inhalation. Blood (Chapter 
4 and Chapter 5) was collected for bacterial load and flow cytometry analysis of immune 
cell proportions; bacterial exudates (Chapter 5) and organs (spleen, kidney, liver; Chapter 
4) were collected for bacterial load; spleen (Chapter 4) and skin (Chapter 5) were 
harvested for histology and immunohistochemistry. 
2.4.2. Determination of bacterial load in blood and organs 
After mice were euthanised by CO2 inhalation, blood was collected immediately by 
cardiac puncture into syringes pre-loaded with 200 µL sterile Alsever’s solution 
(0.0055% (w/v) citric acid, 0.8% (w/v) sodium citrate, 2.05% (w/v) D-Glucose, 0.42% 
(w/v) sodium chloride dissolved in 100 mL MQH2O). Alsever’s solution is an isotonic 
balanced salt solution, routinely used (where citric acid/sodium citrate act as an anti-
coagulant) allowing the storage of blood at 2-8°C for up to 10 weeks [466]. Once 
collected, an aliquot of blood was diluted 1:2 in BHIB and a volume of 100 µL was 
spread plated onto BHIA plates and incubated at 37°C under aerobic conditions 
overnight.  
Organs (spleen, kidney, liver; Chapter 4) were collected, transferred to a tube containing 
2 mL sterile BHIB, weighed and homogenised with the Bio-Gen™ PRO200 homogeniser 
(PRO Scientific, USA). Homogenates were serially diluted in 10-fold increments in 
BHIB and plated on BHIA plates and incubated as described. Swabs of bacterial exudates 
surrounding contaminated implants (Chapter 5) were collected into 1 mL BHIB, mixed 
by vortexing vigorously for 5 s. Exudates were serially diluted, plated onto BHIA plates 
and incubated as described above. Viable bacterial counts for blood, organs and exudates 
were performed following incubation at 37°C for 24 h, and colony counts for organs were 
expressed as CFU/g of tissue. 
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2.4.3. Determination of bacterial-induced damage in organs 
Tissues harvested following euthanasia of mice were embedded in Tissue-Tek® O.C.T™ 
medium (Sakura Finetek, Japan), snap frozen over liquid nitrogen and stored at  
-80°C. Sections were cut at 10 µm thickness on the Leica CM1950 cryostat (Leica, 
Germany) and mounted onto StarFrost® superclean slides (ProSciTech Pty Ltd, Australia) 
and stored at -80°C. 
2.4.3.1. Haematoxylin and eosin staining 
Frozen 10 µm sections of skin, or spleen were fixed in 4% neutral buffered formalin  
(4% (v/v) formaldehyde solution containing 4 g/L NaH2PO4 and 6.5 g/L Na2HPO4; 
Thermo Fisher Scientific, USA). Sections were washed in PBS once, before being stained 
with haematoxylin and eosin. Histological sections were observed under light microscopy 
to determine the extent of damage and inflammation to tissues. Images were captured 
using a Leica DM2500 microscope and Leica Application Suite software (Version 4.3.0; 
Leica), and scoring was performed according to parameters described in each of Chapter 
4 and Chapter 5, respectively.  
2.4.3.2. Immunohistochemical detection of S. aureus and CD11b in organs 
Frozen 10 µm sections of spleen (Chapter 4) or skin (Chapter 5) were fixed in ice-cold 
acetone (Merck KGaA). Sections were air dried and rehydrated in PBS for 10 min, then 
permeabilised with PBS containing 0.2% Triton X-100 (Sigma-Aldrich). Fc Receptor 
blocking was performed by incubation with PBS/1% bovine serum albumin (BSA; 
Sigma-Aldrich) and serum from the host species of the secondary antibody (10% (v/v) 
normal goat serum (NGS) and purified anti-mouse CD16/32 antibody (1:100; BioLegend, 
USA) for 1 h at RT. Slides were inverted to remove excess blocking solution and primary 
antibodies; rabbit anti-S. aureus (1:200; Abcam, UK), and rat anti-mouse CD11b (1:100; 
BioLegend) diluted in PBS/1% BSA, were added and sections were incubated overnight 
at 4°C. Sections were washed three times for 10 min in PBS containing 0.05% Tween-20 
(PBST) and an anti-rabbit Cy3® (Abcam) and anti-rat Alexa Fluor® 488 (Life 
Technologies) conjugated secondary antibodies were added at 1:1000 and 1:800, 
respectively in PBS/1% BSA. Slides were incubated for 1 h at RT. Sections were washed 
three times for 10 min in PBST then slides were incubated with DAPI nuclear stain  
(2 µg/mL; Sigma-Aldrich) in PBS/1% BSA for 20 min at RT (in the dark). Slides were 
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washed frequently in PBST over 30 min, mounted in Mowiol (10% (w/v) Mowiol 4-88 
(Calbiochem, USA), 25% (v/v) Glycerol (Chem-Supply, Australia), 0.1 mol/L Tris, 2.5% 
(w/v) (Merck KGaA), 1,4-diazobicyclo-[2.2.2]-octane (DABCO; Sigma-Aldrich), pH 
6.8). Images were captured using a Leica DM2500 microscope and Leica Application 
Suite software (Version 4.3.0; Leica). Images were overlayed for display using the Adobe 
Photoshop program (Version CC2015.16.0; Adobe, USA). 
2.5. Immunological analysis 
2.5.1.  Blood processing  
Human blood samples were centrifuged in the Heraeus Multifuge 1S-R centrifuge 
(Thermo Fisher Scientific); mouse blood samples were centrifuged in the Heraeus Fresco 
17 refrigerated micro-centrifuge (Thermo Fisher Scientific). All centrifugation steps were 
performed at 500 × g for 5 min at 4°C. Plasma fractions were dispensed into either 
cryovials (Sarstedt) or 1.7 mL micro-centrifuge tubes (Interpath Services, Australia) and 
stored at -80°C. Following this, erythrocytes were lysed in tris-ammonium chloride 
(TAC) red cell lysis buffer (155 mmol/L ammonium chloride (Sigma-Aldrich), 0.1 
mmol/L EDTA (Calbiochem) and 10 mmol/L potassium bicarbonate (BDH), pH 7.2) at 
37°C for 5 min. Cells were centrifuged, and lysed erythrocytes were discarded. Cells were 
washed in FACS wash buffer (section 2.2.3) twice. Cells (including peripheral blood 
mononuclear cells; PBMC) resuspended in FACS wash buffer were dispensed in 500 µL 
into microcentrifuge tubes (Interpath Services) and centrifuged at maximum speed  
(16,000 × g) for 5 min at 4°C. Excess FACS wash was removed and PBMC pellets were 
stored at -80°C. Remaining cells were centrifuged, excess FACS wash buffer was 
discarded and aliquots (500 µL) were made in FACS freeze media (section 2.2.3) and 
slow frozen in the Nalgene® Mr Frosty freezing container (Sigma-Aldrich) at -80°C. 
2.5.2. Spleen processing 
Spleens (Chapter 4 and Chapter 5) were collected from mice into ice-cold DMEM 
complete media (section 2.2.3). Cells were placed in petri dishes and were gently teased 
through a 40 µm cell strainer (Biologix, China). Cells were centrifuged at 500 × g for  
5 min at 4°C, resuspended in TAC lysis buffer (section 2.5.1) and incubated at 37°C for  
5 min to lyse contaminating erythrocytes. Cells were washed in FACS wash buffer 
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(section 2.2.3), centrifuged and resuspended in 500 µL FACS freeze media (section 
2.2.3), and slow frozen in the Nalgene® Mr Frosty freezing container at -80°C. 
2.5.3. Flow cytometry 
For flow cytometry, 106 cells from blood (all studies) or spleen (Chapter 4 and  
Chapter 5) were thawed at 4°C and resuspended in DMEM complete media (section 
2.2.3), centrifuged and resuspended in FACS wash buffer (section 2.2.3). Cells were 
incubated with blocking solution as follows: human studies (Chapter 3); cells were 
incubated with Human TruStain FcX™ (BioLegend), according to manufacturer’s 
specifications (1:20 diluted in FACS wash buffer containing 5% NGS), mouse studies 
(Chapter 4 and Chapter 5); Fc receptor block (Purified anti-mouse CD16/32 Antibody; 
BioLegend), at 4 µg/mL in 50 µL FACS wash buffer for at least 30 min on ice. 
Antibodies for staining of human blood are listed in Table 3.2 (Chapter 3). Antibodies for 
staining of mouse blood and spleen are listed below in Table 2.3. All staining was 
performed in 100 µL FACS wash buffer for at least 30 min on ice. Cells were washed 
twice in FACS wash buffer and if required, incubated with a fluorescently conjugated 
secondary antibody diluted in FACS wash buffer. Cells were washed twice in FACS wash 
buffer, before being resuspended in PBS for data acquisition. 
Table 2.3: Antibodies used in mouse flow cytometry analysis. 
Antibody Clone (host) Conjugate Dilution Source 
α-CD3ε 145-2C11 (rat) Brilliant Violet 421 1:800 BioLegend 
α-CD3ε 145-2C11 (rat) APC/Cy7 1:800 BioLegend 
α-CD4 RM4-5 (rat) eFluor 450 1:1600 eBioscience 
α-CD8a 53-6.7 (rat) PE/Cy7 1:800 BioLegend 
α-CD11b  M1/70 (rat) APC/Cy7 1:800 BioLegend 
α-CD62L MEL-14 (rat) PE/Cy7 1:800 BioLegend 
α-CD162 2PH1  (rat) PE 1:800 BD Biosciences 
α-Ly6G 1A8 (rat) PerCP/Cy5.5 1:800 BioLegend 
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Compensation was performed using UltraComp eBeads (eBioscience, USA) based on the 
single staining of each individual fluorochrome and corrected for auto-fluorescence with 
unstained beads and cells.  
Data was collected using the FACSCanto II flow cytometer (Beckton Dickinson, USA). 
A five-decade logarithmic scale was used to process fluorescence signals and a linear 
scale was used to process light scattering signals. Data analysis was performed using 
FlowJo software (Version 9.7.1: FlowJo, LCC, USA). Single cells were gated and then 
populations of cells were defined as being T lymphocytes (CD3+, CD4+, CD8+), 
monocytes/macrophages (Cd11b+) and neutrophils (Ly6G+ (mice)/CD66b+(human)) as 
well as other cell surface markers. 
2.5.4. Detection of 15-epi-LxA4 in plasma 
2.5.4.1.  Enrichment of plasma proteins and lipids 
Plasma was enriched for proteins and lipid mediators including 15-epi-LxA4, using the 
Bond Elute C18 OH solid phase extraction column (Agilent technologies, USA) prior to 
quantification using an immunoassay. Frozen aliquots of plasma were thawed and 
acidified to pH 3.5 with 1 mol/L hydrochloric acid (HCl; Merck KGaA). Columns were 
pre-conditioned with 2 mL methanol (Merck KGaA) followed by 2 mL of MQH2O. 
Samples were diluted in sterile MQH2O and added to the column (specific dilutions for 
human and mouse plasma are described in section 3.2.2.3.1 and 4.2.4.1). The flow-
through was collected from columns after centrifugation at 500 × g for 5 min at 4°C. The 
eluate was discarded, and columns were washed in 1 mL MQH2O, followed by 1 mL 
petroleum ether (Sigma-Aldrich). Finally, purified plasma proteins and lipid mediators 
were eluted with 2 mL methyl formate (Sigma-Aldrich), and the solvent was evaporated 
under a stream of nitrogen gas. Dried pellets were resolubilised in an appropriate volume 
of 1× 15-epi-LxA4 extraction buffer, supplied in the 15-epi-LxA4 Enzyme Immunoassay 
(EIA) kit (Oxford Biomedical Research Inc, USA), prior to quantification. 
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2.5.4.2.  Quantifying 15-epi-LxA4 in plasma via enzyme linked immunosorbent assay 
(ELISA) 
Purified proteins and lipid mediators enriched from plasma were further diluted (1:10, 
human analysis or 1:5, mouse analysis) in 1× 15-epi-LxA4-Extraction Buffer (prepared in 
MQH2O) supplied in the 15-epi-LxA4 EIA kit (Oxford Biomedical Research). 
Quantification of plasma 15-epi-LxA4 was performed as follows: standards used for 
quantification were prepared in EIA Buffer with final concentrations ranging from  
0 to 2 ng/mL. Prepared standards (50 µL) or pre-diluted plasma (50 µL) were added in 
duplicate to wells of a 96-well Costar® microplate (supplied in the 15-epi-LxA4 EIA kit), 
pre-coated with anti-15-epi-LxA4 rabbit antibody. Next, 50 µL of diluted 15-epi-LxA4-
horseradish peroxidase (HRP) conjugated antibody (1:50 dilution in EIA buffer) was 
added to each well, plates were mixed by shaking gently on a plate shaker for 10 s, 
covered and incubated at RT for 1 h, under static conditions. Following incubation, plates 
were washed three times with 300 µL 1× 15-epi-LxA4-Wash Buffer (prepared in 
MQH2O) and 150 µL 3,3', 5,5' tetramethylbenzidine (TMB) with hydrogen peroxide 
(H2O2) substrate solution was added to each well, plates were mixed on a plate shaker and 
incubated at RT for 30 min. Absorbance was measured at a wavelength of 650 nm using 
the POLARstar Optima multi-detection microplate reader (BMGlabtech, Germany). 
Concentrations of 15-epi-LxA4 were determined using standard curves generated from  
0 to 2 ng/mL, and adjusted for dilution factor and starting volume of plasma.  
2.5.5. Detection of NFκB p65 activation  
2.5.5.1.  Preparation of nuclear and cytoplasmic extracts 
Nuclear and cytoplasmic extracts were prepared from PBMC pellets with the use of the 
NE-PER nuclear and cytoplasmic extraction kit (Pierce, USA), according to the 
manufacturer’s specifications. PBMCs were thawed and washed once in FACS wash 
buffer. Cell pellets were centrifuged at the maximum speed (16,000 × g) for 5 min at  
4°C and excess FACS wash buffer was removed. Cells were washed once in PBS and 
were centrifuged at 500 × g for 5 min at 4°C. Cells were resuspended in ice-cold CER I 
buffer; supplemented with 1× cOmplete ULTRA protease inhibitor cocktail (Roche AG, 
Switzerland), vortexed vigorously for 15 s and incubated on ice for 10 min. Ice-cold  
CER II buffer was added and cells were vortexed vigorously for 5 s and incubated on ice 
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for 1 min. Cells were again vortexed vigorously for 5 s and centrifuged, then supernatants 
(cytoplasmic extracts) were then transferred to a clean pre-chilled microcentrifuge tube 
and stored at -80°C. Remaining pellets (containing nuclei) were resuspended in ice-cold 
NER buffer (supplemented with 1× cOmplete ULTRA protease inhibitor cocktail; Roche 
AG), vortexed vigorously for 15 s and incubated on ice for 10 min. This process was 
repeated every 10 min for a total of 40 min. Cells were centrifuged and supernatants 
(nuclear extracts) were transferred to a clean pre-chilled microcentrifuge tube and stored 
at -80°C. 
2.5.5.2.  Chemiluminescent detection of NFκB p65 activation  
The activation of the NFkB p65 in nuclear extracts (section 2.5.5.1) was detected using 
the NFkB p65 Transcription factor assay (Pierce) according to the manufacturer’s 
specifications. Working Binding Buffer (1×) was prepared in MQH2O containing  
50 µg/mL Poly dI•dC, and 50 µL was added to each well of the 96-well NFκB Assay 
Plate provided. Nuclear extracts were added (10 µL) in duplicate to wells and plate sealer 
was used to cover the plate. Plates were incubated gently shaking on a plate shaker at RT 
for 1 h. Plates were washed three times with 200 µL, 1× NFκB Assay Wash Buffer 
(prepared in MQH2O) and 100 µL NFκB p65 primary antibody (1:1000; prepared in 
supplied Antibody Dilution Buffer) was added to each well. Plates were then incubated at 
RT for 1 h, under static conditions. Following incubation, plates were washed three times 
with 200 µL, 1× Wash Buffer and 100 µL HRP-conjugated secondary antibody (1:10,000 
in Antibody Dilution Buffer) was added. Plates were then incubated at RT for 1 h, under 
static conditions. Following incubation, plates were washed four times with 200 µL,  
1× Wash Buffer and 100 µL substrate working solution (prepared by combining equal 
volumes of supplied Luminol/Enhancer and Stable Peroxide solutions) was added to each 
well. Chemiluminescence expressed as relative fluorescence units (RFU) was detected 
using the luminometer function on the POLARstar Optima multi-detection microplate 
reader (BMGlabtech). 
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2.5.6.  Determination of inflammatory cytokine profile by 
LEGENDplex™ multi-analyte flow assay kit 
Measurements of pro-inflammatory cytokines in plasma samples were taken using the 
LEGENDplex™ Human Inflammation panel (13-plex) (Chapter 3) and Mouse 
Inflammation panel (13-plex) (Chapter 4) flow assays (BioLegend). All procedures were 
performed according to manufacturer’s specifications. Cytokine standards and samples 
were prepared in LEGENDplex™ Assay Buffer and were added to a 96-well  
U-bottom plate (Nunc A/S, Denmark). Sonicated pre-mixed beads and detection 
antibodies were added to each well and then plates were incubated (in the dark) on a plate 
shaker at 600 rpm for 2 h at RT. Following incubation, streptavidin–phycoerythrin (PE) 
solution was added to each well and incubated for 30 min at RT. Samples were analysed 
and data collected on the FACSCanto II (Beckton Dickinson). Data were analysed using 
the LEGENDplexTM Data Analysis Software (BioLegend) with standard curves generated 
from 0 to 50,000 pg/mL, and samples adjusted for dilution factor. 
2.6. Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 6.0 for Macintosh 
(GraphPad Software Inc, USA). The D’Agostino and Pearson omnibus test was applied to 
data to determine normality.  
Where the test result revealed that data were not normally distributed or the value of n 
was too small to be able to determine normality, non-parametric statistical analyses were 
applied. A two-tailed Mann-Whitney Test was used to analyse the differences observed 
between two means at a single time point, where p<0.05 was considered significant. A 
Kruskal-Wallis test was used to analyse the differences observed between multiple 
groups, where p<0.05 was considered significant. 
Where the test result revealed data were normally distributed, parametric statistical 
analyses were applied. A one-way analysis of variance (ANOVA) test was used to 
analyse the differences observed between multiple groups, where p<0.05 was considered 
significant. 
 
	 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Chapter 3 
Investigating the effects of low-dose aspirin as a potential 
adjunct therapy for patients with sepsis  
3.  
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3.1. Introduction 
Sepsis is a worldwide healthcare concern. Despite continued advances in both medical 
and supportive intervention, sepsis remains the leading cause of infection-related death, 
with associated mortality rates of 20-40% [29, 30]. A major reason for the continued high 
morbidity and mortality rates of sepsis are due to delayed identification, as early 
symptoms of this syndrome are indistinguishable from other inflammatory conditions. 
Meta-analyses of sepsis epidemiology have revealed that men develop sepsis more 
frequently than women [1, 4, 29, 30], and incidences of sepsis are often higher in 
minority groups [31-33]. Further, elderly patients and individuals with pre-existing 
comorbidities such as cardiovascular disease, diabetes, renal disease and cancer have 
increased probability of developing sepsis, presumably as they are more susceptible to 
infection in general [26, 29]. The individual response to sepsis is dependent upon the 
causative organism, as well as numerous host factors. It is noteworthy that since 1987, 
there has been an overwhelming increase in the percentage of gram-positive, and to a 
lesser extent fungi-associated sepsis [4, 29]. 
Sepsis develops when the body’s response to infection is not adequately controlled. This 
dysregulated response triggers a cascade of inflammatory responses; mediated by the 
innate immune system [36]. Recognition of pathogens by macrophages results in the 
activation of the inflammatory regulator nuclear factor kappa beta (NFκB). This leads to 
increased production of pro-inflammatory cytokines, as well as cyclooxygenase (COX) 
induced production of pro-inflammatory lipid mediators [436, 467]. Inflammatory 
signalling also delays the apoptosis of neutrophils, permitting migration to tissues, 
mediated by cell surface markers such as P-selectin glycoprotein ligand-1 (PSGL-1). This 
in turn contributes to exacerbated inflammation in tissues, potentially leading to organ 
failure and death [24]. Aside from the hyper-inflammatory response in sepsis, some 
patients enter a state of immunosuppression; triggered by the induced apoptosis of key 
adaptive immune response cells (B and T lymphocytes) [107].  
The implementation of treatment “bundles” as directed by the guidelines from the 
Surviving Sepsis Campaign (SSC) have continued to be the standard of care in sepsis [2, 
149]. Upon identification of sepsis, patients are provided multimodal therapy of 
supportive fluid resuscitation (intravenous fluids and vasopressors, with oxygen therapy 
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and mechanical ventilation) and empiric antibiotics [468]. Early goal directed therapy 
(EGDT) protocols were introduced in 2001, and therapeutic benefits were initially seen in 
sepsis [149], however recent debate has arisen over whether the improvements in 
mortality rate were specifically due to EGDT [11]. Further, none of the current therapies 
offered to patients target the inflammatory responses that contribute to sepsis severity. 
Although numerous animal studies and randomised control trials have been initiated into 
potential adjunct therapeutics (reviewed in [148]), none have shown to be successful in 
reducing sepsis mortality rates.  
Evidence is accumulating that low-dose aspirin could be beneficial as an adjunct therapy 
for sepsis. A number of animal studies have shown that aspirin therapy in sepsis-related 
inflammatory conditions was associated with improved outcomes [16-18]. Further, two 
independent observational studies of patients in ICU with systemic inflammatory 
response syndrome (SIRS) and/or sepsis showed that patients already taking aspirin had 
reduced likelihood of mortality [61, 64, 220]. Taken together these data support the idea 
that low-dose aspirin therapy might be beneficial in patients with severe sepsis.  
Aspirin is a cost-effective alternative to other pharmacological adjunct therapies, and at 
low doses has been shown to mediate resolution of inflammation, and to be associated 
with improved outcomes [469]. Unlike other non-steroidal anti-inflammatory drugs 
(NSAIDs), aspirin acetylates COX-2, triggering the production of specialized pro-
resolving lipid mediators (SPM) such as 15-epi-LxA4; a synthetic analogue of the 
naturally occurring lipoxin A4 (LxA4). Both LxA4 and 15-epi-LxA4 have pro-resolution 
effects in local and systemic inflammation [20, 470]. Previous studies in healthy human 
volunteers have shown the use of low-dose aspirin (75 mg daily dose, for 10 days) 
resulted in a reduced local inflammatory response, presumably via increased production 
of 15-epi-LxA4 [19]. It has also been shown in vitro that aspirin in a dose equivalent to 
1000 mg aspirin inhibits NFκB activation. The lower dose range required to inhibit NFκB 
activation has not yet been determined [18, 433, 471]. 
At present, three randomized clinical studies have been initiated to investigate the 
immunological impact of low-dose aspirin therapy in clinical sepsis (as described in 
section 1.4.2), including the Mechanism of Aspirin THerapy in Sepsis (MATHS) clinical 
trial. The results in this chapter are derived from preliminary analysis of the MATHS 
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trial, a randomised single centre trial initiated at the Victorian Infectious Disease Service 
(VIDS), Melbourne, investigating the effects of low-dose aspirin therapy at 100 mg and 
300 mg doses in patients with sepsis. 
Based on evidence from the literature and the reported mechanisms of aspirin therapy in 
inflammatory conditions described above, the following hypothesis was developed: 
That low doses of aspirin will induce immuno-modulatory effects including production of 
15-epi-LxA4 and inhibition NFκB activation in patients with sepsis, consistent with a  
pro-resolving mechanism of action. 
The MATHS clinical trial was designed to investigate the above hypothesis. This chapter 
describes the planned interim analysis of the first 29 patients. 
In order to address the hypothesis, the specific aims of analyses in this chapter were: 
• To collect and analyse blood from patients in a clinical trial to determine the 
effects of high (300 mg) and low (100 mg) doses of aspirin on the immune 
response in patients with sepsis 
More specifically to:  
o Quantitate levels of 15-epi-LxA4 produced in plasma following aspirin therapy 
o Determine whether aspirin therapy inhibits the activation of NFκB in 
peripheral blood mononuclear cells (PBMC) 
o Determine the impact on cytokine levels in plasma as a measure of 
inflammatory activation 
o Characterise changes in circulating immune cell populations to determine any 
effect of aspirin-therapy 
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3.2. Materials & Methods 
3.2.1.  MATHS clinical trial: patient recruitment and exclusion criteria 
Patients in the Intensive Care Unit (ICU) and VIDS (Royal Melbourne Hospital, 
Melbourne Health, Australia) presenting with signs and symptoms of the SIRS and/or 
sepsis were asked for their voluntary participation In the event of the patients being 
unable to respond, relatives gave informed consent. This study was performed in 
accordance with Human Research Ethics (application number ACTRN12611000649910. 
Protocol v1). Successful enrolment was based on the following inclusion and exclusion 
criteria: 
Inclusion criteria: Critically ill adult patients over 18 years of age with sepsis (infected 
site plus SIRS) according to the criteria defined by Bone et al. (Table 1.1) [22]. 
Exclusion criteria: Patients with a contraindication to aspirin due to hypersensitivity to 
aspirin or NSAID drugs, platelet count <100,000×109/l, coagulopathy with international 
normalised ratio (INR) >2 or active bleeding (e.g., trauma, gastrointestinal or intracranial 
bleeding) were excluded. Patients with pre-existing renal injury as per RIFLE guidelines 
[472] were also excluded. Patients had study medications ceased if there was evidence of 
hypersensitivity to aspirin (new onset of severe bronchospasm or urticarial rash), renal 
injury (serum creatinine doubling /GFR reducing by > 50%) or new onset of bleeding.  
3.2.2. Protocol design for the MATHS clinical trial  
All patients continued to receive optimal, multimodal therapy for their illness. The 
MATHS trial is an open label, randomised controlled trial. Upon enrolment into the 
MATHS trial, patients were randomised to either 100 mg, 300 mg daily aspirin doses or 
placebo (see Table 3.1). Patients regularly taking aspirin continued their regular dose of 
aspirin for the duration of sampling. These doses were selected as they have been shown 
to induce production of 15-epi-LxA4, and a 300 mg dose was proposed to inhibit NFκB. 
Further, these doses are associated with an acceptably low risk of bleeding, based on a 
previous retrospective study that showed odds ratio (OR) of mortality of patients with 
high risk of bleeding was not affected in patients with low APACHE II scores (OR=1) 
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and significantly reduced in patients with APACHE II scores ≥15 (OR<0.5) at admission 
who were regularly taking low-dose aspirin for prevention of cardiovascular events [63].  
Two doses of aspirin were administered orally, or by nasogastric tube in ICU at time 0 
(T0) and Day 1 (T24). Arterial blood sampling was performed immediately prior to first 
dose of aspirin/placebo (T0), and after 1 h (T1), 8 h (T8), 24 h (T24) and 48 h (T48). The 
above time-point intervals were determined on the basis of expected response times for  
15-epi-LxA4 production and NFκB activation (within the first 8 h following aspirin) and 
analysis of immune cell populations over a range of time including before and after 
aspirin administration.  
Patient demographics, background medical history (including history of cardiovascular 
disease, diabetes, renal disease, and/or cancer) were recorded, as well as Acute 
Physiology and Chronic Health Evaluation (APACHE) II score at enrolment (T0) and 
daily Sequential Organ Failure Assessment (SOFA) score (during sampling time). Once 
determined, site and source of sepsis were also recorded. Routine haematology values, 
including mean platelet volume (MPV) data were also recorded once daily, using the 
Coulter® LH 700 haematology analyser (Beckman Coulter, USA) for the duration of 
sampling.  
Table 3.1: Design of the Mechanisms of Aspirin Therapy in Sepsis (MATHS) clinical 
trial. Patients presenting with signs of SIRS/sepsis were asked for their voluntary 
participation. Once enrolled, patients were randomised to one of four trial groups, and a 
total of 180 participants are required to be enrolled for the completion of the trial. 
 
Group Aspirin Dose Exclusions Number of subjects (planned) 
I 100 mg T0/100 mg T24 No aspirin/NSAID in the last 7 days 
45 
II 300 mg T0/300 mg T24 No aspirin/NSAID in the last 7 days 
45 
III Previous dose T0/T24 - 45 
IV Untreated Controls No aspirin/NSAID in the last 7 days 
45 
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This study was powered to detect differences in baseline versus Day 2 15-epi-LxA4 
concentrations in placebo, versus aspirin-treated groups. Baseline 15-epi-LxA4 
concentrations and population standard deviations used to determine sample size were 
derived from published data from a randomised clinical trial of low-dose aspirin in 
healthy human subjects [20]. Baseline 15-epi-LxA4 was measured at 2.45 ng/mL (± 0.96), 
with no significant change over time in healthy subjects not taking aspirin [20]. From this 
it was assumed (regardless of changes occurring during the course of sepsis), that the 
combined aspirin groups would have 15-epi-LxA4 concentrations at least 0.6 ng/mL 
higher than untreated control group. With this in mind, it was calculated that a sample 
size of 45 participants per group (180 participants in total) was required to have 80% 
power to reject the null hypothesis (that change in 15-epi-LxA4 concentration of aspirin 
patients = change in 15-epi-LxA4 concentration of untreated controls, p<0.05), with a 
value of Sigma ± 0.96. This study was not powered to determine changes in clinical 
outcome. Clinical outcomes of patients will not be made available until the end of the 
trial. 
3.2.3. Collection and processing of patient blood 
3.2.3.1.  Collection of blood 
Blood specimens were collected into pre-treated ethylenediaminetetraacetic acid (EDTA) 
vacutainers (Beckton Dickinson) at time-points described in section 3.2.2, and stored at 
4°C. Blood was processed within 4 h of the specimen being taken. 
3.2.3.2.  Processing 
Human blood samples were centrifuged in the Heraeus Multifuge 1S-R centrifuge 
(Thermo Fisher Scientific) as described (section 2.5.1). Plasma fractions were dispensed 
into either cryovials (Sarstedt) or 1.7 mL micro-centrifuge tubes (Interpath Services) and 
stored at -80°C. Erythrocytes were lysed in TAC red cell lysis buffer (section 2.5.1) at 
37°C for 5 min. Following centrifugation lysed erythrocytes were discarded. Cells were 
washed in FACS wash buffer (section 2.2.3) twice, then cells were resuspended in FACS 
wash buffer and 500 µL was dispensed into microcentrifuge tubes (Interpath Services), 
and centrifuged at maximum speed (16,000 × g) for 5 min at 4°C. Excess FACS wash 
was removed and pellets were stored at -80°C. Remaining cells were centrifuged, excess 
FACS wash buffer was discarded and aliquots (500 µL) were made in FACS freeze media 
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(section 2.2.3) and slow frozen in the Nalgene® Mr Frosty freezing container (Sigma-
Aldrich) at -80°C, prior to batch flow cytometry analysis. 
3.2.4.  Detection of 15-epi-LxA4 in plasma of sepsis patients 
3.2.4.1.  Enrichment of plasma proteins and lipids 
Plasma was enriched for proteins and lipid mediators including 15-epi-LxA4, using the 
Bond Elute C18 OH solid phase extraction column (Agilent technologies) prior to 
quantification using an immunoassay (described in section 2.5.4.1). Columns were  
pre-conditioned by washing with methanol and MQH2O. Plasma samples were acidified 
to pH 3.5 with 1 mol/L HCl, then diluted 1:5 in MQH2O and added to columns. Columns 
were centrifuged, and the eluate was discarded. Columns were washed with MQH2O and 
petroleum ether, and plasma proteins and lipids were eluted with methyl formate. 
Solvents were evaporated under a stream of nitrogen gas, and dried pellets were 
resolubilised in 1 mL in 1× 15-epi-LxA4-Extraction Buffer (supplied in the 15-epi-LxA4 
Enzyme Immunoassay (EIA) kit; Oxford Biomedical Research, Inc), prior to 
quantification. 
3.2.4.2. Quantifying 15-epi-LxA4 in plasma via enzyme linked immunosorbent assay 
(ELISA) 
Quantification of plasma 15-epi-LxA4 was performed using the 15-epi-LxA4 EIA kit 
(Oxford Biomedical Research, Inc) according to the manufacturer’s specifications. 
Purified proteins and lipid mediators enriched from plasma were further diluted 1:10 in  
1× 15-epi-LxA4-Extraction Buffer, and 50 µL was added in duplicate to wells of a  
96-well Costar® microplate (supplied in the kit), pre-coated with anti-15-epi-LxA4 rabbit 
antibody. Next, 50 µL of diluted 15-epi-LxA4-HRP conjugated antibody was added to 
each well, plates were mixed by shaking gently on a plate shaker, covered and incubated 
at RT for 1 h. Following incubation, plates were washed three times with 300 µL,  
1× Wash Buffer and TMB substrate solution was added to each well, plates were mixed 
on a plate shaker (as described above) and incubated at RT for 30 min. Absorbance was 
measured at 650 nm using the POLARstar Optima multi-detection microplate reader 
(BMGlabtech). Concentrations of 15-epi-LxA4 were determined using standard curves 
generated from 0 to 2 ng/mL, and adjusted for dilution factor and starting plasma volume.  
Chapter 3	
	
	
	 Page 90 
3.2.5. Detection of NFκB p65 activation  
3.2.5.1.  Preparation of nuclear and cytoplasmic extracts 
PBMC pellets were thawed, washed once in FACS wash buffer (section 2.2.3) and once 
in PBS. Nuclear and cytoplasmic extracts were prepared with the use of the NE-PER 
nuclear and cytoplasmic extraction reagents (Pierce) according to the manufacturers 
specifications. Cells were resuspended in ice-cold CER I buffer (supplemented with  
1× cOmplete ULTRA protease inhibitor cocktail; Roche AG) and ice-cold CER II buffer, 
vortexed vigorously and incubated on ice. Cells were vortexed vigorously for 5 s and 
centrifuged as described and supernatants (cytoplasmic extracts) were transferred to a 
pre-chilled microcentrifuge tube and stored at -80°C. Remaining pellets (containing 
nuclei) were resuspended in ice-cold NER buffer (supplemented with 1× cOmplete 
ULTRA protease inhibitor cocktail; Roche AG), vortexed vigorously for and incubated 
on ice. This process was repeated every 10 min for a total of 40 min. Cells were 
centrifuged and supernatants (nuclear extracts) were transferred to a pre-chilled 
microcentrifuge tube and stored at -80°C. 
3.2.5.2. Chemiluminescent detection of NFκB p65 activation  
The activation of NFkB p65 in nuclear extracts (prepared as described) was detected 
using the NFkB p65 Transcription factor assay (Pierce) according to the manufacturers 
specifications. Working Binding Buffer was added to each well of the 96-well NFκB 
Assay Plate provided, prior to addition of nuclear extracts (added in duplicate). Plates 
were incubated at RT for 1 h (on a plate shaker), then washed three times with 1× NFκB 
Assay Wash Buffer. Plates were incubated with NFκB p65 primary antibody (1:1000; 
prepared in supplied Antibody Dilution Buffer) at RT for 1 h, under static conditions. 
Plates were washed three times as described then incubated with HRP-conjugated 
secondary antibody (1:10,000; prepared in Antibody Dilution Buffer) at RT for 1 h, under 
static conditions. Plates were washed four times as described then substrate working 
solution (prepared as described in section 2.5.5.2) was added. Chemiluminescence 
expressed as relative fluorescence units (RFU) was detected using the luminometer 
function on the POLARstar Optima multi-detection microplate reader (BMGlabtech). 
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3.2.6.  Determination of inflammatory cytokine profile by 
LEGENDplex™ multi-analyte flow assay kit 
Measurements of pro-inflammatory cytokines in plasma samples were made using the 
LEGENDplex™ Human Inflammation panel (13-plex) flow assay (BioLegend). All 
procedures were performed according to manufacturers instructions. Cytokine standards 
and samples were prepared in LEGENDplex™ Assay Buffer and were added to a 96-well 
U-bottom plate (Nunc A/S). Sonicated pre-mixed beads and detection antibodies were 
added to each well and then plates were incubated (in the dark) on a plate shaker at 2 h at 
RT. Following incubation, streptavidin–PE solution was added to each well and further 
incubated for 30 min at RT. Samples were analysed and data collected using the 
FACSCanto II (Beckton Dickinson). Data were analysed using the BioLegend 
LEGENDplexTM Data Analysis Software with standard curves generated from 0 to  
50,000 pg/mL, and adjusted for sample dilution factor. 
3.2.7. Analysis of cell populations 
3.2.7.1.  Preparation of single cells from blood 
Leukocytes from patients were thawed at 4°C, then 500 µL DMEM complete media 
(prepared as described in section 2.2.3) containing 0.5 mmol/L EDTA was added drop 
wise. Specimens were then centrifuged as previously described and excess media was 
removed. The specimens were then washed twice with FACS wash buffer (section 2.2.3).  
3.2.7.2.  Flow cytometry  
Approximately 106 cells were stained in one of the two cocktails that follow, to 
characterize leukocyte and T lymphocyte populations: 
All Analyses: Cells were incubated with Human TruStain FcX™ (BioLegend), according 
to manufacturer’s specifications (1:20) diluted in FACS wash buffer containing 5% 
Normal Goat Serum (NGS) for 30 min on ice. The antibodies used for staining are listed 
in Table 3.1. All antibodies used in this study were sourced from BioLegend. Staining 
was performed in 100 µL FACS wash buffer for 60 min on ice.  
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Cocktail 1: Following staining, cells were washed twice in FACS wash buffer and 
incubated with a fluorescently conjugated secondary antibody diluted in FACS wash 
buffer at 4°C overnight. The following day cells were washed twice in FACS wash buffer 
before being re-suspended in PBS for flow cytometry. 
Cocktail 2: Following staining, cells were washed twice in FACS wash buffer and stored 
in FACS wash buffer at 4°C overnight. The following day cells were washed twice in 
FACS wash buffer before being re-suspended in PBS for flow cytometry. 
Batch 2: The following day cells were washed in 1X Annexin Binding buffer and then 
stained with the Pacific Blue™ Annexin V Apoptosis Detection Kit with 7-AAD 
(BioLegend) at RT for 15 min according to manufacturers specifications. Cells were 
washed once in Annexin binding buffer before being re-suspended in PBS for data 
acquisition. 
Compensation was performed using UltraComp eBeads (eBioscience) based on the single 
staining of each individual fluorochrome and correction for auto-fluorescence with 
unstained beads and cells. Additional control cells labelled with secondary antibody only 
were also tested. 
Data was collected using the FACSCanto II flow cytometer (Beckton Dickinson). A five-
decade logarithmic scale was used to process fluorescence signals and a linear scale was 
used to process light scattering signals. Data analysis was performed using FlowJo 
software (Version 9.7.1). Single cells were gated and then populations of cells were 
defined as being T lymphocytes (CD3+, CD4+, CD8+), monocytes/macrophages (CD11b+) 
and neutrophils (CD66b+) as well as other cell surface markers. 
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Table 3.2: Antibodies used in human flow cytometry analysis. Markers were selected 
based on evidence of an important role in sepsis, or in regulation/resolution of 
inflammation. 
a) Primary Antibodies 
	
b) Secondary Antibodies 
 
	  
Marker Clone Conjugate Dilution Cocktail 
CD3 HIT3a (mouse) APC Cy7 1:20 1, 2 
CD11b ICR44 (mouse) PE Cy7 1:20 1 
CD66b G10F5 (mouse) PerCP Cy5.5 1:20 1 
CD86 IT2.2 (mouse) Alexa Fluor 647 1:20 1 
CD162 KPL-1 (mouse) - 1:100 1 
CD4/CD25 RPA-T4/BC96 (mouse) PE Cy5/PE 1:20 2 (Batch 1) 
CD4 OKT4 (mouse) Alexa Fluor 488 1:20 2 (Batch 2) 
CD45 HI30 (mouse) Brilliant Violet 510 1:20 2 (Batch 2) 
CD8 SK1 (mouse) PE Cy7 1:20 2  
Annexin V - Pacific Blue 1:20 2 (Batch 2) 
7-AAD - - 1:20 2 (Batch 2) 
Specificity Host Conjugate Dilution 
Goat Mouse Brilliant Violet 421 1:1000 
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3.2.8. Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 6.0 for Macintosh 
(GraphPad Software). For baseline patient characteristics, continuous variables (age, 
physiological scores and length of hospital stay) were analysed using a two-tailed Mann-
Whitney Test; categorical variables (gender, admission source, comorbidities and 
infection characteristics) were analysed using a chi square contingency table and 
statistical comparisons determined with Fisher’s exact test where p<0.05 was considered 
significant. For all other immunological analyses, unless stated, differences observed 
between two means were analysed using a two-tailed Mann-Whitney Test where p<0.05 
was considered significant.  
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3.3. Results 
3.3.1.  Baseline patient characteristics 
The MATHS clinical trial is continuing to recruit to a total of 180 participants with 45 
patients per group to be enrolled. The data presented in this chapter represents the 
analysis of parameters measured from the first 29 patients enrolled into the study until 
June 2015. Given that a larger number of total participants were required for statistically 
significant differences to be observed, it should be noted that the analysis provided for 
this subset of patients might not be truly representative of the total cohort of patients in 
the trial.    
Following enrolment into the study, patients were randomly assigned to 100 mg  
aspirin-treated, and 300 mg aspirin-treated and untreated control patients. Subjects 
regularly taking aspirin had blood samples taken as per the other trial patients (Table 3.3). 
Medical history data (including physiological scores, infectious site and source) were also 
collected. The median age (of all patients) was 43 years (IQR; 27-64). The age 
distribution between treatment groups was similar; with the exception of regular aspirin 
takers, who tended to be older and overall had a higher incidence of co-morbidities (67% 
vs 13% or 0 in the other groups; Table 3.3). Combined analysis of all aspirin-treated 
patient groups versus the untreated control group revealed there were no significant 
differences observed in baseline clinical characteristics analysed, with the exception of 
APACHE II score and viral source of infection (Table 3.3).  
A number of possible sources of bias should be noted in the cohort of patients enrolled 
thus far. The untreated control group had the lowest mean APACHE II score of all 
treatment groups (8.25 ± 2.49), however this difference was not significant compared 
with 100 mg or 300 mg aspirin-treated groups. Regular aspirin-taking patients had higher 
APACHE II score (16.33 ± 2.5) compared with other participant groups. As mentioned 
above, these patients were also older and had one or more co-morbidities. It is noteworthy 
that viral infection was the cause of sepsis in 4 patients, all of who were randomised to 
the untreated control group. SOFA scores varied between patients in each group, however 
the mean SOFA score improved in all groups over the two days participants were in the 
trial, regardless of treatment. This is reflective of the absence of sepsis deaths in our trial 
participants as well as the small sample analysed to date. 
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Table 3.3: Patient characteristics for the MATHS trial cohort. At enrolment, general characteristics, physiological scores, comorbidities and 
infection characteristics were recorded for each patient. Significant differences were noted for APACHE scores and viral source of infection. 
* APACHE, Acute Physiology and Chronic Health Evaluation; COPD, Chronic obstructive pulmonary disease; SOFA, Sequential Organ Failure Assessment. 
 
 
 
Treatment Group 
 
 
100 mg aspirin  
(n=8) 
300 mg aspirin  
(n=7) 
Regular aspirin  
(n=6) 
Untreated Control 
(n=8) 
P Value 
General Characteristics 
     
Age, median (IQR) 35 (25-44) 42 (35-50) 73 (64-82) 38 (22-54) 0.253 
Male Gender, % (n) 87.5 (7) 57.1 (4) 83.3 (5) 50 (4) 0.209 
Admission Source, % (n) 
     
    ICU 25 (2) 28.6 (2) 33.3 (2) 12.5 (1) 
0.510     Ward  75 (6) 71.4 (5) 50 (3) 87.5 (7) 
    Other 0 0 16.7 (1) 0 
Length of Hospital Stay,  
Days median (IQR) 
4.5 (3-13.5) 9 (5-28) 7 (6-15) 4.5 (2-8.5) 0.128 
Physiological Scores, % (n) 
     
APACHE* II, mean (SD) 11.25 (9.29) 11.43 (2.64) 16.33 (2.5) 8.25 (2.49) 0.011* 
SOFA*, mean (SD) 
     
    Day 0 2.25 (2.19) 1.29 (1.11) 2.5 (2.43) 1.625 (1.19) 0.993 
    Day 1 1.14 (1.46) 1.14 (1.07) 2.17 (1.72) 1.25 (1.16) 0.821 
    Day 2 1.29 (1.80) 0.57 (1.13) 1.67 (1.37) 1 (1) 1.000 
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 Treatment group  
 
100 mg aspirin  
(n=8) 
300 mg aspirin  
 (n=7) 
Regular aspirin  
(n=6) 
Untreated Control 
(n=8) P  Value 
Comorbidities, % (n)           
    Ischemic Heart Disease 12.5 (1) 0 66.7 (4) 0 0.647 
    Diabetes 12.5 (1) 0 33.3 (2) 12.5 (1) 1.000 
    COPD* 12.5 (1) 0 33.3 (2) 0 0.540 
    Renal Disease 25 (2) 0 0 0 1.000 
    Cancer 0 0 33.3 (2) 12.5 (1) 1.000 
    Other 12.5 (1) 42.9 (5) 100 (6) 75 (6) 0.238 
    None 50 (4) 28.6 (2) 0 37.5 (3) 0.675 
Infection Characteristics, % (n)           
Site of infection      
    Bloodstream 25 (2) 28.6 (2) 0 50 (4) 0.164 
    Respiratory 37.5 (3) 14.3 (1) 83.3 (5) 25 (2) 0.238 
    Urinary 0 28.6 (2) 0 12.5 (1) 1.000 
    Skin/Soft Tissue 25 (2) 0 0 12.5 (1) 1.000 
    Other 37.5 (3) 42.9 (3) 16.7 (1) 25 (2) 1.000 
Source of infection      
    Gram-positive bacteria 25 (2) 14.3 (1) 33.3 (2) 12.5 (1) 0.647 
    Gram-negative bacteria 12.5 (1) 57.1 (4) 0 25 (2) 1.000 
    Virus 0 0 0 50 (4) 0.003* 
    Fungi 0 14.3 (1) 0 0 1.000 
    Specific organism not identified 62.5 (5) 14.3 (1) 66.7 (4) 12.5 (1) 0.110 
Chapter 3 
	
 Page 98 
3.3.2. Analysis of mean platelet volume (MPV) in patients with sepsis 
MPV is a haematological marker of platelet size, function and activation, and is 
commonly used to indicate changes in platelet production rates or platelet stimulation 
[473, 474]. MPV has been used in conjunction with platelet count as predictor for 
mortality in ICU in other inflammatory conditions [475, 476], and recently increased 
MPV and decreased platelet count were shown to be associated with worse outcomes in 
patients with severe sepsis or septic shock [477, 478]. In this study, MPV data from 
diagnostic haematology test (using the Coulter® LH 700 haematology analyser at the 
Royal Melbourne Hospital) was analysed to investigate potential effects of aspirin 
therapy in trial participants (Figure 3.1). Individual patient MPV varied, however, the 
majority of patient values were within the normal MPV range between 7.4 and 10.4 
femtolitres (fL). Combined analysis of all aspirin-treated groups versus the untreated 
control group revealed no significant differences in median values of MPV on any of the 
days sampled (Figure 3.1A). Comparisons of data from each treatment group showed that 
regular aspirin-taking patients had the highest baseline median MPV (10.5 fL), which 
may reflect more severe sepsis, consistent with the presence of co-morbidities and 
increased APACHE II score. Of note 300 mg aspirin-treated patients had the lowest 
baseline median value for MPV (7.9 fL) (Figure 3.1B).   
While aspirin-treatment did not appear to significantly reduce MPV (consistent with 
limited published data) it is interesting to note that 300 mg aspirin-treated patients and 
regular aspirin-treated patients maintained consistent MPV for the duration of sampling 
(regardless of starting value). In contrast, untreated control patients showed a small trend 
in increased MPV over the three-day sampling period from a median value of 8.45 fL 
(day 1) to 10.5 fL (day 3). Likewise 100 mg aspirin-treated patients showed a non-
discriminatory increase from a median value of 8.8 fL (day 1) to 9.5 fL (day 3). On day 3 
statistically significant differences were observed between regular aspirin-taking patients 
and 300 mg aspirin-treated patients, however taking into consideration the baseline 
starting values for each group, this difference was more likely to be due to increased 
severity of condition in the regular aspirin-taking patients, rather than response to aspirin 
treatment 
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Figure 3.1: Mean platelet volume (MPV) in blood is not significantly reduced with 
aspirin therapy in patients with sepsis, but is increased in regular aspirin-taking 
patients with sepsis. A) Combined analysis of all aspirin-treated groups versus untreated 
control group. B) Analysis of individual patient groups. Data are represented as circular 
symbols for individual patients within each group, the bar the mean ± SEM and expressed 
as femtolitre (fL) (n=3-7 per group/time-point, two-tailed Mann-Whitney test, *p<0.05). 
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3.3.3. Quantification of plasma 15-epi-LxA4 in patients with sepsis 
In both clinical studies and animal models of inflammation, 15-epi-LxA4 was shown to 
contribute to resolution of inflammation; associated with improved outcomes [17, 19, 20, 
434]. In this study, levels of 15-epi-LxA4 were measured in plasma, as a surrogate 
measure of resolution of inflammation. Plasma extracted from whole blood of patients 
with sepsis were analysed using a quantitative ELISA. Concentrations derived from  
15-epi-LxA4 standard curves were expressed in ng/mL. 
Figure 3.2 illustrates the levels of 15-epi-LxA4 detected over the 48 h trial timeline in trial 
participants with sepsis. Combined analysis of all aspirin-treated groups versus the 
untreated control group revealed no significant differences in mean production of  
15-epi-LxA4 on any of the days sampled (Figure 3.2A). When analysing the differences 
between individual treatment groups, at 1 h following first aspirin dose, 100 mg aspirin-
treated patients showed a 1.382 ng/mL aspirin-dependent increase in mean 15-epi-LxA4 
levels. While this was not significantly different from untreated control patients, 
significant differences were observed between 100 mg aspirin-treated patients and other 
aspirin-treated patient groups (Figure 3.2B; p<0.05, one-tailed Mann-Whitney). Also of 
note, initial baseline concentrations of 15-epi-LxA4 recorded (prior to aspirin dosing) for 
100 mg aspirin-treated patients and untreated control patients were higher than baseline 
15-epi-LxA4 levels observed in healthy volunteers in a previous study [20], suggesting 
that inflammation alone can trigger the increased production of plasma 15-epi-LxA4. 
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Combined Analysis
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Figure 3.2: Plasma 15-epi-LxA4 production is moderately increased with 100 mg 
aspirin therapy in patients with sepsis. A) Combined analysis of all aspirin-treated 
groups versus untreated control group. B) Analysis of individual patient groups. Data are 
represented as mean ± SEM, and expressed as ng/mL. Dotted line represents the baseline 
concentration of 15-epi-LxA4 (2.45 ng/mL) in healthy patients determined in [20], (n=3-7 
per group/time-point, one-tailed Mann-Whitney test, *p<0.05). 
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3.3.4. Detection of NFκB activation in patients with sepsis 
Production of SPMs such as lipoxins was recently shown to inhibit the activation of 
transcription factors such as NFκB that contribute to exacerbation of inflammatory 
pathways [479, 480]. Nuclear extracts from PBMC pellets were analysed by sandwich 
ELISA. Chemiluminescent detection was used to measure levels of activation of the p65 
subunit of NFκB, and mean values were expressed as the percentage NFκB p65 activation 
of normalised start value.  
Combined analysis of all aspirin-treated patients versus untreated control group are 
shown in Figure 3.3A. Regardless of aspirin treatment, 8 h after first aspirin dose there 
was no increase observed in NFκB p65 activation compared with untreated control 
patients. Comparisons of treatment groups showed that while there was considerable 
variation between patients, the untreated control group had increased NFκB p65 
activation peaking at 8 h following enrolment. In contrast, both 100 and 300 mg aspirin-
treated patients showed no significant change in NFκB p65 activation compared with 
initial start value. Significant differences were seen between 100 mg aspirin-treated 
patients and untreated control patients (Figure 3.3B; p<0.05, one-tailed Mann-Whitney).  
Regular aspirin-taking patients showed a small initial increase in mean NFκB p65 
activation (1 h following aspirin-treatment), however this was not statistically significant. 
Following this NFκB p65 activation returned to a level comparable with other aspirin-
treated groups (at 8 h post-aspirin dose 1), consistent with 15-epi-LxA4-induced 
resolution of inflammation, previously shown in vitro [479]. The high level of variation 
of NFκB p65 activation observed in untreated control and regular aspirin-taking groups is 
likely to be a consequence of the small sample size to date. 
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Figure 3.3: Decreased NFκB activation observed at T8 in 100 mg and 300 mg 
aspirin-treated patients with sepsis. A) Combined analysis of all aspirin-treated groups 
versus untreated control group. B) Analysis of individual patient groups. Data are 
represented as mean ± SEM, and expressed as percentage change from starting value, 
(n=5-8 per group/time-point, one-tailed Mann-Whitney test, *p<0.05).  
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3.3.5.  Inflammatory cytokine production in patients with sepsis 
A key process during the sepsis inflammatory cascade is the production of  
pro-inflammatory cytokines. As 100 mg aspirin treatment led to increased plasma  
15-epi-LxA4 levels, and all aspirin doses inhibited NFκB p65 activation in the initial 
analysis, it was hypothesised that pathways downstream of NFκB activation including the 
production of both inflammatory cytokines and chemokines would be impaired [446]. 
Levels of pro- and anti-inflammatory cytokines and chemokines produced in the plasma 
of patients with sepsis (24 h after the first aspirin dose) were detected using the Human 
Inflammation panel (13-plex) LEGENDplex™ flow assay. Concentrations of IL-1β, IL-6, 
IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33, IFN-α, IFN-γ, MCP-1 and TNF-α 
were assessed, calculated from standard curves with recombinant human cytokine 
standards, and expressed as pg/mL. 
Compared with mean endogenous levels of pro-inflammatory cytokines described for 
normal human plasma by the multiplex assay manufacturer, in this study increases in 
plasma levels of IL-6, IL-8, IFN-γ, MCP-1 (Figure 3.4B-E), IL-17A, IL-18 and IL-23 
(Figure 3.5B-D) were seen in all patients with sepsis. Aside from a few individual 
responses detected in patients of all treatment groups, the levels of IL-1β, TNF-α (Figure 
3.4A, F), IL-12p70 (Figure 3.5A), IFN-α, IL-10 and IL-33 (Figure 3.6A-C) detected were 
however within the normal range of endogenous levels found in normal human plasma. 
No statistically significant change in the early response pro-inflammatory cytokines IL-1β 
and IFN-γ were observed with aspirin-treatment compared with the untreated control 
group. Significant differences in mean plasma TNF-α level were seen in the regular 
aspirin-taking group compared with untreated controls (Figure 3.4F; p<0.05, one-tailed 
Mann-Whitney test). Significant differences were also seen in the mean plasma levels of 
IL-18 in the 100 mg aspirin-treated group compared with the untreated control group 
(Figure 3.5C; p<0.05, one-tailed Mann-Whitney test). 
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Figure 3.4: Participants regularly taking aspirin have increased plasma levels of  
TNF-α. Plasma extracted from patients was analysed for levels of: A) IL-1β, B) IL-6, C) 
IL-8, D) IFN-γ, E) MCP-1 and F) TNF-α at 24 h post-aspirin dose 1. Data are represented 
as circular symbols for individual patients with the mean ± SEM and expressed as plasma 
concentration (pg/mL), (n=5-8 per group, one-tailed Mann-Whitney test, *p<0.05). 
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Figure 3.5: Individual responses in the levels of IL-1 and IL-12 related  
pro-inflammatory cytokines vary in plasma of patients with sepsis. Plasma extracted 
from patients was analysed for levels of: A) IL-12, B) IL-17A C) IL-18 and D) IL-23, at 
24 h post-aspirin dose 1. Data are represented as circular symbols for individual patients 
with the mean ± SEM and expressed as pg/mL, (n=5-8 per group, one-tailed Mann-
Whitney test, *p<0.05). 
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Figure 3.6: Individual responses in levels of other pro-inflammatory and  
anti-inflammatory cytokines detected vary in plasma of patients with sepsis. Plasma 
extracted from patients was analysed for levels of: A) IFN-α, B) IL-10 and C) IL-33, at 
24 h post-aspirin dose 1. Data are represented as circular symbols for individual patients, 
with the mean ± SEM (n=5-8 per group) and expressed as plasma concentration (pg/mL).  
 
 
 
 
	  
Chapter 3 
	
	
	 Page 108 
3.3.6. Analysis of immune cell populations in patients with sepsis 
In order to assess whether aspirin had an overall impact on immune responses in patients 
with sepsis, the proportions of circulating immune cell subsets in whole blood were 
analysed. Following preparation of single cell suspensions, cells were stained with the 
appropriate antibodies and immune cell subsets were quantified by flow cytometry. 
Patient samples were analysed in 2 batches in November 2014 and July 2015. Following 
the initial batch analysis, additional markers were added.  
For all comparative flow cytometry analyses; the same antibodies, voltage settings on the 
flow cytometer (FACS Canto II) and gating strategies were used. The gating strategies for 
FACS experiments are shown in Figure 3.7.  
3.3.6.1.  Analysis of innate immune cell populations 
Phagocytic cell types (monocytes, macrophages and neutrophils) represent the early 
response to systemic infection by mediating clearance of pathogens both directly, and by 
presenting antigens leading to indirect bacterial pathogen clearance by adaptive 
mechanisms. For this reason the main focus of the analysis was these cell populations. 
Sepsis interferes with phagocytic mechanisms depending on pro-inflammatory stimuli, 
and delayed neutrophil apoptosis in sepsis results in organ dysfunction [100]. In this 
study, the proportion of monocytes/macrophages (CD86+, CD11b+, CD66b-) and 
neutrophils (CD86+, CD11b+, CD66b+) were analysed over a 48 h period in patients with 
sepsis. Proportions of CD86+ monocytes/macrophages in all participant groups fell within 
the normal range (<15% of all circulating leukocytes), with regular aspirin-taking patients 
displaying lowest proportions (Figure 3.8A; p<0.05, one-way ANOVA). While there was 
a small increase in mean percentage of monocytes/macrophages was seen in 100 mg 
aspirin-treated patients 1-8 h following first aspirin dose, this was not significantly 
different from other participant groups. Proportions of circulating neutrophils overall 
were higher compared with monocytes/macrophages (Figure 3.7B). Similarly, there was 
no significant effect on proportions of neutrophils in blood for new aspirin-treated 
patients. Subjects who were regular taking aspirin had a significantly lower starting 
percentage of neutrophils and this remained lower than other groups (Figure 3.8B; 
p<0.005, p<0.0001, one-way ANOVA).  
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Figure 3.7: Gating strategy and definition of monocyte/macrophage, neutrophil and 
CD4+/CD8+ T lymphocyte populations for analysis of immune cell subsets by flow 
cytometry. Representative FACS plots of cell suspensions isolated from the whole blood 
of critically ill patients with sepsis. Cells were differentiated into a leukocyte/lymphocyte 
gate according to their side scatter (SSC-A) and forward scatter (FSC-A) profiles (top left 
panel). Forward height (FSC-H) and forward area (FSC-A) parameters were used to 
identify single cells (bottom left panel). Cells were then defined as being CD3- or CD3+ 
(top middle panel). In the CD3+ population, cells were defined as CD4+ T lymphocytes, 
and CD8+ T lymphocytes (top right panel). In the CD3- population, cells were defined as 
being CD86+ or CD86- (bottom middle panel). In the CD86+ population, CD11b+ CD66b- 
cells were defined as monocytes/macrophages, and the double positive population for 
CD11b and CD66b were defined as neutrophils (bottom right panel).  
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Figure 3.8: Proportions of monocytes/macrophages and neutrophils are altered 
following 100 mg aspirin in patients with sepsis. A) Overall, regular aspirin-taking 
patients had significantly less monocytes/macrophages than new 100 mg aspirin-treated 
patients. B) Regular aspirin-taking patients had significantly less neutrophils than all 
other treatment groups. Data are the combination of two independent batch analyses, 
represented as mean ± SEM, and expressed as a percentage of the total leukocyte gate 
(n=4-8 per group/time-point, one-way ANOVA, *p<0.05, ***p<0.005, ****p<0.0001). 
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3.3.6.1.1. Expression of cell surface activation and migration marker PSGL-1  
PSGL-1 is expressed on surfaces of neutrophils, and has a high affinity for binding  
P-selectin on endothelial surfaces to facilitate rolling, adhesion and subsequent migration 
across vascular the endothelium [481]. It was of interest therefore to investigate PSGL-1 
expression on the surface of CD86+ neutrophils, in blood of aspirin-treated patients with 
sepsis as an indicator of possible effects on tissue inflammation. 
Mean PSGL-1 expression on neutrophils appeared to be altered in aspirin-treated patients 
with sepsis, with the 300 mg aspirin-treated group and 100 mg aspirin-treated patients 
both showing increases in mean PSGL-1 at 8 h and 24 h following first aspirin dose, 
respectively (Figure 3.9A). However, further detailed analysis at each time-point showed 
that these mean increases were due to single outlier patients with extreme responses in the  
300 mg (Figure 3.9Bi) and 100 mg aspirin-treated groups (Figure 3.9Bii). As a result, it 
was concluded that there was no significant difference in PSGL-1 expression on the 
surface of neutrophils in aspirin-treated groups compared with untreated control patients.   
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Figure 3.9: Mean changes in PSGL-1 expression on neutrophils are due to 
variability in individual patients. A) Changes in PSGL-1 surface expression on 
neutrophils. Data represent the mean ± SEM (n=3-8 per group/time-point), and expressed 
as % change from start value. B) Percentage change PSGL-1 surface expression at i) 8 h, 
and ii) 24 h post aspirin dose 1. Differences in means observed were due to single outliers 
in 300 mg and 100 mg aspirin-treated groups respectively, therefore no significant 
differences were observed between groups. Data represented as square symbols for 
individual patients and the bar, the mean ± SEM, (n= 3-6 per group). 
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3.3.6.2. Analysis of T lymphocyte populations 
Several studies in both animal models [482, 483] and human sepsis [107] have shown that 
a decrease in circulating lymphocytes, accompanied by an increase in lymphocyte 
apoptosis, leads to immunosuppression and contributes to severity of this inflammatory 
condition. In this study, the proportions of CD4+ and CD8+ T lymphocytes circulating in 
whole blood of patients with sepsis were evaluated (over a 48 h period), to determine 
whether aspirin-treatment impacted these cells. Figure 3.10A represents the change in 
proportions of CD4+ and CD8+ T lymphocytes. While the detected proportions were 
lower (<2% and <3% total leukocytes respectively) compared with what is seen 
proportionally in healthy humans, this was consistent with published data from trauma 
patients [108]. Interestingly proportions of CD4+ T lymphocytes remained similar for all 
aspirin-treated groups, but increases were observed in the untreated control patients by  
48 h following first aspirin dose (Figure 3.10A; p<0.05, one-way ANOVA).  
To investigate lymphocyte apoptosis, in a subset of 14 patients (Batch 2), the proportions 
of Annexin V+, CD4+ and CD8+ T lymphocytes were also analysed (Figure 3.10B). 
Overall the proportion of apoptotic cells was higher than reported in previous studies. 
Small changes in levels of apoptosis in circulating CD4+ T lymphocytes were observed, 
however in contrast with the study by Hotchkiss et al. [107], no significant increases in 
apoptosis were observed, and no apparent effect of aspirin was noted (Figure 3.10C, left 
panel). Likewise, analysis of apoptosis in CD8+ T lymphocytes again showed similar 
proportions of apoptotic cells across all treatment groups. Again, no significant effect of 
aspirin-treatment was seen in the levels of CD8+ T lymphocyte apoptosis. 
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Figure 3.10: Aspirin therapy reduces proportions of T lymphocyte populations, but 
does not impact lymphocyte apoptosis. A) Analysis of CD4+ and CD8+ T lymphocyte 
proportions in whole blood from patients with sepsis. Data are the combination of two 
independent batch analyses, represented as mean ± SEM and expressed as a percentage of 
total leukocyte gate (n=4-8 per group/time-point, one-way ANOVA, *p<0.05).  
B) T lymphocyte apoptosis was determined in batch 2 analysis, using Annexin V and  
7-AAD. Apoptotic cells were defined as Annexin V+/7-AAD- population. C) Proportion 
of apoptotic circulating CD4+ and CD8+ T lymphocytes. Data represent the mean ± SEM 
and expressed as percentage of apoptotic cells (n=1-5 per group/time-point). 
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3.4. Discussion 
For a potential adjunct therapy of sepsis to be successful, it should be inexpensive to 
produce and easy to administer. It is accepted that adjunct therapies should also aim to 
resolve inflammation and promote a return to homeostasis, rather than inhibiting 
inflammation all together [484-486], as this can lead to immunosuppression. At low doses 
(equivalent with doses taken for cardio-protective effects), aspirin is the only NSAID 
shown to induce the production of SPMs including 15-epi-LxA4 [14]. Increased 
production of 15-epi-LxA4 not only interferes with inflammatory signaling (via inhibition 
of NFκB) [216, 479], but also acts to resolve inflammation by: restoring neutrophil 
apoptosis, inhibiting neutrophil chemotaxis to reduce tissue damage [101, 487, 488], and 
promoting increased phagocytosis of pathogens and apoptotic neutrophils from 
circulation [446].  
Observational studies have demonstrated an association between long-term aspirin usage 
and reduced sepsis mortality [61, 64, 220], however none of these studies were able to 
investigate the inflammatory pathways that may have mediated reduced mortality in these 
patients. To address this, the MATHS clinical trial was initiated, to investigate the effects 
of aspirin-therapy on surrogate markers of inflammation (primarily 15-epi-LxA4 and 
NFκB), and other immunological parameters in patients with sepsis. 
The data presented here represents the preliminary analysis of all patients enrolled to date 
(n=29) in the MATHS clinical trial (single-centre study). It should be noted that not all 
patients had all time-points sampled (either due to early discharge, or voluntary 
withdrawal of participation), which may have impacted the degree of variation seen in 
some analyses. The main findings of this study showed that regular aspirin-taking patients 
were the most severely ill of all groups, as they were older and presented with one or 
more co-morbidities, and these patients had the highest APACHE II and SOFA scores on 
enrolment. MPV was not impacted by aspirin therapy. Analysis of primary read out 
parameters of surrogate markers revealed an increase in plasma 15-epi-LxA4 in 100 mg 
aspirin-treated patients within the 1 h of first aspirin dose. Also, all aspirin-treated groups 
showed a degree of NFκB inhibition, compared with untreated controls. Increased levels 
of some pro-inflammatory cytokines were observed among all patient groups, however a 
significant additional increase in levels of TNF-α was seen in regular aspirin-taking 
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group, and increases in plasma IL-18 levels in 100 mg aspirin-treated group, compared 
with untreated control group. Circulating CD86+ monocyte/macrophage and neutrophil 
populations were altered soon after aspirin therapy, however the level of PSGL-1 
expression on innate immune cell surfaces was not affected. Circulating proportions of T 
lymphocytes were decreased in all aspirin-treated groups, compared with the untreated 
control group, but no effect of aspirin on levels of lymphocyte apoptosis was observed. 
Of the patients enrolled in the trial, the most severely ill (according to physiological 
scores and MPV values) were those regularly taking aspirin. These patients were also 
significantly older than patients in the other participant groups and presented with at least 
one comorbidity, which may have predisposed these individuals to develop sepsis [1]. 
While analysis of MPV data in all patients showed no clear effect of aspirin therapy on 
platelet volume, over the three days of sampling, untreated control patients showed a 
small increase in platelet volume. While these increases were moderate, larger increases 
in mean platelet volume are often associated with disease severity, suggesting the 
potential use of MPV as a prognostic biomarker for sepsis severity [473, 477, 478]. These 
results are consistent with the limited published data available, suggesting that aspirin has 
no role in actively decreasing MPV, however it should be noted that the both of these 
studies only analysed patients regularly taking aspirin as a cardio-protective therapy [489, 
490]. Another published study in healthy volunteers receiving 7 days of aspirin treatment 
(81 mg daily)[491], also showed no decrease in MPV, consistent with the data presented 
in this study for 100 mg aspirin-treated patients. 
This study was focused on the “pro-resolving” outcomes associated with aspirin therapy, 
and analysis of plasma 15-epi-LxA4 and inhibition of NFκB as surrogate markers were 
performed. Increases in plasma 15-epi-LxA4 levels were seen in 100 mg aspirin-treated 
individuals 1 h following aspirin treatment, however no significant differences seen in 
absolute concentration with that of the untreated control group. It has also been reported 
by others that detectable levels of 15-epi-LxA4 (2-3 ng/mL) can be seen in the absence of 
aspirin therapy [19, 20]; similarly confirmed in this study with quantifiable levels of  
15-epi-LxA4 seen in untreated control patients. It was also noted that the baseline mean 
plasma 15-epi-LxA4 levels in two of the participant groups in this study were higher than 
what has previously been reported in healthy patients. This suggests that 15-epi-LxA4 
production is increased under inflammatory conditions, and levels are further increased 
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following aspirin therapy. While the source of this non-aspirin induced 15-epi-LxA4 is 
unknown, it has been hypothesised that in the absence of aspirin, COX-2 may still 
become acetylated by endogenously produced acetylating agents, leading to the 
production of basal levels of 15-epi-LxA4 [20]. 
Although aspirin was the first pharmacological agent shown to induce the production of 
15-epi-LxA4, it is not the only known inducer of 15-epi-LxA4. Statins including 
atorvastatin and pioglitazone can also promote the production of 15-epi-LxA4, via the  
S-nitrosylation of COX-2 in animal models of inflammation [443, 444]. One human 
studiy of statin therapy did show a similar response, however 4-week period yielded a 
less significant change in levels of 15-epi-LxA4 (~0.83 ng/mL), compared with levels 
shown in the present study with low-dose aspirin (mean change ~1.48 ng/mL in 100 mg 
aspirin-treated patients) [445]. Clinical patient data regarding patient medication will not 
be made available until the trial is completed, and as such post-hoc analysis will need to 
be performed in order to evaluate the relative effect of statin therapy on 15-epi-LxA4 
production. 
A recent study by Morris and colleagues also showed that the phenotypic variation in  
15-epi-LxA4 production seen in a skin blister model in healthy volunteers [492], could be 
due to acute-inflammatory response time. “Early resolving” participants exhibited low 
initial 15-epi-LxA4 levels with levels increasing with increased inflammation, and 
“delayed resolvers” exhibiting initially increased 15-epi-LxA4 levels, that decreased as 
inflammation progressed. While this may contribute to the variation in plasma  
15-epi-LxA4 levels seen in patients in this study, the MATHs trial was powered to 
determine differences in a larger sample size (45 patients per group) and so no final 
conclusions can be drawn until recruitment has been completed. Analysis of a larger 
cohort of patients would be required to determine whether increases in 15-epi-LxA4 
production were significantly different with low-dose aspirin therapy. While the 
preliminary results are promising, aspirin also triggers the production of a number of 
other SPMs. Resolution of inflammation is a complex process; proposed to be mediated 
by SPMs in combination [464]. As such, there is increased interest into the roles of other 
SPMs derived from polyunsaturated fatty acids (PUHA) in resolution of inflammation 
including: resolvins, protectins and maresins. Future studies, including the analysis in this 
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trial should investigate the role of resolvins, protectins and maresins following aspirin 
therapy, to determine their contribution to resolution of inflammation. 
In the current study, aspirin-treatment prohibited the activation of NFκB by 8 h following 
first aspirin dose, regardless of the dose given, or prior therapy. This is the first study to 
show aspirin-induced inhibition of NFκB in vivo in a human clinical trial of sepsis, and 
the results presented are consistent with that reported from in vitro analyses of NFκB 
inhibition [216, 433, 493], as well as rodent models of inflammation [494]. While only  
5-6 patients per group contributed to analysis at this time-point, these results are 
encouraging, and support the potential for aspirin-induced resolution of inflammation in 
sepsis acting via NFκB inhibition among other mechanisms. A recent study also showed 
that aspirin-triggered resolvin D1 inhibited NFκB activation, decreased neutrophil influx 
into kidney tissue, protecting against acute kidney injury in rats [13], further supporting a 
role for other SPMs with potent anti-inflammatory actions. NFκB is a key driver of 
inflammation by facilitating transcription of pro-inflammatory cytokines, therefore it was 
expected that inhibition of NFκB would impact the level of cytokines produced 
downstream. The novel information we aimed to provide is the lower range of aspirin 
required to produce this effect on NFκB. 
This study is one of very few investigating a broad panel of cytokines in patients with 
sepsis or taking aspirin. Levels of pro-inflammatory and anti-inflammatory cytokines in 
plasma were consistent with early inflammation, however these were for the most part 
lower that what has been reported in patients with severe sepsis and septic shock [495]. 
This study did not include a healthy control group, but the plasma concentrations of pro-
inflammatory cytokines and chemokines in this study were either moderately increased or 
unchanged compared with endogenous levels in healthy human plasma (shown in the 
LEGENDplex™ manufacturer information). The majority of the cytokine and chemokine 
panel investigated showed no effect of aspirin at the time-points assessed, similarly 
shown in exudates of blister fluid in healthy volunteers treated with low-doses of aspirin 
[19]. Significant increases were seen in plasma levels of TNF-α in the regular aspirin-
taking group compared with untreated controls. While this suggested a more severe 
disease status, measured levels in this study were lower than seen in another study of 
severe sepsis and septic shock [495], and therefore no further conclusions can be drawn 
until the data from all samples in the trial (once completed) are available.   
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Levels of IL-18 were shown to increase in patients with sepsis, compared with trauma 
patients and healthy controls in a previous study, suggesting this marker could be used as 
an identifying marker of sepsis [496]. While all patient groups in the current study 
showed a high level of plasma IL-18 (>350 pg/mL) indicative of sepsis, mean plasma 
levels of IL-18 in the 100 mg aspirin-treated group were significantly higher than 
untreated control group. A number of biological roles have been described for IL-18, 
most notably in IFN-γ regulation [497], which was shown in one study to promote the 
resolution of bacterial infection in mice [498]. As plasma increases of IL-18 were seen 
with 100 mg aspirin-therapy, this might suggest that low-dose aspirin increases this 
cytokine in conjunction with 15-epi-LxA4, and may contribute to pro-resolving pathways 
in patients with sepsis.  
Another key target of the sepsis inflammatory cascade are the host innate and adaptive 
immune responses. In this study, CD86 expression was analysed on the surface both 
monocytes/macrophages and neutrophils. For the duration of sampling the proportion of 
CD86+ monocytes/macrophages was lower in regular aspirin takers; keeping with the 
knowledge that sepsis decreases surface expression of CD86 resulting in macrophage 
dysfunction [66], which along with other data suggests more severe disease state. Further, 
a significant increase in the proportion of CD86+ monocytes/macrophages was seen with 
100 mg aspirin-treatment (8 h) compared with regular aspirin takers (p<0.05, one-way 
ANOVA); suggestive of increased antigen-presenting capability, which may lead to 
enhanced phagocytosis of bacteria in circulation [446]. 
While not commonly expressed on neutrophil surfaces, pro-inflammatory stimuli can 
induce co-stimulatory molecule CD86 expression, which can induce signaling for  
T lymphocyte activation. Delayed neutrophil apoptosis is a known contributing factor to 
sepsis inflammation, organ dysfunction and increased mortality, demonstrated by 
increased CD86 surface expression following pro-inflammatory stimuli [499, 500]. This 
could be true for untreated control patients in this study (see Figure 3.8B), with increases 
in CD86 expression on neutrophils occurring at similar timeframe as increased NFκB 
activation (Figure 3.3 and 3.8B), however no significant correlations were found in the 
available datasets. Initial increases in proportions of CD86+ neutrophils were also seen 
early in 100 mg aspirin-treated patients (1 h following aspirin treatment), however this 
was not found to be statistically significant. As production of 15-epi-LxA4 has been 
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reported to override the signals for delayed apoptosis in neutrophils [101], it is possible 
that this mechanism contributes to the small proportional decrease of CD86+ neutrophils 
that was observed in this group of patients, occurring 8 h following aspirin-treatment and 
production of 15-epi-LxA4 (at times consistent with inhibition of NFκB).  
Cell surface expression of PSGL-1 and CD11b mediates adhesion of leukocytes to both 
platelets and vascular endothelium to promote rolling and migration. In a previous study 
however, 15-epi-LxA4 was shown to interfere with neutrophil binding on vascular 
endothelium, preventing chemotaxis and transmigration and this contributed to resolving 
inflammation [487]. This inhibitory mechanism of 15-epi-LxA4 could also explain why 
an initial increase in the proportion of CD86+ neutrophils was seen in this group of 
patients. Analysis of cell surface expression of PSGL-1 on CD86+ neutrophils showed an 
initial decrease in 100 mg aspirin-treated patients, however because no significant 
differences in PSGL-1 expression were determined, it is difficult to speculate whether 
aspirin impacted neutrophil rolling and migration. Further, soluble 15-epi-LxA4 
interaction with its surface receptor ALX on neutrophil surfaces have been suggested to 
trigger anti-inflammatory and pro-resolution effects during acute inflammation [501]. 
However, surface expression of ALX on neutrophils in this study appeared to be 
constitutive and did not change in all participant groups (data not shown). Analysis of cell 
surface expression PSGL-1 on circulating CD86+ monocytes/macrophages was also 
investigated, however no significant increases in proportion of these cells were seen in 
any of the treatment groups (data not shown). 
The role of adaptive immune responses in the early development of sepsis have been 
debated, however one described effect of sepsis to the adaptive immune response is 
immunosuppression. In both experimental animal models and clinical studies alike, 
within 7 days of sepsis development a profound depletion of CD4+ T lymphocytes was 
observed [107, 483]. The proportions of both CD4+ and CD8+ T lymphocytes in this 
study appeared lower compared with proportions observed in healthy patients in a 
previous study [108], however no significant change was seen with any of the aspirin-
treated patients over 48 h. Untreated control patients had significantly increased 
proportions of CD4+ T lymphocytes subsets at the 48 h sampling time, suggesting that the 
decrease in lymphocytes described by Hotchkiss et al. occurs following 48 h of 
identification of sepsis [107]. Also, the preliminary investigation into lymphocyte 
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apoptosis in the current study did not show any significant effect of aspirin therapy. 
Proportions of apoptotic CD4+ and CD8+ T lymphocytes did appear higher in patients in 
this study, compared with other published studies [107, 502]. This data suggests that our 
patients were entering immunosuppression phase of sepsis, however it should be noted 
that the number of patients per group in this batch analysis was very small (n=1-5). 
Further, levels of CD4+ T lymphocyte apoptosis measured at T0 did not correlate with 
APACHE II scores, suggesting that the apoptosis data presented here is not truly 
reflective of the total population of patients analysed.  
As previously stated, the design of MATHS clinical trial was not powered to detect 
improvements in clinical outcomes. Complete clinical outcome data will not be released 
until the completion of the trial and as such it cannot be determined whether aspirin 
therapy improves outcomes at this time.  
Other limitations of this study include a lack of samples from healthy patient controls for 
comparative analysis. This group was omitted from this initial trial due to difficulties in 
gaining human ethics approval to collect blood from healthy patients.  Future studies 
should also include a healthy (non-septic) control group, for determination of baseline 
characteristics particularly for NFκB activation and immunological parameters measured 
by flow cytometry (plasma cytokines and immune cell populations). Further, the 
contribution of other SPMs in resolution of inflammation should be considered in these 
patients, as these have recently been shown to reduce inflammation in animal models of 
systemic infection [13, 435, 503]. In this study, all analyses were performed the blood 
collected from patients with sepsis. While the results of this study to date are promising 
and support a role for low-dose aspirin induced resolution of inflammation, it is still 
unclear whether the effects seen in circulation extend to tissue inflammation, contributing 
to reduced organ-damage. With this in mind, an animal model of systemic bloodstream 
infection was established (described in Chapter 4 of this thesis). This model permits the 
investigation of tissue damage and potential organ failure seen in early development of 
sepsis.  
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3.5. Conclusion 
Despite the number of adjunct therapies investigated for their potential in targeting 
excessive inflammation in sepsis, none have shown therapeutic benefit in clinical setting. 
Both animal models of infection, and observational studies in patients have shown 
increased evidence to support the use of low-dose aspirin in patients with sepsis; 
proposed to be mediated primarily by anti-inflammatory/pro-resolving actions  
[16-18, 61, 64, 220].  
The results of this study to date are in keeping with the hypothesis and have shown that 
low-dose aspirin therapy (100 mg daily) induced the increased production of 15-epi-LxA4 
within 1 h of administration, with downstream effects including inhibiting NFκB 
activation (not seen previously with this dose). Further, low-dose aspirin moderately 
altered circulating leukocyte proportions, consistent with mechanisms of aspirin shown in 
other inflammatory conditions. While the results of this study are preliminary and 
extended analyses are required in a larger subset of patients to achieve statistical 
significance, the therapeutic benefits of aspirin therapy shown here are encouraging for 
the support of low-dose aspirin as an adjunct therapy of sepsis.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Investigating the effects of aspirin treatment in a murine 
model of gram-positive induced sepsis  
4.  
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4.1. Introduction 
Sepsis is a complex inflammatory condition that occurs in response to infection, and at its 
most severe, a hyper-inflammatory state leading to organ failure and death [24, 483]. 
Epidemiological studies have revealed that since 1987 there has been a shift, toward 
gram-positive organisms as the leading source of bloodstream infections [4]. Among 
these, Staphylococcus aureus is the most important pathogen that causes a range of 
diseases, from mild skin infections to septic shock. Currently, S. aureus is the most 
frequently isolated gram-positive organism in patients with sepsis. Animal models are 
widely used to study the immunology of infections and associated inflammatory 
conditions including sepsis, allowing the extended analysis of target organs commonly 
damaged.  
Recently a number of published reports have prompted a debate as to whether mouse 
models of sepsis are a good representation of human disease (discussed in section 1.2.6). 
A meta-analysis of transcription profiles of inflammatory genes in PBMC, initially 
suggested a poor correlation between human systemic inflammation and the mouse 
models [222]. However, a later study analysed the same data sets using different 
methodology and concluded that the gene expression patterns were in fact similar [223]. 
Given the significant experimental differences between models that neither of these 
studies took into account, the issue remains controversial. For inter-species comparisons 
to be useful, considerations must be made in regards to time frames, doses used, and 
parameters measured in experimental protocols, as well as any acknowledging genetic 
variables that may exist [224].  
Animal models are also commonly used in the development of novel adjunct therapies of 
sepsis. Of the many pharmacological agents showing promise in animal models of sepsis, 
none have shown considerable therapeutic benefit in human clinical trials; reflecting a 
lack of mouse models that accurately represent the human clinical condition, most likely 
due to the differences in responses to infection and inflammation (reviewed in [148]). 
One way to shed more light on the limitations of animal models is to carefully develop 
models to closely mimic that seen in patients, and to measure similar parameters as 
markers of outcome or severity. 
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The study described in the previous chapter suggests that low-dose aspirin therapy 
impacts immunological pathways as an adjunct therapeutic in clinical sepsis, more 
specifically by increasing the production of plasma 15-epi-LxA4 and inhibiting the 
activation of NFκB. Further, aspirin therapy via production of 15-epi-LxA4, can lead to 
increased activation of monocytes/macrophages while inhibiting activation and migration 
of neutrophils, and contribute to resolution of inflammation (reviewed in [469, 504]).  
Aspirin and other NSAIDs have also been shown to induce L-selectin shedding on 
neutrophils, to reduced inflammation in tissues [505]. PSGL-1 is a well-described ligand 
of L-selectin [97], and an integral surface adhesion molecule for recruitment of 
neutrophils to tissues [98]. Decreased surface PSGL-1 on activated leukocytes has also 
been suggested to impact recruitment to other tissues. Therefore, it was of interest to 
investigate the expression of these two markers on leukocyte surfaces to determine 
whether sepsis or aspirin therapy had an effect. 
A number of studies have shown a similar mechanism of action for aspirin therapy in 
other rodent models of inflammation (discussed in section 1.4.3). Of those showing 
similar beneficial effects of aspirin described above, aspirin doses administered in rodent 
model studies were 20-times higher than doses administered to patients in the clinical 
study in the previous chapter [18, 214]. In order to mirror the clinical study more closely, 
lower doses of aspirin were selected for this study. 
The study described within this chapter aimed to establish a model of gram-positive 
bloodstream infection using S. aureus, in order to further explore the hypothesis that 
underlies the clinical trial described in the previous chapter. In order to facilitate 
comparison of this animal model with our human trial participants, where possible the 
same parameters measured in patients were studied in mice. In addition, the effect of 
aspirin treatment on the impact of sepsis on target organs was investigated. 
The hypothesis was therefore; that low-doses of aspirin will induce immuno-modulatory 
effects in mice with S. aureus-induced sepsis.  
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In order to address the hypothesis, the specific aims of the experiments in this chapter 
were: 
• To establish a model of gram-positive sepsis using S. aureus in wild-type 
C57BL/6 mice 
• To determine the effects of two doses of aspirin (1 mg/kg and/or 10 mg/kg) on 
immune responses in wild-type C57BL/6 mice with gram-positive sepsis 
More specifically to: 
o Determine whether aspirin could improve clinical outcomes in mice with 
staphylococcal-induced sepsis 
o Quantitate levels of 15-epi-LxA4 produced in plasma of septic mice to 
determine an effect of aspirin therapy 
o Determine whether aspirin therapy inhibits the activation of NFκB in PBMC 
o Determine the impact on cytokine levels in plasma as a measure of 
inflammatory activation 
o Characterise changes in immune cell sub-populations in blood and spleen as a 
representative organ in mice with sepsis to assess the effects of aspirin-therapy 
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4.2. Materials & Methods 
4.2.1. Animal model of gram-positive sepsis 
A bloodstream infection was induced by injecting 1×107 CFU of S. aureus into the tail 
vein of female wild-type C57BL/6 mice. Mice were monitored for 2 days. At the end of 
the experiment, blood and target organs (spleen, kidney and liver) were sampled for 
bacteria and histology. Systemic inflammatory responses were also assessed. 
Experiments involving animals were carried out with the approval of the RMIT Animal 
Ethics Committee (AEC Permit Number 1213). Six to eight-week-old female C57BL/6 
mice were sourced from the Animal Resource Centre (ARC). Prior to experimentation, 
mice were acclimatised for a minimum of seven days within the RMIT Animal facility 
(RAF) (RMIT University, Australia). A maximum of four mice were housed in a single 
housing unit, were fed standard rodent chow and had access to sterilised-water ad libitum. 
4.2.1.1. Bacterial strain used in systemic infections 
The methicillin-susceptible S. aureus ATCC 25923 (SA25923) strain was used to 
establish a blood-stream infection in C57BL/6 mice. The selection of this strain (rather 
than an MRSA) was primarily for safety reasons to decrease risks to personnel. This 
strain was kindly provided by Senior Technical Officer, Helen Williams (RMIT 
University, Australia).  
SA25923 was grown in broth culture at 37°C overnight, and the absorbance at 595 nm 
was measured. The broth culture was diluted to achieve an absorbance measurement of 
1.0 (equivalent to approximately 1 × 108 CFU/mL) and then bacteria were harvested by 
centrifugation, washed and re-suspended in sterile PBS to achieve a final concentration of 
1 × 108 CFU/mL. 
4.2.1.2. Mouse model of systemic infection  
Experimental groups of 14-15 mice received a single dose of 1 × 107 CFU of SA25923 (in 
PBS) in a total volume of 100 µL by intravenous tail-vein injection (see Figure 4.1). 
Viable counts were determined by plating serial dilutions of the inoculum. 
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Figure 4.1: Timeline for S. aureus sepsis model. Female C57BL/6 mice (n=44) received 107 CFU of SA25923 by i.v injection in the tail-vein. 
Mice received oral low-dose aspirin by gavage (represented in red symbols) (1 mg/kg; n=14), or high dose aspirin (represented in blue symbols) 
(10 mg/kg; n=15). Aspirin was administered in two doses; 1 h following infection and 24 h following first aspirin dose. Naïve mice (represented 
in purple; n=10) were not infected and did not receive aspirin therapy, and infected only mice (represented in green symbols; n=15) did not 
receive aspirin. Mice were weighed prior to infection, monitored every 2-4 h and weighed every 6 h for signs and symptoms of systemic 
inflammation. Monitoring was performed for 2 days according to established criteria (Table 2.2).  
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Aspirin  (1 mg/kg or 10 mg/kg; equivalent to a human dose of 100 mg (low-dose) or  
1000 mg (high-dose) respectively, prepared as described in section 2.2.2, Sigma-Aldrich) 
was administered to groups of 14-15 mice by oral gavage using a s/steel blunt ended 
gavage needle (18G; Popper and Sons Inc, USA). Infected only control mice (n=15) did 
not receive aspirin. Aspirin treatment was administered on day 0 and on day 1 of the 
experiment (~24 h following the first treatment). 
Mice were weighed every 6 h and monitored every 2-4 h following infection and aspirin 
treatment for signs and symptoms, indicating the progression/resolution of sepsis. 
Monitoring was performed for 2 days according to the criteria as outlined in Table 2.2 
(Chapter 2). Humane end-point criteria for this study were: mice displaying a clinical 
score of 3 for any one criterion, or a total score from multiple criteria of ≥10 (note >9 was 
expected), or mice displaying ≥15% weight loss. 
4.2.1.3. Termination of experiment and sample collection 
On day 2, mice were euthanised via CO2 inhalation; blood was collected immediately by 
cardiac puncture into syringes pre-loaded with 200 µL sterile Alsever’s solution 
(described in section 2.4.2). Mice were transferred to a biosafety level 2 cabinet to 
minimise contamination with air microorganisms, organs were removed and divided into 
sections for analysis of bacterial load, histology and other immunological parameters. 
Blood was processed by centrifugation as described in section 2.5.1, then plasma and 
PBMC pellets were aliquoted into microcentrifuge tubes and stored at -80°C, for batch 
analysis. 
4.2.2. Determination of bacterial load in blood and organs 
An aliquot of blood collected into Alsever’s solution was diluted 1:2 in BHIB, and a total 
volume of 100 µL was then spread plated onto BHIA and colony counts were performed 
after overnight incubation at 37°C. 
Spleen, kidney and liver were collected into pre-weighed tubes containing 2 mL BHIB, 
filled tubes were weighed and the tissue was homogenised with the Bio-Gen™ PRO200 
homogeniser (PRO Scientific). Homogenates (100 µL) were spread plated onto BHIA, 
and colony counts were performed as described above. 
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4.2.3. Histological assessment of organ damage 
Tissues harvested from mice were embedded in Tissue-Tek® O.C.T™ medium (Sakura 
Finetek) and stored at -80°C. Sections were cut (as described in Section 2.4.3), mounted 
onto StarFrost® superclean slides (ProSciTech) and stored at -80°C. 
4.2.3.1. Haematoxylin and eosin staining and scoring of inflammation 
Frozen 10 µm sections of spleen were fixed in 4% neutral buffered formalin (Thermo 
Fisher Scientific). Sections were washed in PBS once before being stained with 
haematoxylin and eosin. Stained sections were examined under light microscopy for 
assessment and scoring of tissue damage. Images were captured using a Leica DM2500 
microscope and Leica Application Suite software (Leica).  
H & E stained spleen sections were scored in a blinded manner for the presence of 
inflammation. A semi-quantitative scoring system was used, as described by Wiersinga  
et al. [506] where assessment of inflammation, apoptosis/necrosis leading to abscess 
formation and thrombus formation was made. Minor modifications were made to the 
score-range, with each parameter listed above being graded on a scale of 0 to 3: 0, none; 
1, mild; 2, moderate; 3, severe. The total “splenic inflammation score” was expressed as 
the sum of the scores for each parameter, with the maximum total spleen inflammation 
score being 12. 
4.2.3.2. Immunohistochemical detection of S. aureus in spleen 
Frozen 10 µm sections of spleen were fixed in ice-cold acetone. Sections were air dried 
and rehydrated in PBS for 10 min then were permeabilised with PBS containing 0.2% 
Triton X-100. Fc Receptor blocking was performed by incubation with PBS/1% BSA and 
serum from the host species of the secondary antibody (described in section 2.4.3.2) for  
1 h at RT. Slides were inverted to remove excess blocking solution, and the primary 
antibodies were added (rabbit anti-S. aureus, (1:200; Abcam), and rat anti-mouse CD11b, 
(1:100; BioLegend) in PBS/1% BSA) and sections were incubated overnight at 4°C. 
Sections were washed three times for 10 min in PBST and secondary antibodies were 
added (anti-rabbit Cy3 (1:1000; Abcam) and anti-rat Alexa Fluor® 488 (1:800; Life 
Technologies) in PBS/1% BSA), and slides were incubated for 1 h at RT. Following this, 
slides were washed 3 times in PBST then incubated with DAPI nuclear stain in PBS/1% 
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BSA (2 µg/mL) for 20 min at RT (in the dark). Slides were washed frequently in PBST 
over 30 min, mounted in Mowiol (described in section 2.4.3.2) and examined the 
following day. Images were captured as described above. Images were overlayed for 
display using Adobe Photoshop software (Adobe). 
4.2.4. Detection of 15-epi-LxA4 in plasma of mice with sepsis 
4.2.4.1. Enrichment of plasma proteins and lipids 
Plasma was enriched for proteins and lipid mediators including 15-epi-LxA4, using the 
Bond Elute C18 OH solid phase extraction column (Agilent technologies) prior to 
quantification using an immunoassay (described in section 2.5.4.1). Columns were pre-
conditioned by washing with methanol and MQH2O. Plasma samples (500 µL) were 
acidified to pH 3.5 with 1 mol/L HCl, then diluted 1:4 in MQH2O and added to columns. 
Columns were centrifuged as described, and the eluate was discarded. Columns were 
washed with MQH2O and petroleum ether, and plasma proteins and lipids were eluted 
with methyl formate. Solvents were evaporated under a stream of nitrogen gas, and dried 
pellets were resolubilised in 100 µL 1× 15-epi-LxA4-Extraction Buffer, prior to 
quantification using the 15-epi-LxA4 EIA kit (Oxford Biomedical Research Inc). 
4.2.4.2. Quantification of 15-epi-LxA4 in plasma by ELISA 
Quantification of plasma 15-epi-LxA4 was performed according to the manufacturers 
specifications. Purified proteins and lipid mediators enriched from plasma were further 
diluted 1:5 in 1× 15-epi-LxA4-Extraction Buffer, and 50 µL was added in duplicate to 
wells of a 96-well Costar® microplate, pre-coated with anti-15-epi-LxA4 rabbit antibody. 
Next, 50 µL of diluted 15-epi-LxA4-HRP conjugated antibody was added to each well, 
plates were mixed briefly by shaking gently on a plate shaker, covered and incubated at 
RT for 1 h. Following incubation, plates were washed three times with 300 µL, 1× Wash 
Buffer and TMB substrate solution was added to each well, plates were mixed on a plate 
shaker (as described above) and incubated at RT for 30 min. Absorbance was measured at 
650nm using the POLARstar Optima multi-detection microplate reader (BMGlabtech). 
Concentrations of 15-epi-LxA4 were determined using standard curves generated from  
0 to 2 ng/mL, and adjusted for dilution factor and starting volume of plasma.  
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4.2.5. Detection of NFκB activation  
4.2.5.1. Preparation of nuclear and cytoplasmic extracts 
Nuclear and cytoplasmic extracts were prepared with the use of the NE-PER nuclear and 
cytoplasmic extraction reagents (Pierce) according to the manufacturers specifications. 
PBMC pellets were washed once in FACS wash buffer and once in PBS. Then cells were 
resuspended in ice-cold CER I buffer (supplemented with 1× cOmplete ULTRA protease 
inhibitor cocktail; Roche AG) and ice-cold CER II buffer, vortexed vigorously and 
incubated on ice. Cells were vortexed vigorously for 5 s and centrifuged as described and 
supernatants (cytoplasmic extracts) were transferred to a pre-chilled microcentrifuge tube 
and stored at -80°C. Remaining pellets (containing nuclei) were resuspended in ice-cold 
NER buffer (supplemented with 1× cOmplete ULTRA protease inhibitor cocktail; Roche 
AG), vortexed vigorously for and incubated on ice. This process was repeated every  
10 min for a total of 40 min. Cells were centrifuged and supernatants (nuclear extracts) 
were transferred to a pre-chilled microcentrifuge tube and stored at -80°C. 
4.2.5.2.  Chemiluminescent detection of NFκB p65 activation  
The activation of the NFkB p65 in nuclear extracts (prepared as described) was detected 
using the NFkB p65 Transcription factor assay (Pierce) according to the manufacturers 
specifications. Working Binding Buffer was added to each well of the 96-well NFκB 
Assay Plate provided, prior to addition of nuclear extracts (added in duplicate). Plates 
were incubated at RT for 1 h (on a plate shaker), and washed three times with 1× NFκB 
Assay Wash Buffer. Plates were incubated with NFκB p65 primary antibody (1:1000; in 
supplied Antibody Dilution Buffer) at RT for 1 h, under static conditions. Plates were 
washed three times as described then incubated with HRP-conjugated secondary antibody 
(1:10,000) at RT for 1 h, under static conditions. Plates were washed four times as 
described then substrate working solution (prepared as described in section 2.5.5.2) was 
added. Chemiluminescence expressed as relative fluorescence units (RFU) was detected 
using the luminometer function on the POLARstar Optima multi-detection microplate 
reader (BMGlabtech). 
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4.2.6. Quantification of plasma cytokine levels using the 
LEGENDplex™ multi-analyte flow assay kit 
Levels of pro-inflammatory cytokines in plasma samples were quantified using the 
LEGENDplex™ Mouse Inflammation panel (13-plex) flow assay (BioLegend). All 
procedures were performed according to manufacturers instructions (as described in 
section 2.5.6). Cytokine standards and samples were prepared in LEGENDplex™ Assay 
buffer and were added to a 96-well U-bottom plate (Nunc A/S). Sonicated pre-mixed 
beads and detection antibodies were added to each well and then plates were incubated (in 
the dark) on a plate shaker at 600 rpm for 2 h at RT. Following incubation, streptavidin–
PE solution was added to each well and further incubated for 30 min at RT. Samples were 
analysed and data collected using the FACSCanto II (Beckton Dickinson). Data were 
analysed using the BioLegend LEGENDplexTM Data Analysis Software with standard 
curves generated from 0 to 50,000 pg/mL, and samples adjusted for dilution factor. 
4.2.7. Analysis of cell populations 
4.2.7.1. Preparation of single cell suspensions 
4.2.7.1.1. Blood 
Following centrifugation and removal of plasma, cells were re-suspended in TAC red cell 
lysis buffer (prepared as described in section 2.5.1) and incubated at 37°C for 5 min to 
lyse contaminating erythrocytes. Cells were then washed by centrifugation and re-
suspended in FACS wash buffer (prepared as described in section 2.2.3). 
4.2.7.1.2. Spleen 
Spleens were collected into ice-cold DMEM complete media (prepared as described in 
section 2.2.3). Cells were placed in petri dishes and were gently teased through a 40 µm 
cell strainer (Biologix). Following a washing step cells were re-suspended in TAC red 
cell lysis buffer and incubated at 37°C for 5 min to lyse contaminating erythrocytes. Cells 
were then washed and re-suspended in FACS wash buffer. 
4.2.7.2. Flow cytometry 
For flow cytometry, 106 cells from blood or spleen were incubated with Fc receptor block 
(purified anti-mouse CD16/32 Antibody; BioLegend), at 4 µg/mL in 50 µL FACS wash 
Chapter 4	
	
	
	 Page 134 
buffer for 30 min on ice. The antibodies used for staining are listed in Table 2.3 (Chapter 
2). Staining was performed in 100 µL FACS wash buffer for at least 30 min on ice. 
Following this cells were washed twice in FACS wash buffer, before being re-suspended 
in PBS for data acquisition. 
Compensation was performed using UltraComp eBeads (eBioscience) based on the single 
staining of each individual fluorochrome and correction for auto-fluorescence with 
unstained beads and cells. Data was collected using the FACSCanto II as described 
above. A five-decade logarithmic scale was used to process fluorescence signals and a 
linear scale was used to process light scattering signals. Single cells were gated and 
populations of cells were defined as T lymphocytes (CD3+, CD4+, CD8+), 
monocytes/macrophages (CD3-, CD11b+, Ly6G-) and neutrophils (CD3-, CD11b+, 
Ly6G+). 
4.2.8. Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 6.0 for Macintosh 
(GraphPad Software). Unless stated, the differences observed between two means were 
analysed using a two-tailed Mann-Whitney test where p<0.05 was considered significant.  
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4.3. Results 
4.3.1. Establishing a model of gram-positive sepsis in C57BL/6 wild-type 
mouse strain 
Two dose-finding studies were performed in order to determine the number of  
S. aureus (SA25923) that would induce sepsis in wild-type C57BL/6 mice, and permit 
analysis over an approximately 48 h, without reaching the humane endpoint criteria. Mice 
were initially infected with either 106 or 107 CFU by tail vein injection and monitored 
every 2-4 h for a period of 48 h (to mirror human subject sampling times described in 
section 3.2.2) and weight and clinical parameters were recorded (see Table 2.2).  
Although mice were monitored for changes over a range of criteria, the only criteria that 
represented a measurable difference were change in weight. Mice infected with 106 CFU 
S. aureus, displayed few detectable symptoms and varying degrees of weight loss 
indicating this dose was not effective in inducing sepsis. When compared with naïve 
mice, mice that received the 107 CFU dose of S. aureus displayed moderate loss of weight 
over time (10-15% weight lost compared with initial start value) (data not shown). A 
dosage of 107 CFU was chosen for the following studies. 
4.3.2. Effect of aspirin treatment in mice with gram-positive sepsis 
4.3.2.1. Observations of clinical and physical parameters 
Mice were infected with 107 CFU of S. aureus by tail-vein injection at time 0 (T0). 
Control mice were not infected or treated with aspirin, and used to determine baseline 
values (naïve mice). Following this, two doses of aspirin (at 1 h and 24 h post-infection) 
were administered orally, to groups of 14-15 mice. A separate group of mice (n=15) were 
also infected but did not receive aspirin therapy (infected only control mice). For the 
duration of the experiment the mice were monitored every 2-4 h for changes in weight 
and clinical parameters for sepsis progression (according to criteria outlined in Table 2.2). 
None of the mice that were infected with S. aureus met the criteria for humane end-point 
intervention during the course of the study (described in section 4.2.1.2).  
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Naïve mice maintained a steady weight over time. In contrast, mice infected with  
S. aureus began to lose weight 12 h after infection (Figure 4.2A; p<0.05, one-way 
ANOVA). After a second dose of aspirin (24 h post-infection), low-dose aspirin-treated 
mice (1 mg/kg) began to re-gain weight, with mean weights returning to starting values 
equivalent with naïve mice 48 h post-infection (Figure 4.2A; p<0.05, one-way ANOVA). 
Interestingly, mice treated with high-dose aspirin (10 mg/kg) and infected only control 
group displayed significant weight loss (p<0.05, one-way ANOVA) compared with naïve 
mice.  
This trend was also shown in clinical scores. Although individual variation was seen in 
mice of all treatment groups, following a second dose, clinical scores of low-dose aspirin-
treated group decreased, compared with infected only and high dose aspirin groups, 
which continued to increase (Figure 4.2B; p<0.05, one-way ANOVA). 
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Figure 4.2: Wild-type mice with S. aureus sepsis demonstrate improvements in A) 
weight and B) clinical score following low-dose aspirin therapy. C57BL/6 Mice were 
weighed and clinical scores determined at T0 and every 6 h until 48 h post-infection. 
Infected control mice and high-dose aspirin-treated mice exhibited significant weight 
loss; low-dose aspirin-treated mice regained weight and were equivalent to naïve mice by 
48 h. Clinical scores of infected control mice and high-dose aspirin-treated mice 
increased significantly; clinical scores of low-dose aspirin-treated mice decreased 
following a second dose of aspirin. Weight data are expressed as percentage change from 
start weight; Clinical scores are expressed as range between 0-4 (according to criteria in 
Table 2.3), and all data represent mean ± SEM (n=3-15 per group/time-point, one-way 
ANOVA, *p<0.05).  
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4.3.2.2. Bacterial load of S. aureus in blood and organs 
The bacterial burden was enumerated in mice to determine whether aspirin treatment 
improved clearance of bacteria from blood and organs. Evidence from a previous study 
suggests that wild-type C57BL/6 mice are more resistant to infection with S. aureus, than 
other strains [241], and this may be why a relatively high dose of 107 was required to 
induce observable symptoms of sepsis.  
Blood was diluted 1:2 and plated onto BHI agar plates. No viable bacteria were measured 
in the blood or organs of naïve mice (data not shown). Within 12 h of being infected with 
107 CFU S. aureus, all mice showed a minimum 3-fold drop in the number of viable 
bacteria in the bloodstream. Decreases in bacterial load continued, with lowest counts 
observed at 48 h post-infection (Figure 4.2A).  
In order to determine the extent of the systemic spread of bacteria to organs, homogenates 
of spleen, kidney and livers were diluted and plated onto BHI agar plates. Initial counts at 
12 h post-infection in organs showed the highest level of bacterial burden with colony-
forming units (CFU) in spleen, comparable with the initial inoculum. Following this time-
point there was a gradual decrease in bacterial counts retrieved (as seen in the blood), 
suggestive of bacterial clearance.  
No significant differences were seen between treatment groups at either 12 or 24 h post-
infection (Figure 4.3B-D). Remarkably, at 48 h post-infection low-dose aspirin-treated 
mice showed a 4-5 log reduction in bacterial count with complete clearance of viable 
bacteria observed in all target organs assessed, while infected only controls and high-dose 
aspirin-treated mice still had detectable bacterial counts (Figure 4.3; p<0.05).  
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Figure 4.3: Effective clearance of S. aureus from organs in low-dose aspirin-treated 
mice by 48 h post-infection. A) Blood was diluted two-fold and plated onto BHI agar 
plates determine colony-forming units (CFU) normalized for volume (mL). B) Spleen,  
C) kidney, and D) liver homogenates were ten-fold diluted and plated on BHI agar plates 
to determine CFU/g tissue. At 48 h post-infection, low-dose aspirin-treated mice showed 
complete clearance of viable bacteria in the target organs sampled compared with infected 
control and high-dose aspirin-treated mice. Data represent mean ± SEM, (n=4-5 per 
group/time-point, two-tailed Mann-Whitney test *p<0.05). 
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4.3.2.3. Assessment of organ damage in S. aureus infected and aspirin-treated 
C57BL/6 mice 
4.3.2.3.1. Histological scoring 
The extent of damage sustained by organs induced by systemic staphylococcal infection 
in all treatment groups was determined 48 h post-infection. Spleens of naïve, infected and 
aspirin-treated mice (n=3-5 per group) were stained with haematoxylin and eosin (H & 
E). When compared with the naïve mice (Figure 4.4A), no significant increase in 
inflammation or organ damage was seen in any of the treatment groups, with all spleen 
sections receiving scores of 0 for all parameters (Figures 4.4B-D). From bacterial load 
results (Figure 4.3), remaining bacteria in infected only mice and high-dose aspirin-
treated mice at 48 h post-infection did not appear to induce extended tissue damage, and 
no differences were seen compared with low-dose aspirin-treated mice that demonstrated 
complete bacterial clearance at this time-point. Attempts to perform histological analyses 
of other organs were unsuccessful, as incorrect freezing technique caused tissue damage.  
4.3.2.3.2. Immunolocalisation of S. aureus and inflammatory cells in spleen tissue 
To confirm the presence of bacteria and immune cells in organs 48 h after systemic 
staphylococcal infection, spleen sections were analysed by immunfluorescence (IF) 
microscopy. Spleen sections from naïve (n=3), infected (n=5) and aspirin-treated mice 
(n=4), at 48 h post-infection were stained for the localisation of S. aureus, as well as 
monocyte/macrophage surface marker CD11b. Representative images are shown in 
Figure 4.5. Infected control and high-dose aspirin-treated mice had positively stained  
S. aureus at 48 h post-infection, while low-dose aspirin-treated mice did not have any 
detected S. aureus staining, comparable with naïve control mice. These data were 
reflective of bacterial loads retrieved from spleen of low-dose aspirin-treated mice 
(Figure 4.3). Staining of S. aureus within the spleen showed no specific localization 
patterns, with bacteria visible in all areas of the spleen. CD11b+ cells were detectable in 
all treatment groups, and co-localisation of CD11b+ cells and S. aureus was visible in 
infected and high-dose aspirin-treated groups, suggestive of leukocyte-mediated bacterial 
clearance. These leukocyte populations were also further assessed by flow cytometry 
analysis in both blood and spleen populations (see section 4.3.2.7). 
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Figure 4.4: No evidence of tissue damage in spleen of C57BL/6 mice with S. aureus 
sepsis. Haematoxylin and eosin (H & E) stained sections of spleen were observed under 
light microscopy. Representative sections from A) naïve, B) infected only, C) infected 
and low-dose aspirin and D) infected and high-dose aspirin. Scale bar: 50 µm. Original 
magnification: 10x. 
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Figure 4.5: S. aureus and CD11b+ cells are co-localised in spleen at 48 h post-infection. Representative images showing the detection of  
S. aureus (red) and CD11b (green), in mouse spleens. Infected only and high-dose aspirin-treated mice had detectable S. aureus in spleen. Low-
dose aspirin-treated mice had no detectable S. aureus in the spleen. Scale bar: 50 µm. Original magnification: 40x. Arrows indicate 
immunoreactivity for S. aureus.  
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4.3.2.4. Quantification of plasma 15-epi-LxA4 in mice with sepsis 
Plasma 15-epi-LxA4 was used as a surrogate marker of resolving inflammation. In this 
study, proteins and lipids were enriched in plasma from naïve mice, infected only controls 
and infected mice treated with either low or high-dose aspirin, and levels of 15-epi-LxA4 
were analysed using a quantitative ELISA. Concentrations were analysed for individual 
mice and mean values were expressed in ng/mL derived from standard curves (as 
described in section 4.2.3). All infected mice tended to have increasing levels of  
15-epi-LxA4 compared with naïve mice, however no significant differences in  
15-epi-LxA4 levels were seen between infected only controls and aspirin-treated mice 
(Figure 4.6).  
4.3.2.5. Determination of NFκB activation 
In order to determine whether the inhibition of NFκB activation observed in aspirin-
treated patients in clinical study (see Chapter 3) also occurs in the mouse model of 
systemic infection, nuclear extracts from PBMC pellets from whole blood of naïve, 
infected and aspirin-treated mice were analysed using a p65 specific sandwich ELISA. 
Chemiluminescent detection was used to measure levels of activation of the p65 subunit 
of NFκB, and mean values of luminescence were expressed as a percentage of normalised 
start value. When compared with naïve mice, all infected and aspirin-treated mice showed 
increase in NFκB p65 activation by 24 h post-infection (Figure 4.7). Of interest, high-
dose aspirin-treated mice showed a significant increase in NFκB p65 activation, 
compared with naïve mice (Figure 4.7; p<0.05). At 12 h post-infection, no significant 
differences were observed between infected only mice and low-dose aspirin-treated mice. 
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Figure 4.6: Levels of 15-epi-LxA4 detected in plasma of C57BL/6 mice with sepsis 
were not affected by aspirin treatment. Levels of plasma 15-epi-LxA4 were measured 
by immunoassay at baseline (0 h), 12 h and 24 h post-infection. All data are represented 
as mean ± SEM, (n=3-5 mice per group/time-point). 
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Figure 4.7: Low-dose aspirin did not significantly affect activation of NFκB in 
nuclear extracts of C57BL/6 mice with sepsis. Nuclear extracts from naïve, infected 
and aspirin-treated mice at baseline (0 h), 12 h and 24 h post-infection were analysed for 
activation of the p65 subunit of NFκB. High dose aspirin-treated mice showed 
significantly increased NFκB activation, compared with naïve mice. All data are 
represented as mean ± SEM and expressed as percentage change from (0 h) time-point 
(n=3-5 per group/time-point, two-tailed Mann-Whitney test, *p<0.05). 
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4.3.2.6. Levels of inflammatory cytokine production 
Analysis of 13 different cytokines in the plasma extracted from mice with systemic 
staphylococcal infection was performed using the bead-based sandwich LEGENDplex™ 
immunoassay. The concentrations of IL-1α, IL-1β, IL-6, IL-10, IL-12p70, IL-17A, IL-23, 
IL-27, MCP-1, IFN-β, IFN-γ, TNF-α, and GM-CSF were assessed and the mean values 
expressed as pg/mL, derived from standard curves performed with corresponding 
recombinant mouse cytokine standards (described in section 4.2.5). 
While no significant differences were observed between infected or treatment groups for 
IL-1β production, individual mice showed some increased production; with a single 
mouse in the infected only group (366.33 pg/mL) at 24 h post-infection, and a single 
mouse in the low-dose aspirin-treated group (439.26 pg/mL) at 48 h post-infection 
(Figure 4.8A). A significant increase in the production of IL-6 was seen at 24 h post-
infection, in the infected only (mean concentration of 721.87 pg/mL) and aspirin-treated 
mice (low-dose and high-dose aspirin-treated mice 508.87 pg/mL and 1,019.78 pg/mL, 
respectively), compared with the naïve mice (17.23 pg/mL) (Figure 4.8B). Mean 
concentrations of IFN-γ and MCP-1 were also elevated at the 24 h time-point, but there 
was considerable variation between individuals, only MCP-1 in infected only mice 
showed significant differences compared with naïve mice. Similar to IL-1β production, 
levels of GM-CSF or TNF-α did not differ. Interestingly, the same mice that showed 
increases in IL-1β levels also showed similar increases in detected levels of GM-CSF and 
TNF-α (Figure 4.8C and 4.8F). 
No significant differences were observed in plasma levels of IL-1α, IL-10, IL-12p70,  
IL-17A, IL-23, IL-27, or IFN-β in infected or aspirin-treated mice compared with naïve 
mice at either 24 h or 48 h post-infection, however responses for cytokines varied with 
individual mice from each group exhibiting some increased production (Figure 4.9 and 
4.10). One mouse in the low-dose aspirin-treated group showed increased levels of IL-1α 
(483.26 pg/mL), IL-10 (1183.51 pg/mL) and IFN-β (48.44 pg/mL) compared with plasma 
levels of naïve mice at 48 h post-infection.  
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Figure 4.8: Plasma IL-6 is significantly increased in wild-type mice with sepsis. 
Levels of (A) IL-1β, (B) IL-6, (C) GM-CSF, (D) IFN-γ, (E) MCP-1 and (F) TNF-α in the 
plasma of mice at 24 h and 48 h post-infection. Data are represented as circular symbols 
for individual mice with the bar mean ± SEM, (n=3-5 per group/time-point, two-tailed 
Mann-Whitney test, *p<0.05).  
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Figure 4.9: Individual mice with sepsis showed increases in IL-12 related cytokines 
in plasma. Levels of: A) IL-12p70, B) IL-17A, C) IL-23 and D) IL-27 at 24 h and 48 h in 
the plasma of mice at 24 h and 48 h post-infection. Data are represented as circular 
symbols for individual mice with the bar mean ± SEM, (n=3-5 per group/time-point).  
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Figure 4.10: Individual mice with sepsis showed increases of pro-inflammatory and 
anti-inflammatory cytokines in plasma. Levels of: A) IL-1α, B) IL-10 and C) IFN-β in 
the plasma of mice at 24 h and 48 h post-infection. Data are represented as circular 
symbols for individual mice with the bar mean ± SEM, (n=3-5 per group/time-point).  
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4.3.2.7. Analysis of leukocyte/lymphocyte populations in S. aureus infected and 
aspirin-treated C57BL/6 mice 
In order to determine whether aspirin treatment has an effect on immune responses in 
mice with S. aureus-induced sepsis, flow cytometry analysis on whole blood and spleen 
was performed. Following preparation of single cell suspensions, cells were stained with 
the appropriate antibodies and immune cell subsets were quantified. For all comparative 
flow cytometry analyses; the same antibodies, voltage settings on the flow cytometer 
(FACS Canto II) and gating strategies were used. The gating strategies for the FACS 
experiments are shown in Figure 4.11. In the CD3- population, monocytes/macrophages 
were defined as CD11b+, Ly6G-, and neutrophils as CD11b+, Ly6G+ populations. CD3+ T 
lymphocytes were defined as either CD4+ or CD8+ T lymphocytes (Figure 4.12) 
Proportions of monocyte/macrophage and neutrophil populations in C57BL/6 mice were 
analysed in blood and spleen at 12, 24 and 48 h post-infection (see Figure 4.13). All mice 
showed moderate decreases in the proportion of monocytes/macrophages in blood by  
48 h post-infection, however no significant differences were seen cell proportions in 
either blood or spleen, compared with naïve mice.  
T lymphocytes are important for regulation of innate immune response [36], however 
there is debate regarding the role of T lymphocytes in early sepsis (within the first 48 h 
following onset of symptoms). Here, the proportions of CD4+ and CD8+ T lymphocytes in 
whole blood and spleen were analysed at 12, 24 and 48 h post-infection. No significant 
differences in the proportions of circulating CD4+ or CD8+ T lymphocytes was observed 
in infected and aspirin-treated mice, compared with naïve mice. In contrast, proportions 
of splenic CD4+ T lymphocytes decreased at times in low-dose aspirin-treated mice, 
compared with naïve mice (Figure 4.14; p<0.05, one-way ANOVA), and splenic CD8+  
T lymphocytes decreased at times in infected control mice, compared with naïve mice 
(p<0.05, one-way ANOVA). 
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Figure 4.11: Gating strategy for analysis of immune cell subsets in blood and spleen 
of C57BL/6 mice. Representative FACS plots of cells isolated from the spleen or whole 
blood of naïve, infected and aspirin-treated mice over a period of 48 h. Approximately 
105 events were collected. The leukocyte gate was set using side scatter (SSC-A) and 
forward scatter (FSC-A) profiles (left panel). Forward height (FSC-H) and forward area 
(FSC-A) parameters were used to identify single cells (middle panel). Histograms were 
used to define CD3- or CD3+ (right panel). 
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Figure 4.12: Definition of leukocyte sub-populations in blood and spleen of C57BL/6 
mice. In the CD3- population, monocytes/macrophages were defined as CD11b+, Ly6G-, 
and neutrophils as CD11b+, Ly6G+ populations (Left panel). CD3+ T lymphocyte, CD4+ 
and CD8+ cell populations (right panel). 
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Figure 4.13: Proportions of circulating and splenic monocyte/macrophage and 
neutrophil populations were not significantly affected by infection or aspirin 
therapy. Neither infection nor aspirin treatment had an effect on the percentage of 
CD11b+Ly6G- monocytes/macrophages or CD11b+Ly6G+ neutrophils in either the blood 
or spleen of mice, compared with naïve mice. Data are represented as mean ± SEM, and 
expressed as a percentage of total events collected though the leukocyte gate (n=3-6 per 
group/time-point). 
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Figure 4.14: Proportions of circulating CD4+ or CD8+ T lymphocytes were not 
significantly affected by infection or aspirin treatment. In contrast, low-dose aspirin-
treated mice had significantly reduced splenic CD4+ T lymphocytes, compared with naïve 
mice. Infected control mice showed a significant decrease in proportion of CD8+  
T lymphocytes in spleen, compared with naïve mice. Data are represented as mean ± 
SEM, and expressed as a percentage of total events collected though the leukocyte gate 
(n=3-6 per group/time-point, one-way ANOVA, *p<0.05). 
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4.3.2.7.1. Markers of activation and migration markers 
Cell surface activation and migration markers were analysed, to determine whether 
aspirin therapy might inhibit migration of lymphocytes to tissues limiting inflammatory 
damage. L-selectin is a well known cellular activation and migration marker expressed on 
the surfaces of all leukocytes. PSGL-1 (described in Chapter 3) is also expressed on the 
surface of leukocytes and facilitates migration into inflamed tissues [481, 507]. 
No significant differences in the proportion of circulating L-selectin+CD11b+Ly6G- 
monocytes/macrophages were seen at 24 h post-infection, compared with the naïve group 
(Figure 4.15A, left panel). In contrast, all infected and aspirin-treated groups showed 
significant increases in proportions of L-selectin+ monocytes/macrophages, compared 
with the naïve group (Figure 4.15B, left panel; p<0.05), with a small non-significant 
decrease observed with low-dose aspirin. High-dose aspirin-treated mice showed 
significant increases in proportions of L-selectin+CD11b+Ly6G+ neutrophils in blood, 
compared with infected mice (Figure 4.15A, middle panel; p<0.05), however no 
significant differences were seen compared with naïve mice. In spleen, neither infection 
nor aspirin therapy affected proportions of L-selectin+ neutrophils compared with the 
naïve group (Figure 4.15B, middle panel). Proportions of L-selectin+ CD3+ T lymphocytes 
were low in all of the groups; however all infected mouse groups had increased 
proportions in blood compared with naïve mice (Figure 4.15A, right panel; p<0.05). 
Splenic proportions of L-selectin+ CD3+ T lymphocytes were significantly higher in high-
dose aspirin-treated mice, compared with naïve group (Figure 4.15B, right panel; 
p<0.05).  
Proportions of PSGL-1+monocytes/macrophages in blood at 24 h post-infection were 
decreased in infected control and low-dose aspirin-treated groups, compared with the 
naïve mice (p<0.05; Figure 4.16A, left panel). Splenic proportions of PSGL-1+ 
monocytes/macrophages were also decreased in infected only group compared with naïve 
mice (Figure 4.16B, left panel; p<0.05). No significant differences were observed in the 
proportion of PSGL-1+neutrophils, consistent with what was seen in patients in the 
previous chapter study (Figure 4.16, middle panel). Similarly, PSGL-1 expression on 
CD3+ T lymphocytes was not affected by infection or aspirin therapy (Figure 4.16, right 
panel). 
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In summary, neither bloodstream infection with S. aureus, nor aspirin treatment 
significantly impacted proportions of circulating or splenic monocyte/macrophage or 
neutrophil populations. In contrast, infection with S. aureus decreased proportions of 
splenic CD8+ T lymphocytes and low-dose aspirin decreased splenic CD4+ T lymphocyte 
proportions.  
Proportions of circulating L-selectin+ monocytes/macrophages were not affected by 
bloodstream infection or aspirin therapy, however infection lead to increased L-selectin 
expression on splenic monocytes/macrophages. High-dose aspirin-treated mice had 
increased L-selectin+ neutrophils, compared with infected mice. PGSL-1 expression was 
reduced on monocytes/macrophages in blood of infected mice and aspirin increased this. 
Taken together with the observation that low dose aspirin-treated mice had cleared 
bacteria by 48 h post-infection, these relatively small shifts in cell populations are 
reflections of the impact of aspirin in inflammatory response. 
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Figure 4.15: Proportions of L-selectin positive monocytes/macrophages, neutrophils and CD3+ T lymphocytes in A) blood and B) spleen 
of C57BL/6 mice, 24 h post-infection with S. aureus. Data are represented as circular symbols for individual mice with the mean ± SEM, and 
expressed as percentage of L-selectin positive cells, (n=3-6 per group, two-tailed Mann-Whitney test, *p<0.05). 
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Figure 4.16: Proportions of P-selectin Glycoprotein Ligand 1 (PSGL-1) positive monocytes/macrophages, neutrophils and CD3+  
T lymphocytes in A) blood and B) spleen of C57BL/6 mice, 24 h post-infection with S. aureus. Data are represented as circular symbols for 
individual mice with the mean ± SEM, and expressed as percentage of positive cells (n=3-6 per group, two-tailed Mann-Whitney test, *p<0.05). 
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4.4. Discussion 
The limited number of published studies investigating aspirin treatment in animal models 
of inflammation report encouraging results, with increased survival seen in a canine 
model of endotoxemia with 40-100 mg/kg aspirin for example [508]. Similarly, in mouse 
models of systemic inflammation both treatment with aspirin or epimeric lipoxins (like 
15-epi-LxA4) resulted in attenuation of lung and kidney injury [214, 509] and had 
protective effects in a gram-negative induced peritonitis [17]. As S. aureus is a frequent 
cause of sepsis in a clinical setting [4], this study aimed to determine whether aspirin 
treatment (low-dose or high dose) contributes to resolution of inflammatory conditions in 
wild-type C57BL/6 mice with S. aureus-induced sepsis. An additional aim was to 
develop a mouse model that will closely mimic human sepsis and facilitate future detailed 
analysis in target organs. C57BL/6 mice were selected for use in this study, as they are 
less susceptible to systemic infection with S. aureus [241], therefore providing a robust 
model for the analysis of immunological responses  in the early development of sepsis.   
The primary read-outs from this study were CFU of S. aureus in organs and body weight 
(as a surrogate of overall condition). To dissect pathways that may be involved in 
reductions in inflammation, plasma 15-epi-LxA4 levels, NFκB activation in PBMCs, 
cytokine profiles and immune cell populations were all measured.  
The results from the primary read-outs show that that low-dose aspirin therapy does 
improve outcomes in C57BL/6 mice with S. aureus sepsis. Low-dose aspirin-treated mice 
recovered more quickly from weight loss, had reduced disease severity (clinical scores) 
(Figure 4.2) and remarkably, a complete clearance of detectable bacteria from organs by  
48 h post-infection (Figure 4.3 & 4.5). Interestingly, and unlike the clinical study neither 
15-epi-LxA4 production nor NFκB inhibition were significantly impacted in infected 
mice, regardless of aspirin therapy (Figure 4.6 and Figure 4.7, respectively). Low-dose 
aspirin therapy appears to enhance bacterial clearance and inflammation by other means, 
presumably by affecting immune function. Flow cytometry analysis did reveal impacts of 
low dose aspirin on monocytes/macrophage and neutrophil populations, particularly on 
expression of markers of activation and migration (Figure 4.14 and 4.15). 
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One of the difficulties encountered in this study of the mouse model of sepsis was the 
difficulty in identifying the signs of sepsis. While monitoring was performed according to 
accepted criteria (see Table 2.2), and body temperature was also recorded, weight loss 
was the only consistent indicator that correlated with disease severity. This is likely to be 
in part due to the instinctive behavior or rodents to avoid showing any signs of weakness 
that might alert a predator. This clinical signs and inflammatory changes in this study 
were consistent with early development of sepsis following bloodstream infection. As this 
model represents early stages of sepsis, it is likely that symptomatic responses had not yet 
fully developed. Low-dose aspirin-treated mice did start regaining weight following the 
second aspirin dose, returning to start weight values comparable with naïve mice 
indicating improved overall clinical condition. At 48 h post-infection these mice also 
demonstrated complete clearance of S. aureus in all organs sampled (Figure; p<0.05). 
C57BL/6 mice were shown in a previous study to have an enhanced capacity to limit 
bacterial growth in target organs following intravenous infection with S. aureus, 
compared with other more susceptible strains of mice [241]. While this could explain 
why in the present study histological analysis of the spleen revealed no obvious organ 
damage, despite high bacterial loads (Figure 4.3). It is more likely that this model 
represents early stages of sepsis development and 48 h post-infection may have been too 
early for damage to be apparent. These findings, along with decreases in bacterial load, 
raised the question of the role of innate immune responses in mediating enhanced 
bacterial clearance. Immunohistochemistry revealed monocytes/macrophages/neutrophils 
(CD11b+) co-localised with S. aureus, supporting their role in clearance. Consistent with 
the bacterial load data, no S. aureus was detected in spleens of low-dose aspirin-treated 
mice.  
The 1 mg/kg dosage given to mice (equivalent to 81-100 mg daily doses administered in 
published clinical studies proposing that) is hypothesised to induce the increase  
15-epi-LxA4, leading to activation of monocyte/macrophage populations with the 
understanding being that this activation may enhance phagocytosis [446, 484], and 
similarly reduces influx of neutrophils associated with inflammation and damage [19]. 
While the 10 mg/kg dose is only 10 times greater, its equivalent dosage in humans would 
be ~1000 mg daily dose, closer to the dosage administered for pain relief. At this dose, it 
is not anticipated that the resolving pathways are activated (as this has only been shown 
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with low doses), and therefore not activate the proposed phagocytosis and clearance of 
bacteria. 
The results of our human randomized controlled clinical study described in Chapter 3 
showed moderate increases in plasma 15-epi-LxA4 production and decreases in NFκB 
activation in blood of 100 mg aspirin-treated patients with sepsis. Although small 
increases in plasma 15-epi-LxA4 production were seen in all infected groups of mice in 
this study, the overall levels were lower compared with levels seen in patients in the 
previous chapter, and no apparent effect of aspirin was noted. Post-treatment with LxA4 
and 15-epi-LxA4 have also been linked to better outcomes in numerous animal sepsis 
models [17, 510]. Mice with gram-negative sepsis showed reduced bacterial load and 
improved survival when treated with a combination 15-epi-LxA4 and ceftadizime 
therapies [17].  
While this differed with results observed in our clinical study, it is comparable with data 
reported in studies investigating lipoxin production in other rodent models of infection, 
even with aspirin doses 10 times greater than in this study [214]. In a previous study of 
LPS treated mice, 15-epi-LxA4 was detected in lung fluid but not blood after treatment 
with 10 mg/kg aspirin, the maximum dose used in the present study. Indeed, significant 
increases in plasma 15-epi-LxA4 have been observed in mice when treated with doses of 
200 mg/kg of aspirin or greater [18]. Similar to what has been shown in both trial 
participants in Chapter 3 and other published clinical studies, infected only mice in this 
study did produce detectable levels 15-epi-LxA4 in the absence of aspirin, with 48 h 
levels comparable with levels seen in trial participants. While the source of this  
15-epi-LxA4 is unclear, these results confirm that inflammation alone can moderately 
increase 15-epi-LxA4 production in the absence of aspirin [19, 214]. 
It is possible that the reason for the lack of aspirin-dependent responses observed in this 
study is due to the time frame over which the mice were sampled for analysis. This 
animal model of sepsis was designed following analysis of the first batch of patients from 
the MATHS trial, where interim results showed changes in primary parameters of  
15-epi-LxA4 and NFκB occurring later (8 h following aspirin). This provided the basis for 
the 12, 24 and 48 h time-points selected in the current study. However, these time-points 
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are no longer reflective of patient response times (~1-8 h aspirin-induced response) and as 
such, the peak increases for both of these parameters will likely have been missed. 
While patients enrolled in the clinical study have sepsis on entry to the trial, mice in this 
study were infected at T0 and did not have pre-existing bacteremia at the time of the first 
aspirin dose. This will likely have affected the responses, with baseline concentrations of 
15-epi-LxA4 lower in mice, compared with patients (Figures 4.6 and 3.2, respectively). 
Plasma 15-epi-LxA4 production was shown to moderately increase within 1 h of aspirin 
therapy in sepsis patients in Chapter 3. The kinetics of 15-epi-LxA4 synthesis in organs 
that are the primary site of inflammation may differ from that in plasma, and warrant 
further investigation in future studies. In a recent mouse study, levels of 15-epi-LxA4 
were shown in lungs to increase as rapidly as 15-30 min following aspirin treatment, 
while plasma levels did not change [214]. Future studies should investigate the 
production of 15-epi-LxA4 in plasma at earlier time-points following aspirin 
administration, as well as evaluating 15-epi-LxA4 production in target organs; to 
determine whether the aspirin-specific response occurs rapidly as seen in patients 
(Chapter 3). Further, 15-epi-LxA4 production has been linked to the inhibition of NFκB 
[216, 480, 493]. 
Infected and aspirin-treated mice showed increased activation of NFκB, suggesting the 
progression of inflammatory signalling, but again no effect of aspirin was shown. 
Interestingly, high-dose aspirin-treated mice (equivalent to 1000 mg daily dose) showed 
the highest proportional increase in NFκB activation, contradicting what has been shown 
previously with similar doses in both in vitro and ex vivo models of inflammation [18, 
432, 433].  
During sepsis, inflammation is regulated by transcriptional activation of pro-
inflammatory cytokines and mediators that contribute to prolonged inflammation and 
organ damage [124, 511]. The cytokines IL-1β, IL-6, IFN-γ and TNF-α have been studied 
in a number of other reports on mouse models of sepsis. In an attempt to identify new 
possible biomarkers, and markers of aspirin treatment, a wider panel of cytokines was 
chosen. A significant increase in plasma levels IL-6 was seen in all infected and aspirin-
treated mice (p<0.05), however no effect of aspirin was shown. A number of biological 
roles have been described for IL-6 in sepsis, including controlling the induction of acute-
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phase responses and temperature regulation [126]. Body temperatures were measured in 
all mice during the experiment using an infrared thermometer, but measurements were 
highly variable and this parameter was not a clear measure of sepsis progression in this 
model (data not shown), and no correlations could be made with levels of IL-6 measured. 
IL-6 production has also been used a prognostic marker for outcome in sepsis patients, 
and has been previously suggested as a diagnostic biomarker for bacteraemia (as 
discussed in section 1.2.4). IL-6 production in infected mice in this study remained raised 
even 48 h following infection, allowing for clear differentiation with naïve mice, and 
therefore in this model IL-6 could be used in the confirmation of bacterial sepsis in future 
animal studies. Small increases were also observed with chemokine MCP-1 (Figure 4.8) 
in infected mice at 24 h, further confirming systemic inflammation in these mice. Of the 
other cytokines analysed, individual responses varied, however mice in infected control 
group displaying increased levels of plasma cytokines at 24 h also had higher bacterial 
counts in organs, consistent with systemic inflammation. While IL-1β and TNF-α are two 
of the most documented cytokines involved in the sepsis inflammatory cascade [512, 
513], no significant increase was observed for either cytokine in plasma of infected or 
aspirin-treated mice. The lack of differences observed in these cytokines could be due to 
the time frame of sampling for analysis, the production of different cytokines will occur 
at various stages of acute sepsis progression [514]. Additionally, the half-lives of 
cytokines are predominantly short in vivo and cytokines are often restricted to local site of 
production. It would be of interest in future studies to measure local cytokine production, 
in target organs following inflammation, to determine if there is any aspirin-related effect. 
Early response cytokines IL-1β and TNF-α are involved in the initiation of the sepsis 
inflammatory cascade, the results from 24 to 48 h time-points analysed in this study also 
suggest that infected mice were in between early and late phases of inflammation [515].  
Aspirin only has documented antibacterial effects in high doses. Therefore, It is unlikely 
that the clearance of bacteria from organs was due to a direct antibacterial effect of 
aspirin therapy [17, 218, 516]. Our flow cytometry analysis focused on 
monocyte/macrophage and neutrophil populations as effector populations for bacterial 
clearance. Although there was no significant difference in the proportions of 
monocytes/macrophages (CD11b+ Ly6G-), or neutrophils (CD11b+ Ly6G+) in blood or 
spleen compared with naïve mice, a general trend in decreased monocyte/macrophage 
proportions in blood was noted over the course of the experiment. The most likely 
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explanation for this is that following activation monocyte/macrophage populations are 
migrating to target tissues in order to mediate bacterial clearance. 
Activation and tissue migration markers L-selectin and PSGL-1 were analysed on 
leukocyte surfaces in blood and spleen of mice. L-selectin expression on circulating 
monocytes/macrophages in this study were not significantly impacted by infection or 
aspirin treatment, however there were increased proportions of monocytes/macrophages 
expressing L-selectin in spleen of all infected mice at 24 h post-infection. This suggests 
that these cells were activated and targeted to enter circulation and other target organs. In 
contrast, decreased proportions of PSGL-1+ monocytes/macrophages in blood of all 
infected mice, which was moderately increased with aspirin (Figure 4.15A left panel), 
also suggesting these cells were more likely to be activated for recruitment to tissues.  
These relatively small shifts in the monocyte/macrophage populations at 24 h post-
infection in low-dose aspirin-treated mice led to complete clearance in bacteria from 
organs by 48 h, indicating that the migration and activation of this population are critical 
for their effector function. Further, decreases in L-selectin expression observed in low-
dose aspirin-treated groups could be due to the ability of aspirin to induce L-selectin 
shedding, preventing neutrophil-endothelial interactions, and facilitate resolving 
inflammation as shown in previous studies [505, 517]. While the effects of infection on 
leukocyte PSGL-1 expression are limited, decreases of PSGL-1 expression observed in 
this study could be due to a similar shedding event as described for L-selectin, with 
similar reductions in inflammation proposed [518]. To ascertain whether this is the case, 
it would be necessary in future to determine levels of soluble L-selectin and PSGL-1 in 
plasma and tissues. Future studies should also consider the transcriptional analysis of  
L-selectin and PSGL-1 ligands on endothelial surfaces to determine whether surface 
expression of these markers on leukocytes is indicative of adhesion and migration. As 
PSGL-1 is a major ligand for L-selectin, it was also suggested that PSGL-1 and L-selectin 
form complexes on cell surfaces for effective leukocyte transmigration and thus 
expression of each marker could be dependent on the other [519]. 
Analysis of lymphocyte populations was less revealing, however the proportion of splenic 
CD4+ T lymphocytes was significantly reduced in low-dose aspirin-treated mice, 
compared with naïve mice (Figure 4.13; p<0.05, one-way ANOVA), and splenic CD8+  
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T lymphocytes were significantly reduced in infected control mice compared with naïve 
mice (Figure 4.13; p<0.05, one-way ANOVA). 
The role of the adaptive immune response in the early stages of sepsis has been widely 
debated. Given that the current model represents early stages of sepsis,  
the lack of significant changes in T lymphocyte populations is consistent with previous 
studies suggesting that T lymphocytes are not critical for early sepsis responses [110, 
520]. While significant increases in L-selectin expression was observed in all infected and 
aspirin-treated mice, the proportion of CD3+ (inclusive of both CD4+ and CD8+)  
T lymphocytes expressing L-selectin were lower by comparison with 
monocyte/macrophage and neutrophil cells, further confirming these cells are not 
critically involved in early immune responses in sepsis. Interestingly and unlike  
L-selectin, expression of PSGL-1 was high on CD3+ T lymphocytes in both blood and 
spleen for all mice (including naïve group). One study also recently showed that unlike 
monocytes/macrophages and neutrophils, PSGL-1 is expressed on T lymphocytes, but the 
modifying enzymes required for functional activity are not constitutively expressed [521]. 
Further analysis would need to be performed to determine whether PSGL-1 on CD3+  
T lymphocytes is functionally active in this model. 
A number of differences in responses were seen between patients and mice in this sepsis 
model (due to time frame of infection, modes of infection, progression of infection prior 
to treatment with aspirin, age differences). The results of our analysis suggest that while 
some similarities were observed with regular aspirin taking patients, this model of 
infection was not an accurate representation of the overall responses seen in other patient 
groups in the clinical study. In order to address these differences, future studies will aim 
to investigate a number of additional variables including: further adaptation to timelines 
for sampling to more closely mirror the response timeline with that of the patients.  
Patients in the MATHS clinical trial (described in the previous chapter) were already 
identified as having sepsis prior to commencement of aspirin-therapy (with the exception 
of regular aspirin takers), thus future models of infection should consider inclusion of a 
group that are infected for a minimum of 12-24 h to induce inflammatory response prior 
to administration of aspirin therapy. Another major difference between this model and the 
standard patient care for sepsis is the absence of antibiotic therapy. Any impacts on 
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immunological or clinical parameters in the current study were the effect of low-dose 
aspirin in the absence of antibiotic therapy. As the role of aspirin in the treatment of 
sepsis is to serve as an adjunct therapy, future studies will consider the combined use of 
aspirin and antibiotic therapy. Also, a high proportion of participants in the MATHS 
clinical trial presented with at least one pre-existing health condition that can increase 
likelihood of infection and sepsis development. Given this, future studies should 
investigate the parameters measured in this study in a variety of mouse strains (including 
diabetic and other immuno-compromised mice) to ascertain whether aspirin improves 
recovery or outcomes. 
While there is evidence to suggest aspirin at all doses affects the GI tract and can cause 
adverse bleeding, the doses used in this study (equivalent with 100 mg and 1000 mg daily 
dose, administered for two days) were chosen to represent low- and medium-doses 
administered in humans, and delivered in 2 doses over a 48 h period. As such, it was not 
anticipated that adverse bleeding effects would be seen (based on the study by  
Winning et al. (2010) [63]). Indeed, aspirin given to mice at a 5 mg/kg daily dose for up 
to 5 days did not result in any adverse bleeding, in a previous study [522]. Having said 
this, the limitations of not having an aspirin only control should be considered, with 
clinical measurements of weight loss being a primary parameter, if aspirin did affect the 
GI tract of mice in this study, it may have contributed to early weight loss. It would be 
useful to include an aspirin-only control group in future studies to investigate whether this 
is indeed the case, and evaluate any other potential adverse effects of low-dose aspirin 
(such as bleeding), in the absence of infection. Further, aspirin alone was shown in 
healthy volunteers to impact the neutrophil-endothelial interactions by inducing 
premature shedding of activation marker L-selectin [505], it would also be worthwhile to 
confirm this in our mouse model. And while it is unclear what effects aspirin alone has on 
the surface expression of PSGL-1, an aspirin-only control group to investigate this in this 
mouse model should be considered. An aspirin-only control group could also serve as an 
added comparison, providing baseline responses for the anti-inflammatory effects of  
low-dose aspirin (15-epi-LxA4 production, NFκB inhibition), in the absence of infection.     
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4.5. Conclusion 
In this study, the effects of aspirin therapy on our inflammatory pathways of prior 
interest, (plasma 15-epi-LxA4 and NFκB activation) seen in patients, were not observed 
in mice. It is however clear, that low-dose aspirin therapy had a beneficial effect in mice, 
with complete clearance of bacteria from organs shown in the absence of supportive 
antibiotic therapy.  
Taken together, these results support the potential for low-dose aspirin as an adjunct 
therapeutic within this model of sepsis. Future studies will investigate the mechanism in 
which aspirin-therapy mediates clearance of bacteria from organs and will include a 
group of mice also receiving anti-microbial therapy, to better model the current therapies 
offered to patients with sepsis. 
  
	  
Chapter 5 
Investigating the effects of aspirin treatment in in vitro 
and in vivo models of device-related biofilm infection 
5.  
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5.1. Introduction 
Biofilm forming bacteria are implicated in a number of serious infectious diseases, and 
the use of indwelling medical devices such as intravenous and urinary catheters, as well 
as pacemakers and orthopaedic devices, present opportunity for planktonic nosocomial 
bacteria such as Staphylococcus species to attach and “switch” to biofilm forming 
phenotypes [5-8]. Staphylococcus aureus and Staphylococcus epidermidis are well-
studied human pathogens. A common constituent of the nasal microflora, S. aureus has 
the potential to establish opportunistic infections upon disruption of epithelial barriers 
[523, 524]. Many staphylococcal species have the ability to form biofilms. The increased 
incidence of anti-microbial resistance, coupled with advances in medical care for severe 
illness, necessitating the use of indwelling medical devices. This can lead to both an 
increased likelihood of developing device-related biofilm infection, and risk of severe 
outcomes [525, 526].  
Several bacterial factors are involved in the formation of S. aureus biofilms. Previous 
studies have shown the significance of the intracellular adhesion (ica) locus in the 
attachment of staphylococcal biofilms and production of the polysaccharide intracellular 
adhesion (PIA), the main contributor to total biofilm [270, 527, 528]. Quorum-sensing 
molecules including the accessory gene regulator locus (agr) [337, 338], staphylococcal 
accessory regulator (SarA) [339, 340] and transcription factor Sigma B (σB) [529, 530] 
are involved in regulating the formation of staphylococcal biofilms. Cell death, lysis and 
subsequent release of genomic DNA during biofilm development in S. aureus is highly 
regulated by cidA (murein hydrolase regulator with other functions in reducing antibiotic 
tolerance) [531]. Analysis of biofilm structure has also showed that extracellular DNA 
(eDNA) is abundant in staphylococcal biofilms, similarly described in biofilms of 
Pseudomonas aeruginosa (P. aeruginosa). Extracellular DNA contributes to the integrity 
of the biofilm structure and also in resistance to conventional antibiotic therapy [532]. 
Exposure to DNases results in diminished eDNA in the biofilm matrix (in both S. aureus 
and other organisms) contributing to decreased biofilm stability [328, 533] and adherence 
[534] in vitro. This effect also translates to the clinical setting, where recombinant human 
DNAses have been successfully used in conjunction with antibiotic therapy to treat cystic 
fibrosis patients with P. aeruginosa infections [535]. Similarly, recombinant human 
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DNase therapy was shown to be effective in diminishing eDNA in biofilms isolated in 
young children with recurrent otitis media [536]. 
As discussed in section 1.3.5.3, biofilm infections are difficult to treat, particularly in the 
case of prostheses such as hip joints, and there is a need for new therapeutic options [537-
539].  
Salicylic acid (SA), a major metabolite of aspirin inhibits NFκB and other intracellular 
signalling pathways in mammalian cells [61, 432]. Salicylic acid has anti-biofilm effects 
against other biofilm forming organisms [540, 541]. Treatment with SA in vitro was 
shown to inhibit biofilms of P. aeruginosa and species of Candida, Salmonella and 
Streptococcus [542][35-37]. The effects of SA inhibition on P. aeruginosa have been 
well studied, with flagella-mediated motility [319, 543] and quorum-sensing in biofilm 
regulation impacted [544]. Similarly, therapeutic doses of aspirin were shown to impact 
levels of secreted proteases in biofilms and planktonic cultures of Candida spp [541, 545, 
546]. Recent evidence supporting the potential for SA inhibition of staphylococcal 
biofilms was shown in an in vitro model of infective endocarditis by Kupferwasser et al. 
[221]. Staphylococcal cultures treated with SA at therapeutic concentrations were 
significantly impacted via global regulatory pathways mediated by sarA, contributing to 
reduced bacterial adhesion and virulence [221]. The same group also reported that aspirin 
therapy impacted the ability of S. aureus to cause chronic bacterial endocarditis in an in 
vivo rabbit model [384].  
The experimental approach of this chapter addresses the hypothesis that treatment with 
SA will impact staphylococcal biofilm formation in vitro by interfering with PIA 
production and eDNA release. Further, the effect of aspirin therapy on biofilm formation 
and inflammation in vivo was tested in a mouse model of staphylococcal device-related 
biofilm infection. 
 
 
 
Chapter 5	
	
	
	 Page 172 
The specific aims of experiments outlined in this chapter were: 
• To determine whether SA treatment impacts in vitro staphylococcal biofilm 
formation 
More specifically: 
o The effect of SA treatment on polysaccharide production and bacterial 
viability 
o The effect of SA treatment on extracellular DNA release 
o The effect of SA treatment on the transcriptional regulation of biofilm-related 
target genes 
 
• To investigate staphylococcal biofilms in a model of device-related infection in 
C57BL/6 mice 
More specifically: 
o The effect of low-dose aspirin treatment on staphylococcal biofilm 
polysaccharide production on stainless steel and catheter implants 
o The effects of low-dose aspirin treatment on bacterial growth in infected sites 
surrounding stainless steel and catheter implants 
o The effects of low-dose aspirin treatment on both local and systemic 
inflammation induced by stainless steel and catheter implants 
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5.2. Materials & Methods 
5.2.1. In vitro study 
5.2.1.1. Bacterial strains  
Strains of S. aureus and S. epidermidis used in this study are outlined in Table 2.1.  
5.2.1.2. Culturing of bacterial biofilms with or without SA 
Stock solutions of SA (1 mol/L) were prepared by dissolving lyophilised SA (Sigma-
Aldrich) in 70% ethanol (Merck KGaA), and diluted 1:50 in Brain Heart Infusion broth 
(BHIB: Oxoid) to a final concentration of 20 mmol/L SA. Vehicle controls were prepared 
by diluting 70% ethanol 1:50 in BHIB to a final concentration of 1.5% (vehicle control). 
Bacterial cultures grown overnight at 37°C were diluted in BHIB containing 20 mmol/L 
SA or vehicle in 200 µL in a suspension of 105 CFU. Negative control wells contained 
only BHI broth and either 20 mmol/L SA or vehicle. Plates were covered and incubated 
at 37°C for either 24 or 48 h. 
5.2.1.3. Quantitative biofilm assay (crystal violet method)  
Biofilm assays were performed using published methods [547] with minor modifications. 
Following incubation of the biofilm culture, the contents of each well were aspirated and 
washed three times with 200 µL tap water. Plates were stained with 200 µL aqueous 
crystal violet solution (2.3% (v/v): Sigma-Aldrich) for 15 min at RT. Excess stain was 
removed and wells were washed briefly with tap water twice. Plates were left to air dry at 
RT. Once dried, biofilms were resolubilised in 300 µL of 33% (v/v) glacial acetic acid 
(Merck KGaA). Crystal violet staining was quantitated by measuring absorbance at a 
wavelength of 595 nm using an iMark™ microplate reader (Bio-Rad, USA).  
5.2.1.4. Bacterial viability analysis 
Following incubation of biofilms, planktonic cells were removed and wells were washed 
twice with tap water as above. The adherent material in each well was re-suspended in 
100 µL BHI broth after scraping and vigorous pipetting. A 20 µL aliquot of this 
suspension was 10-fold serially diluted in BHI broth and plated on BHI agar medium. 
Viable bacterial counts were performed following incubation 37°C for 24 h. 
Chapter 5	
	
	
	 Page 174 
5.2.1.5. Confocal microscopy 
Sterilised glass coverslips (13 mm round: ProSciTech) were placed in individual wells of 
a sterile 24-well plate. Following this 1 mL bacterial culture (diluted as described above) 
in BHIB containing 20 mmol/L SA (prepared as described in section 5.2.1.2) or an equal 
concentration of 70% ethanol (vehicle) was added to each well. Biofilms were incubated 
at 37°C as described in Table 5.1. 
Table 5.1: Treatment groups for the qualitative analysis of 48 h bacterial biofilms by 
immunofluorescent confocal microscopy. 
a BHIB with vehicle control media  equal concentrations as SA containing media 
b SA in BHIB 
Following incubation, excess culture media was aspirated and wells were washed twice in 
PBS (Bioline), then fixed in 4% neutral buffered formalin (Thermo Fisher Scientific) for 
10 min. Biofilms were then permeabilised in 0.2% Triton X-100 (Sigma-Aldrich) for 10 
min, and washed three times in PBS. Coverslips were then incubated on 25 µL of rabbit 
anti-S. aureus antibody (1:200; Abcam) in PBS/1% BSA for 60 min. Following 
incubation, coverslips were returned to the wells and washed three times in PBS/0.1% 
BSA, before being incubated on 25 µL of goat anti-rabbit Cy3 (1:1000; Abcam), and 
SYTOX Green nucleic acid direct stain (2 µmol/L) (Life Technologies) in PBS/1% BSA 
for 45 min. Following incubation coverslips were returned to the wells, washed three 
times in PBS/0.1% BSA, and once in sterile MQH2O. Coverslips were then mounted in 
Mowiol (prepared as described in section 2.4.3.2). Imaging was performed using a Nikon 
Treatment Media incubation (first 24 h) Media Incubation (second 24 h) 
Group 1 
(-/- SA) 
SA1698 or SE35984 biofilm in 
BHIB/vehiclea  
BHIB/vehicle replaced with fresh 
BHIB/vehicle 
Group 2 
(-/+ SA) 
SA1698 or SE35984 biofilm in 
BHIB/vehicle 
BHIB/vehicle replaced with  
BHIB/SAb  
Group 3 
(+/- SA) 
SA1698 or SE35984 biofilm in 
BHIB/SA  BHIB/SA replaced with BHIB/vehicle  
Group 4 
(+/+ SA) 
SA1698 or SE35984 biofilm in 
BHIB/SA 
BHIB/SA replaced with fresh 
BHIB/SA 
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A1 inverted confocal microscope and NIS Elements C control software (Nikon, Japan) 
using lasers at 405, 488, 561 nm. Images were overlayed for display using the Adobe 
Photoshop program (Adobe). 
5.2.1.6. Quantitation of extracellular DNA (eDNA) release in biofilms 
Biofilms of SA1698 and SE35984 were grown at 37°C for 24 h in 96-well plates in either 
BHIB containing 1, 5, 10 or 20 mmol/L SA or vehicle (prepared as described in section 
5.2.1.2). Following incubation, the contents of each plate were aspirated and washed 
twice in PBS. Biofilms were then fixed in 4% neutral buffered formalin (Thermo Fisher 
Scientific) for 10 min and stained with SYTOX Green (2 µmol/L) in PBS (Life 
Technologies) for 45 min. Following incubation; biofilms were washed three times with 
PBS and the contents of each well were resuspended in 100 µL of PBS. Fluorescence 
absorbance was measured at a wavelength of 488 nm using the POLARstar Optima multi-
detection microplate reader (BMGlabtech).  
5.2.1.7. Gene expression analysis  
5.2.1.7.1.  Isolation of RNA from staphylococcal biofilms 
Following incubation of bacterial biofilms, excess media was removed and RNA was 
isolated using the Isolate II RNA mini kit (Bioline) according to the manufacturers 
protocol with some minor adaptations. 100 µL TE buffer (10 mmol/L Tris-HCl (Merck 
KGaA), 1 mmol/L EDTA (Calbiochem) pH 8.0) containing 50 µg/mL lysostaphin 
(Sigma-Aldrich) and 3 mg/mL lysozyme (Sigma-Aldrich) was added to each well. 
Biofilms were scraped into the buffer to form a lysate and contents were transferred to a 
microcentrifuge tube and incubated at 37°C for 1 h. Next, 350 µL of Buffer RLY 
(Bioline) containing 1% β-mercaptoethanol (Bio-Rad) was added to each tube and 
vortexed vigorously for 5 s. The combined contents of each tube were transferred to an 
ISOLATE II filter (violet) in a 2 mL collection tube and centrifuged at 11,000 × g for  
1 min at RT to reduce viscosity. Next, 350 µL of 70% ethanol was added to each lysate 
and mixed by pipetting, then contents were transferred to an ISOLATE II RNA Mini 
column (blue) in a 2 mL collection tube, which was centrifuged again at 11,000 × g for  
30 s. The flow through was discarded and 350 µL Membrane Desalting Buffer (MEM) 
was added to the column, which was centrifuged again at 11,000 × g for 1 min. Samples 
were then washed by addition of 200 µL Buffer RW1, and centrifuged at 11,000 × g for 
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30 s. Next, 600 µL Buffer RW2 was added and centrifugation was performed as described 
above, followed by an additional wash in 250 µL Buffer RW2, and centrifuged at 11,000 
× g for 2 min to dry the membrane completely. Columns were then placed into a new 
microcentrifuge tube and RNA was eluted in a total volume of 80 µL in nuclease-free 
water (elution was performed in two steps of 40 µL nuclease-free water). Contaminating 
DNases were removed using the TURBO DNA-free™ kit (Life Technologies) according 
to the manufacturers specifications. Concentration and purity of the total RNA were 
determined using the NanoDrop 2000™ (Thermo Fisher Scientific). 
5.2.1.7.2. Reverse transcription of RNA 
cDNA was synthesised from ~1 µg in vitro RNA using the Omniscript RT Kit (Qiagen, 
Australia) with 0.8 µg/µL Random Hexamers (Qiagen) according to the manufacturer's 
instructions. The cDNA was then precipitated by ethanol precipitation (as a clean-up 
step), and the resulting cDNA was then used as the template in a semi-quantitative SYBR 
green assay (qRT-PCR). 
5.2.1.7.3.  Ethanol precipitation of DNA 
To purify and concentrate cDNA 2.5 volumes of ice-cold 96% (v/v) ethanol and  
0.1 volume of sodium acetate were added to DNA preparations. The DNA was 
precipitated at -20°C for 1 h and pelleted by centrifugation (13,000 × g, 15 min, 4°C). 
After washing the pellet with 70% ethanol the reaction was centrifuged as above. The 
DNA pellet was dried in a laminar flow hood and resuspended in 10 µL nuclease-free 
water (Qiagen). 
5.2.1.7.4.  Semi-quantitative real-time PCR (qRT-PCR) 
Real-Time semi-quantitative PCR analysis for the genes listed in Table 5.2, were 
performed using the Rotor-Gene Q real-time cycler and software (Qiagen) and 2× 
SensiFAST™ SYBR® Green master mix (Bioline), with cycling conditions according to 
the manufacturer’s specifications. PCR reactions contained 10 ng template DNA, 10 pmol 
oligonucleotides, and were performed in duplicate in a total volume of 20 µL. Each series 
contained a non-template control (NTC). All oligonucleotides were purchased from 
GeneWorks (GeneWorks, Australia) according to publications listed in Table 5.2, or were 
designed using Primer 3 plus software [548], on the basis of nucleotide sequences for  
Chapter 5	
	
	
	 Page 177 
S. aureus genes of interest. RT-PCR conditions were as follows: denaturation 95°C for  
5 min, followed by 40 cycles of 95°C for 30 s, 60°C for 15 s and 72°C for 30 s. A final 
extension phase of 72°C for 7 min was used. The gyrB (staphylococcal DNA gyrase sub-
unit B) gene was used as reference gene for quantifications. Relative gene expression was 
calculated using the method previously described by Pfaffl [549] and expressed as fold 
change. 
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Table 5.2: Oligonucleotides used in quantitative real-time PCR in this study. 
Gene Name Type Sequence Tm (°C) 
Amplicon 
Length  Function Source 
gyrB 
F 5’- GGTGGCGACTTTGATCTAGC-3’ 54 
170 bp DNA gyrase subunit B  (Reference gene) [296] R 5’- TTATACAACGGTGGCTGTGC-3’ 52 
agr 
F 5’-TCACAGACTCATTGCCCATT-3’ 50 
193 bp 
Global gene regulator 
Virulence determinant 
(Pathogenesis) 
[296] 
R 5’-CACCGATGCATAGCAGTGTT-3’ 52 
sarA 
F 5′-TTTCGTTGTTTGCTTCAGTG-3′ 48 
398 bp 
Global regulator of multiple 
virulence and biofilm related 
genes 
[530] 
R 5′-TCGAGCAAGATGCATCAAA-3′ 47 
sigB 
F 5′-TTGATTCTTGGCCCAATTTC-3′ 48 
355 bp Transcription factor affecting RNA Polymerase [530] R 5′-GCGAAAGAGTCGAAATCAGC-3′ 52 
SpA 
F 5′-TATGCCTAACTTAAATGCTG-3′ 46 
119 bp Cell surface associated virulence factor [296] R 5′-TTGGAGCTTGAGAGTCATTA-3′ 48 
cidA 
F 5′-ATGGATGTTGCTTCCGAAAT-3′ 48 
166 bp Membrane-associated murein hydrolase regulator This study R 5′-GGCTTGCACGTAATCATTCA-3′ 50 
CcpA 
F 5′-GTGTCGCGTGTTGTTAATGG-3′ 52 
190 bp 
Catabolite control protein 
regulates polysaccharide 
production 
This study 
R 5′-GTCCACGAGCAAGTTGTGAA-3′ 52 
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5.2.2. In vivo biofilm infection model 
A mouse model of contaminated medical devices was established by implanting 
contaminated stainless steel (s/s) or catheter section implants in a subcutaneous pocket in 
C57BL/6 mice. Mice were monitored for 4 days. At the end of the experiment the implant 
site was sampled for bacteria and histology. Systemic inflammatory responses were also 
assessed. 
Experiments involving animals were carried out with the approval of the RMIT Animal 
Ethics Committee (AEC Permit Number 1426). Six to eight-week-old female C57BL/6 
mice were sourced from the Animal Resource Centre (ARC, Australia). Prior to 
experimentation, mice were acclimatised for a minimum of seven days within the RMIT 
Animal facility (RAF) (RMIT University). A maximum of four mice were housed in a 
single housing unit, mice were fed standard rodent chow and had access to sterilised-
water ad libitum. 
5.2.2.1. Contaminated implants 
SA1698 was grown in BHIB at 37°C overnight. In this study, sterile 4 mm diameter 
surgical grade s/s balls (Bearings Australia, Australia) as a model of a contaminated metal 
prosthesis, or ~5mm sections of urinary catheter (Bard, Australia) were contaminated 
with SA1698. Implants were incubated at 37°C for 3 h in a 100 µL suspension of 
approximately 3 × 105 CFU SA1698, prior to implantation. Non-implanted s/s and 
catheter implants incubated with SA1698 were briefly sonicated and cultured to confirm 
the infective dose upon implantation. 
5.2.2.2. Mouse implant model 
Six mice per experimental group received either s/s ball to represent a prosthetic joint, or 
latex-coated catheter implants to represent an indwelling catheter, contaminated with 
SA1698 (see Figure 5.1). Mice were anaesthetised via intra-peritoneal injection of 
ketamine (100 mg/kg - Ketamav: Mavlab, Australia)/xylazine (10 mg/kg - Rompun: 
Bayer, Germany). Once mice were deeply anaesthetised, fur on the back of the mouse 
was shaved to expose the skin and washed with 80% ethanol. A 10 mm incision was 
made with a sterile scalpel and a sub-cutaneous pocket was introduced under the surface 
of the skin by inserting blunt end scissors to a depth of 10 mm.  
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Figure 5.1: Timeline for mouse implant infection model. Female C57BL/6 mice were anaesthetized and had either s/s (n=6) or catheter 
implants (n=6) inserted into subcutaneous pockets of skin. Following surgery, half of the mice in each implant group (n=3 represented in red and 
blue symbols) received an oral dose of aspirin by gavage (1 mg/kg). Aspirin was administered once daily for a period of 4 days. Green and grey 
symbols represent mice with s/s and catheter implants (respectively) not receiving aspirin therapy. Sham surgery mice (represented in purple 
symbol) underwent surgery but did not receive an implant or aspirin therapy. Mice were weighed prior to surgery, and mice were weighed and 
monitored for signs and symptoms of inflammation twice daily. Monitoring was performed according to established criteria as outlined in the 
previous study (Table 2.2). 
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Contaminated implants were inserted into the subcutaneous pockets, incisions were 
closed with 2 sutures (Dysilk 12 mm black braided: Dynek Pty Ltd., Australia) and 
wounds were covered with standard adhesive dressing (Leukoplast®: Smith & Nephew, 
Australia). Aspirin (1 mg/kg, prepared as described in section 4.2.1.5, Sigma-Aldrich) 
was administered by oral gavage to half of the mice in experimental implant groups (n=3; 
see Figure 5.1). A separate group of mice underwent mock-surgery (n=3), whereby a  
10 mm incision was made and closed with 2 sutures as described above, without an 
implant being inserted (sham surgery group). 
5.2.2.3. Termination of experiment and sample collection 
Mice were euthanised via CO2 inhalation; blood was collected immediately by cardiac 
puncture into syringes pre-loaded with 200 µL sterile Alsever’s solution (prepared as 
described in section 2.4.2). Mice were transferred to the biosafety level 2 cabinet to 
minimise contamination with air microorganisms, swabs of contaminated exudate sites 
were taken and stored in BHIB for quantification of bacterial load and implants were 
removed for quantification of surface biofilm. Skin surrounding contaminated implants 
was removed for analysis of inflammatory infiltrates by histology and 
immunohistochemistry.  
5.2.2.4. Determination of bacterial load 
Swabs collected into 1 mL BHIB were serially diluted and 100 µL was spread plated on 
the surface of BHIA plates and incubated at 37°C overnight, following which viable 
bacteria were quantified.  
Blood collected by cardiac puncture was diluted 1:2 in BHIB and a volume of 100 µL 
was then spread plated onto BHIA and incubated as described above. 
5.2.2.5. Determination of bacterial-induced damage in organs 
Tissues harvested following euthanasia of mice were embedded in Tissue-Tek® O.C.T™ 
medium (Sakura Finetek) immediately following harvest and were snap frozen over 
liquid nitrogen. Sections were cut at 10 µm thickness, mounted onto StarFrost® 
superclean slides (ProSciTech Pty Ltd) and stored at -80°C. 
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5.2.2.5.1.  Haematoxylin and eosin staining and scoring of inflammation 
Frozen 10 µm sections of skin were fixed in 4% neutral buffered formalin (Thermo Fisher 
Scientific). Sections were washed in PBS once before being stained with haematoxylin 
and eosin. Histological sections were observed under light microscopy to determine the 
extent of damage and inflammation to tissues. Images were captured using a Leica 
DM2500 microscope and Leica Application Suite software (Leica). Epidermal thickness 
was measured (µm) to determine effects on wound healing, using the Leica Application 
Suite software (Leica).  
H & E stained skin sections were scored in a blinded manner for the presence of 
inflammation. A semi-quantitative scoring system was used, as described in the study by 
Kugelberg et al. [550]. The parameters used to describe the inflammatory response 
included inflammation in the dermis and subcutaneous tissues (inclusive of influx of 
leukocytes, and epidermal thickening observed in these tissues). The parameters listed 
were scored from 0-3, as follows: 0, no inflammation (no evidence of leukocyte influx); 
1, minimal inflammation (a few leukocytes present); 2, moderate inflammation (moderate 
presence of leukocytes); 3, severe inflammation (abundance of leukocytes present).   
5.2.2.5.2.  Immunohistochemical detection of S. aureus in skin 
Frozen 10 µm sections of skin were fixed in ice-cold acetone. Sections were air dried and 
rehydrated in PBS for 10 min, then permeabilised with PBS containing 0.2%  
Triton X-100. Fc Receptor blocking was performed as described in section 2.4.3.2, for 1 h 
at RT. Slides were inverted to remove excess blocking solution and primary antibodies 
(rabbit anti-S. aureus, 1:200; Abcam, and rat anti-mouse CD11b, 1:100; BioLegend) in 
PBS/1% BSA were added, and sections were incubated overnight at 4°C. Sections were 
washed three times for 10 min in PBST and an anti-rabbit Cy3® (1:1000; Abcam) and 
anti-rat Alexa Fluor® 488 (1:800; Life Technologies) conjugated secondary antibodies in 
PBS/1% BSA were added. Slides were incubated for 1 h at RT. Sections were washed 
three times for 10 min in PBST then slides were incubated with DAPI nuclear stain in 
PBS/1% BSA (2 µg/mL) for 20 min at RT (in the dark). Slides were washed frequently in 
PBST over 30 min, mounted in Mowiol (section 2.4.3.2) and examined the following day. 
Images were captured as described above. Images were overlayed for display using 
Adobe Photoshop software (Adobe). 
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5.2.2.6. Analysis of cell populations 
5.2.2.6.1.  Preparation of single cell suspensions for flow cytometry 
5.2.2.6.1.1. Blood 
Following centrifugation and removal of plasma, cells were re-suspended in TAC red cell 
lysis buffer (prepared as described in section 2.5.1) and incubated at 37°C for 5 min to 
lyse contaminating erythrocytes. Cells were then washed by centrifugation and 
resuspended in FACS wash buffer (prepared as described in section 2.2.3). 
5.2.2.6.1.2.  Spleen 
Spleens were collected into ice-cold DMEM complete media (prepared as described in 
section 2.2.3). Cells were placed in petri dishes and were gently teased through a 40 µm 
cell strainer (Biologix). Following a washing step cells were re-suspended in TAC red 
cell lysis buffer (prepared as described in section 2.5.1) and incubated at 37°C for 5 min 
to lyse contaminating erythrocytes. Cells were then washed and resuspended in FACS 
wash buffer. 
5.2.2.6.2. Flow cytometry 
For flow cytometry, 106 cells from blood or spleen were incubated with Fc receptor block 
(Purified anti-mouse CD16/32 Antibody, BioLegend), at 4 µg/mL in 50 µL FACS wash 
buffer for 30 min on ice. The antibodies used for staining are listed in Table 2.3 (Chapter 
2). Staining was performed in 100 µL FACS wash buffer for at least 30 min on ice. 
Following this cells were washed twice in FACS wash buffer before being re-suspended 
in PBS for data acquisition. 
Data was collected using the FACSCanto II (Beckton Dickinson). A five-decade 
logarithmic scale was used to process fluorescence signals and a linear scale was used to 
process light scattering signals. Data analysis was performed using FlowJo software 
(Version 9.7.1). Single cells were gated and then populations of cells were defined as 
being T lymphocytes (CD3+, CD4+, CD8+), monocytes/macrophages (CD11b+) and 
neutrophils (Ly6G+) as well as other cell surface markers. 
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5.2.3. Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 6.0 for Macintosh 
(GraphPad Software). Unless stated, differences observed between two means were 
analysed using a two-tailed Mann-Whitney Test, where p<0.05 was considered 
significant.  
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5.3. Results 
5.3.1. In vitro study 
5.3.1.1. The effects of SA on growing staphylococcal biofilms 
Staphylococcal biofilms were grown in 24-well plates in the presence or absence of  
20 mmol/L SA over 24 h or 48 h and the ability to form biofilms was assessed 
quantitatively using the crystal violet method.  
Figure 5.2A shows the biomass of biofilms after 24 h incubation. There was a significant 
2.4-fold decrease in biofilm formation in the SA1698 (reference-MRSA) strain treated 
with SA when compared to the vehicle (p<0.0001). Likewise, SE35984 (a known biofilm 
former) showed a 12.4-fold decrease in biofilm formation when treated with SA, 
compared with vehicle-treated (p<0.0001). Weak biofilm forming S. aureus clinical 
isolate 6 also showed a 1.2-fold decrease in biofilm formation following 24 h incubation 
(p<0.0001). Figure 5.2B shows total biofilms formed after 48 h incubation. A significant 
(2.8-fold) decrease in biofilm formation was also seen in the SA1698 treated with SA 
compared to the vehicle (p<0.0001). SE35984 showed a significant (17.2-fold) decrease 
in biofilm formation when treated with SA, compared to the vehicle (p<0.0001). 
Following 48 h incubation, weak biofilm forming S. aureus clinical isolates 5 and 6 also 
showed small decreases (1.3-fold and 1.5-fold, respectively) in biofilm formation 
(p<0.0001).  
5.3.1.2. The effect of SA on viability of staphylococcal species  
Biofilms of staphylococcal isolates were grown over a 48 h period in the presence or 
absence of SA as previously described and bacterial viability was determined. Figure 5.3 
illustrates the differences seen between treated and untreated biofilms. All of the biofilm 
isolates grown in the absence of 20 mmol/L SA displayed a significant increase in CFU 
of at least 3.5 log10 on BHIA compared with SA-treated biofilms; where bacterial counts 
comparable with initial inoculum (p<0.05, p<0.005).  
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Figure 5.2: SA treatment significantly reduces staphylococcal biofilm formation. 
Biofilms of clinical isolates and reference strains SA1698 and SE35984 were grown in 
the presence or absence of 20 mmol/L SA at 37°C. Biofilm formation was measured by 
crystal violet absorbance at 595nm. Graphs represent; A) 24 h incubation, B) 48 h 
incubation. Data represent mean ± SEM of three independent experiments (n=15 per 
group, two-tailed Mann-Whitney test, ****p<0.0001 vs. vehicle). 
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Figure 5.3: SA treatment impacts staphylococcal post-biofilm growth. Biofilms of 
clinical isolates and reference strains SA1680, SA1698 and SE35984 were grown in the 
presence or absence of 20 mmol/L SA at 37°C for 48 h. Planktonic cells were removed 
and samples were serially diluted and plated for viable CFU. Data represent mean ± SEM 
of three independent experiments (n=6 per group, two-tailed Mann-Whitney test,  
* p<0.05, ** p<0.005 vs. vehicle) and expressed as (Log10 CFU/mL). 
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5.3.1.3. Confocal microscopy analysis of staphylococcal biofilms 
Formation of bacterial biofilms of SA1698 and SE35984 were also assessed by 
immunofluorescence confocal microscopy. Biofilms were grown on glass coverslips over 
a 48 h period in the presence or absence of 20 mmol/L SA to assess the impact of SA on 
biofilm formation (see Table 5.1). Coverslips were then stained with Staphylococcus anti-
sera and detected with a Cy3-conjugated secondary antibody and SYTOX green (showing 
eDNA). Images taken on the Nikon A1 confocal microscope are shown in Figure 5.4.  
Biofilms formed in absence of SA for 48 h demonstrated a uniform 3-dimensional mature 
biofilm with an abundance of extracellular DNA as shown by the SYTOX green staining 
(80-100% biofilm surface coverage). In contrast biofilms formed in the presence of SA 
for 48 h showed minimal detection of attached of bacteria but no uniform 3-dimensional 
biofilm, and no visual detection of extracellular DNA (0-15% biofilm surface coverage). 
Biofilms formed in the presence of SA in the first 24 h then replaced with vehicle 
medium demonstrated some bacterial attachment and maturation, however there were 
visible gaps in biofilm structure and less detectable extracellular DNA compared with 
biofilms formed in vehicle media for 48 h. Interestingly, biofilms formed in vehicle 
media for 24 h then replaced with SA containing media showed differences between 
SA1698 and SE35984; with greater impact seen in weaker biofilm forming strain 
SA1698.  
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Figure 5.4: SA treatment impacts staphylococcal biofilm formation. Biofilms of reference strains SA1698 and SE35984 were formed in the 
presence or absence of 20 mmol/L SA at 37°C. Over 48 h, biofilms were grown on glass coverslips at 37°C as follows: 1) Vehicle only (48 h); 
2) Vehicle (24 h), then SA (24 h); 3) SA (24 h), then vehicle (24 h); or 4) SA (48 h). Coverslips were fixed and stained with SYTOX green and 
anti-Staphylococcus (Cy3, red). Staining was visualised by confocal microscopy. Original magnification: 10x 
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5.3.1.4. Quantification of eDNA in staphylococcal biofilms 
Confocal microscopy analysis demonstrated the impact of 20 mmol/L SA treatment on 
biofilms of grown over 48 h. In order to further determine the extent to which SA 
treatment impacted biofilm formation, staphylococcal biofilms (SA1698 and SE35984) 
were grown in the presence of increasing concentrations of SA for 48 h. Determination of 
eDNA release was performed by SYTOX green nucleic staining and relative fluorescence 
intensity units (RFU) was measured. 
Figure 5.5 represents the fluorescence output for both SA1698 and SE35984. For both 
strains, SA treatment as low as 1 mmol/L significantly impaired eDNA release in 
biofilms grown over 48 h (Figure 5.5A; p<0.005). Weaker biofilms formed by SA1698 
were more significantly impacted, with SA concentrations of 1 mmol/L reducing the total 
amount of eDNA by half (p<0.0001), compared with vehicle. Stronger biofilms formed 
by SE35984 showed increased resistance to SA treatment, with the same level of eDNA 
decrease seen with SA concentrations of 5 mmol/L or greater (Figure 5.5B). The 
strongest effect of SA treatment was shown in both strains with 10 mmol/L and  
20 mmol/L SA with decrease in eDNA release below 0.5 × 105 RFU (p<0.0001). 
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Figure 5.5: SA impairs extracellular DNA release in staphylococcal biofilms. 
Biofilms of A) SA1698 and B) SE35984 were grown in 96-well plates in BHIB/vehicle 
or BHIB containing, 1, 5, 10 or 20 mmol/L SA at 37°C for 48 h. Release of eDNA was 
semi-quantitatively measured by SYTOX green fluorescence (2 µmol/L in PBS). Data are 
expressed as relative fluorescence units (RFU) and represent the mean ± SEM of three 
independent experiments (n=19 per group, two-tailed Mann-Whitney test, ** p<0.005, 
**** p<0.0001 vs. vehicle). 
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5.3.1.5. The effect of SA on biofilm-related gene expression in S. aureus 
Many genes have been implicated in the formation and maturation of staphylococcal 
biofilms. Of note, the genes involved in the regulation of the biofilm process such as the 
accessory gene regulator (agr), staphylococcal accessory regulator (sarA), alternative 
sigma factor B (sigB) and other virulence factors such as staphylococcal protein A (spa). 
Changes in gene transcription were assessed in biofilms of SA1698, in the presence or 
absence of 5 mmol/L SA. Treatment with 5 mmol/L SA showed a significant decrease in 
the gene expression of sarA when compared to both an untreated and vehicle treated 
biofilms. A trend toward decreased gene expression of sigB was also seen, however the 
differences between SA treated and vehicle treated biofilms were not statistically 
significant (Figure 5.6). 
Other genes previously reported as contributing to regulation of the biofilm were 
analysed to determine whether SA treatment interfered with their gene expression. 
Membrane-spanning protein CidA forms part of a two-component regulatory system to 
facilitate bacterial lysis and cell death, contributing to the release of eDNA [328]. In the 
above analysis eDNA levels were impacted by SA treatment, thus gene expression of 
(cidA) was assessed. Catabolite control protein (CcpA) is activated in the presence of 
glucose or sucrose, and was shown to up-regulate the genes responsible for synthesis of 
polysaccharide for the biofilm [551]. As a result, gene expression of CcpA was evaluated 
for a potential impact of SA treatment. No significant differences were observed between 
vehicle and SA treated biofilms for either of the above genes of interest (Figure 5.6). 
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Figure 5.6: SA treatment decreases gene expression of key biofilm regulatory gene 
sarA in mature staphylococcal biofilms. Biofilms of reference MRSA strain SA1698 
were grown in the presence or absence of 5 mmol/L SA at 37°C for 48 h. Relative 
transcript levels were compared against gyrB for a panel of biofilm related genes 
including agr, sarA, sigB, cidA and CcpA as well as a virulence gene spA. Data expressed 
as fold-change relative to gyrB and represents the mean ± SEM of three independent 
experiments (n= 3-5 per group, two-tailed Mann-Whitney test, *p<0.05 vs. vehicle). 
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5.3.2. The effects of low-dose aspirin in an in vivo model of  
device-related biofilm infection 
5.3.2.1. Analysis of clinical parameters associated with inflammation 
Mice had either 4mm s/s balls or catheter implants contaminated with reference MRSA 
strain SA1698 surgically implanted into subcutaneous pockets of skin to induce a 
localised biofilm infection. Approximately 3 × 105 CFU per s/s implant (Standard 
Deviation [SD] = 1.3× 105) and approximately 2.7 × 105 CFU per catheter ([SD] = 5.9× 
104) was delivered to subcutaneous pockets for infection. For comparison, a separate 
group of mice underwent mock-surgery (but did not receive an implant or aspirin 
treatment), to determine baseline values (sham surgery mice). Following this, low-dose 
aspirin (1 mg/kg: equivalent to a dose of 100 mg/day in a human) was administered to 
mice from each experimental group; the first dose administered 1 h following surgery. 
Aspirin treatment was given once daily for the following three days. For the duration of 
the experiment the mice were monitored for changes in weight as a primary parameter for 
change in condition. None of the mice with S. aureus contaminated implants displayed 
dramatic weight loss meeting criteria for humane end-point intervention (described in 
section 4.2.1.2).  
As shown in Figure 5.7, all mice displayed initial weight loss (within 24 h of surgery), no 
significant differences in weight loss were observed among experimental groups with all 
mice maintaining weight or regaining weight by termination of the experiment (96 h post-
implantation). Aspirin treatment did not have any significant effect on weight change in 
implanted mice. 
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Figure 5.7: No significant differences were observed in weight loss of mice with 
subcutaneous implants, regardless of aspirin therapy. Mice were weighed prior to 
surgery and aspirin treatment, then were monitored and weighed twice daily (morning 
and evening) for a total of 4 days. Data represents the mean ± SEM and expressed as 
percentage of start weight (n=3 per group). 
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5.3.2.2. Analysis of the effects of low-dose aspirin treatment on biofilm formation 
Following termination of the experiment, implants were removed and the surface of each 
implant was assessed for measurable biofilm formation using the crystal violet 
absorbance method [547]. Quantitative detection of biofilms formed on implants retrieved 
from mice after 4 days incubation is shown in Figure 5.8A. All implanted mice had 
detectable biofilms formed on the surface of implants; catheters appeared to provide 
better surface for bacterial attachment and biofilm formation compared with s/s implants. 
Small differences were observed between aspirin and non aspirin-treated mice with s/s 
implants with a two-fold decrease in biofilm formation in aspirin-treated mice (Figure 
5.8A; p<0.05, one-tailed Mann-Whitney). No statistically significant differences were 
observed in catheter-implanted mice. 
Bacterial load in exudates surrounding skin were quantified to determine whether aspirin 
treatment improved mediated clearance of bacteria. Following removal of implants, 
exudates in surrounding areas were swabbed and incubated in BHI broth. In order to 
determine bacterial load, swabs were spread plated onto BHIA plates. CFU were counted 
following incubation at 37°C for 24 h. SA1698 growth was not seen in exudates from 
sham surgery mice (data not shown). Following 4 days incubation, all exudates from 
infected sites yielded viable bacterial growth (Figure 5.8B). No significant differences 
observed between treatment groups and there was no apparent effect of aspirin noted. No 
bacteria were detected in the blood of any of the mice (regardless of implant and aspirin 
therapy) confirming that this infection was localised to the site of implantation (data not 
shown).  
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Figure 5.8: A) Aspirin treatment results in decreased biofilm formation on 
contaminated s/s implants removed from C57BL/6 mice. Contaminated implants were 
removed and analysed for surface biofilm formation. Data represents mean ± SEM (n=3 
per group, one-tailed Mann-Whitney test, *p<0.05 vs. s/s non-aspirin treated),  
B) Bacterial load of exudates surrounding contaminated implant sites were not 
significantly reduced with aspirin treatment. Swabs were taken from contaminated 
implant sites and incubated in BHIB. Following this samples were plated on BHIA, 
colonies were counted and data was log transformed. Data represents mean ± SEM (n=3 
per group). 
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5.3.2.3. Analysis of inflammation and damage in skin surrounding infected sites 
5.3.2.3.1.  Histological scoring 
To assess whether aspirin treatment had a beneficial effect on inflammation, sections of 
skin surrounding the surgical site of implant were analysed. Sections of skin from sham 
surgery, s/s-implanted mice and catheter-implanted mice were stained with haematoxylin 
and eosin. Assessment of inflammation in dermis and subcutaneous tissues were scored 
as described in section 5.2.3.5.1, and epidermal thickness was measured. Skin from 
infected mice showed signs of inflammation with varying degrees of distortion of 
subcutaneous tissues, and increased infiltration of leukocytes seen in dermis and 
subcutaneous tissue compared with sham surgery mice (shown in Figure 5.9). Aspirin-
treated mice had slightly lower mean inflammation scores compared with non aspirin-
treated mice, however as individual variation was seen in each group, this was not 
statistically significant (Figure 5.10). Interestingly in implanted mice, inflammation due 
to contaminated implants also resulted in significantly increased thickness observed in the 
epidermal layer of the skin (p<0.005, one-way ANOVA) possibly due to scar tissue 
development, and this was reduced with aspirin therapy (p<0.05, one-way ANOVA). 
5.3.2.3.2.  Immunofluorescence microscopy analysis 
As S. aureus was detected in exudates surrounding tissue, immunofluorescence (IF) 
microscopy was performed to determine localisation of S. aureus and presence of 
leukocytes (monocytes/macrophages and neutrophils) in skin surrounding contaminated 
implants. Skin sections from sham surgery, aspirin and non aspirin-treated s/s and 
catheter-implanted mice (n=3 group) were stained for S. aureus and 
monocyte/macrophage/neutrophil surface marker CD11b. No detectable staining for  
S. aureus was seen in sham surgery mice (Figure 5.11 top left panel). In contrast, all 
implanted groups (both aspirin and non aspirin-treated) showed immunoreactivity for  
S. aureus, (indicated by arrows in Figure 5.11, left panel) and CD11b. Likewise weak 
immunoreactivity was seen for CD11b in sham surgery skin sections compared with 
implanted mice groups. S. aureus appeared to localise toward the edge of epidermal skin 
surfaces. CD11b+ cells appeared to be co-localised with S. aureus indicating leukocyte 
mediated clearance of bacteria. Aspirin treatment appeared to moderately reduce the 
amount of CD11b positive cells infiltrating into the skin of catheter-implanted mice. 
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Figure 5.9: Aspirin therapy results in modest reductions in inflammation and 
epithelial thickness in skin of implanted mice. Haematoxylin and eosin (H & E) stained 
sections of skin were assessed for levels of inflammation. Representative sections from: 
A) sham surgery, B) s/s implant with aspirin, C) s/s implant without aspirin, D) catheter 
implant with aspirin, and E) catheter implant without aspirin groups are shown (n=3 per 
group). Arrows indicate increasing leukocyte inflammation in dermis and subcutaneous 
tissues, as well as increased epithelial thickness. Ep, Epidermis; D, Dermis; and SC, 
Subcutaneous tissue. Scale bar: 50 µm. Original magnification 10x.  
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Figure 5.10: Inflammation scores for skin sections of s/s and catheter-implanted 
mice show a trend towards reduced inflammation and reduced epidermal thickness 
with low-dose aspirin treatment. H & E stained skins sections were scored according to 
levels of inflammation in dermis and subcutaneous tissues, and relative epidermal 
thickness. Data expressed inflammation (score) or thickness (µm) with symbols 
representing individual mice, and the bar the mean ± SEM (n=3 per group, one-way 
ANOVA *p<0.05, **p<0.005).   
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Figure 5.11: S. aureus and CD11b+ cells are co-localised in infected skin surrounding 
s/s and catheter implants 4 days post-implantation. Representative images showing the 
detection of S. aureus (Cy3, red) and CD11b (Alexa Fluor® 488, green) in mouse skin. 
No significant effect of aspirin therapy was seen in the skin of s/s-implanted mice, small 
reduction of CD11b+ cells in skin of catheter-implanted mice treated with aspirin. Scale 
bar: 50 µm. Original magnification: 10x. Arrows indicate immunoreactivity for S. aureus.  
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5.3.2.4. Analysis of leukocyte populations 
In order to determine whether aspirin treatment has an effect on immune responses in 
mice with S. aureus contaminated s/s or catheter implants, the proportions of circulating 
immune cell subsets in blood and spleen were analysed. Following preparation of single 
cell suspension, cells were stained with the appropriate antibodies and immune cell 
subsets were quantified by flow cytometry. For all comparative flow cytometry analyses; 
the same antibodies, voltage settings on the flow cytometer (FACS Canto II) and gating 
strategies were used. The gating strategies for the FACS experiments are shown in Figure 
4.10 and 4.11 (Chapter 4). 
5.3.2.4.1.  Monocyte/macrophage and neutrophil populations 
The role of innate immune cells (monocytes/macrophages and neutrophils) has previously 
reported as early responders of infection and inflammation. The proportions of 
monocyte/macrophage and neutrophil populations in C57BL/6 mice were analysed in 
both blood and spleen 96 h after surgical implantation of contaminated s/s and catheter 
implants. There was a small increase in blood monocyte/macrophage and neutrophil 
populations in catheter-implanted mice compared with sham surgery mice and s/s-
implanted mice, however this was not significant (Figure 5.12; p=0.05). Aspirin-treated 
mice with s/s implants showed a trend to a decrease in circulating neutrophils compared 
with non aspirin-treated mice and sham surgery mice, although again this was not 
significant (Figure 5.12; p=0.05). Analysis of populations of monocytes/macrophages and 
neutrophils in spleen showed the highest proportion of these cells were in sham surgery 
mice and aspirin-treated s/s-implanted mice. 
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Figure 5.12: Proportions of monocytes/macrophages and neutrophils were not 
significantly altered in blood in blood of catheter-implanted mice and in spleen of all 
implanted mice. Leukocytes were extracted from the blood and spleen of female 
C57BL/6 mice, stained for surface epitopes and analysed by flow cytometry. Data 
represents the mean ± SEM of cell number in leukocyte gate (n=3 per group), differences 
between means were analysed by one-tailed Mann-Whitney test. 
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5.3.2.4.1.1. Cell surface expression of L-selectin and PSGL-1 
Cell surface expression of L-selectin and PSGL-1 on monocytes/macrophages and 
neutrophils in blood and spleen were assessed as markers of activation and migration. 
Expression levels of L-selectin and PSGL-1 on monocyte/macrophage surfaces were low 
in blood and spleen of all mice (Figure 5.13). 
No significant differences were seen in blood or spleen for L-selectin expression on 
monocytes/macrophages in either s/s or catheter-implanted mice compared with sham 
surgery mice. Catheter-implanted mice displayed the lowest proportion of L-selectin 
expression on monocytes/macrophages (Figure 5.13Ai and iii). L-selectin expression on 
neutrophils in blood remained unchanged in all mice, regardless of aspirin treatment 
(Figure 5.13Aii). In spleen, a 2-fold reduction in the expression of L-selectin on 
neutrophils was seen in both s/s and catheter-implanted mice compared with sham 
surgery mice (Figure 5.13Aiv). Aspirin treatment however did not affect L-selectin 
expression on neutrophils in spleen. Mean PSGL-1 expression on circulating 
monocytes/macrophages was lower in all implanted mice compared with sham surgery 
mice. Mice with s/s implants had a small reduction in PSGL-1 expression on the surface 
of both monocyte/macrophage and neutrophils in spleen with aspirin treatment (Figure 
5.11Biii and iv). PSGL-1 on neutrophils in blood (Figure 5.13Bii) showed a small 
decrease in s/s-implanted mice compared with sham surgery mice, however no significant 
effect of aspirin was seen.  
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Figure 5.13: A) L-selectin and B) PSGL-1 expression on monocytes/macrophages 
and neutrophils were not significantly altered in blood and spleen of mice with 
contaminated implants. Small decreases in blood and splenic expression of PSGL-1 in 
monocytes/macrophages and neutrophils in aspirin-treated s/s-implanted mice. Data are 
expressed as percentage of total monocytes/macrophages or neutrophils. Data represents 
mean ± SEM (n=3 per group). 
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5.3.2.4.2.  Analysis of T lymphocyte populations 
To evaluate the extent of contribution of the adaptive immune response in this model of 
device-related biofilm infection, the proportions of CD4+ and CD8+ T lymphocytes in 
C57BL/6 mice were determined in both blood and spleen, 96 h following surgical 
implantation of contaminated s/s and catheter implants (Figure 5.14). Similar to 
proportions observed in innate immune cell populations, catheter-implanted mice had the 
highest counts of CD4+ T lymphocytes in blood, with counts 34-fold higher (aspirin-
treated) and 25.8-fold higher (non aspirin-treated) than sham surgery mice, however this 
was not found to be statistically significant (Figure 5.14; p=0.05). In contrast, splenic 
CD4+ T lymphocyte analysis revealed that implanted mice had a minimum of 6-fold 
reduction in CD3+CD4+ cells, compared with sham surgery mice. Proportions of CD8+  
T lymphocytes in blood were low (<100 CD3+CD8+ cells), however the highest counts 
were seen in catheter-implanted mice. The trends observed for CD4+ T lymphocytes in 
the spleen were also seen in CD8+ T lymphocytes proportions, however none of these 
differences were statistically significant. Sham surgery mice had the highest splenic  
CD8+ T lymphocyte response compared with implanted mice.   
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Figure 5.14: Proportion of CD4+ And CD8+ T lymphocytes were not significantly 
altered in blood in blood of catheter-implanted mice and reduced in spleen of all 
implanted mice. Lymphocytes were extracted from the blood and spleen of female 
C57BL/6 mice, stained for surface epitopes and analysed by flow cytometry. Data are 
represented as mean ± SEM of cell number in leukocyte gate (n=3 per group), differences 
between means were analysed by one-tailed Mann-Whitney test. 
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5.4. Discussion 
S. aureus, P. aeruginosa and Candida spp are three of the most common sources of 
biofilm infections. Unsurprisingly, these pathogens are also frequent sources of 
bloodstream infections contributing to development of sepsis [552, 553]. Biofilms formed 
by these pathogens on devices have been shown to be resistant to both phagocytosis by 
macrophages and neutrophils [312, 554, 555] and antibiotic therapy [556, 557]. Failure to 
effectively clear infection contributes to persistence of biofilm. Anti-biofilm activities of 
aspirin and its major metabolite SA against models of P. aeruginosa and Candida spp 
infections have been shown, promoting investigation into the potential as an adjunct 
therapy of staphylococcal biofilm infections. 
5.4.1. In vitro study 
The main findings of this study are that formation of staphylococcal biofilms was 
impaired with the sub-inhibitory concentration of 20 mmol/L SA. Viability of the bacteria 
was not impacted, however growth rate was impaired. Concentrations of as low as  
1 mmol/L SA reduced levels of eDNA released in staphylococcal biofilms, with 
maximum decrease seen with 20 mmol/L SA. At the transcriptional level, out of a panel 
of known biofilm regulating genes, only the transcription of sarA was significantly 
impacted in mature biofilms with 5 mmol/L SA under the conditions tested. 
Inhibitory effects of aspirin and its major metabolite SA have been shown in vitro in 
biofilms of P. aeruginosa [540, 558] and Candida spp [541, 546], and to reduce growth 
rates of P. aeruginosa [558]. In this study, growth rates of SA1698 and SE35984 treated 
with 20 mmol/L SA were affected, with reduced numbers of growing bacteria in 
logarithmic phase (data not shown). SA-treated cultures also demonstrated an 
approximate 8 h delay in growth time to reach stationary phase. The bacteriostatic effect 
of SA was also shown in the viable number of bacteria recovered, following biofilm 
formation, with SA-treated biofilms comparable with initial inoculum.  
Extracellular DNA is an integral part of staphylococcal biofilms; crosslinking of eDNA 
within the extracellular polymeric matrix contributes to increased resistance to 
antimicrobial therapy and immune attack. In a previous study, staphylococcal biofilms 
treated with increasing concentrations of DNAse I showed a significant reduction in 
detectable levels of eDNA [345]. Likewise in this study, concentrations of SA as low as  
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1 mmol/L lead to a significant reduction in eDNA in the biofilm. Biofilms treated with  
20 mmol/L SA showed maximum reduction of eDNA release and this was confirmed by 
both confocal microscopy (Figure 5.3) and semi-quantitative analysis (Figure 5.4). To my 
knowledge, this is the first study to address the impacts of SA-treatment on the release of 
eDNA as a mechanism of inhibition in staphylococcal biofilms. SA-treatment was shown 
in this study to impact two key components of staphylococcal biofilm-formation; biomass 
(detected by crystal violet absorption) and eDNA release (semi-quantitative fluorescent 
detection), which lead to reduced structural integrity of the biofilm.  
Resistance of staphylococcal biofilms to host immune responses was shown in a previous 
study, with macrophages failing to successfully phagocytose staphylococcal biofilms in a 
co-culture model [357]. Similar results were seen in this study, confirmed in a single 
experiment, where RAW 264.7 cells (mouse macrophage cell line) failed to phagocytose 
mature biofilms of SA1698 or SE35984 (data not shown). Polymorphonuclear neutrophils 
(PMN) were shown in a previous study to successfully mediate phagocytosis of 
staphylococcal biofilms [345]. Similarly, it has been shown that low-dose aspirin therapy 
leads to increased leukocyte phagocytosis of bacteria in vivo [446]. It was of interest 
therefore to investigate whether pre-treatment of leukocytes with aspirin enhanced 
phagocytic ability. In a single experiment performed in this study, leukocytes purified 
from whole blood of mice were able to phagocytose staphylococcal biofilms, however 
there was no improvement in phagocytic ability when leukocytes were pre-treated with  
1 mmol/L aspirin (data not shown). SA-treatment does appear to impair mechanisms of 
staphylococcal biofilms regulation, however it is still unclear whether this impacts 
susceptibility to immune attack. It was also of interest to determine whether the effects of 
SA treatment on S. aureus biofilms were impacted at a transcriptional level. 
In other published studies on SA-treated biofilms of P. aeruginosa, quorum-sensing 
pathways that contribute to regulation of biofilm formation were impacted [559]. Similar 
mechanisms have been described in the regulation of staphylococcal biofilm formation 
[325]; with transcription of genes involved quorum sensing significantly decreased 
following treatment with SA [221]. Here, expression of the global regulator sarA was 
significantly reduced in SA-treated mature biofilms of SA1698. Other genes involved in 
regulating biofilm formation appeared to be unaffected: including genes associated with 
regulation of autolysis (contributing to eDNA release) and PIA production (contributing 
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to biomass) (Figure 5.5). This result was unexpected as the production both of these 
components were both impaired in biofilms treated with SA. It may be that regulation of 
these processes is occurring at an earlier stage of biofilm formation, and therefore not 
detected at the times investigated. Given this, future studies should investigate the impact 
of SA treatment on these genes at earlier stages of biofilm formation. While the exact 
regulatory mechanisms of SA-mediated inhibition are still poorly understood, this study 
has demonstrated two key components of staphylococcal biofilm-formation (biomass 
production and eDNA release) are physically impaired with SA treatment. These results 
support the potential of salicylates in the adjunct therapy of device-related biofilm 
infections; and raise the question of whether aspirin therapy has similar impacts on 
biofilm formation in an in vivo model of device-related infection? To address this, the 
effects of aspirin therapy on biofilm development in vivo, and host immune responses 
were investigated in a wild-type mouse model of device-related biofilm infection. 
5.4.2. In vivo study 
Implantation of contaminated s/s balls or catheter sections into subcutaneous pockets of 
C57BL/6 mice resulted in the development of an acute biofilm infection, which remained 
localised. Low-dose aspirin therapy (1 mg/kg/day for 5 days) impacted biofilm formation 
(2-fold decrease) on the surface of s/s implants, however the number of CFU determined 
in exudates surrounding s/s implants was however not affected. Aspirin therapy had no 
effect on biofilm or CFU in mice catheter implants. Modest reductions in skin 
inflammation scores were seen with aspirin therapy in both s/s and catheter-implant 
models, with reduced leukocyte influx into subcutaneous tissues and dermal layers of 
skin. Immunohistochemistry of skin surrounding implants showed the co-localising of  
S. aureus and CD11b+ cells. A decrease in inflammation in the vicinity of catheter 
implants was evident by the number of CD11b+ cells present. Flow cytometry analysis 
showed systemic inflammation and a general increase in the proportion of inflammatory 
cells in catheter-implanted mice (regardless of aspirin therapy), with significantly higher 
proportions of circulating monocytes/macrophages (CD11b+ Ly6G-), neutrophils 
(CD11b+ Ly6G+) and T lymphocytes (CD4+ and CD8+ T lymphocytes) in blood, 
compared with s/s-implanted mice.  
Of the published studies of device-related biofilm infection models in vivo, none have 
investigated the potential therapeutic benefit of low-dose aspirin. The results of this  
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in vivo study have confirmed that low-dose aspirin therapy reduces staphylococcal 
biofilms formed on s/s-implanted mice, however this effect was not similarly observed in  
catheter-implanted mice. This difference is likely to relate to the differences in surface 
characteristics for promoting biofilm formation as catheters were found to support 
development of greater biofilm biomass than s/s implants. Stainless steel implants in 
previous animal-implant studies more readily allowed for the formation of a fibrous 
capsule in vivo, providing bacteria an optimal surface for attachment and biofilm 
formation, when compared to titanium surfaces [560, 561]. In contrast, hydrogel-coated 
latex catheters have been associated with reduced adhesion of bacteria [562], however in 
the sectioning of catheters in this study, inner latex surfaces of catheters were exposed to 
bacteria. As a result, there was an increase in total surface area, and surface roughness 
(compared with hydrogel coated outer sections), which may have contributed to increased 
bacterial attachment. To address whether the differences between implant surfaces truly 
impact biofilm formation and resistance, future studies should further characterise the 
differences in surface characteristics between s/s and catheter implants, and the impact on 
bacterial attachment and maturation of biofilms in vivo.   
Aspirin therapy has been shown to improve outcomes in the rabbit model of endocarditis 
where disease is contributed to by biofilm formation. Reduced vegetation weight and 
bacterial load were found in rabbits treated with 4-50 mg/kg dose range of aspirin [384, 
516, 563]. In the mouse model described here, similar decreases in biofilm formation 
were seen in s/s-implanted mice treated with lower doses of aspirin than the rabbit studies 
(Figure 5.8A). While bacterial loads at the implant site were not affected by low-dose 
aspirin therapy (Figure 5.8B), it should be noted that mice in our study had not received 
antibiotics as would be routinely done in a clinical setting. Evidence from in vitro studies 
have shown that aspirin and vancomycin combined had a greater inhibitory effect against 
staphylococcal biofilm formation, than either treatment did individually [564]. 
There were limitations associated with the “swab and count” technique used to enumerate 
bacterial load of exudates in this model. The technique was reliant on careful swabbing of 
the exudate area, in order to avoid contamination from other commensal flora of the skin. 
Further, the number of planktonic bacteria in the exudate solution may have been present 
in fewer numbers, and swabbing may not have given a true representative level of 
bacterial burden in the skin and surrounding areas. The use of more regulated sampling 
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techniques, for example; sampling of standard section of skin surrounding wound, then 
homogenising and plating on appropriate selective media (as described for other systemic 
organ CFU counts), or sampling a restricted volume of exudate (as similarly described for 
blood CFU counts) may have yielded more reliable measurements and should be 
considered in future experiments.  
Clinically relevant outcomes flow from aspirin use in preventing other biofilm associated 
diseases. Embolic complications are reduced in patients with infective endocarditis who 
are on long term aspirin [565]. Also, in an observational study of haemodialysis patients 
with tunnelled catheters, patients previously taking aspirin had decreased risk of 
developing of staphylococcal bacteraemia [218].  
A scenario can be constructed where pre and post-operative aspirin could be used to 
prevent device-related infections. Various strategies are currently used to prevent venous 
thromboembolism. Heparinoids are most commonly used but these are associated with 
bleeding including into prosthetic joints. Many orthopaedic surgeons prefer alternatives 
including aspirin. Large retrospective studies have shown that aspirin is equally effective 
as DVT prophylaxis with no increase in bleeding risk [566]. As mentioned above, 
significant reductions were shown in S. epidermidis biofilm formation (up to 99%), when 
biofilms were treated with aspirin combined with vancomycin [564]. In the absence of 
aspirin, this effect was not seen. Aspirin could be used as prophylaxis against device-
related biofilm infection, then to potentiate killing with in combination with  
post-operative antibiotics.   
In this study, although systemic inflammation was detected, bacteria were not found in 
the blood of any of the mice (data not shown), suggesting that in this model the infection 
remained localised to the vicinity of the implant in subcutaneous pockets of the skin, 
regardless of aspirin therapy.  
Aspirin therapy was recently shown in a previous study to delay wound healing in mice, 
by reducing the production of 12-hydroxyheptadecatrienoic acid (a derivative of 
arachidonic acid); resulting in impaired re-epithelialization and delayed wound closure 
[567]. This detrimental effect only occurs at high-doses (180 mg/kg; equivalent to 14g 
dose for a human of ~80 kg). In contrast, the production of specialised pro-resolving 
mediators (SPMs) such as lipoxins and resolvins triggered by low-dose aspirin were 
Chapter 5	
	
	
	 Page 213 
shown to enhance wound healing [19, 568]. In the current study, histological analysis 
showed complete re-epithelialization and wound healing, with increased epidermal 
thickness seen in all implanted mice (Figure 5.9). Epidermal thickness was reduced in 
aspirin-treated mice, suggesting enhanced wound healing. Future studies will investigate 
a range of time-points to determine if the time frame for wound healing is reduced in the 
presence of aspirin, and to further characterise the contribution of SPMs produced in local 
sites surrounding implants in potentially accelerating wound healing and reducing 
inflammation. Immunohistochemistry of skin surrounding the implant showed infiltrates 
of CD11b+ cells co-localised with S. aureus, suggesting interactions with 
monocytes/macrophages/neutrophils to initiate bacterial clearance from tissues, however 
no significant effect of aspirin therapy could be determined at the time-points analysed 
for s/s-implanted mice (Figure 5.11). Direct analysis of interaction of 
monocytes/macrophages with biofilm on the implant surface in vivo were not possible in 
this study, but will be addressed in future studies.  
Complications of intravascular device biofilm infections in vivo include dissemination 
leading to bacteraemia and development of sepsis [569, 570]. With this in mind, the focus 
of the immunological analysis performed in this study was detecting bacteraemia and 
measuring the systemic inflammatory response. Regardless of aspirin therapy, mice with 
catheter implants had a tendency to greater weight loss, increased bacteria in exudates, 
and increased proportions of all immune cell populations (monocytes/macrophages, 
neutrophils and T lymphocytes) in blood. Although bacteria were not detected in the 
blood of these mice, significant increases in systemic inflammatory responses suggest 
that infection with catheter-implant may lead to the development of the systemic 
inflammatory response syndrome (SIRS). In contrast, s/s-implanted mice did not appear 
to have altered proportions of circulating monocytes/macrophages, neutrophils or T 
lymphocytes and no effect of aspirin was noted.  
Although proportions of circulating neutrophils were not impacted by aspirin therapy, 
analysis of cell surface markers of activation and migration (L-selectin and PSGL-1) were 
performed (mirroring the analyses performed in patients with sepsis (Chapter 3) and mice 
with systemic staphylococcal infection (Chapter 4)). Levels of migration marker PSGL-1 
expression was reduced 2-fold in monocytes/macrophages and neutrophils of aspirin-
treated mice with s/s implants, consistent with the possibility that chemotaxis is being 
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inhibited. However, as this was not statistically different a more detailed analysis of 
infiltrates at the local implant site as well as other target organs (such as kidney and liver) 
would be required to assess this in future.  
The main difference between this model and the standard patient care for device-related 
infections is the absence of antibiotic therapy. This study is the first to my knowledge to 
demonstrate effects of aspirin therapy in an in vivo model of device-related biofilm 
infection. Reductions on biofilm formation were seen in s/s-implanted mice in the 
absence of antibiotics. Indeed, clinical studies of low-dose aspirin therapy (equivalent to 
80-100 mg) have not shown any direct anti-bacterial action [218, 384]. Future studies will 
investigate the effects of low-dose aspirin in conjunction with antibiotic therapy, to 
replicate therapeutic approaches currently given in patients with similar device-related 
infections.  
The sub-cutaneous models of device-related biofilm infection described in this 
preliminary in vivo study, used contaminated urinary catheter sections and s/s balls and 
foreign body implants due to the ease of use and standardised implant sizes. The study 
allowed the observation of the effects of low-dose aspirin on biofilm formation on the 
implant and bacterial burden in surrounding tissues, as well as histological damage and to 
some degree the host inflammatory responses. However, the design for these 
experimental models was limited to only mimic sub-cutaneous local infection, and may 
not truly represent prosthetic-joint infection or catheter-related infection in a clinical 
setting.  
Developments to the experimental design of these models could potentially allow for 
greater understanding of the biofilm formation in the context of the respective infection, 
and may show a clearer effect of aspirin therapy. For example, the use of intravascular 
catheters inserted in the sub-cutaneous pockets might be a better material to better 
replicate the localised infection, and the potential spread to the bloodstream, and 
development of sepsis [360]. This is on the basis of a previous clinical study showing that 
prophylactic aspirin therapy reduced risk of bloodstream infection in patients with 
intravascular catheters inserted [218]. Alternatively, the use of urinary catheter with 
adjustments made the experimental design should be considered. Insertion the catheter in 
closer proximity to, or directly into the bladder (as described in the studies by Guiton et 
al. [571, 572]) would broaden the scope of this study, allowing the investigation aspirin-
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related effects on catheter-associated urinary tract biofilm-infections.  
Similarly, adjustments could be made to the s/s-implant model to better replicate clinical 
prosthetic-joint infections. Clinical prosthetic-joint infection are difficult to treat as 
interstitial spaces near joints lack suitable blood flow, which in turn limits access to both 
critical immune responses and effective delivery of antimicrobial therapy [355]. The 2011 
study by Prabhakara et al. used contaminated s/s insect pins that were inserted in the tibia 
of C57BL/6 mice to study the characteristics of biofilm development and host immune 
responses, closely mimicking clinical prosthetic-implant infection [356]. Similarly, anti-
microbial coated orthopaedic-grade s/s Kirschner (K)-wires were inserted in mouse femur 
prior to infection with S. aureus, to evaluate the efficacy of antimicrobial coatings as a 
preventative approach of biofilm formation [573]. Developments made to the type of 
implant used and the location of implant insertion (closer to a joint) in the present model 
would similarly permit the investigation of aspirin therapy in a more representative model 
of prosthetic joint infection. 
Further, while effects seen with low-dose aspirin seen in this study are encouraging, 
higher doses of aspirin therapy (5-10 mg/kg) in endocarditis models of infection were 
shown to be more effective in reducing bacterial vegetations and should be considered in 
future studies in these models of device-related biofilm infection. Further development of 
this model could also include an experimental group with aspirin therapy administered  
24 h after contaminated implants are inserted, to determine whether responses to aspirin 
treatment are clearer following onset of inflammation. This group could more accurately 
represent a subset of patients with established device-related infections [218, 385]. Also, 
future studies should investigate in more detail the local immune response; particularly 
the effect of inflammation induced by NFκB, as this was shown to be reduced with low-
dose aspirin therapy in patients with systemic inflammation (Chapter 3). Detailed analysis 
of measures in local infection site will improve our understanding of the mechanism of 
low-dose aspirin therapy in these implant models of device-related infection. 
As previously discussed in section 1.4.2, aspirin at all doses can potentially cause damage 
to the gastrointestinal (GI) tract. The extent of the damage however is dependent on 
several factors including dose and term of administration [422]. As previously mentioned 
in section 4.4, doses used in this mouse study were aimed at mimicking low-dose aspirin 
therapy (100 mg) in humans, which in short-term administration did not significantly 
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increase GI injury [63]. Similarly, aspirin given to mice at a 5 mg/kg daily dose for up to 
5 days in a previous study, did not result in any adverse bleeding [522]. Given that the 
dosage of aspirin administered to mice in this study was at a lower dose (1 mg/kg) over a 
4 day period, it was not anticipated that there would be any significant damage to the GI 
tract. However, the inclusion of an aspirin only control group should be considered, to 
confirm there is no evidence of GI damage.  
In summary, this study has shown that SA affects staphylococcal biofilm formation by 
decreasing total biomass and impacting extracellular DNA release; supporting the 
hypothesis that SA-treatment results in weakened staphylococcal biofilms formed  
in vitro. Future studies will investigate the impact of phagocytosis on these weakened 
biofilms, as well as examining the response of SA-weakened staphylococcal biofilms to 
traditional antibiotic therapy. The in vivo study of device-related MRSA infection showed 
a moderate reduction of biofilm formation on the surface of s/s balls with low-dose 
aspirin. Catheter-implanted mice were less impacted by aspirin therapy, and displayed a 
systemic inflammatory response characteristic of SIRS. This suggests that infection on 
this type of implant can lead to a more severe inflammatory state. To determine what 
contributes to these systemic inflammatory responses; future studies will first investigate 
local sites of inflammation, to improve our understanding of interactions between host 
immune response and bacteria on the surface on the implant. This will also clarify the 
potential impact of low-dose aspirin therapy on local inflammatory processes.  
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5.5. Conclusion 
Infectious complications associated with indwelling medical devices are a major 
healthcare problem. Current approaches in treating complex device-related biofilm 
infections are invasive and do not always effectively clear infection, leading to  
re-establishment of biofilm [574]. Further, replacement of contaminated devices can 
increase the risk of bacterial dissemination resulting in bloodstream infection and 
development of sepsis. Results of studies described within this chapter have shown that 
the aspirin’s major metabolite SA impacts regulatory processes in vitro resulting in 
impaired staphylococcal biofilm formation. Low-dose aspirin also reduced biofilm 
formed on s/s implant surfaces in vivo. These results, along with its cost-effectiveness and 
ease of use, highlight a potential role for low-dose aspirin as an adjunct therapeutic of 
device-related biofilm infections.  
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As discussed in section 1.2.5, current therapies for severe sepsis do not directly target the 
hyper-inflammatory/suppressed immune responses that characterise the sepsis syndrome, 
and indeed careful analysis over eight years of EGDT have not shown any significant 
benefit in reducing sepsis mortality rates [11]. Although a number of pharmacological 
agents have been investigated for their potential as adjunct therapies, none have shown 
significant therapeutic benefit when reaching clinical trials in humans (reviewed in 
[148]). For a novel adjunct therapy of sepsis to be successful, it should be inexpensive, be 
effective against all sources of sepsis, and aim to mediate resolution of inflammation 
rather than trying to inhibit inflammation completely.  
Evidence is accumulating to support the potential of aspirin in the adjunct therapy of 
sepsis, with the prediction that the mechanisms of action previously described in other 
inflammatory conditions (via production of pro-resolving lipid mediators including  
15-epi-LxA4) [19, 20], will also be beneficial in sepsis patients. In October 2015, in a 
review was published by Toner et al., also proposing a role for aspirin in the adjunct 
therapy of sepsis, with proposed mechanisms of action similarly described as above 
[575]. In addition, improved outcomes have been reported in animal and observational 
studies of septic patients [18, 61, 214, 220]. With this in mind, the MATHs clinical trial 
and contributing studies of this thesis were initiated, to investigate any effect of aspirin-
therapy in clinical sepsis, as well as experimentally in mouse models of gram-positive 
sepsis and device-related biofilm infection.  
In this discussion, the key findings of this work will be discussed, with a particular focus 
on how the results contribute to the greater understanding of mechanisms of aspirin 
therapy in affecting systemic inflammatory responses. The limitations and strengths of 
these studies and in particular the differences between sepsis in humans and the mouse 
model will be discussed. Furthermore, the potential implications of these findings will be 
discussed along with suggestions for future experiments stemming from this work. 
6.1. Key findings of this study 
Overall, the findings of the interim analysis on the first patients in the MATHS clinical 
trial are that short-term administration of low-dose aspirin therapy (100 mg/day) does in 
fact impact immunological pathways in patients with sepsis, and these could potentially 
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lead to improved outcomes. In addition, aspirin therapy at equivalent doses showed 
therapeutic benefit in mice with S. aureus-induced sepsis, and impacted biofilm formation 
in mice with contaminated s/s implants.  
6.2. Low-dose aspirin as a potential adjunct therapy of 
systemic inflammation 
6.2.1. The role of pro-resolving lipid mediators 
Lipoxins and aspirin-triggered epimers are well-studied lipid mediators with functions in 
resolving inflammation. These mediators were first described by Charles Serhan and 
colleagues in 1984, and are produced via the metabolism of AA in human leukocytes 
[576]. In this study, 15-epi-LxA4 was used as a primary read-out parameter for 
determining an effect of aspirin therapy in both patients with sepsis and mice with  
S. aureus-induced sepsis. 
Previous studies have shown that lipoxin production occurs rapidly following onset of 
inflammation [12, 439]. Similarly, plasma levels of 15-epi-LxA4 increase rapidly 
following aspirin administration [19, 214]. Peak responses of 15-epi-LxA4 in plasma of 
patients in this study were seen within 1 hour of receiving low-dose aspirin therapy; 
consistent with reports from studies investigating localised 15-epi-LxA4 production 
following inflammation, leading to resolution of inflammation [19]. Interestingly, 
detectable levels of 15-epi-LxA4 were also observed in the absence of aspirin therapy in 
both the human and animal studies, as was seen in previous studies [19, 214]. A number 
of sources have been suggested including the endogenous production of 15R-HETE, 
leading to 15-epi-LxA4 production by cytochrome p450 [577], and in the case of the 
participants in the trial it is also possible that statin therapy could also result in moderate 
increases in 15-epi-LxA4 production [443]. In future studies, the source of this 
endogenously produced 15-epi-LxA4 should be investigated further. A number of 
downstream effects of 15-epi-LxA4 production have been described contributing to 
resolution of inflammation, however very few of these have been studied within the 
context of sepsis. 
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The production of 15-epi-LxA4 leads to the inhibition of NFκB, and this has been shown 
in vitro in both human and mouse cell types [480, 493], and in ex vivo stimulation of 
human leukocytes [216]. To my knowledge, this study is one of only a few that has 
investigated the in vivo activation of NFκB in PBMCs in both patients and mice with 
sepsis. Development of sepsis increased activation of NFκB in both untreated control 
patients and infected mice, indicating increases in inflammation, and an inhibitory effect 
of aspirin therapy was shown in patients within 8 h of receiving aspirin therapy, 
regardless of dose administered. These results are promising considering the sample size, 
and support the potential for NFκB as indicative marker for aspirin-induced  
anti-inflammatory/pro-resolution effects in sepsis. 
A consequence of NFκB activation in sepsis is the production of pro-inflammatory 
cytokines and chemokines. Lipoxin A4 and 15-epi-LxA4 have been shown to impact 
transcription and subsequent production of pro-inflammatory cytokines [128, 216]. 
Similarly, post-treatment with LxA4 and 15-epi-LxA4 lead to attenuated production of 
pro-inflammatory cytokines and chemokines, with improved outcomes shown in animal 
models of sepsis [17, 510].  
The levels of pro-inflammatory cytokines and chemokines produced in both patients and 
mice in this study were indicative of early inflammation, plasma cytokine levels in a 
lower range when compared with levels reported from patients with severe sepsis and 
septic shock [495]. The only significant aspirin-related effect seen was an increase in 
levels of plasma IL-18 in patients treated with 100 mg aspirin. In a previous study, an 
increase in IL-18 contributed to resolution of bacterial infection in mice [498]. It is 
possible that the same mechanism of action is responsible in the current study; however 
further investigation would be required to confirm any correlation.  
Levels of TNF-α were also significantly increased in regular aspirin-taking patients, 
although as levels were within normal range, the only conclusions that can be made are 
that these patients were more severely ill compared with other groups. This was also 
evident from other clinical characteristics including increased age, presence of co-
morbidities, and highest MPV recorded. Further, this effect on TNF-α was not seen in 
mice, possibly because mice did not have existing bacteraemia prior to receiving aspirin 
therapy. Other well-known pro-inflammatory cytokines and chemokines did not appear to 
Chapter 6	
	
	
	 Page 222 
be affected by aspirin therapy, keeping with results seen in both exudates from localised 
infection in humans, and mice with induced peritonitis following low-dose aspirin 
therapy in a previous study [19]. Future studies will investigate whether the lack of 
differences seen in other plasma cytokine levels were due the time frame for analysis, by 
performing similar analysis on plasma sampled at earlier time-points following aspirin 
administration. The short half-life of cytokines in circulation could also account for why 
significant differences were not seen for commonly reported cytokines. Moreover, it is 
possible that detected levels of cytokines in plasma are dilute and do not adequately 
reflect the expected level of inflammation in affected tissues. Future studies should 
consider the measurement of cytokines either directly from affected tissues for a clearer 
understanding of more localised inflammatory responses, or measurement from in vitro 
stimulated PBMC to determine the predominant leukocyte type for cytokine production in 
sepsis. 
Both LxA4 and 15-epi-LxA4 are produced as a result of interactions between cells of the 
host immune response following inflammation, and both mediate impact innate immune 
responses in inflammation, most notably by interfering with the activation and functions 
of neutrophils [14]. During sepsis, activation of neutrophils is prolonged, delaying 
apoptosis; leading to exacerbated inflammation, damage and organ failure contributing to 
increased mortality rates [578]. Pre-treatment with 15-epi-LxA4 was shown to reverse the 
delayed apoptosis of isolated human neutrophils in a previous study [101]. Further, LxA4 
and 15-epi-LxA4 were both shown to attenuate activation and migration of neutrophils, 
which lead to reduced neutrophil-mediated tissue damage [487].  
In this study, CD86 expression was analysed on the surface of circulating 
monocytes/macrophages as a marker of antigen presenting activity, and in the case of 
neutrophils, delayed apoptosis [499]. Increases in the proportions of circulating 
monocytes/macrophages and neutrophils expressing CD86 were seen shortly after the 
first aspirin dose in 100 mg aspirin-treated patients, however these were not significantly 
different from other treatment groups. Further, no significant difference was seen in 
surface expression of the known activation and migration marker PSGL-1 on circulating 
neutrophils in patients with sepsis, or in blood or spleen of mice with S. aureus-induced 
sepsis or device-related infection, regardless of aspirin therapy. Interestingly, differences 
were seen in mice with sepsis following low-dose aspirin therapy in the proportion of 
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splenic and circulating PSGL-1+ monocytes/macrophages and splenic L-selectin+ 
monocytes/macrophages, suggesting that in the early stages of sepsis, aspirin therapy 
activates monocytes/macrophages, for enhanced phagocytic-mediated clearance of 
bacteria [446]. Complete clearance of viable bacteria was seen in target organs of low-
dose aspirin-treated mice with S. aureus-induced sepsis following second dose, in the 
absence of antibiotic therapy. As low-dose aspirin is does not appear to be directly anti-
bacterial, further investigation is required to confirm whether this is a downstream effect 
of aspirin. Additionally, immunohistochemistry analysis of spleen as a representative 
organ also revealed the co-localisation of S. aureus and CD11b+ cells (including 
monocytes/macrophages and neutrophils). The combination of these results supports the 
idea that at least in the early stage sepsis shown in this study aspirin does not significantly 
impact neutrophils, however activates monocytes/macrophages, leading to the enhanced 
clearance of bacteria from organs often damaged in sepsis. 
All of the studies described in this thesis showed a benefit of aspirin therapy, current 
knowledge suggesting that 15-epi-LxA4-mediated actions contribute to this, as these 
actions are both anti-inflammatory and contribute to the resolution of inflammation. It is 
known however, that 15-epi-LxA4 is not the only SPM synthesised following aspirin 
therapy. As outlined in section 1.4.6.2, a number of recent studies have shown that aspirin 
also triggers the synthesis a number of other epimeric SPMs including resolvins and 
protectins. As similarly described for 15-epi-LxA4, aspirin-triggered resolvin D1 (AT-
RvD1) is a more potent anti-inflammatory mediator than naturally produced RvD1, with a 
greater capacity to inhibit of leukocyte infiltration, and increased resistance to 
inactivation by enzymes [503]. Post-treatment with AT-RvD1 also protected mice from 
both inflammation induced acute lung injury and endotoxin-induced acute kidney injury 
by inhibiting NFκB-mediated activation [13, 503]. Taking this into consideration, it is 
unlikely resolution of inflammation is due to any of these SPMs individually, but more 
likely the contribution of many, with a switch from traditional pro-inflammatory lipid 
mediators to the production of anti-inflammatory mediators, which combined trigger 
resolution of inflammation [464]. With this in mind, future studies in all models should 
consider what role other naturally occurring and aspirin-triggered SPMs play in resolution 
of inflammation following sepsis. 
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The design of the MATHS clinical trial could be improved by adding a time-point 
approximately 1 h after the second dose, and the inclusion of a healthy control group (or 
access to one). This is currently restricted by the limitations of the human ethics aspects 
of the study and number of samples that could be taken from seriously ill patients. These 
additional samples would make the analysis easier to interpret.  
The results from patients enrolled in the MATHS clinical trial will also contribute to 
understanding the immunological basis for effects of aspirin therapy in an ongoing 
primary prevention trial; the AspiriN To Inhibit SEPSIS (ANTI SEPSIS) study, which is 
a sub-study of ASPirin in Reducing Events in the Elderly (ASPREE) trial. The ANTI 
SEPSIS trial will determine whether the prophylactic administration of low-dose aspirin 
can reduce mortality in the elderly population as a result of sepsis, as well as reduce the 
development of severe infections requiring hospitalisation and minimising ICU admission 
following identification of severe sepsis in hospitals.  
As mentioned, differences were observed in aspirin-dependent responses between trial 
participants and mice with sepsis. These factors lead to the conclusion that the current 
mouse model used was not an accurate comparison with human systemic inflammatory 
disease. The significance and implications of these differences as well as suggestions for 
future studies are discussed below. 
6.2.2. Differences observed between patients with sepsis and the mouse 
model 
Although aspirin therapy did have beneficial effects in the mouse model of S. aureus-
induced sepsis described in this study, the predicted changes in surrogate markers of 
increased plasma 15-epi-LxA4 and NFκB inhibition were not seen. 
The major difference between these two studies is the time frame and model 
development. Patients in the clinical study described in Chapter 3 were enrolled into the 
clinical trial following identification of SIRS/sepsis, and then aspirin therapy was 
administered. In contrast, mice were infected with S. aureus, and aspirin therapy was 
administered after 1 h. Therefore, in mice bacteraemia had not yet developed and induced 
septic changes prior to aspirin administration. Moreover, patients had different infectious 
sources, and initial sites of infection contributing to the development and severity sepsis, 
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whereas mice were infected via the same route with the same strain of  
S. aureus. While the animal model is a more defined system for investigation of the 
immunological responses of sepsis in target organs as well as the bloodstream, it cannot 
represent all of the responses that can arise from different sources and sites of infection 
that contribute to sepsis in humans [1, 30]. Future studies should also include a number of 
pathogenic sources (gram-positive and gram-negative bacteria, as well as fungal sources) 
so that the impact of aspirin can be tested in a range of infections, to better model the 
spectrum of infections seen in humans.  
The factors that can be addressed to enhance the mouse model include allowing 
bacteraemia and sepsis symptoms to develop before administration of aspirin, and 
sampling at earlier and additional time-points to permit clarification of the question as to 
whether timing aspirin does induce changes in the key surrogate markers in mice.  
There were two significant considerations that directed the current design of the mouse 
model. In order to allow mice to develop sepsis for 24 h prior to administering aspirin the 
experiment duration would have had to been extended to 72 h, given that sepsis can lead 
to rapid mortality, and there would likely be a high mortality in the untreated control 
group. Animal welfare and issues are not insignificant in this type of study, and animal 
ethics committees do not consider death an acceptable endpoint. For this reason the 
decision was taken to perform experiments using a wild-type strain of mice with some 
relative resistance to S. aureus, and administer aspirin immediately following infection, in 
the initial 48 h study to give the best chance of detecting an effect of aspirin. Based on the 
data that has now been obtained, an improved model would include additional 
parameters, including a group where sepsis is allowed to develop for 24 h before aspirin 
treatment, and groups where mice are given supportive antibiotic therapy as well as 
aspirin as adjunct therapy.  
The sampling time-points used in the current mouse study were initially selected based on 
data from a preliminary analysis of the first 15 patients in the trial (Batch 1), which 
indicated that the peak responses for all parameters were expected to be in the 8-24 h time 
frame. Later, the combined analysis of the 29 septic patients enrolled to date now suggest 
that the response is more rapid, however it may not be possible to clearly predict this until 
the trial is complete. Also, the prohibitive cost of analysis of multiple parameters meant 
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that a limited number of time-points had to be selected, as a result of the selection of the 
12, 24 and 48 h time-points it is likely that aspirin-induced changes in the surrogate 
markers were missed.  
Similar differences were also noted for NFκB inhibition. Although increases in NFκB 
activation were seen, the observed change in mice were of a lower magnitude compared 
to patients, with largest differences measured at 24 h post-infection; consistent with early 
development of inflammation. Given that maximum inflammation driven by NFκB had 
not fully developed, it is therefore not surprising that an effect of aspirin was not seen. In 
future developments of the model described above; inducing sepsis prior to aspirin 
therapy will allow for the detection of 15-epi-LxA4 within time frames previously 
published as well as the inhibition of established inflammation driven by NFκB, as seen 
in patients and other previously published studies [19, 214, 216, 480]. 
There are number of other differences that should be taken into consideration in the future 
development animal models of sepsis; epidemiological evidence suggests that in 
Australia, men are more likely to develop sepsis than women [29, 30]. Also, age and 
presence of comorbidities contribute to increases the risk of patients developing sepsis [4, 
579-581]. A high proportion of the patients enrolled into the clinical study had at least 
one pre-existing condition. In fact, patients regularly taking aspirin were older, and all 
presented with at least one co-existing disease that contributed to their overall increased 
severity of inflammation. In contrast, mice used in sepsis studies were all healthy female, 
wild-type C57BL/6 strain of mice, age-matched at 6-8 weeks old. A previous study 
reported that C57BL/6 demonstrate increased resistance to bloodstream infections with  
S. aureus due to their genetic background [241], and this strain was chosen for initial 
studies to reduce the risk of rapid mortality after bloodstream infection. The laboratory 
mice in this study were also specific pathogen free (SPF), meaning that they would also 
have a reduced spectrum of pre-existing immune memory to bacterial pathogens.  
Future development of this model to reflect a more accurate representation of the 
spectrum of human clinical sepsis will need to consider all of the previously described 
variables including: inducing sepsis in mice of both genders, in a variety of ages, and 
strains of mice with increased susceptibility (such as BALB/c or A/J mice), or strains of 
mice representing patients with co-morbidities like Type 2 diabetes (e.g. B6.Cg-m +/+ 
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Leprdb/J (db/db) obese type 2 diabetic mice). Further, considerations should also include a 
group of mice that also receive antibiotic therapy, mirroring the multi-modal therapies 
offered to patients with sepsis and in a previous study, was shown to decrease systemic 
inflammation and improve survival in a mouse model of gram-negative sepsis [17]. 
Additionally, the inclusion of an aspirin-only group should be considered, in order to 
determine any effect of aspirin on the gastro-intestinal tract. This group of mice would 
also facilitate determination of baseline 15-epi-LxA4 and NFκB responses to aspirin, in 
the absence of infection. 
Regardless of the differences in time lines, protocols and surrogate measures compared 
with patients, it remains that aspirin therapy did have beneficial effects in mice with  
S. aureus-induced sepsis. Clinical outcomes including changes in weight and clinical 
scores given on the basis of parameters outlined in Table 2.2 were significantly improved 
in mice treated with low-dose aspirin (equivalent to 100 mg dose in patients with sepsis). 
Additionally, low-dose aspirin-treated mice showed complete clearance of S. aureus from 
target organs by 48 h post-infection, in the absence of traditional antibiotic therapy.  
6.3. Low-dose aspirin as a potential adjunct therapy of device-
related biofilm infection 
A series of studies were performed to investigate the additional direct effects of aspirin on 
pathogenic bacteria. Aspirin and its major metabolite SA have previously been shown by 
others to inhibit formation of biofilms of P. aeruginosa [540, 558] and Candida spp [541, 
546]. In a manner that extends these observations and broadens the range of pathogens, 
this study has shown that SA inhibits staphylococcal biofilm formation in vitro. The 
mechanism by which this occurs is by impacting major regulatory processes including, 
production of polysaccharide biomass and extracellular DNA release. Given that these 
two processes are integral to resistance of the biofilm [312, 556], the combined effect of 
SA leads to formation of a weaker biofilm that could potentially be more susceptible to 
both immune attack and traditional antimicrobial therapies. Further, this study confirmed 
that transcription of global regulator gene sarA was significantly decreased in biofilm 
forming strains even up to 24 h following treatment with SA [221]. These results raised 
the question of whether aspirin therapy similarly impacts biofilm formation in vivo. 
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Beneficial effects have been shown following aspirin use in biofilm-associated diseases. 
Reductions in bacterial vegetation size and weight have been shown in aspirin-treated 
rabbits with biofilm-related endocarditis [384, 563]. Further, aspirin therapy is associated 
with reduced embolic complications in patients with infective endocarditis, and was 
considered a suitable prophylactic therapy in preventing thromboembolism [385, 565, 
566]. Aspirin therapy also contributed to reduced incidence of staphylococcal 
bacteraemia in haemodialysis patients with tunnelled catheters [218]. These studies 
provided further evidence supporting the potential benefit of aspirin therapy in device-
related biofilm infections. 
This study is the first to demonstrate an effect of low-dose aspirin therapy in an in vivo 
model of subcutaneous device-related biofilm infection. Mice with S. aureus 
contaminated s/s implants had reduced biofilm formation, following 4 days of low-dose 
aspirin therapy. In contrast, mice with catheter implants were not affected by aspirin 
therapy; this was also reflected in the different systemic responses observed between the 
different implant types. Aspirin therapy was also shown to reduce epidermal thickness, in 
skin surrounding infected wounds which in other localised infection studies was 
suggestive of enhanced wound healing through rapid resolution of inflammation, 
presumably facilitated by the local production of pro-resolving mediators including  
15-epi-LxA4 [19, 568]. Future investigations in this model should include the 
quantification of local 15-epi-LxA4 production and NFκB inhibition, and subsequent 
impact on local inflammation following aspirin therapy in device-related biofilm 
infections. 
6.3.1. Differences observed between patients with device-related 
infections and mouse models in this study 
As similarly noted in section 6.2.2, there were a number of differences noted between the 
mice in the experimental models of device-related biofilm infections study and their 
clinical counterparts, which need be considered.  
Although the models investigated in this study did provide useful information on the 
effects of aspirin as an adjunct therapy for sub-cutaneous device-related biofilm 
infections, they were not ideal representative models of clinical intravascular catheter 
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infections, or prosthetic joint infections. Adaptations to the experimental models (as 
discussed in section 5.4.2), such as use of intravascular catheter inserted into the 
bloodstream, would better facilitate investigations into the systemic spread of localised 
infections, mimicking the predisposition of patients with intravascular catheters to 
bloodstream infection, endocarditis and sepsis development [582, 583]. Similarly, the 
continued use of urinary catheters with the adjustment of inserting closer to or directly 
into the bladder would allow the investigation of catheter-associated urinary tract 
infection, and determining the potential for aspirin as an adjunct therapeutic in this model 
[366, 376, 584]. Further, modifications to both the shape and size of s/s implants, as well 
as inserting implants in closer proximity to joints would permit the evaluation of aspirin 
therapy in a more representative model of clinical prosthetic-joint infections [573].  
Aside from modifications to experimental implant designs, there are other considerations 
to be made when comparing the mice in the present study, to humans with clinical 
device-related infections. As similarly noted in section 6.2.2, age and presence of other 
pre-existing conditions were two clear points of difference. Patients with clinical device-
related infections are older by comparison and have numerous pre-disposing health issues 
(patients requiring joint replacement, due to deterioration of natural joints, or patients 
requiring catheterisation; either for replenishment of fluids, or to assist urinary 
excretions) and in some cases these patients had deteriorating immune responses [353].  
In contrast, mice used in the device-related biofilm models were all healthy female 
C57BL/6 strain of mice, age-matched at 6-8 weeks old. Mice in this study were also 
specific-pathogen free (SPF), and thus would not have pre-existing memory response to 
infectious pathogens. In order to more reliably reflect the patients commonly presenting 
with these types of infections, future studies should consider the use of aged mice of both 
genders, as well as mice from a variety of different genetic backgrounds (as described in 
section 6.2.2). In this way, the study would be able to determine the potential therapeutic 
range of low-dose aspirin, in these device-related infection models.  
The beneficial effects of aspirin therapy in this model were similar to that observed in 
mice with sepsis in the absence of antibiotic therapy. Indeed, in vitro studies have 
demonstrated increased efficiency in diminishing biofilm formation of staphylococci, 
following incubation with salicylate and vancomycin in combination [564]. Further, 
combination therapy including administration of 15-epi-LxA4 and ceftadizime improved 
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clinical outcomes in mice with systemic inflammation [17], supporting a more significant 
impact of aspirin as an adjunct therapy. In order to replicate therapies given to patients 
and determine whether outcomes are more significantly impacted, future studies of this 
model should also include antibiotic therapy. Furthermore, while therapeutic benefit was 
shown in this study, only one low dose of aspirin was investigated. Significant reduction 
of bacterial vegetations was observed in rabbits with infective endocarditis when treated 
with higher doses of aspirin (8-12 mg/kg) [384, 516, 563]. Indeed, high doses of aspirin  
(100 mg/kg and above, 10 fold greater than the highest dose used in the current study) are 
associated with bleeding and other negative side effects in both humans and rodents [585, 
586]. In future studies however, it would be worthwhile investigating doses of aspirin 
comparative with the endocarditis studies (3-10 mg/kg); to determine whether a 
moderately increased aspirin dose would be more or less beneficial in adjunct therapy of 
device-related biofilm infection models. As similarly described in section 6.2.2, the 
inclusion of an aspirin-only control group should be considered in future studies, to 
determine any effects on the gastro-intestinal tract, and provide baseline responses to 
aspirin in the absence of infection. 
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6.4. Conclusion 
In summary, this thesis has contributed to the understanding of the therapeutic benefits of 
low-dose aspirin therapy in systemic and localised inflammation following infection. 
Low-dose aspirin (100 mg) increases plasma 15-epi-LxA4 production, inhibited NFκB 
activation and changes in circulating innate immune cell proportions in patients with 
sepsis. While effects on these parameters were not shown in mice with S. aureus-induced 
sepsis, overall clinical condition was improved and complete clearance of bacteria from 
target organs was seen with equivalent aspirin doses, in the absence of antibiotic therapy. 
Future improvements to the design of the model will be required to better model the 
human spectrum of disease. Further, this study showed for the first time that low-dose 
aspirin therapy decreased biofilm formation on the surface s/s implants in a mouse model 
of device-related biofilm infection.  
The results from this study provide support for a role for low-dose aspirin in the adjunct 
therapy of both sepsis and device-related biofilm infection. Completion of the MATHs 
clinical trial will be required to provide definitive evidence to support advancing to a 
prospective trial in septic patients. Further research is required in the development of both 
mouse models, in order to dissect the mechanisms of aspirin-induced responses and 
determine whether adapted models are more representative of patients of sepsis and 
device-related infections, respectively. 
	  
  
 
	  
7.  References 
 
References	
	
	
	 Page 233 
1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: 
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, 
and associated costs of care. Critical Care Medicine 2001, 29(7):1303-1310. 
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, 
Sprung CL, Douglas IS, Jaeschke R: Surviving sepsis campaign: international 
guidelines for management of severe sepsis and septic shock: 2012. Intensive care 
medicine 2013, 39(2):165-228. 
3. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. New England 
Journal of Medicine 2003, 348(2):138-150. 
4. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United 
States from 1979 through 2000. New England Journal of Medicine 2003, 348(16):1546-
1554. 
5. Karchmer AW: Staphylococcus aureus bacteremia and native valve endocarditis: the 
role of antimicrobial therapy. Infectious Diseases in Clinical Practice 2012, 20(2):100-
108. 
6. Raad II, Sabbagh MF: Optimal duration of therapy for catheter-related 
Staphylococcus aureus bacteremia: a study of 55 cases and review. Clinical Infectious 
Diseases 1992, 14(1):75-82. 
7. Lee JW, Devanarayan V, Barrett Y, Weiner R, Allinson J, Fountain S, Keller S, Weinryb 
I, Green M, Duan L et al: Fit-for-purpose method development and validation for 
successful biomarker measurement. Pharmaceutical Research 2006, 23(2):312-328. 
8. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K: Use 
of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration 
inhibitory factor, soluble urokinase-type plasminogen activator receptor, and 
soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose 
infections: a prospective study. Critical Care 2007, 11(2):R38. 
9. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, Moretti E, 
Nguyen HB, Gunnerson KJ, Milzman D: A prospective, multicenter derivation of a 
biomarker panel to assess risk of organ dysfunction, shock, and death in emergency 
department patients with suspected sepsis. Critical Care Medicine 2009, 37(1):96-104. 
10. Fitousis K, Moore LJ, Hall J, Moore FA, Pass S: Evaluation of empiric antibiotic use in 
surgical sepsis. The American Journal of Surgery 2010, 200(6):776-782. 
11. The ARISE investigators, The ANZICS APD Management Committee: The outcome of 
patients with sepsis and septic shock presenting to emergency departments in 
Australia and New Zealand. Critical Care and Resuscitation 2007, 9(1):8-18. 
12. Markworth JF, Vella L, Lingard BS, Tull DL, Rupasinghe TW, Sinclair AJ, Maddipati 
KR, Cameron-Smith D: Human inflammatory and resolving lipid mediator responses 
to resistance exercise and ibuprofen treatment. American Journal of Physiology-
Regulatory, Integrative and Comparative Physiology 2013, 305(11):R1281-R1296. 
13. Chen J, Shetty S, Zhang P, Gao R, Hu YX, Wang SX, Li ZY, Fu J: Aspirin-triggered 
resolvin D1 down-regulates inflammatory responses and protects against endotoxin-
induced acute kidney injury. Toxicology and Applied Pharmacology 2014, 277(2):118-
123. 
14. Chiang N, Takano T, Clish CB, Petasis NA, Tai H-H, Serhan CN: Aspirin-triggered 15-
epi-Lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis 
exudates: Development of a specific 15-epi-LXA4 ELISA. Journal of Pharmacology 
and Experimental Therapeutics 1998, 287(2):779-790. 
References	
	
	
	 Page 234 
15. Serhan Charles N, Fredman G, Yang R, Karamnov S, Belayev Ludmila S, Bazan 
Nicolas G, Zhu M, Winkler Jeremy W, Petasis Nicos A: Novel proresolving aspirin-
triggered DHA pathway. Chemistry & Biology 2004, 18(8):976-987. 
16. Jin S-W, Zhang L, Lian Q-Q, Liu D, Wu P, Yao S-L, Ye D-Y: Posttreatment with 
aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute 
lung injury in mice: the role of heme oxygenase-1. Anesthesia & Analgesia 2007, 
104(2):369-377. 
17. Ueda T, Fukunaga K, Seki H, Miyata J, Arita M, Miyasho T, Obata T, Asano K, 
Betsuyaku T, Takeda J: Combination therapy of 15-epi-Lipoxin A4 with antibiotics 
protects mice from Escherichia coli-induced sepsis. Critical Care Medicine 2014, 
42(4):e288-e295. 
18. Paul-Clark MJ, van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW: 15-epi-Lipoxin 
A4-mediated induction of nitric oxide explains how aspirin inhibits acute 
inflammation. The Journal of Experimental Medicine 2004, 200(1):69-78. 
19. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, 
Bellingan G, Gilroy DW: Effects of low-dose aspirin on acute inflammatory responses 
in humans. The Journal of Immunology 2009, 183(3):2089-2096. 
20. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN: Aspirin triggers 
antiinflammatory 15-epi-Lipoxin A4 and inhibits thromboxane in a randomized 
human trial. Proceedings of the National Academy of Sciences of the United States of 
America 2004, 101(42):15178-15183. 
21. Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN: Infection 
regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012, 
484(7395):524-528. 
22. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald 
WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative 
therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American 
College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 
101(6):1644-1655. 
23. Russell JA: Management of sepsis. New England Journal of Medicine 2006, 
355(16):1699-1713. 
24. Cohen J: The immunopathogenesis of sepsis. Nature 2002, 420(6917):885-891. 
 
25. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, 
Vincent J-L, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis 
definitions conference. Intensive Care Medicine 2003, 29(4):530-538. 
26. Moore LJ, McKinley BA, Turner KL, Todd SR, Sucher JF, Valdivia A, Sailors RM, Kao 
LS, Moore FA: The epidemiology of sepsis in general surgery patients. The Journal of 
Trauma and Acute Care Surgery 2011, 70(3):672-680  
27. Burchardi H, Schneider H: Economic aspects of severe sepsis: a review of Intensive 
Care Unit costs, cost of illness and cost effectiveness of therapy. PharmacoEconomics 
2004, 22(12):793-813. 
28. Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A: Inpatient care for septicemia or 
sepsis: a challenge for patients and hospitals. . NCHS Data Brief 2011, 62:1-8. 
29. Sundararajan V, MacIsaac CM, Presneill JJ, Cade JF, Visvanathan K: Epidemiology of 
sepsis in Victoria, Australia. Critical Care Medicine 2005, 33(1):71-80  
References	
	
	
	 Page 235 
30. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J: Adult-population 
incidence of severe sepsis in Australian and New Zealand intensive care units. 
Intensive Care Medicine 2004, 30(4):589-596. 
31. Barnato AE, Alexander SL, Linde-Zwirble WT, Angus DC: Racial variation in the 
incidence, care, and outcomes of severe sepsis: analysis of population, patient, and 
hospital characteristics. American Journal of Respiratory and Critical Care Medicine 
2008, 177(3):279-284. 
32. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Occurrence and outcomes of 
sepsis: Influence of race. Critical Care Medicine 2007, 35(3):763-768. 
33. Davis JS, Cheng AC, McMillan M, Humphrey AB, Stephens DP, Anstey NM: Sepsis in 
the tropical Top End of Australia's Northern Territory: disease burden and impact 
on Indigenous Australians. The Medical Journal of Australia 2011, 194(10):519-524. 
34. Tong SY, van Hal SJ, Einsiedel L, Currie BJ, Turnidge JD: Impact of ethnicity and 
socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: 
a heavy burden in indigenous Australians. BioMed Central Infectious Diseases 2012, 
12(249):1-9. 
35. Pène F, Mira J-P, Chiche J-D: Nobel Prize laureates pave the way for therapeutic 
advances in sepsis. Intensive Care Medicine 2012, 38(2):183-185. 
36. Shelley O, Murphy T, Paterson H, Mannick JA, Lederer JA: Interaction between the 
innate and adaptive immune systems is required to survive sepsis and control 
inflammation after injury. Shock 2003, 20(2):123-129. 
37. Skirecki T, Borkowska-Zielińska U, Złotorowicz M, Hoser G: Sepsis 
immunopathology: Perspectives of monitoring and modulation of the immune 
disturbances. Archivum Immunologiae et Therapiae Experimentalis 2012, 60(2):123-
135. 
38. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-
like drugs. Nature: New Biology 1971, 231(25):232-235. 
39. Xie W, Robertson DL, Simmons DL: Mitogen-inducible prostaglandin G/H synthase: 
A new target for nonsteroidal antiinflammatory drugs. Drug Development Research 
1992, 25(4):249-265. 
40. Bernard G, Reines H, Halushka P, Higgins S, Metz C, Swindell B, Wright P, Watts F, 
Vrbanac J: Prostacyclin and thromboxane A2 formation is increased in human sepsis 
syndrome: effects of cyclooxygenase inhibition. American Review of Respiratory 
Disease 1991, 144(5):1095-1101. 
41. Beckman JS: Oxidative damage and tyrosine nitration from peroxynitrite. Chemical 
Research in Toxicology 1996, 9(5):836-844. 
42. Muszynski JA, Hall MW: Sepsis-induced innate and adaptive immune suppression. 
The Open Inflammation Journal 2001, 4:67-73. 
43. Bronte V, Zanovello P: Regulation of immune responses by L-arginine metabolism. 
Nature Reviews Immunology 2005, 5(8):641-654. 
44. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI: Streptococcus 
pneumoniae anchor to activated human cells by the receptor for platelet-activating 
factor. Nature 1995, 377(6548):435-438. 
	  
References	
	
	
	 Page 236 
45. Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, Higgins J, Visai L, 
Speziale P, Cox D, Foster TJ: Fibronectin‐binding proteins of Staphylococcus aureus 
mediate activation of human platelets via fibrinogen and fibronectin bridges to 
integrin GPIIb/IIIa and IgG binding to the FcγRIIa receptor. Molecular 
Microbiology 2006, 59(1):212-230. 
46. Sakamaki F, Ishizaka A, Handa M, Fujishima S, Urano T, Sayama K, Nakamura H, 
Kanazawa M, Kawashiro T, Katayama M: Soluble form of P-selectin in plasma is 
elevated in acute lung injury. American Journal of Respiratory and Critical Care 
Medicine 1995, 151(6):1821-1826. 
47. Fijnheer R, Frijns C, Korteweg J, Rommes H, Peters J, Sixma J, Nieuwenhuis H: The 
origin of P-selectin as a circulating plasma protein. Thrombosis and Haemostasis 
1997, 77(6):1081-1085. 
48. Levi M, Schultz M: Coagulopathy and platelet disorders in critically ill patients. 
Minerva Anestesiologica 2010, 76(10):851-859. 
49. Levi M: Platelets in critical illness. In: Seminars in thrombosis and hemostasis: 2016. 
Thieme Medical Publishers: 252-257. 
50. Cognasse F, Hamzeh‐Cognasse H, Lafarge S, Acquart S, Chavarin P, Courbil R, 
Fabrigli P, Garraud O: Donor platelets stored for at least 3 days can elicit activation 
marker expression by the recipient's blood mononuclear cells: an in vitro study. 
Transfusion 2009, 49(1):91-98. 
51. Andrews RK, Arthur JF, Gardiner EE: Neutrophil extracellular traps (NETs) and the 
role of platelets in infection. Thromb Haemost 2014, 112(4):659-665. 
52. Wang X, Qin W, Sun B: New strategy for sepsis: targeting a key role of platelet-
neutrophil interaction. Burns and Trauma 2014, 2(3):114-120. 
53. Peters M, Dixon G, Kotowicz K, Hatch D, Heyderman R, Klein N: Circulating platelet-
neutrophil complexes represent a subpopulation of activated neutrophils primed for 
adhesion, phagocytosis and intracellular killing. British Journal of Haematology 1999, 
106(2):391-399. 
54. Weber B, Schuster S, Zysset D, Rihs S, Dickgreber N, Schürch C, Riether C, Siegrist M, 
Schneider C, Pawelski H: TREM-1 deficiency can attenuate disease severity without 
affecting pathogen clearance. Public Library of Science Pathogens 2014, 
10(1):e1003900. 
55. Xiang B, Zhang G, Guo L, Li X-A, Morris AJ, Daugherty A, Whiteheart SW, Smyth SS, 
Li Z: Platelets protect from septic shock by inhibiting macrophage-dependent 
inflammation via the cyclooxygenase 1 signalling pathway. Nature Communications 
2013, 4:2657-2686. 
56. Aydemir H, Piskin N, Akduman D, Kokturk F, Aktas E: Platelet and mean platelet 
volume kinetics in adult patients with sepsis. Platelets 2015, 26(4):331-335. 
57. Venkata C, Kashyap R, Farmer JC, Afessa B: Thrombocytopenia in adult patients with 
sepsis: Incidence, risk factors, and its association with clinical outcome. Journal of 
Intensive Care 2013, 1(1):9. 
58. de Stoppelaar SF, van’t Veer C, Claushuis TA, Albersen BJ, Roelofs JJ, van der Poll T: 
Thrombocytopenia impairs host defense in gram-negative pneumonia–derived sepsis 
in mice. Blood 2014, 124(25):3781-3790. 
59. Zarbock A, Singbartl K, Ley K: Complete reversal of acid-induced acute lung injury 
by blocking of platelet-neutrophil aggregation. Journal of Clinical Investigation 2006, 
116(12):3211-3219. 
References	
	
	
	 Page 237 
60. Tőkés-Füzesi M, Woth G, Ernyey B, Vermes I, Mühl D, Bogár L, Kovács GL: 
Microparticles and acute renal dysfunction in septic patients. Journal of Critical Care 
2013, 28(2):141-147. 
61. Eisen DPMD, Reid D, McBryde ESP: Acetyl salicylic acid usage and mortality in 
critically ill patients with the systemic inflammatory response syndrome and sepsis. 
Critical Care Medicine 2012, 40(6):1761-1767. 
62. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ: Prehospitalization antiplatelet 
therapy is associated with a reduced incidence of acute lung injury: a population-
based cohort study. Chest 2011, 139(2):289-295. 
63. Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, Lösche W: 
Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. 
Critical Care Medicine 2010, 38(1):32-37. 
64. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA, Bauer 
M, Lösche W: Anti-platelet drugs and outcome in severe infection: clinical impact 
and underlying mechanisms. Platelets 2009, 20(1):50-57. 
65. Koziel J, Maciag-Gudowska A, Mikolajczyk T, Bzowska M, Sturdevant DE, Whitney 
AR, Shaw LN, DeLeo FR, Potempa J: Phagocytosis of Staphylococcus aureus by 
macrophages exerts cytoprotective effects manifested by the upregulation of 
antiapoptotic factors. Public Library of Science One 2009, 4(4):e5210. 
66. Newton S, Ding Y, Chung C-S, Chen Y, Lomas-Neira JL, Ayala A: Sepsis-induced 
changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of 
anti-inflammatory IL-10 response. Surgical Infections 2004, 5(4):375-383. 
67. Verdrengh M, Tarkowski A: Role of macrophages in Staphylococcus aureus-induced 
arthritis and sepsis. Arthritis & Rheumatism 2000, 43(10):2276-2282. 
68. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A: Gram-positive cell walls 
stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human 
monocytes. Infection and Immunity 1994, 62(7):2715-2721. 
69. Wang Y, Braun OÖ, Zhang S, Norström E, Thorlacius H: Monocytes regulate systemic 
coagulation and inflammation in abdominal sepsis. American Journal of Physiology-
Heart and Circulatory Physiology 2015, 308(5):H540-H547. 
70. Peters K, Koberg K, Rosendahl T, Klosterhalfen B, Straub A, Zwadlo-Klarwasser G: 
Macrophage reactions in septic arthritis. Archives of Orthopaedic and Trauma Surgery 
1996, 115(6):347-350. 
71. Ngo LY, Kasahara S, Kumasaka DK, Knoblaugh SE, Jhingran A, Hohl TM: 
Inflammatory monocytes mediate early and organ-specific innate defense during 
systemic candidiasis. Journal of Infectious Diseases 2013, 209(1):109-119.  
72. Nathan CF, Hibbs Jr JB: Role of nitric oxide synthesis in macrophage antimicrobial 
activity. Current Opinion in Immunology 1991, 3(1):65-70. 
73. Guenther F, Stroh P, Wagner C, Obst U, Hänsch GM: Phagocytosis of staphylococci 
biofilms by polymorphonuclear neutrophils: S. aureus and S. epidermidis differ with 
regard to their susceptibility towards the host defense. The International Journal Of 
Artificial Organs 2009, 32(9):565-573. 
74. Smith JA: Neutrophils, host defense, and inflammation: a double-edged sword. 
Journal of Leukocyte Biology 1994, 56(6):672-686. 
75. Territo MC, Golde DW: Granulocyte function in experimental human endotoxemia. 
Blood 1976, 47(4):539-544. 
References	
	
	
	 Page 238 
76. Spitzer J, Zhang P, Mayer A: Functional characterization of peripheral circulating 
and liver recruited neutrophils in endotoxic rats. Journal of Leukocyte Biology 1994, 
56(2):166-173. 
77. Fierro I, Barja-Fidalgo C, Cunha F, Ferreira S: The involvement of nitric oxide in the 
anti-Candida albicans activity of rat neutrophils. Immunology 1996, 89(2):295-300. 
78. Thiel M, Holzer K, Kreimeier U, Moritz S, Peter K, Messmer K: Effects of adenosine on 
the functions of circulating polymorphonuclear leukocytes during hyperdynamic 
endotoxemia. Infection and Immunity 1997, 65(6):2136-2144. 
79. Simms HH, D'Amico R: Polymorphonuclear leukocyte dysregulation during the 
systemic inflammatory response syndrome. Blood 1994, 50(2):1398-1407. 
80. Hofman P, Piche M, Far DF, Le Negrate G, Selva E, Landraud L, Alliana-Schmid A, 
Boquet P, Rossi B: Increased Escherichia coli phagocytosis in neutrophils that have 
transmigrated across a cultured intestinal epithelium. Infection and Immunity 2000, 
68(2):449-455. 
81. Stephan F, Yang K, Tankovic J, Soussy C-J, Dhonneur G, Duvaldestin P, Brochard L, 
Brun-Buisson C, Harf A, Delclaux C: Impairment of polymorphonuclear neutrophil 
functions precedes nosocomial infections in critically ill patients. Critical Care 
Medicine 2002, 30(2):315-322. 
82. Regel G, Nerlich M, Dwenger A, Seidel J, Schmidt C, Sturm J: Phagocytic function of 
polymorphonuclear leukocytes and the RES in endotoxemia. Journal of Surgical 
Research 1987, 42(1):74-84. 
83. Wenisch C, Parschalk B, Patruta S, Brustbauer R, Graninger W: Effect of polyclonal 
immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production 
in patients with gram-negative septicemia. Infection 1999, 27(3):183-186. 
84. Kaufmann I, Hoelzl A, Schliephake F, Hummel T, Chouker A, Peter K, Thiel M: 
Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing 
sepsis severity. Shock 2006, 26(3):254-261. 
85. Hofman P, Flatau G, Selva E, Gauthier M, Le Negrate G, Fiorentini C, Rossi B, Boquet 
P: Escherichia coli cytotoxic necrotizing factor 1 effaces microvilli and decreases 
transmigration of polymorphonuclear leukocytes in intestinal T84 epithelial cell 
monolayers. Infection and Immunity 1998, 66(6):2494-2500. 
86. Borregaard N: Neutrophils, from marrow to microbes. Immunity 2010, 33(5):657-670. 
87. Taneja R, Sharma A, Hallett M, Findlay G, Morris M: Immature circulating 
neutrophils in sepsis have impaired phagocytosis and calcium signaling. Shock 2008, 
30(6):618-622. 
88. Mare TA, Treacher DF, Shankar-Hari M, Beale R, Lewis SM, Chambers DJ, Brown KA: 
The diagnostic and prognostic significance of monitoring blood levels of immature 
neutrophils in patients with systemic inflammation. Critical Care 2015, 19:57. 
89. Drifte G, Dunn-Siegrist I, Tissieres P, Pugin J: Innate immune functions of immature 
neutrophils in patients with sepsis and severe systemic inflammatory response 
syndrome. Critical Care Medicine 2013, 41(3):820-832. 
90. Bevilacqua M, Ph. D, Michael P, Nelson PD, Richard M, Mannori M, Ph. D, Gianna, 
Cecconi M, Oliviero: Endothelial-leukocyte adhesion molecules in human disease. 
Annual Review of Medicine 1994, 45(1):361-378. 
91. Venturi GM, Tu L, Kadono T, Khan AI, Fujimoto Y, Oshel P, Bock CB, Miller AS, 
Albrecht RM, Kubes P et al: Leukocyte migration is regulated by L-Selectin 
endoproteolytic release. Immunity 2003, 19(5):713-724. 
References	
	
	
	 Page 239 
92. Skubitz KM, Campbell KD, Skubitz AP: CD66a, CD66b, CD66c, and CD66d each 
independently stimulate neutrophils. Journal of Leukocyte Biology 1996, 60(1):106-
117. 
93. Orr Y, Taylor JM, Cartland S, Bannon PG, Geczy C, Kritharides L: Conformational 
activation of CD11b without shedding of L-selectin on circulating human 
neutrophils. Journal of Leukocyte Biology 2007, 82(5):1115-1125. 
94. Schmidt T, Brodesser A, Schnitzler N, Gr¸ger T, Brandenburg K, Zinserling J, Z¸ndorf J: 
CD66b overexpression and loss of C5a receptors as surface markers for 
Staphylococcus aureus-induced neutrophil dysfunction. Public Library of Science One 
2015, 10(7):e0132703. 
95. McEver R, Moore K, Cummings R: Leukocyte trafficking mediated by selectin-
carbohydrate interactions. Journal of Biological Chemistry 1995, 270(19):11025-
11028. 
96. Ferri LE, Chia S, Benay C, Giannias B, Christou NV: L-selectin shedding in sepsis 
limits leukocyte mediated microvascular injury at remote sites. Surgery 2009, 
145(4):384-391. 
97. Spertini O, Cordey A-S, Monai N, Giuffrè L, Schapira M: P-selectin glycoprotein ligand 
1 is a ligand for L-selectin on neutrophils, monocytes, and CD34+ hematopoietic 
progenitor cells. The Journal of Cell Biology 1996, 135(2):523-531. 
98. Asaduzzaman M, Rahman M, Jeppsson B, Thorlacius H: P-selectin glycoprotein ligand-
1 regulates pulmonary recruitment of neutrophils in a platelet-independent manner 
in abdominal sepsis. British Journal of Pharmacology 2009, 156(2):307-315. 
99. Luo HR, Loison F: Constitutive neutrophil apoptosis: Mechanisms and regulation. 
American Journal of Hematology 2008, 83(4):288-295. 
100. Taneja R, Parodo J, Jia SH, Kapus A, Rotstein OD, Marshall JC: Delayed neutrophil 
apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane 
potential and reduced caspase-9 activity. Critical Care Medicine 2004, 32(7):1460-
1469. 
101. El Kebir D, József L, Khreiss T, Pan W, Petasis NA, Serhan CN, Filep JG: Aspirin-
triggered lipoxins override the apoptosis-delaying action of serum amyloid A in 
human neutrophils: A novel mechanism for resolution of inflammation. The Journal 
of Immunology 2007, 179(1):616-622. 
102. Monneret G, Debard A-L, Venet F, Bohe J, Hequet O, Bienvenu J, Lepape A: Marked 
elevation of human circulating CD4+CD25+ regulatory T-cells in sepsis-induced 
immunoparalysis. Critical Care Medicine 2003, 31(7):2068-2071  
103. Kelly-Scumpia KM, Scumpia PO, Weinstein JS, Delano MJ, Cuenca AG, Nacionales 
DC, Wynn JL, Lee PY, Kumagai Y, Efron PA et al: B cells enhance early innate 
immune responses during bacterial sepsis. The Journal of Experimental Medicine 
2011, 208(8):1673-1682. 
104. Pasare C, Medzhitov R: Control of B-cell responses by Toll-like receptors. Nature 
2005, 438(7066):364-368. 
105. Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, 
Figueiredo J-L, Iwamoto Y, Theurl I: Innate response activator B cells protect against 
microbial sepsis. Science 2012, 335(6068):597-601. 
106. Weber GF, Chousterman BG, Hilgendorf I, Robbins CS, Theurl I, Gerhardt LMS, 
Iwamoto Y, Quach TD, Ali M, Chen JW et al: Pleural innate response activator B cells 
protect against pneumonia via a GM-CSF-IgM axis. The Journal of Experimental 
Medicine 2014, 211(6):1243-1256. 
References	
	
	
	 Page 240 
107. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE, Hui JJ, Chang KC, Osborne DF, 
Freeman BD, Cobb JP, Buchman TG et al: Sepsis-induced apoptosis causes 
progressive profound depletion of B and CD4+ T lymphocytes in humans. The 
Journal of Immunology 2001, 166(11):6952-6963. 
108. Martignoni A, Tschöp J, Goetzman HS, Choi LG, Reid MD, Johannigman JA, Lentsch 
AB, Caldwell CC: CD4-expressing cells are early mediators of the innate immune 
system during sepsis. Shock 2008, 29(5):591-597. 
109. Kasten KR, Tschöp J, Goetzman HS, England LG, Dattilo JR, Cave CM, Seitz AP, 
Hildeman DA, Caldwell CC: T-cell activation differentially mediates the host 
response to sepsis. Shock 2010, 34(4):377-383. 
110. Enoh VT, Lin SH, Etogo A, Lin CY, Sherwood ER: CD4+ T-cell depletion is not 
associated with alterations in survival, bacterial clearance, and inflammation after 
cecal ligation and puncture. Shock 2008, 29(1):56-64. 
111. O'Sullivan ST, Lederer JA, Horgan AF, Chin D, Mannick JA, Rodrick ML: Major 
injury leads to predominance of the T helper-2 lymphocyte phenotype and 
diminished interleukin-12 production associated with decreased resistance to 
infection. Annals of Surgery 1995, 222(4):482-490. 
112. Wherry EJ: T-cell exhaustion. Nature Immunology 2011, 12(6):492-499. 
113. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, Griffith TS, 
Green DR, Schoenberger SP: CD4 T-cell help controls CD8 T-cell memory via 
TRAIL-mediated activation-induced cell death. Nature 2005, 434(7029):88-93. 
114. Zhu J, Paul WE: CD4 T-cells: fates, functions, and faults. Blood 2008, 112(5):1557-
1569. 
115. Banham AH: Cell-surface IL-7 receptor expression facilitates the purification of 
FOXP3+ regulatory T-cells. Trends in Immunology 2006, 27(12):541-544. 
116. Campbell DJ, Ziegler SF: FOXP3 modifies the phenotypic and functional properties 
of regulatory T-cells. Nature Reviews Immunology 2007, 7(4):305-310. 
117. MacConmara MP, Maung AA, Fujimi S, McKenna AM, Delisle A, Lapchak PH, Rogers 
S, Lederer JA, Mannick JA: Increased CD4+ CD25+ T regulatory cell activity in 
trauma patients depresses protective Th1 immunity. Annals of Surgery 2006, 
244(4):514. 
118. Venet F, Chung C-S, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohé J, Lepape A, 
Ayala A, Monneret G: Increased circulating regulatory T-cells (CD4+ CD25+ CD127-
) contribute to lymphocyte anergy in septic shock patients. Intensive Care Medicine 
2009, 35(4):678-686. 
119. Cao C, Ma T, Chai Y-f, Shou S-t: The role of regulatory T-cells in immune 
dysfunction during sepsis. World Journal of Emergency Medicine 2015, 6(1):5-9. 
120. Epstein FH, Gabay C, Kushner I: Acute-phase proteins and other systemic responses 
to inflammation. New England Journal of Medicine 1999, 340(6):448-454. 
121. Ho K, Towler S: A comparison of eosinopenia and C-reactive protein as a marker of 
bloodstream infections in critically ill patients: a case control study. Anaesthesia and 
Intensive Care 2009, 37(3):450-456. 
122. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J: Serum procalcitonin and C-
reactive protein levels as markers of bacterial infection: a systematic review and 
meta-analysis. Clinical Infectious Diseases 2004, 39(2):206-217. 
References	
	
	
	 Page 241 
123. Becker KL, Snider R, Nylen ES: Procalcitonin assay in systemic inflammation, 
infection, and sepsis: clinical utility and limitations. Critical Care Medicine 2008, 
36(3):941-952. 
124. Schulte W, Bernhagen J, Bucala R: Cytokines in sepsis: potent immunoregulators and 
potential therapeutic targets-an updated view. Mediators of Inflammation 2013, 
2013:165974. 
125. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ: The evolving experience 
with therapeutic TNF inhibition in sepsis: Considering the potential influence of risk 
of death. Expert Opinion on Investigational Drugs 2011, 20(11):1555-1564. 
126. Leon LR, White AA, Kluger MJ: Role of IL-6 and TNF in thermoregulation and 
survival during sepsis in mice. American Journal of Physiology-Regulatory, Integrative 
and Comparative Physiology 1998, 275(1):R269-R277. 
127. Patel R, Deen K, Youngs D, Warwick J, Keighley M: Interleukin 6 is a prognostic 
indicator of outcome in severe intra‐abdominal sepsis. British Journal of Surgery 
1994, 81(9):1306-1308. 
128. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S: Lipoxin A4 inhibits IL-1β-
induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial 
fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. The 
Journal of Immunology 2000, 164(5):2660-2666. 
129. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR: Neutrophils express the 
high affinity receptor for IgG (FcγRI, CD64) after in vivo application of 
recombinant human granulocyte colony-stimulating factor. Blood 1991, 78. 
130. Cardelli P, Ferraironi M, Amodeo R, Tabacco F, De Blasi R, Nicoletti M, Sessa R, 
Petrucca A, Costante A, Cipriani P: Evaluation of neutrophil CD64 expression and 
procalcitonin as useful markers in early diagnosis of sepsis. International Journal of 
Immunopathology and Pharmacology 2008, 21(1):43-49. 
131. Nuutila J, Hohenthal U, Laitinen I, Kotilainen P, Rajamäki A, Nikoskelainen J, Lilius E-
M: Simultaneous quantitative analysis of FcγRI (CD64) expression on neutrophils 
and monocytes: a new, improved way to detect infections. Journal of Immunological 
Methods 2007, 328(1):189-200. 
132. Gámez-Díaz LY, Enriquez LE, Matute JD, Velásquez S, Gómez ID, Toro F, Ospina S, 
Bedoya V, Arango CM, Valencia ML et al: Diagnostic accuracy of HMGB-1, sTREM-
1, and CD64 as markers of sepsis in patients recently admitted to the Emergency 
Department. Academic Emergency Medicine 2011, 18(8):807-815. 
133. Genel F, Atlihan F, Gulez N, Kazanci E, Vergin C, Terek DT, Yurdun OC: Evaluation of 
adhesion molecules CD64, CD11b and CD62L in neutrophils and monocytes of 
peripheral blood for early diagnosis of neonatal infection. World Journal of Pediatrics 
2012, 8(1):72-75. 
134. Papathanassoglou ED, Moynihan JA, Ackerman MH: Does programmed cell death 
(apoptosis) play a role in the development of multiple organ dysfunction in critically 
ill patients? A review and a theoretical framework. Critical care medicine 2000, 
28(2):537-549. 
135. Mikić D, Vasilijić S, Ćućuz M, Čolić M: Clinical significance of soluble Fas plasma 
levels in patients with sepsis. Vojnosanitetski pregled 2015, 72(7):608-613. 
136. Paunel-Gorgulu A, Flohé S, Scholz M, Windolf J, Logters T: Increased serum soluble 
Fas after major trauma is associated with delayed neutrophil apoptosis and 
development of sepsis. Critical Care 2011, 15(1):R20. 
References	
	
	
	 Page 242 
137. Huttunen R, Syrjänen J, Vuento R, Laine J, Hurme M, Aittoniemi J: Apoptosis markers 
soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with 
bacteremia: A prospective cohort study. Journal of Infection 2012, 64(3):276-281. 
138. Riedel S, Carroll KC: Laboratory detection of sepsis: biomarkers and molecular 
approaches. Clinics in Laboratory Medicine 2013, 33(3):413-437. 
139. Gaibani P, Rossini G, Ambretti S, Gelsomino F, Pierro AM, Varani S, Paolucci M, 
Landini MP, Sambri V: Blood culture systems: rapid detection–how and why? 
International Journal of Antimicrobial Agents 2009, 34:S13-S15. 
140. Wallet F, Nseir S, Baumann L, Herwegh S, Sendid B, Boulo M, Roussel‐Delvallez M, 
Durocher A, Courcol R: Preliminary clinical study using a multiplex real‐ time PCR 
test for the detection of bacterial and fungal DNA directly in blood. Clinical 
Microbiology and Infection 2010, 16(6):774-779. 
141. Bravo D, Blanquer J, Tormo M, Aguilar G, Borrás R, Solano C, Clari MA, Costa E, 
Muñoz-Cobo B, Argüeso M: Diagnostic accuracy and potential clinical value of the 
LightCycler SeptiFast assay in the management of bloodstream infections occurring 
in neutropenic and critically ill patients. International Journal of Infectious Diseases 
2011, 15(5):e326-e331. 
142. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 
116(2):281-297. 
143. Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie L: Serum microRNA signatures 
identified by Solexa sequencing predict sepsis patients’ mortality: a prospective 
observational study. Public Library of Science One 2012, 7(6):e38885. 
144. Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q: Next-generation sequencing of microRNAs for 
breast cancer detection. BioMed Research International 2011, 2011. 
145. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R: A 
five-microRNA signature identified from genome-wide serum microRNA expression 
profiling serves as a fingerprint for gastric cancer diagnosis. European Journal of 
Cancer 2011, 47(5):784-791. 
146. Liu SF, Malik AB: NF-κB activation as a pathological mechanism of septic shock and 
inflammation. American Journal of Physiology-Lung Cellular and Molecular Physiology 
2006, 290(4):L622-L645. 
147. Serhan CN: Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid 
mediators of endogenous anti-inflammation and resolution. Prostaglandins, 
Leukotrienes and Essential Fatty Acids 2005, 73(3–4):141-162. 
148. Fink MP: Animal models of sepsis. Virulence 2014, 5(1):143-153. 
149. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, 
Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and 
septic shock. New England Journal of Medicine 2001, 345(19):1368-1377. 
150. Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki L-M, Pettilä V: Hemodynamic 
variables related to outcome in septic shock. Intensive Care Medicine 2005, 
31(8):1066-1071. 
151. Engoren M: The effect of prompt physician visits on intensive care unit mortality and 
cost. Critical Care Medicine 2005, 33(4):727-732  
152. Kern JW, Shoemaker WC: Meta-analysis of hemodynamic optimization in high-risk 
patients Critical Care Medicine 2002, 30(8):1686-1692. 
References	
	
	
	 Page 243 
153. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, Tomlanovich 
MC: Early lactate clearance is associated with improved outcome in severe sepsis 
and septic shock. Critical Care Medicine 2004, 32(8):1637-1642  
154. McKenna M: Controversy swirls around early goal-directed therapy in sepsis: 
pioneer defends ground-breaking approach to deadly disease. Annals of Emergency 
Medicine 2008, 52(6):651-654. 
155. Rivers EP, Coba V, Whitmill M: Early goal-directed therapy in severe sepsis and 
septic shock: A contemporary review of the literature. Current Opinion in 
Anesthesiology 2008, 21(2):128-140  
156. Wheeler AP, Bernard GR: Treating patients with severe sepsis. New England Journal 
of Medicine 1999, 340(3):207-214. 
157. Dellinger R, Levy M, Carlet J, Bion J, Parker M, Jaeschke R, Reinhart K, Angus D, Brun-
Buisson C, Beale R et al: Surviving Sepsis Campaign: international guidelines for 
management of severe sepsis and septic shock: 2008. Intensive Care Medicine 2008, 
34(1):17-60. 
158. Antibiotic Expert Groups: Therapeutic guidelines: antibiotic. Version 15. Melbourne; 
2014. 
159. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, 
Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on 
the outcome of patients admitted to the intensive care unit with sepsis. Critical Care 
Medicine 2003, 31(12):2742-2751. 
160. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W: 
Adequacy of early empiric antibiotic treatment and survival in severe sepsis: 
experience from the MONARCS Trial. Clinical Infectious Diseases 2004, 38(2):284-
288. 
161. Esmon CT: The protein C anticoagulant pathway. Arteriosclerosis and Thrombosis 
1992, 12(2):135-145. 
162. Eichacker PQ, Natanson C: Recombinant human activated protein C in sepsis: 
inconsistent trial results, an unclear mechanism of action, and safety concerns 
resulted in labeling restrictions and the need for phase IV trials. Critical Care 
Medicine 2003, 31(1):S94-S96. 
163. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, 
Steingrub JS, Garber GE, Helterbrand JD, Ely EW et al: Efficacy and safety of 
recombinant human activated protein C for severe sepsis. New England Journal of 
Medicine 2001, 344(10):699-709. 
164. Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated 
protein C treatment for severe sepsis. New England Journal of Medicine 2002, 
347(13):1027-1030. 
165. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, 
Keh D, Marshall JC, Parker MM: Surviving Sepsis Campaign guidelines for 
management of severe sepsis and septic shock. Intensive Care Medicine 2004, 
30(4):536-555. 
166. Brar S, Manns B: Activated protein C: cost-effective or costly? Critical Care 2007, 
11(5):164. 
167. Dhainaut J-F, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, Charpentier J, 
Belger M, Cobas-Meyer M, Maier C et al: Extended drotrecogin alfa (activated) 
treatment in patients with prolonged septic shock. Intensive Care Medicine 2009, 
35(7):1187-1195. 
References	
	
	
	 Page 244 
168. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, 
Levy H, Angle R, Wang D et al: Drotrecogin alfa (activated) in children with severe 
sepsis: a multicentre phase III randomised controlled trial. The Lancet 2007, 
369(9564):836-843. 
169. Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, 
Brückmann M, Rea-Neto Á et al: Drotrecogin alfa (activated) for adults with severe 
sepsis and a low risk of death. New England Journal of Medicine 2005, 353(13):1332-
1341. 
170. Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, Gårdlund B, 
Marshall JC, Rhodes A, Artigas A et al: Drotrecogin alfa (activated) in adults with 
septic shock. New England Journal of Medicine 2012, 366(22):2055-2064. 
171. Marti-Carvajal AJ, Sola I, Lathyris D, Cardona AF: Human recombinant activated 
protein C for severe sepsis. Cochrane Database of Systematic Reviews 
2011(4):CD004388. 
172. Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt G, Harbour R, 
Haugh M, Henry D: Grading quality of evidence and strength of recommendations. 
The British Medical Journal 2004, 328(7454):1490. 
173. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, 
Raskob G, Lewis SZ, Schunemann H: Grading strength of recommendations and 
quality of evidence in clinical guidelines: report from an American College of Chest 
Physicians task force. Chest 2006, 129(1):174-181. 
174. Riedemann NC, Guo R-F, Neff TA, Laudes IJ, Keller KA, Sarma VJ, Markiewski MM, 
Mastellos D, Strey CW, Pierson CL: Increased C5a receptor expression in sepsis. The 
Journal of clinical investigation 2002, 110(1):101-108. 
175. Sprong T, Brandtzaeg P, Fung M, Pharo AM, Høiby EA, Michaelsen TE, Aase A, van der 
Meer JW, van Deuren M, Mollnes TE: Inhibition of C5a-induced inflammation with 
preserved C5b-9-mediated bactericidal activity in a human whole blood model of 
meningococcal sepsis. Blood 2003, 102(10):3702-3710. 
176. Morgan BP: Complement membrane attack on nucleated cells: resistance, recovery 
and non-lethal effects. Biochemical Journal 1989, 264(1):1. 
177. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya 
A, Coyle L, De Castro C, Fu C-L: Multicenter phase 3 study of the complement 
inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal 
hemoglobinuria. Blood 2008, 111(4):1840-1847. 
178. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, 
Cohen DR, Gregory WM, Hillmen P: Long-term treatment with eculizumab in 
paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. 
Blood 2011, 117(25):6786-6792. 
179. Legendre CM, Licht C, Muus P, Greenbaum L, Babu S, Bedrosian C, Bingham C, Cohen 
D, Delmas Y, Douglas K: Terminal complement inhibitor eculizumab in atypical 
hemolytic–uremic syndrome. New England Journal of Medicine 2013, 368(23):2169-
2181. 
180. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, 
Elebute MO, Nakamura R et al: The complement inhibitor eculizumab in paroxysmal 
nocturnal hemoglobinuria. New England Journal of Medicine 2006, 355(12):1233-
1243. 
181. Ward PA, Guo R-F, Riedemann NC: Manipulation of the Complement System for 
Benefit in Sepsis. Critical Care Research and Practice 2012, 2012:8. 
References	
	
	
	 Page 245 
182. Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, 
Browne P, Maciejewski JP, Schubert J et al: Long-term safety and efficacy of sustained 
eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. 
Brazillian Journal of Haematology 2013, 162(1):62-73. 
183. Buras JA, Rice L, Orlow D, Pavlides S, Reenstra WR, Ceonzo K, Stahl GL: Inhibition of 
C5 or absence of C6 protects from sepsis mortality. Immunobiology 2004, 209(8):629-
635. 
184. Huber-Lang M, Barratt-Due A, Pischke SE, Sandanger Ø, Nilsson PH, Nunn MA, Denk 
S, Gaus W, Espevik T, Mollnes TE: Double blockade of CD14 and complement C5 
abolishes the cytokine storm and improves morbidity and survival in polymicrobial 
sepsis in mice. The Journal of Immunology 2014, 192(11):5324-5331. 
185. Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, Raffin TA: 
Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic 
primates. Journal of Clinical Investigation 1986, 77(6):1812. 
186. Hangen DH, Stevens JH, Satoh PS, Hall EW, O'Hanley PT, Raffin TA: Complement 
levels in septic primates treated with anti-C5a antibodies. Journal of Surgical 
Research 1989, 46(3):195-199. 
187. Patel GP, Balk RA: Systemic steroids in severe sepsis and septic shock. American 
Journal of Respiratory and Critical Care Medicine 2012, 185(2):133-139. 
188. Meduri GU: An historical review of glucocorticoid treatment in sepsis. Disease 
pathophysiology and the design of treatment investigation. Sepsis 1999, 3(1):21-38. 
189. Stanbury RM, Graham EM: Systemic corticosteroid therapy-side effects and their 
management. British Journal of Ophthalmology 1998, 82(6):704-708. 
190. Posey WC, Nelson HS, Branch B, Pearlman DS: The effects of acute corticosteroid 
therapy for asthma on serum immunoglobulin levels. Journal of Allergy and Clinical 
Immunology 1978, 62(6):340-348. 
191. Katz JA: Treatment of inflammatory bowel disease with corticosteroids. 
Gastroenterology Clinics of North America 2004, 33(2):171-189. 
192. Alderson P, Roberts I: Corticosteroids in acute traumatic brain injury: systematic 
review of randomised controlled trials. The British Medical Journal 1997, 
314(7098):1855. 
193. Schumer W: Steroids in the treatment of clinical septic shock. Annals of Surgery 1976, 
184(3):333-341. 
194. Coiitss Study Investigators, Annane D, Cariou A, Maxime V, Azoulay E, D'Honneur G, 
Timsit JF, Cohen Y, Wolf M, Fartoukh M et al: Corticosteroid treatment and intensive 
insulin therapy for septic shock in adults: a randomized controlled trial. JAMA : The 
Journal of the American Medical Association 2010, 303(4):341-348. 
195. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ: 
Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the 
literature. Critical Care Medicine 1995, 23(8):1430-1439. 
196. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, 
Tendler MD, Karpf M: The effects of high-dose corticosteroids in patients with septic 
shock. New England Journal of Medicine 1984, 311(18):1137-1143. 
197. Annetta MG, Maviglia R, Proietti R, Antonelli M: Use of corticosteroids in critically ill 
septic patients: A review of mechanisms of adrenal insufficiency in sepsis and 
treatment. Current Drug Targets 2009, 10(9):887-894. 
References	
	
	
	 Page 246 
198. Annane D, Bellissant E, Bollaert P, et al.: Corticosteroids in the treatment of severe 
sepsis and septic shock in adults: a systematic review. JAMA : The Journal of the 
American Medical Association 2009, 301(22):2362-2375. 
199. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, 
Benbenishty J, Kalenka A, Forst H et al: Hydrocortisone therapy for patients with 
septic shock. New England Journal of Medicine 2008, 358(2):111-124. 
200. Young PJ, Saxena MK, Beasley RW: Fever and antipyresis in infection. The Medical 
Journal of Australia 2011, 195(8):458-459. 
201. Kramer MS, Naimark LE, Roberts-Bräuer R, McDougall A, Leduc DG: Risks and 
benefits of paracetamol antipyresis in young children with fever of presumed viral 
origin. The Lancet 1991, 337(8741):591-594. 
202. Schulman CI, Namias N, Doherty J, Manning RJ, Li P, Elhaddad A, Lasko D, Amortegui 
J, Dy CJ, Dlugasch L: The effect of antipyretic therapy upon outcomes in critically ill 
patients: a randomized, prospective study. Surgical Infections 2005, 6(4):369-375. 
203. Kluger MJ, Kozak W, Conn CA, Leon LR, Soszynski D: The adaptive value of fever. 
Infectious Disease Clinics of North America 1996, 10(1):1-20. 
204. Mourvillier B, Tubach F, van de Beek D, et al.: Induced hypothermia in severe 
bacterial meningitis: a randomized clinical trial. JAMA : The Journal of the American 
Medical Association 2013, 310(20):2174-2183. 
205. Young PJ, Saxena MK, Bellomo R, Freebairn RC, Hammond NE, van Haren FM, 
Henderson SJ, McArthur CJ, McGuinness SP, Mackle D: The HEAT trial: A protocol 
for a multicentre randomised placebo-controlled trial of IV paracetamol in ICU 
patients with fever and infection. Critical Care and Resuscitation 2012, 14(4):290-296. 
206. Hart FD, Huskisson EC: Non-steroidal anti-inflammatory drugs. Drugs 1984, 
27(3):232-255. 
207. Hall-Angeras M, Saljo A, Hasselgren PO: Effect of methylprednisolone, indomethacin, 
and diethylcarbamazine on survival rate following trauma and sepsis in rats. 
Circulatory shock 1986, 20(3):231-238. 
208. Van Esch A, Van Steensel-Moll HA, Steyerberg EW, Offringa M, Habbema JDF, 
Derksen-Lubsen G: Antipyretic efficacy of ibuprofen and acetaminophen in children 
with febrile seizures. Archives of Pediatrics & Adolescent Medicine 1995, 149(6):632-
637. 
209. Galt SW, Bech FR, McDaniel MD, Dain BJ, Yeager MP, Schneider JR, Walsh DB, 
Zwolak RM, Cronenwett JL: The effect of ibuprofen on cardiac performance during 
abdominal aortic cross-clamping. Journal of Vascular Surgery 1991, 13(6):876-884. 
210. Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB, Group IS: Effect of 
ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter 
study. Critical Care Medicine 1991, 19(11):1339-1347. 
211. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson 
WJ, Wright PE, Christman BW, Dupont WD et al: The effects of ibuprofen on the 
physiology and survival of patients with sepsis. New England Journal of Medicine 
1997, 336(13):912-918. 
212. Vane JR, Botting RM: The mechanism of action of aspirin. Thrombosis Research 2003, 
110(5–6):255-258. 
 
 
References	
	
	
	 Page 247 
213. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Huang M-H, Perez-Polo JR, Uretsky BF: 
Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks 
the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. 
Prostaglandins & Other Lipid Mediators 2007, 83(1–2):89-98. 
214. Kirkby NS, Chan MV, Lundberg MH, Massey KA, Edmands WM, MacKenzie LS, 
Holmes E, Nicolaou A, Warner TD, Mitchell JA: Aspirin-triggered 15-epi-lipoxin A4 
predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the 
circulation: implications for a clinical test. Federation of American Societies for 
Experimental Biology Journal 2013, 27(10):3938-3946. 
215. Hachicha M, Pouliot M, Petasis NA, Serhan CN: Lipoxin (LX) A4 and aspirin-
triggered 15-epi-LXA4 inhibit Tumor Necrosis Factor 1α–initiated neutrophil 
responses and trafficking: Regulators of a cytokine–chemokine axis. The Journal of 
Experimental Medicine 1999, 189(12):1923-1930. 
216. József L, Zouki C, Petasis NA, Serhan CN, Filep JG: Lipoxin A4 and aspirin-triggered 
15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and 
IL-8 gene expression in human leukocytes. Proceedings of the National Academy of 
Sciences 2002, 99(20):13266-13271. 
217. Falcone M, Russo A, Cangemi R, Farcomeni A, Calvieri C, Barillà F, Scarpellini MG, 
Bertazzoni G, Palange P, Taliani G et al: Lower mortality rate in elderly patients with 
community-onset pneumonia on treatment with aspirin. Journal of the American 
Heart Association 2015, 4(1):e001595. 
218. Sedlacek M, Gemery JM, Cheung AL, Bayer AS, Remillard BD: Aspirin treatment is 
associated with a significantly decreased risk of Staphylococcus aureus bacteremia in 
hemodialysis patients with tunneled catheters. American Journal of Kidney Diseases 
2007, 49(3):401-408. 
219. Sossdorf M, Otto G, Boettel J, Winning J, Losche W: Benefit of low-dose aspirin and 
non-steroidal anti-inflammatory drugs in septic patients. Critical Care 2012, 
17(1):402. 
220. O’Neal HR, Koyama T, Koehler EAS, Siew E, Curtis BR, Fremont RD, May AK, 
Bernard GR, Ware LB: Prehospital statin and aspirin use and the prevalence of 
severe sepsis and ALI/ARDS. Critical Care Medicine 2011, 39(6):1343-1350. 
221. Kupferwasser LI, Yeaman MR, Nast CC, Kupferwasser D, Xiong Y-Q, Palma M, Cheung 
AL, Bayer AS: Salicylic acid attenuates virulence in endovascular infections by 
targeting global regulatory pathways in Staphylococcus aureus. The Journal of 
Clinical Investigation 2003, 112(2):222-233. 
222. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, 
McDonald-Smith GP, Gao H, Hennessy L et al: Genomic responses in mouse models 
poorly mimic human inflammatory diseases. Proceedings of the National Academy of 
Sciences 2013, 110(9):3507-3512. 
223. Takao K, Miyakawa T: Genomic responses in mouse models greatly mimic human 
inflammatory diseases. Proceedings of the National Academy of Sciences 2015, 
112(4):1167-1172. 
224. Shay T, Lederer JA, Benoist C: Genomic responses to inflammation in mouse models 
mimic humans: We concur, apples to oranges comparisons won’t do. Proceedings of 
the National Academy of Sciences 2015, 112(4):E346. 
225. Myers AK, Robey JW, Price RM: Relationships between tumour necrosis factor, 
eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock 
in mice. British Journal of Pharmacology 1990, 99(3):499-502. 
References	
	
	
	 Page 248 
226. Giral M, Balsa D, Ferrando R, Merlos M, Garcia‐Rafanell J, Forn J: Effects of UR-
12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic 
shock. British Journal of Pharmacology 1996, 118(5):1223-1231. 
227. Ogata M, Matsumoto T, Koga K, Takenaka I, Kamochi M, Sata T, Yoshida S, 
Shigematsu A: An antagonist of platelet-activating factor suppresses endotoxin-
induced tumor necrosis factor and mortality in mice pretreated with carrageenan. 
Infection and Immunity 1993, 61(2):699-704. 
228. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y: Therapeutic effects of TAK-
242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse 
endotoxin shock model. European Journal of Pharmacology 2007, 571(2):231-239. 
229. Alves-Filho JC, Freitas A, Souto FO, Spiller F, Paula-Neto H, Silva JS, Gazzinelli RT, 
Teixeira MM, Ferreira SH, Cunha FQ: Regulation of chemokine receptor by Toll-like 
receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis. 
Proceedings of the National Academy of Sciences 2009, 106(10):4018-4023. 
230. Bitto A, Minutoli L, David A, Irrera N, Rinaldi M, Venuti FS, Squadrito F, Altavilla D: 
Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the 
inflammatory response and protects mice from sepsis. Critical Care 2012, 16(1):R32. 
231. Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, Justen KL, Vonderfecht SL, Na S: 
Adoptive transfer of in vitro-stimulated CD4+CD25+ regulatory T-Cells increases 
bacterial clearance and improves survival in polymicrobial sepsis. The Journal of 
Immunology 2005, 174(11):7141-7146. 
232. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL: Balance of 
inflammatory cytokines related to severity and mortality of murine sepsis. Infection 
and Immunity 1996, 64(11):4733-4738. 
233. Verdrengh M, Springer TA, Gutierrez-Ramos JC, Tarkowski A: Role of intercellular 
adhesion molecule 1 in pathogenesis of staphylococcal arthritis and in host defense 
against staphylococcal bacteremia. Infection and Immunity 1996, 64(7):2804-2807. 
234. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, Missiakas DM: Genetic 
requirements for Staphylococcus aureus abscess formation and persistence in host 
tissues. Federation of American Societies for Experimental Biology Journal 2009, 
23(10):3393-3404. 
235. Morton D, Griffiths P: Guidelines on the recognition of pain, distress and discomfort 
in experimental animals and an hypothesis for assessment. Veterinary Record 1985, 
116(16):431-436. 
236. Shrum B, Anantha RV, Xu SX, Donnelly M, Haeryfar SMM, McCormick JK, Mele T: A 
robust scoring system to evaluate sepsis severity in an animal model. BioMed Central 
Research Notes 2014, 7:233-233. 
237. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation t, 
Investigators tHRtI: Acute inflammatory response to endotoxin in mice and humans. 
Clinical and Diagnostic Laboratory Immunology 2005, 12(1):60-67. 
238. da Silva AMT, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL: 
Shock and multiple-organ dysfunction after self-administration of Salmonella 
endotoxin. New England Journal of Medicine 1993, 328(20):1457-1460. 
239. Meng J, Wang H, Hou Z, Chen T, Fu J, Ma X, He G, Xue X, Jia M, Luo X: Novel anion 
liposome-encapsulated antisense oligonucleotide restores susceptibility of 
Methicillin-Resistant Staphylococcus aureus and rescues mice from lethal sepsis by 
targeting mecA. Antimicrobial Agents and Chemotherapy 2009, 53(7):2871-2878. 
References	
	
	
	 Page 249 
240. Svahn SL, Grahnemo L, Pálsdóttir V, Nookaew I, Wendt K, Gabrielsson B, Schéle E, 
Benrick A, Andersson N, Nilsson S et al: Dietary polyunsaturated fatty acids increase 
survival and decrease bacterial load during septic Staphylococcus aureus infection 
and improve neutrophil function in mice. Infection and Immunity 2015, 83(2):514-521. 
241. von Köckritz-Blickwede M, Rohde M, Oehmcke S, Miller LS, Cheung AL, Herwald H, 
Foster S, Medina E: Immunological mechanisms underlying the genetic 
predisposition to severe Staphylococcus aureus infection in the mouse model. The 
American Journal of Pathology 2008, 173(6):1657-1668. 
242. Hume EBH, Cole N, Khan S, Garthwaite LL, Aliwarga Y, Schubert TL, Willcox MDP: A 
Staphylococcus aureus mouse keratitis topical infection model: cytokine balance in 
different strains of mice. Immunology and Cell Biology 2005, 83(3):294-300. 
243. Ahn S-H, Deshmukh H, Johnson N, Cowell LG, Rude TH, Scott WK, Nelson CL, Zaas 
AK, Marchuk DA, Keum S: Two genes on A/J chromosome 18 are associated with 
susceptibility to Staphylococcus aureus infection by combined microarray and QTL 
analyses. Public Library of Science Pathogens 2010, 6(9):e1001088. 
244. Ogston A: Micrococcus Poisoning. Journal of Anatomy and Physiology 1882, 16(4):526-
567. 
245. Iorio NLP, Ferreira RBR, Schuenck RP, Malvar KL, Brilhante AP, Nunes APF, Bastos 
CCR, dos Santos KRN: Simplified and reliable scheme for species-level identification 
of staphylococcus clinical isolates. Journal of Clinical Microbiology 2007, 45(8):2564-
2569. 
246. Dickinson RB, Nagel JA, McDevitt D, Foster TJ, Proctor RA, Cooper SL: Quantitative 
comparison of clumping factor- and coagulase-mediated Staphylococcus aureus 
adhesion to surface-bound fibrinogen under flow. Infection and Immunity 1995, 
63(8):3143-3150. 
247. Oliveira DC, Lencastre Hd: Multiplex PCR strategy for rapid identification of 
structural types and variants of the mec element in Methicillin-Resistant 
Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2002, 46(7):2155-
2161. 
248. Bernardo K, Pakulat N, Macht M, Krut O, Seifert H, Fleer S, Hünger F, Krönke M: 
Identification and discrimination of Staphylococcus aureus strains using matrix-
assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics 
2002, 2(6):747-753. 
249. Barber M, Rozwadowska-Dowzenko M: Infection by penicillin-resistant staphylococci. 
The Lancet 1948, 252(6530):641-644. 
250. Jevons MP, Rolinson G, Knox R: "Celbenin"-Resistant Staphylococci. The British 
Medical Journal 1961:124-126. 
251. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG: The 
evolutionary history of Methicillin-Resistant Staphylococcus aureus (MRSA). 
Proceedings of the National Academy of Sciences 2002, 99(11):7687-7692. 
252. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson 
SK, Vandenesch F, Fridkin S, O'Boyle C: Comparison of community- and health care-
associated Methicillin-Resistant Staphylococcus aureus infection. JAMA : the journal 
of the American Medical Association 2003, 290(22):2976-2984. 
253. Okuma K, Iwakawa K, Turnidge JD, Grubb WB, Bell JM, O'Brien FG, Coombs GW, 
Pearman JW, Tenover FC, Kapi M et al: Dissemination of new Methicillin-Resistant 
Staphylococcus aureus clones in the community. Journal of Clinical Microbiology 
2002, 40(11):4289-4294. 
References	
	
	
	 Page 250 
254. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC: 
Pulsed-field gel electrophoresis typing of Oxacillin-Resistant Staphylococcus aureus 
isolates from the United States: establishing a national database. Journal of Clinical 
Microbiology 2003, 41(11):5113-5120. 
255. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-Resistant 
Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. 
Journal of Antimicrobial Chemotherapy 1997, 40(1):135-136. 
256. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, 
Rudrik JT, Pupp GR, Brown WJ et al: Infection with Vancomycin-Resistant 
Staphylococcus aureus containing the vanA resistance gene. New England Journal of 
Medicine 2003, 348(14):1342-1347. 
257. Hiramatsu K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic 
resistance. The Lancet Infectious Diseases 2001, 1(3):147-155. 
258. Howden BP, Ward PB, Charles PGP, Korman TM, Fuller A, du Cros P, Grabsch EA, 
Roberts SA, Robson J, Read K et al: Treatment outcomes for serious infections caused 
by Methicillin-Resistant Staphylococcus aureus with reduced vancomycin 
susceptibility. Clinical Infectious Diseases 2004, 38(4):521-528. 
259. Kluytmans J, van Belkum A, Verbrugh H: Nasal carriage of Staphylococcus aureus: 
epidemiology, underlying mechanisms, and associated risks. Clinical Microbiology 
Reviews 1997, 10(3):505-520. 
260. Williams R: Healthy carriage of Staphylococcus aureus: Its prevalence and 
importance. Bacteriological Reviews 1963, 27(1):56-71. 
261. Schwaber MJ, Masarwa S, Navon-Venezia S, Kandlik Y, Chmelnitsky I, Smollan G, 
Glick R, Neria G, Carmeli Y: High prevalence of methicillin-resistant Staphylococcus 
aureus among residents and staff of long-term care facilities, involving joint and 
parallel evolution. Clinical Infectious Diseases 2011, 53(9):910-913. 
262. Chambers HF: The changing epidemiology of Staphylococcus aureus? Emerging 
Infectious Diseases 2001, 7(2):178-182. 
263. Wertheim HFL, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, 
Nouwen JL: The role of nasal carriage in Staphylococcus aureus infections. The 
Lancet Infectious Diseases 2005, 5(12):751-762. 
264. Muder RR, Brennen C, Rihs JD, Wagener MM, Obman A, Obman A, Stout JE, Yu VL: 
Isolation of Staphylococcus aureus from the urinary tract: association of isolation 
with symptomatic urinary tract infection and subsequent staphylococcal bacteremia. 
Clinical Infectious Diseases 2006, 42(1):46-50. 
265. Marrie TJ, Costerton JW: Morphology of bacterial attachment to cardiac pacemaker 
leads and power packs. Journal of Clinical Microbiology 1984, 19(6):911-914. 
266. Zimmerli W, Trampuz A, Ochsner PE: Prosthetic-joint infections. New England 
Journal of Medicine 2004, 351(16):1645-1654. 
267. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Saïd-Salim B, Porcella SF, 
Long RD, Dorward DW, Gardner DJ, Kreiswirth BN et al: Insights into mechanisms 
used by Staphylococcus aureus to avoid destruction by human neutrophils. The 
Journal of Immunology 2005, 175(6):3907-3919. 
268. Patti JM, Allen BL, McGavin MJ, Hook M: MSCRAMM-mediated adherence of 
microorganisms to host tissues. Annual Reviews in Microbiology 1994, 48(1):585-617. 
 
References	
	
	
	 Page 251 
269. Chavakis T, Wiechmann K, Preissner KT, Herrmann M: Staphylococcus aureus 
interactions with the endothelium The role of bacterial “Secretable Expanded 
Repertoire Adhesive Molecules“ (SERAM) in disturbing host defense systems. 
Thrombosis and Haemostasis 2005, 94(8):278-285. 
270. Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, Scherpe S, 
Davies AP, Harris LG, Horstkotte MA et al: Polysaccharide intercellular adhesin or 
protein factors in biofilm accumulation of Staphylococcus epidermidis and 
Staphylococcus aureus isolated from prosthetic hip and knee joint infections. 
Biomaterials 2007, 28(9):1711-1720. 
271. Hussain M, Heilmann C, Peters G, Herrmann M: Teichoic acid enhances adhesion of 
Staphylococcus epidermidis to immobilized fibronectin. Microbial Pathogenesis 2001, 
31(6):261-270. 
272. Foster TJ, Geoghegan JA, Ganesh VK, Hook M: Adhesion, invasion and evasion: the 
many functions of the surface proteins of Staphylococcus aureus. Nature Reviews 
Microbiology 2014, 12(1):49-62. 
273. Sinha B, François PP, Nüße O, Foti M, Hartford OM, Vaudaux P, Foster TJ, Lew DP, 
Herrmann M, Krause K-H: Fibronectin-binding protein acts as Staphylococcus aureus 
invasin via fibronectin bridging to integrin α5β1. Cellular Microbiology 1999, 
1(2):101-117. 
274. Herrmann M, Vaudaux PE, Pittet D, Auckenthaler R, Lew PD, Schumacher-Perdreau F, 
Peters G, Waldvogel FA: Fibronectin, fibrinogen, and laminin act as mediators of 
adherence of clinical staphylococcal isolates to foreign material. The Journal of 
Infectious Diseases 1988, 158(4):693-701. 
275. Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, Foster TJ, Cunnion KM: 
Clumping factor A interaction with Complement factor I increases C3b cleavage on 
the bacterial surface of Staphylococcus aureus and decreases complement-mediated 
phagocytosis. Infection and Immunity 2010, 78(4):1717-1727. 
276. O´Brien L, Kerrigan SW, Kaw G, Hogan M, Penadés J, Litt D, Fitzgerald DJ, Foster TJ, 
Cox D: Multiple mechanisms for the activation of human platelet aggregation by 
Staphylococcus aureus: Roles for the clumping factors ClfA and ClfB, the serine-
aspartate repeat protein SdrE and protein A. Molecular Microbiology 2002, 
44(4):1033-1044. 
277. Haim M, Trost A, Maier CJ, Achatz G, Feichtner S, Hintner H, Bauer JW, Önder K: 
Cytokeratin 8 interacts with clumping factor B: a new possible virulence factor 
target. Microbiology 2010, 156(12):3710-3721. 
278. Kang M, Ko Y-P, Liang X, Ross CL, Liu Q, Murray BE, Höök M: Collagen-binding 
Microbial Surface Components Recognizing Adhesive Matrix Molecule 
(MSCRAMM) of gram-positive bacteria inhibit complement activation via the 
classical pathway. Journal of Biological Chemistry 2013, 288(28):20520-20531. 
279. Hienz SA, Schennings T, Heimdahl A, Flock J-I: Collagen binding of Staphylococcus 
aureus is a virulence factor in experimental endocarditis. Journal of Infectious 
Diseases 1996, 174(1):83-88. 
280. Xu Y, Rivas JM, Brown EL, Liang X, Höök M: Virulence potential of the 
staphylococcal adhesin CNA in experimental arthritis is determined by its affinity 
for collagen. Journal of Infectious Diseases 2004, 189(12):2323-2333. 
281. Gomez MI, Lee A, Reddy B, Muir A, Soong G, Pitt A, Cheung A, Prince A: 
Staphylococcus aureus protein A induces airway epithelial inflammatory responses 
by activating TNFR1. Nature Medicine 2004, 10(8):842-848. 
References	
	
	
	 Page 252 
282. Palmqvist N, Foster T, Tarkowski A, Josefsson E: Protein A is a virulence factor in 
Staphylococcus aureus arthritis and septic death. Microbial Pathogenesis 2002, 
33(5):239-249. 
283. Gouda H, Torigoe H, Saito A, Sato M, Arata Y, Shimada I: Three-dimensional solution 
structure of the B domain of staphylococcal protein A: comparisons of the solution 
and crystal structures. Biochemistry 1992, 31(40):9665-9672. 
284. Starovasnik MA, Skelton NJ, O'Connell MP, Kelley RF, Reilly D, Fairbrother WJ: 
Solution structure of the E-domain of staphylococcal protein A. Biochemistry 1996, 
35(48):15558-15569. 
285. Forsgren A, Quie PG: Effects of staphylococcal protein A on heat labile opsonins. The 
Journal of Immunology 1974, 112(3):1177-1180. 
286. Kim HK, Cheng AG, Kim H-Y, Missiakas DM, Schneewind O: Nontoxigenic protein A 
vaccine for Methicillin-Resistant Staphylococcus aureus infections in mice. The 
Journal of Experimental Medicine 2010, 207(9):1863-1870. 
287. Rooijakkers SHM, van Kessel KPM, van Strijp JAG: Staphylococcal innate immune 
evasion. Trends in Microbiology 2005, 13(12):596-601. 
288. Bekeredjian-Ding I, Inamura S, Giese T, Moll H, Endres S, Sing A, Zähringer U, 
Hartmann G: Staphylococcus aureus Protein A triggers T-cell-independent B-cell 
proliferation by sensitizing B-cells for TLR2 ligands. The Journal of Immunology 
2007, 178(5):2803-2812. 
289. Romagnani S, Amadori A, Giudizi MG, Biagiotti R, Maggi E, Ricci M: Different 
mitogenic activity of soluble and insoluble staphylococcal protein A (SPA). 
Immunology 1978, 35(3):471-478. 
290. Sakane T, Green I: Protein A from Staphylococcus aureus - A mitogen for human T 
lymphocytes and B lymphocytes but not L lymphocytes. The Journal of Immunology 
1978, 120(1):302-311. 
291. O'Seaghdha M, van Schooten CJ, Kerrigan SW, Emsley J, Silverman GJ, Cox D, Lenting 
PJ, Foster TJ: Staphylococcus aureus protein A binding to von Willebrand factor A1 
domain is mediated by conserved IgG binding regions. Federation of European 
Biochemical Societies Journal 2006, 273(21):4831-4841. 
292. Hartleib J, Köhler N, Dickinson RB, Chhatwal GS, Sixma JJ, Hartford OM, Foster TJ, 
Peters G, Kehrel BE, Herrmann M: Protein A is the von Willebrand factor binding 
protein on Staphylococcus aureus. Blood 2000, 96(6):2149-2156. 
293. Gómez MI, O'Seaghdha M, Magargee M, Foster TJ, Prince AS: Staphylococcus aureus 
protein A activates TNFR1 gignaling through conserved IgG binding domains. 
Journal of Biological Chemistry 2006, 281(29):20190-20196. 
294. Alston WK, Elliott DA, Epstein ME, Hatcher VB, Tang M, Lowy FD: Extracellular 
matrix heparan sulfate modulates endothelial cell susceptibility to Staphylococcus 
aureus. Journal of Cellular Physiology 1997, 173(1):102-109. 
295. Lowy FD: Staphylococcus aureus infections. New England Journal of Medicine 1998, 
339(8):520-532. 
296. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, 
Vazquez V, Höök M, Etienne J et al: Staphylococcus aureus Panton-Valentine 
leukocidin causes necrotizing pneumonia. Science 2007, 315(5815):1130-1133. 
 
 
References	
	
	
	 Page 253 
297. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes 
M, Greenland T, Reverdy M-E: Community-acquired Methicillin-Resistant 
Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide 
emergence. Emerging Infectious Diseases 2003, 9(8):978-984. 
298. Damian CM, Willem BvL, Hélène AMB, Justine KP, Henri AV, Alex van B: Panton-
Valentine leukocidin genes in Staphylococcus aureus. Emerging Infectious Diseases 
2006, 12(7):1174. 
299. Kaneko J, Kamio Y: Bacterial two-component and hetero-heptameric pore-forming 
cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. 
Bioscience, Biotechnology and Biochemistry 2004, 68(5):981-1003. 
300. Watanabe I, Ichiki M, Shiratsuchi A, Nakanishi Y: TLR2-mediated survival of 
Staphylococcus aureus in macrophages: A novel bacterial strategy against host 
innate immunity. The Journal of Immunology 2007, 178(8):4917-4925. 
301. Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, Golda A, Maciag-
Gudowska A, Brix K, Shaw L et al: A potential new pathway for Staphylococcus 
aureus dissemination: The silent survival of S. aureus phagocytosed by human 
monocyte-derived macrophages. Public Library of Science One 2008, 3(1):e1409. 
302. Fischer A, Lisowska-Grospierre B, Anderson D, Springer T: Leukocyte adhesion 
deficiency: molecular basis and functional consequences. Immunodeficiency Reviews 
1988, 1(1):39. 
303. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C: Incidence, severity, and prevention 
of infections in chronic granulomatous disease. The Journal of Pediatrics 1989, 114(4, 
Pt 1):555-560. 
304. Postma B, Poppelier MJ, van Galen JC, Prossnitz ER, van Strijp JAG, de Haas CJC, van 
Kessel KPM: Chemotaxis inhibitory protein of Staphylococcus aureus binds 
specifically to the C5a and formylated peptide receptor. The Journal of Immunology 
2004, 172(11):6994-7001. 
305. Haggar A, Ehrnfelt C, Holgersson J, Flock J-I: The extracellular adherence protein 
from Staphylococcus aureus inhibits neutrophil binding to endothelial cells. Infection 
and Immunity 2004, 72(10):6164-6167. 
306. Flock J-I: Extracellular-matrix-binding proteins as targets for the prevention of 
Staphylococcus aureus infections. Molecular Medicine Today 1999, 5(12):532-537. 
307. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC: Staphylococcus aureus 
strains that express serotype 5 or serotype 8 capsular polysaccharides differ in 
virulence. Infection and Immunity 2005, 73(6):3502-3511. 
308. Laarman AJ, Ruyken M, Malone CL, van Strijp JA, Horswill AR, Rooijakkers SH: 
Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate 
immune evasion. The Journal of Immunology 2011, 186(11):6445-6453. 
309. Braff MH, Jones AL, Skerrett SJ, Rubens CE: Staphylococcus aureus exploits 
cathelicidin antimicrobial peptides produced during early pneumonia to promote 
staphylokinase-dependent fibrinolysis. Journal of Infectious Diseases 2007, 
195(9):1365-1372. 
310. Wiseman GM: The hemolysins of Staphylococcus aureus. Bacteriological Reviews 
1975, 39(4):317-344. 
311. Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, Roth J, Kahl BC, 
Proctor RA, Peters G: Staphylococcus aureus Panton-Valentine leukocidin is a very 
potent cytotoxic factor for human neutrophils. Public Library of Science Pathogens 
2010, 6(1):e1000715. 
References	
	
	
	 Page 254 
312. Vuong C, Voyich JM, Fischer ER, Braughton KR, Whitney AR, DeLeo FR, Otto M: 
Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis 
against major components of the human innate immune system. Cellular 
Microbiology 2004, 6(3):269-275. 
313. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR: The cell wall components 
peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to 
cause shock and multiple organ failure. Proceedings of the National Academy of 
Sciences 1995, 92(22):10359-10363. 
314. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM: 
Emergence of community-acquired Methicillin-Resistant Staphylococcus aureus 
USA 300 clone as the predominant cause of skin and soft-tissue infections. Annals of 
Internal Medicine 2006, 144(5):309-317. 
315. Australian Insititute of Health and Welfare: Australian hospital statistics 2012-13: 
Staphylococcus aureus bacteraemia in Australian public hospitals. Health services 
series 53 Cat no HSE 144 Canberra: AIHW 2013. 
316. Donlan RM: Biofilms: microbial life on surfaces. Emerging Infectious Diseases 2002, 
8(9):881-890. 
317. Beyenal H, Donovan C, Lewandowski Z, Harkin G: Three-dimensional biofilm 
structure quantification. Journal of Microbiological Methods 2004, 59(3):395-413. 
318. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G: The application of 
biofilm science to the study and control of chronic bacterial infections. The Journal of 
Clinical Investigation 2003, 112(10):1466-1477. 
319. Dong Y, Huang C, Park J, Wang G: Growth inhibitory levels of Salicylic acid decrease 
Pseudomonas aeruginosa fliC flagellin gene expression. Journal of Experimental 
Microbiology and Immunology 2012, 16:73-78. 
320. Zogaj X, Nimtz M, Rohde M, Bokranz W, Römling U: The multicellular morphotypes 
of Salmonella typhimurium and Escherichia coli produce cellulose as the second 
component of the extracellular matrix. Molecular Microbiology 2001, 39(6):1452-
1463. 
321. Boles BR, Thoendel M, Roth AJ, Horswill AR: Identification of genes involved in 
polysaccharide-independent Staphylococcus aureus biofilm formation. Public Library 
of Science One 2010, 5(4):e10146. 
322. Jakubovics NS, Shields RC, Rajarajan N, Burgess JG: Life after death: the critical role 
of extracellular DNA in microbial biofilms. Letters in Applied Microbiology 2013, 
57(6):467-475. 
323. Kiran MD, Giacometti A, Cirioni O, Balaban N: Suppression of biofilm related, device-
associated infections by staphylococcal quorum sensing inhibitors. The International 
Journal Of Artificial Organs 2008, 31(9):761-770. 
324. Parsek MR, Greenberg E: Sociomicrobiology: the connections between quorum 
sensing and biofilms. Trends in Microbiology 2005, 13(1):27-33. 
325. Yarwood JM, Bartels DJ, Volper EM, Greenberg EP: Quorum sensing in 
Staphylococcus aureus biofilms. Journal of Bacteriology 2004, 186(6):1838-1850. 
326. Hendrickx L, Hausner M, Wuertz S: Natural genetic transformation in monoculture 
Acinetobacter sp. strain BD413 biofilms. Applied and Environmental Microbiology 
2003, 69(3):1721-1727. 
 
 
References	
	
	
	 Page 255 
327. Joshi SG, Paff M, Friedman G, Fridman G, Fridman A, Brooks AD: Control of 
Methicillin-Resistant Staphylococcus aureus in planktonic form and biofilms: a 
biocidal efficacy study of nonthermal dielectric-barrier discharge plasma. American 
Journal of Infection Control 2010, 38(4):293-301. 
328. Rice KC, Mann EE, Endres JL, Weiss EC, Cassat JE, Smeltzer MS, Bayles KW: The 
cidA murein hydrolase regulator contributes to DNA release and biofilm 
development in Staphylococcus aureus. Proceedings of the National Academy of 
Sciences 2007, 104(19):8113-8118. 
329. Rice KC, Nelson JB, Patton TG, Yang S-J, Bayles KW: Acetic acid induces expression 
of the Staphylococcus aureus cidABC and lrgAB murein hydrolase regulator 
operons. Journal of Bacteriology 2005, 187(3):813-821. 
330. Robinson R: Biofilm adherence and detachment pathway elucidated. Public Library 
of Science Biology 2011, 9(2):e1001012. 
331. Otto M: Staphylococcal infections: Mechanisms of biofilm maturation and 
detachment as critical determinants of pathogenicity. Annual Review of Medicine 
2013, 64(1):175-188. 
332. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton J, Greenberg E: The 
involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 
1998, 280(5361):295-298. 
333. De Kievit T: Quorum sensing in Pseudomonas aeruginosa biofilms. Environmental 
Microbiology 2009, 11(2):279-288. 
334. Cady NC, McKean KA, Behnke J, Kubec R, Mosier AP, Kasper SH, Burz DS, Musah 
RA: Inhibition of biofilm formation, quorum sensing and infection in Pseudomonas 
aeruginosa by natural products-inspired organosulfur compounds. Public Library of 
Science One 2012, 7(6):e38492. 
335. Dufour D, Lévesque CM: Cell death of Streptococcus mutans induced by a quorum-
sensing peptide occurs via a conserved streptococcal autolysin. Journal of 
Bacteriology 2013, 195(1):105-114. 
336. Senadheera D, Cvitkovitch D: Quorum sensing and biofilm formation by 
Streptococcus mutans. In: Bacterial Signal Transduction: Networks and Drug Targets. 
Edited by Utsumi R, vol. 631: Springer New York; 2008: 178-188. 
337. Traber KE, Lee E, Benson S, Corrigan R, Cantera M, Shopsin B, Novick RP: agr 
function in clinical Staphylococcus aureus isolates. Microbiology 2008, 154(8):2265-
2274. 
338. Boles BR, Horswill AR: agr Mediated Dispersal of Staphylococcus aureus Biofilms. 
Public Library of Science Pathogens 2008, 4(4):e1000052. 
339. Tormo MÁ, Martí M, Valle J, Manna AC, Cheung AL, Lasa I, Penadés JR: SarA is an 
essential positive regulator of Staphylococcus epidermidis biofilm development. 
Journal of Bacteriology 2005, 187(7):2348-2356. 
340. Valle J, Toledo-Arana A, Berasain C, Ghigo J-M, Amorena B, Penadés JR, Lasa I: SarA 
and not σB is essential for biofilm development by Staphylococcus aureus. Molecular 
Microbiology 2003, 48(4):1075-1087. 
341. Catlin B, Cunningham L: Studies of extracellular and intracellular bacterial 
deoxyribonucleic acids. Journal of General Microbiology 1958, 19(3):522-539. 
 
 
References	
	
	
	 Page 256 
342. Manzenreiter R, Kienberger F, Marcos V, Schilcher K, Krautgartner WD, Obermayer A, 
Huml M, Stoiber W, Hector A, Griese M: Ultrastructural characterization of cystic 
fibrosis sputum using atomic force and scanning electron microscopy. Journal of 
Cystic Fibrosis 2012, 11(2):84-92. 
343. Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L, Tsang LH, 
Smeltzer MS, Horswill AR, Bayles KW: Modulation of eDNA release and degradation 
affects Staphylococcus aureus biofilm maturation. Public Library of Science One 2009, 
4(6):e5822. 
344. Fujimoto DF, Brunskill EW, Bayles KW: Analysis of genetic elements controlling 
Staphylococcus aureus lrgAB expression: Potential role of DNA topology in SarA 
regulation. Journal of Bacteriology 2000, 182(17):4822-4828. 
345. Meyle E, Stroh P, Günther F, Hoppy-Tichy T, Wagner C, Hänsch GM: Destruction of 
bacterial biofilms by polymorphonuclear neutrophils: relative contribution of 
phagocytosis, DNA release, and degranulation. The International Journal Of Artificial 
Organs 2010, 33(9):608-620. 
346. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A: The economic 
impact of Staphylococcus aureus infection in New York City hospitals. Emerging 
Infectious Diseases 1999, 5(1):9-17. 
347. Lynch AS, Robertson GT: Bacterial and fungal biofilm infections. Annual Review of 
Medicine 2008, 59:415-428. 
348. Rams TE, Feik D, Slots J: Staphylococci in human periodontal diseases. Oral 
Microbiology and Immunology 1990, 5(1):29-32. 
349. Lew DP, Waldvogel FA: Osteomyelitis. The Lancet 2004, 364(9431):369-379. 
350. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS: Role of 
the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. 
Infection and Immunity 1995, 63(9):3373-3380. 
351. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME: Osteomyelitis and the role 
of biofilms in chronic infection. Federation of European Microbiological Societies 
Immunology & Medical Microbiology 2008, 52(1):13-22. 
352. Günther F, Wabnitz GH, Stroh P, Prior B, Obst U, Samstag Y, Wagner C, Hänsch GM: 
Host defence against Staphylococcus aureus biofilms infection: phagocytosis of 
biofilms by polymorphonuclear neutrophils (PMN). Molecular Immunology 2009, 
46(8):1805-1813. 
353. Ramanathan V, Riosa S, Al-Sharif AH, Mansouri MD, Tranchina A, Kayyal T, Abreo 
AP, Aslam S, Nassar G, Darouiche RO: Characteristics of biofilm on tunneled cuffed 
hemodialysis catheters in the presence and absence of clinical infection. American 
Journal of Kidney Diseases 2012, 60(6):976-982. 
354. Nichols RL, Raad II: Management of bacterial complications in critically ill patients: 
surgical wound and catheter-related infections. Diagnostic Microbiology and 
Infectious Disease 1999, 33(2):121-130. 
355. Costerton J, Montanaro L, Arciola C: Biofilm in implant infections: its production and 
regulation. The International Journal of Artificial Organs 2005, 28(11):1062-1068. 
356. Prabhakara R, Harro JM, Leid JG, Harris M, Shirtliff ME: Murine immune response to 
a chronic Staphylococcus aureus biofilm infection. Infection and Immunity 2011, 
79(4):1789-1796. 
 
References	
	
	
	 Page 257 
357. Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, Williams SH, Engebretsen IL, 
Bayles KW, Horswill AR, Kielian T: Staphylococcus aureus biofilms prevent 
macrophage phagocytosis and attenuate inflammation in vivo. The Journal of 
Immunology 2011, 186(11):6585-6596. 
358. Webb DR: Animal models of human disease: inflammation. Biochemical 
Pharmacology 2014, 87(1):121-130. 
359. Williams SM, Haines JL, Moore JH: The use of animal models in the study of complex 
disease: all else is never equal or why do so many human studies fail to replicate 
animal findings? BioEssays 2004, 26(2):170-179. 
360. Rupp ME, Ulphani JS, Fey PD, Bartscht K, Mack D: Characterization of the 
importance of polysaccharide intercellular adhesin/hemagglutinin of Staphylococcus 
epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign 
body infection model. Infection and Immunity 1999, 67(5):2627-2632. 
361. Kokai-Kun JF, Chanturiya T, Mond JJ: Lysostaphin eradicates established 
Staphylococcus aureus biofilms in jugular vein catheterized mice. Antimicrobial 
Agents and Chemotherapy 2009. 
362. Luong TT, Lei MG, Lee CY: Staphylococcus aureus Rbf activates biofilm formation 
in vitro and promotes virulence in a murine foreign body infection model. Infection 
and Immunity 2009, 77(1):335-340. 
363. Hanke ML, Heim CE, Angle A, Sanderson SD, Kielian T: Correction: targeting 
macrophage activation for the prevention and treatment of Staphylococcus aureus 
biofilm infections. The Journal of Immunology 2013, 190(12):6709-6710. 
364. Hachem R, Reitzel R, Borne A, Jiang Y, Tinkey P, Uthamanthil R, Chandra J, Ghannoum 
M, Raad I: Novel antiseptic urinary catheters for prevention of urinary tract 
infections: correlation of in vivo and in vitro test results. Antimicrobial Agents and 
Chemotherapy 2009, 53(12):5145-5149. 
365. Gottenbos B, van der Mei HC, Klatter F, Nieuwenhuis P, Busscher HJ: In vitro and in 
vivo antimicrobial activity of covalently coupled quaternary ammonium silane 
coatings on silicone rubber. Biomaterials 2002, 23(6):1417-1423. 
366. Pickard R, Lam T, MacLennan G, Starr K, Kilonzo M, McPherson G, Gillies K, 
McDonald A, Walton K, Buckley B: Antimicrobial catheters for reduction of 
symptomatic urinary tract infection in adults requiring short-term catheterisation in 
hospital: a multicentre randomised controlled trial. The Lancet 2012, 
380(9857):1927-1935. 
367. Andriole V, Nagel D, Southwick W: A paradigm for human chronic osteomyelitis. The 
Journal of Bone and Joint Surgery 1973, 55(7):1511. 
368. Mayberry-Carson K, Tober-Meyer B, Smith J, Lambe D, Costerton J: Bacterial 
adherence and glycocalyx formation in osteomyelitis experimentally induced with 
Staphylococcus aureus. Infection and Immunity 1984, 43(3):825-833. 
369. Gristina AG, Costerton J: Bacterial adherence and the glycocalyx and their role in 
musculoskeletal infection. The Orthopedic clinics of North America 1984, 15(3):517-
535. 
370. Harris LG, Richards RG: Staphylococci and implant surfaces: a review. Injury 2006, 
37(2):S3-S14. 
371. Fitzgerald RH: Experimental osteomyelitis: description of a canine model and the 
role of depot administration of antibiotics in the prevention and treatment of sepsis. 
The Journal of Bone & Joint Surgery 1983, 65(3):371-380. 
References	
	
	
	 Page 258 
372. Fuchs T, Stange R, Schmidmaier G, Raschke MJ: The use of gentamicin-coated nails in 
the tibia: preliminary results of a prospective study. Archives of orthopaedic and 
trauma surgery 2011, 131(10):1419-1425. 
373. Romero D, Kolter R: Will biofilm disassembly agents make it to market? Trends in 
Microbiology 2011, 19(7):304-306. 
374. Warren HS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B, Liang X, 
Valentine C, Hellman J, Hayden D: Resilience to bacterial infection: difference 
between species could be due to proteins in serum. Journal of Infectious Diseases 
2010, 201(2):223-232. 
375. Bolker J: Model organisms: there's more to life than rats and flies. Nature 2012, 
491(7422):31-33. 
376. Frank DN, Wilson SS, Amand ALS, Pace NR: Culture-independent microbiological 
analysis of foley urinary catheter biofilms. Public Library of Science One 2009, 
4(11):e7811. 
377. Bouza E, Menasalvas A, Muñoz P, Vasallo FJ, Moreno MDM, Fernández MAG: 
Infective endocarditis-A prospective study at the end of the twentieth century: new 
predisposing conditions, new etiologic agents, and still a high mortality. Medicine 
2001, 80(5):298-307. 
378. Moreillon P, Que Y-A: Infective endocarditis. The Lancet 2004, 363(9403):139-149. 
379. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, 
Stoner SM, Baddour LM: Risk factor analysis of permanent pacemaker infection. 
Clinical Infectious Diseases 2007, 45(2):166-173. 
380. Riedel DJ, Weekes E, Forrest GN: Addition of rifampin to standard therapy for 
treatment of native valve infective endocarditis caused by Staphylococcus aureus. 
Antimicrobial Agents and Chemotherapy 2008, 52(7):2463-2467. 
381. Bayer AS, Bolger AF, Taubert KA, Wilson W, Steckelberg J, Karchmer AW, Levison M, 
Chambers HF, Dajani AS, Gewitz MH et al: Diagnosis and management of infective 
endocarditis and its complications. Circulation 1998, 98(25):2936-2948. 
382. Pruitt AA: Neurologic complications of infective endocarditis. Current Treatment 
Options in Neurology 2013, 15(4):465-476. 
383. Baskin TW, Rosenthal A, Pruitt B: Acute bacterial endocarditis: a silent source of 
sepsis in the burn patient. Annals of Surgery 1976, 184(5):618. 
384. Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Sullam PM, Filler SG, Bayer AS: 
Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial 
dissemination, and frequency of embolic events in experimental Staphylococcus 
aureus endocarditis through antiplatelet and antibacterial effects. Circulation 1999, 
99(21):2791-2797. 
385. Eisen DP, Corey GR, McBryde ES, Fowler Jr VG, Miro JM, Cabell CH, Street AC, Paiva 
MG, Ionac A, Tan R-S et al: Reduced valve replacement surgery and complication 
rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. 
Journal of Infection 2009, 58(5):332-338. 
386. Jeffreys D: Aspirin: The remarkable story of a wonder drug: Bloomsbury; 2004. 
387. Sneader W: The discovery of aspirin: A reappraisal. The British Medical Journal 2000, 
321(7276):1591-1594. 
388. Beaver W: Mild analgesics. A review of their clinical pharmacology. The American 
Journal of Medical Sciences 1965, 250(5):577-604. 
References	
	
	
	 Page 259 
389. Sachs CJ: Oral analgesics for acute nonspecific pain. American Family Physician 2005, 
71(5):913-918. 
390. Aronoff D: Cyclooxygenase inhibition in sepsis: is there life after death? Mediators of 
Inflammation 2012, 2012:7. 
391. Starko KM, Ray CG, Dominguez LB, Stromberg WL, Woodall DF: Reye's syndrome 
and salicylate use. Pediatrics 1980, 66(6):859-864. 
392. Soumerai SB, Ross-Degnan D, Kahn JS: Effects of professional and media warnings 
about the association between aspirin use in children and Reye's syndrome. The 
Milbank Quarterly 1992, 70(1):155-182. 
393. Craven L: Experiences with aspirin (Acetylsalicylic acid) in the nonspecific 
prophylaxis of coronary thrombosis. Mississippi Valley Medical Journal 1953, 
75(1):38. 
394. Rona G: The pathogenesis of human myocardial infarction. Canadian Medical 
Association Journal 1966, 95(20):1012-1019. 
395. Weiss HJ, Aledort LM, Kochwa S: The effect of salicylates on the hemostatic 
properties of platelets in man. Journal of Clinical Investigation 1968, 47(9):2169-2180. 
396. Buerke M, Pittroff W, Meyer J, Darius H: Aspirin therapy: optimized platelet 
inhibition with different loading and maintenance doses. American Heart Journal 
1995, 130(3):465-472. 
397. De Berardis G, Lucisano G, D’Ettorre A, et al.: Association of aspirin use with major 
bleeding in patients with and without diabetes. JAMA : The Journal of the American 
Medical Association 2012, 307(21):2286-2294. 
398. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on 
gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy 
humans. Gastroenterology 1999, 117(1):17-25. 
399. Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet 
thromboxane production by low-dose aspirin in healthy subjects. Journal of Clinical 
Investigation 1982, 69(6):1366-1372. 
400. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D: 
Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low 
dose aspirin. Journal of the American College of Cardiology 1994, 24(1):33-38. 
401. Montalescot G, Drobinski G, Maclouf J, Maillet F, Salloum J, Ankri A, Kazatchkine M, 
Eugène L, Thomas D, Grosgogeat Y: Evaluation of thromboxane production and 
complement activation during myocardial ischemia in patients with angina pectoris. 
Circulation 1991, 84(5):2054-2062. 
402. Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations, 
and medications: case control results from the Melbourne colorectal cancer study. 
Cancer Research 1988, 48(15):4399-4404. 
403. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). Journal of the 
National Cancer Institute 1998, 90(21):1609-1620. 
404. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). Journal of the 
National Cancer Institute 1998, 90(20):1529-1536. 
405. Cook NR, Lee I, Gaziano J, et al.: Low-dose aspirin in the primary prevention of 
cancer. The women’s health study: a randomized controlled trial. JAMA : The 
Journal of the American Medical Association 2005, 294(1):47-55. 
References	
	
	
	 Page 260 
406. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, 
Moher D: The use of aspirin for primary prevention of colorectal cancer: A 
systematic review prepared for the U.S. preventive services task force. Annals of 
Internal Medicine 2007, 146(5):365-375. 
407. Garcia-Albeniz X, Chan AT: Aspirin for the prevention of colorectal cancer. Best 
Practice & Research Clinical Gastroenterology 2011, 25(0):461-472. 
408. Friis S, Riis AH, Erichsen R, Baron JA, Sørensen HT: Low-dose aspirin or 
Nonsteroidal Anti-inflammatory Drug use and colorectal cancer risk: a population-
based, case–control study NSAID use and colon cancer risk. Annals of Internal 
Medicine 2015, 163(5):347-355. 
409. Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of 
aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. 
Gastroenterology 2003, 124(1):47-56. 
410. Algra AM, Rothwell PM: Effects of regular aspirin on long-term cancer incidence 
and metastasis: a systematic comparison of evidence from observational studies 
versus randomised trials. The Lancet Oncology 2012, 13(5):518-527. 
411. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow 
WH, Dubrow R, Ahsan H, Mayne ST et al: Use of aspirin and other nonsteroidal anti-
inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiology 
Biomarkers & Prevention 1998, 7(2):97-102. 
412. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ: A 
large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and 
prostate cancer incidence. Journal of the National Cancer Institute 2005, 97(13):975-
980. 
413. Lapi F, Levi M, Simonetti M, Cancian M, Parretti D, Cricelli I, Sobrero A, Cricelli C: 
Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. 
International Journal of Cancer 2016, 139(1):205-211. 
414. Terry M, Gammon MD, Zhang F, et al.: Association of frequency and duration of 
aspirin use and hormone receptor status with breast cancer risk. JAMA : The Journal 
of the American Medical Association 2004, 291(20):2433-2440. 
415. Lazzeroni M, Petrera M, Marra D, DeCensi A: Aspirin and breast cancer prevention. 
Curr Breast Cancer Rep 2013, 5(3):202-207. 
416. Streicher SA, Yu H, Lu L, Kidd MS, Risch HA: Case-control study of aspirin use and 
risk of pancreatic cancer. Cancer Epidemiology Biomarkers & Prevention 2014. 
417. Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, Sinha AA, 
Asgari MM, Sturgeon S, Tang JY: Aspirin is associated with lower melanoma risk 
among postmenopausal Caucasian women. Cancer 2013:1562-1569. 
418. Trabert B, Ness RB, Lo-Ciganic W-H, Murphy MA, Goode EL, Poole EM, Brinton LA, 
Webb PM, Nagle CM, Jordan SJ et al: Aspirin, nonaspirin nonsteroidal anti-
inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian 
cancer: a pooled analysis in the Ovarian Cancer Association Consortium. Journal of 
the National Cancer Institute 2014, 106(2):djt431. 
419. Wang D, DuBois RN: The role of COX-2 in intestinal inflammation and colorectal 
cancer. Oncogene 2009, 29(6):781-788. 
420. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer 
agents: mechanistic, pharmacologic, and clinical issues. Journal of the National 
Cancer Institute 2002, 94(4):252-266. 
References	
	
	
	 Page 261 
421. Baron JA, Senn S, Voelker M, Lanas A, Laurora I, Thielemann W, Brückner A, 
McCarthy D: Gastrointestinal adverse effects of short-term aspirin use: a meta-
analysis of published randomized controlled trials. Drugs in Research & Development 
2013, 13(1):9-16. 
422. Sostres C, Gargallo CJ: Gastrointestinal lesions and complications of low-dose aspirin 
in the gastrointestinal tract. Best Practice & Research Clinical Gastroenterology 2012, 
26(2):141-151. 
423. Sostres C, Lanas A: Epidemiology of low dose aspirin damage in the lower 
gastrointestinal tract. Current Pharmaceutical Design 2015, 21(35):5094-5100. 
424. Lanas A: Gastrointestinal bleeding associated with low-dose aspirin use: relevance 
and management in clinical practice. Expert Opinion on Drug Safety 2011, 10(1):45-
54. 
425. Yeomans ND, Lanas AI, Talley NJ, Thomson ABR, Daneshjoo R, Eriksson B, 
Appelman-Eszczuk S, LÅNgstrÖM G, Naesdal J, Serrano P et al: Prevalence and 
incidence of gastroduodenal ulcers during treatment with vascular protective doses 
of aspirin. Alimentary Pharmacology & Therapeutics 2005, 22(9):795-801. 
426. Cayla G, Collet J-P, Silvain J, Thiefin G, Woimant F, Montalescot G: Prevalence and 
clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low 
Dose Aspirin: The UGLA survey. International Journal of Cardiology 2012, 156(1):69-
75. 
427. Iwamoto J, Mizokami Y, Saito Y, Shimokobe K, Honda A, Ikegami T, Matsuzaki Y: 
Small-bowel mucosal injuries in low-dose aspirin users with obscure gastrointestinal 
bleeding. World Journal of Gastroenterology 2014, 20(36):13133-13138. 
428. Matsui H, Shimokawa O, Kaneko T, Nagano Y, Rai K, Hyodo I: The pathophysiology 
of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in 
stomach and small intestine. Journal of Clinical Biochemistry and Nutrition 2011, 
48(2):107-111. 
429. Endo H, Hosono K, Inamori M, Kato S, Nozaki Y, Yoneda K, Akiyama T, Fujita K, 
Takahashi H, Yoneda M et al: Incidence of small bowel injury induced by low-dose 
aspirin: a crossover study using Capsule Endoscopy in healthy volunteers. Digestion 
2009, 79(1):44-51. 
430. Legras A, Giraudeau B, Jonville-Bera A-P, Camus C, François B, Runge I, Kouatchet A, 
Veinstein A, Tayoro J, Villers D et al: A multicentre case-control study of 
nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic 
shock. Critical Care 2009, 13(2):R43. 
431. Stables MJ, Newson J, Ayoub SS, Brown J, Hyams CJ, Gilroy DW: Priming innate 
immune responses to infection by cyclooxygenase inhibition kills antibiotic-
susceptible and -resistant bacteria. Blood 2010, 116(16):2950-2959. 
432. Yin M-J, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and 
salicylate inhibit the activity of I[kappa]B kinase-[beta]. Nature 1998, 396(6706):77-
80. 
433. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 
1994, 265(5174):956-959. 
434. Svensson CI, Zattoni M, Serhan CN: Lipoxins and aspirin-triggered lipoxin inhibit 
inflammatory pain processing. The Journal of Experimental Medicine 2007, 
204(2):245-252. 
435. Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate 
inflammation-resolution programmes. Nature 2007, 447(7146):869-874. 
References	
	
	
	 Page 262 
436. Tak PP, Firestein GS: NF-κB: a key role in inflammatory diseases. Journal of Clinical 
Investigation 2001, 107(1):7-11. 
437. Lawrence T: The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor 
Perspectives in Biology 2009, 1(6):a001651. 
438. Zandi E, Chen Y, Karin M: Direct phosphorylation of IκB by IKKα and IKKβ: 
discrimination between free and NF-κB-bound substrate. Science 1998, 
281(5381):1360-1363. 
439. Romano M, Serhan CN: Lipoxin generation by permeabilized human platelets. 
Biochemistry 1992, 31(35):8269-8277. 
440. Edenius C, Haeggström J, Lindgren JÅ: Transcellular conversion of endogenous 
arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. 
Biochemical and Biophysical Research Communications 1988, 157(2):801-807. 
441. Fiore S, Serhan CN: Formation of lipoxins and leukotrienes during receptor-
mediated interactions of human platelets and recombinant human 
granulocyte/macrophage colony-stimulating factor-primed neutrophils. The Journal 
of Experimental Medicine 1990, 172(5):1451-1457. 
442. Clària J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by 
human endothelial cell-leukocyte interactions. Proceedings of the National Academy of 
Sciences 1995, 92(21):9475-9479. 
443. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, Martinez JD, Huang M-H, Uretsky 
BF, Perez-Polo JR: Augmentation of myocardial production of 15-epi-Lipoxin-A4 by 
Pioglitazone and Atorvastatin in the rat. Circulation 2006, 114(9):929-935. 
444. Planagumà A, Pfeffer MA, Rubin G, Croze R, Uddin M, Serhan CN, Levy BD: 
Lovastatin decreases acute mucosal inflammation via 15-epi-Lipoxin A4. Mucosal 
Immunology 2010. 
445. Gutierrez AD, Sathyanarayana P, Konduru S, Ye Y, Birnbaum Y, Bajaj M: The effect of 
Pioglitazone treatment on 15-epi-Lipoxin A4 levels in patients with type 2 diabetes. 
Atherosclerosis 2012, 223(1):204-208. 
446. Prescott D, McKay DM: Aspirin-triggered lipoxin enhances macrophage 
phagocytosis of bacteria while inhibiting inflammatory cytokine production. 
American Journal of Physiology, Gastrointestinal and Liver Physiology 2011, 
301(3):G487-497. 
447. Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, Aliberti J: Anti-
inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 
dependent. Nature Medicine 2006, 12(3):330-334. 
448. Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, Miyasho T, Takamiya R, 
Asano K, Ishizaka A et al: The anti-inflammatory and proresolving mediator 
Resolvin E1 protects mice from bacterial pneumonia and acute lung injury. The 
Journal of Immunology 2010, 184(2):836-843. 
449. Fullerton JN, O’Brien AJ, Gilroy DW: Lipid mediators in immune dysfunction after 
severe inflammation. Trends in Immunology 2014, 35(1):12-21. 
450. Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N: Protectins and maresins: New 
pro-resolving families of mediators in acute inflammation and resolution bioactive 
metabolome. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of 
Lipids 2015, 1851(4):397-413. 
451. Eisen D: Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-
inflammatory drugs on sepsis. Intensive Care Medicine 2012, 38(8):1249-1257. 
References	
	
	
	 Page 263 
452. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K: Novel functional 
sets of lipid-derived mediators with antiinflammatory actions generated from 
Omega-3 fatty acids via cyclooxygenase 2-Nonsteroidal antiinflammatory drugs and 
transcellular processing. The Journal of Experimental Medicine 2000, 192(8):1197-
1204. 
453. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, Taguchi R, Masuda 
K, Sasaki K, Urabe D et al: Identification and structure determination of novel anti-
inflammatory mediator Resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. The 
Journal of Biological Chemistry 2012, 287(13):10525-10534. 
454. Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN: Resolvin E1 metabolome in 
local inactivation during inflammation-resolution. The Journal of Immunology 2008, 
180(5):3512-3519. 
455. El Kebir D, Gjorstrup P, Filep JG: Resolvin E1 promotes phagocytosis-induced 
neutrophil apoptosis and accelerates resolution of pulmonary inflammation. 
Proceedings of the National Academy of Sciences 2012, 109(37):14983-14988. 
456. Liao Z, Dong J, Wu W, Yang T, Wang T, Guo L, Chen L, Xu D, Wen F: Resolvin D1 
attenuates inflammation in lipopolysaccharide-induced acute lung injury through a 
process involving the PPARgamma/NF-kappaB pathway. Respiratory Research 2012, 
13:110. 
457. Wang B, Gong X, Wan J-y, Zhang L, Zhang Z, Li H-z, Min S: Resolvin D1 protects 
mice from LPS-induced acute lung injury. Pulmonary Pharmacology & Therapeutics 
2011, 24(4):434-441. 
458. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, 
Serhan CN: Resolvin D2 is a potent regulator of leukocytes and controls microbial 
sepsis. Nature 2009, 461(7268):1287-1291. 
459. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, Yang R, Colgan SP, Petasis 
NA: Anti-inflammatory actions of Neuroprotectin D1/Protectin D1 and its natural 
stereoisomers: assignments of dihydroxy-containing docosatrienes. The Journal of 
Immunology 2006, 176(3):1848-1859. 
460. Kohli P, Levy BD: Resolvins and protectins: mediating solutions to inflammation. 
British Journal of Pharmacology 2009, 158(4):960-971. 
461. Hong S, Gronert K, Devchand PR, Moussignac R-L, Serhan CN: Novel docosatrienes 
and 17S-Resolvins generated from docosahexaenoic acid in murine brain, human 
blood, and glial cells: Autacoids in anti-inflammation. Journal of Biological Chemistry 
2003, 278(17):14677-14687. 
462. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M: 
Maresins: novel macrophage mediators with potent antiinflammatory and 
proresolving actions. The Journal of Experimental Medicine 2009, 206(1):15-23. 
463. Serhan CN, Dalli J, Karamnov S, Choi A, Park C-K, Xu Z-Z, Ji R-R, Zhu M, Petasis NA: 
Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and 
controls pain. The Federation of American Societies for Experimental Biology Journal 
2012, 26(4):1755-1765. 
464. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching 
during acute inflammation: signals in resolution. Nature Immunology 2001, 2(7):612-
619. 
 
 
References	
	
	
	 Page 264 
465. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN: Neutrophil-mediated changes in 
vascular permeability are inhibited by topical application of aspirin-triggered 15-
epi-Lipoxin A4 and novel Lipoxin B4 stable analogues. Journal of Clinical 
Investigation 1998, 101(4):819-826. 
466. Alsever JB, Ainslie RB: A new method for the preparation of dilute blood plasma 
and the operation of a complete transfusion service. NY State J Med 1941, 41:126-131. 
467. Ramsay R, Ciznadija D, Vanevski M, Mantamadiotis T: Transcriptional regulation of 
cyclo-oxygenase expression: three pillars of control. International Journal of 
Immunopathology and Pharmacology 2003, 16(2; SUPP):59-67. 
468. Levy M, Dellinger R, Townsend S, Linde-Zwirble W, Marshall J, Bion J, Schorr C, 
Artigas A, Ramsay G, Beale R et al: The Surviving Sepsis Campaign: results of an 
international guideline-based performance improvement program targeting severe 
sepsis. Intensive Care Medicine 2010, 36(2):222-231. 
469. Serhan CN: Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update 
and role in anti-inflammation and pro-resolution. Prostaglandins & Other Lipid 
Mediators 2002, 68:433-455. 
470. Hennekens CH, Schneider WR, Pokov A, Hetzel S, DeMets D, Serebruany V, Schröder 
H: A randomized trial of aspirin at clinically relevant doses and nitric oxide 
formation in humans. Journal of Cardiovascular Pharmacology and Therapeutics 2010. 
471. Weber C, Erl W, Pietsch A, Weber PC: Aspirin inhibits nuclear factor–κB 
mobilization and monocyte adhesion in stimulated human endothelial cells. 
Circulation 1995, 91(7):1914-1917. 
472. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - 
definition, outcome measures, animal models, fluid therapy and information 
technology needs: the Second International Consensus Conference of the Acute 
Dialysis Quality Initiative (ADQI) Group. Critical Care 2004, 8(4):R204-212. 
473. Jackson S, Carter J: Platelet volume: laboratory measurement and clinical 
application. Blood Reviews 1993, 7(2):104-113. 
474. Yuri Gasparyan A, Ayvazyan L, P Mikhailidis D, D Kitas G: Mean platelet volume: a 
link between thrombosis and inflammation? Current Pharmaceutical Design 2011, 
17(1):47-58. 
475. Gunebakmaz O, Kaya MG, Kaya EG, Ardic I, Yarlioglues M, Dogdu O, Kalay N, Akpek 
M, Sarli B, Ozdogru I: Mean platelet volume predicts embolic complications and 
prognosis in infective endocarditis. International Journal of Infectious Diseases 2010, 
14(11):e982-e985. 
476. Bilici S, Sekmenli T, Göksu M, Melek M, Avci V: Mean platelet volume in diagnosis 
of acute appendicitis in children. African Health Sciences 2011, 11(3). 
477. Zampieri FG, Ranzani OT, Sabatoski V, de Souza HP, Barbeiro H, da Neto LM, Park M, 
da Silva FP: An increase in mean platelet volume after admission is associated with 
higher mortality in critically ill patients. Annals of Intensive Care 2014, 4(1):20. 
478. Kim CH, Kim SJ, Lee MJ, Kwon YE, Kim YL, Park KS, Ryu HJ, Park JT, Han SH, Yoo 
T-H: An increase in mean platelet volume from baseline is associated with mortality 
in patients with severe sepsis or septic shock. Public Library of Science One 2015, 
10(3):e0119437. 
 
 
References	
	
	
	 Page 265 
479. Kure I, Nishiumi S, Nishitani Y, Tanoue T, Ishida T, Mizuno M, Fujita T, Kutsumi H, 
Arita M, Azuma T et al: Lipoxin A4 reduces lipopolysaccharide-induced 
inflammation in macrophages and intestinal epithelial cells through inhibition of 
nuclear factor-κB activation. Journal of Pharmacology and Experimental Therapeutics 
2010, 332(2):541-548. 
480. Huang Y-H, Wang H-M, Cai Z-Y, Xu F-Y, Zhou X-Y: Lipoxin A4 inhibits NF-κB 
activation and cell cycle progression in RAW264.7 cells. Inflammation 2014, 
37(4):1084-1090. 
481. Moore KL, Patel KD, Bruehl RE, Li F, Johnson DA, Lichenstein HS, Cummings RD, 
Bainton DF, McEver RP: P-selectin glycoprotein ligand-1 mediates rolling of human 
neutrophils on P-selectin. The Journal of Cell Biology 1995, 128(4):661-671. 
482. Bommhardt U, Chang KC, Swanson PE, Wagner TH, Tinsley KW, Karl IE, Hotchkiss 
RS: Akt decreases lymphocyte apoptosis and improves survival in sepsis. The Journal 
of Immunology 2004, 172(12):7583-7591. 
483. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE: Apoptosis in 
lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-
cell-deficient mice. Critical Care Medicine 1997, 25(8):1298-1307. 
484. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LAJ, Perretti M, 
Rossi AG, Wallace JL: Resolution of inflammation: state of the art, definitions and 
terms. Federation of American Societies for Experimental Biology Journal 2007, 
21(2):325-332. 
485. Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. 
Nature Immunology 2005, 6(12):1191-1197. 
486. Spite M, Serhan CN: Novel lipid mediators promote resolution of acute inflammation. 
Circulation Research 2010, 107(10):1170-1184. 
487. Fierro IM, Colgan SP, Bernasconi G, Petasis NA, Clish CB, Arita M, Serhan CN: 
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil 
migration: comparisons between synthetic 15 epimers in chemotaxis and 
transmigration with microvessel endothelial cells and epithelial cells. The Journal of 
Immunology 2003, 170(5):2688-2694. 
488. Filep JG, Khreiss T, József L: Lipoxins and aspirin-triggered lipoxins in neutrophil 
adhesion and signal transduction. Prostaglandins, Leukotrienes and Essential Fatty 
Acids 2005, 73(3–4):257-262. 
489. Colkesen Y, Coskun I, Muderrisoglu H: The effect of aspirin on mean platelet volume 
in patients with paroxysmal atrial fibrillation. Platelets 2012, 24(4):263-266. 
490. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W: Is 
elevated mean platelet volume associated with a worse outcome in patients with 
acute ischemic cerebrovascular events? Stroke 2004, 35(7):1688-1691. 
491. Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS: Mean platelet volume 
reproducibility and association with platelet activity and anti-platelet therapy. 
Platelets 2014, 25(3):188-192. 
492. Morris T, Stables M, Colville-Nash P, Newson J, Bellingan G, de Souza PM, Gilroy DW: 
Dichotomy in duration and severity of acute inflammatory responses in humans 
arising from differentially expressed proresolution pathways. Proceedings of the 
National Academy of Sciences 2010, 107(19):8842-8847. 
 
References	
	
	
	 Page 266 
493. Wang Y-P, Wu Y, Li L-Y, Zheng J, Liu R-G, Zhou J-P, Yuan S-Y, Shang Y, Yao S-L: 
Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses 
by inhibiting activation of NF-kB and MAPKs in BV-2 microglial cells. Journal of 
Neuroinflammation 2011, 8:95. 
494. Jung KJ, Kim JY, Zou Y, Kim YJ, Yu BP, Chung HY: Effect of short-term, low dose 
aspirin supplementation on the activation of pro-inflammatory NF-κB in aged rats. 
Mechanisms of Ageing and Development 2006, 127(3):223-230. 
495. Gogos CA, Drosou E, Bassaris HP, Skoutelis A: Pro- versus anti-inflammatory 
cytokine profile in patients with severe sepsis: A marker for prognosis and future 
therapeutic options. Journal of Infectious Diseases 2000, 181(1):176-180. 
496. Oberholzer A, Steckholzer U, Kurimoto M, Trentz O, Ertel W: Interleukin-18 plasma 
levels are increased in patients with sepsis compared to severely injured patients. 
Shock 2001, 16(6):411-414. 
497. Nakamura K, Okamura H, Wada M, Nagata K, Tamura T: Endotoxin-induced serum 
factor that stimulates gamma interferon production. Infection and Immunity 1989, 
57(2):590-595. 
498. Bohn E, Sing A, Zumbihl R, Bielfeldt C, Okamura H, Kurimoto M, Heesemann J, 
Autenrieth IB: IL-18 (IFN-γ-Inducing factor) regulates early cytokine production in, 
and promotes resolution of, bacterial infection in mice. The Journal of Immunology 
1998, 160(1):299-307. 
499. Bankey PE, Banerjee S, Zucchiatti A, De M, Sleem RW, Lin C-FL, Miller-Graziano CL, 
De AK: Cytokine induced expression of programmed death ligands in human 
neutrophils. Immunology Letters 2010, 129(2):100-107. 
500. Gosselin E, Wardwell K, Rigby W, Guyre P: Induction of MHC class II on human 
polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating 
factor, IFN-gamma, and IL-3. The Journal of Immunology 1993, 151(3):1482-1490. 
501. Chiang N, Arita M, Serhan CN: Anti-inflammatory circuitry: Lipoxin, aspirin-
triggered lipoxins and their receptor ALX. Prostaglandins, Leukotrienes and Essential 
Fatty Acids 2005, 73(3–4):163-177. 
502. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas 
R, Fauchet R, Drénou B: Early circulating lymphocyte apoptosis in human septic 
shock is associated with poor outcome. Shock 2002, 18(6):487-494. 
503. Eickmeier O, Seki H, Haworth O, Hilberath J, Gao F, Uddin M, Croze R, Carlo T, Pfeffer 
M, Levy B: Aspirin-triggered resolvin D1 reduces mucosal inflammation and 
promotes resolution in a murine model of acute lung injury. Mucosal Immunology 
2013, 6(2):256-266. 
504. McMahon B, Godson C: Lipoxins: endogenous regulators of inflammation. American 
Journal of Physiology - Renal Physiology 2004, 286(2):F189-F201. 
505. Díaz-González F, González-Alvaro I, Campanero MR, Mollinedo F, del Pozo MA, 
Muñoz C, Pivel JP, Sánchez-Madrid F: Prevention of in vitro neutrophil-endothelial 
attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. 
Journal of Clinical Investigation 1995, 95(4):1756-1765. 
506. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, Limmathurotsakul 
D, Chierakul W, Leendertse M, Florquin S, de Vos AF et al: Toll-like receptor 2 
impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei 
(Melioidosis). Public Library of Science Medicine 2007, 4(7):e248. 
 
References	
	
	
	 Page 267 
507. Yang J, Hirata T, Croce K, Merrill-Skoloff G, Tchernychev B, Williams E, Flaumenhaft 
R, Furie BC, Furie B: Targeted gene disruption demonstrates that P-selectin 
glycoprotein ligand-1 (PSGL-1) is required for P-selectin-mediated but not E-
selectin-mediated neutrophil rolling and migration. The Journal of Experimental 
Medicine 1999, 190(12):1769-1782. 
508. Hinshaw L, Solomon L, Erdös E, Reins D, Gunter B: Effects of acetylsalicylic acid on 
the canine response to endotoxin. Journal of Pharmacology and Experimental 
Therapeutics 1967, 157(3):665-671. 
509. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA: Platelet 
depletion and aspirin treatment protect mice in a two-event model of transfusion-
related acute lung injury. The Journal of Clinical Investigation 2009, 119(11):3450. 
510. Walker J, Dichter E, Lacorte G, Kerner D, Spur B, Rodriguez A, Yin K: Lipoxin A4 
increases survival by decreasing systemic inflammation and bacterial load in sepsis. 
Shock 2011, 36(4):410-416. 
511. Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the 
pathogenesis of septic shock. Chest 1997, 112(6 Suppl):321S-329S. 
512. Kurt ANC, Aygun AD, Godekmerdan A, Kurt A, Dogan Y, Yilmaz E: Serum IL-1β, IL-
6, IL-8, and TNF-α levels in early diagnosis and management of neonatal sepsis. 
Mediators of Inflammation 2007, 2007:31397. 
513. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E: Serum cytokine 
levels in human septic shock. Relation to multiple-system organ failure and 
mortality. Chest 1993, 103(2):565-575. 
514. Cavaillon J-M, Adib-conquy M, Fitting C, Adrie C, Payen D: Cytokine cascade in 
sepsis. Scandinavian Journal of Infectious Diseases 2003, 35(9):535-544. 
515. Villa P, Sartor G, Angelini M, Sironi M, Conni M, Gnocchi P, Isetta AM, Grau G, 
Buurman W, Van Tits L: Pattern of cytokines and pharmacomodulation in sepsis 
induced by cecal ligation and puncture compared with that induced by endotoxin. 
Clinical and Diagnostic Laboratory Immunology 1995, 2(5):549-553. 
516. Nicolau DP, Freeman CD, Nightingale CH, Quintiliani R, Coe CJ, Maderazo EG, Cooper 
BW: Reduction of bacterial titers by low-dose aspirin in experimental aortic valve 
endocarditis. Infection and Immunity 1993, 61(4):1593-1595. 
517. Ferri LE, Pascual J, Seely AJE, Chaudhury P, Christou NV: Soluble L-selectin 
attenuates tumor necrosis factor-alpha-mediated leukocyte adherence and vascular 
permeability: a protective role for elevated soluble L-selectin in sepsis. Critical Care 
Medicine 2002, 30(8):1842-1847. 
518. Davenpeck KL, Brummet ME, Hudson SA, Mayer RJ, Bochner BS: Activation of 
human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1, CD162) 
and adhesion to P-selectin in vitro. The Journal of Immunology 2000, 165(5):2764-
2772. 
519. Stadtmann A, Germena G, Block H, Boras M, Rossaint J, Sundd P, Lefort C, Fisher CI, 
Buscher K, Gelschefarth B et al: The PSGL-1–L-selectin signaling complex regulates 
neutrophil adhesion under flow. The Journal of Experimental Medicine 2013, 
210(11):2171-2180. 
520. Delano MJ, Thayer T, Gabrilovich S, Kelly-Scumpia KM, Winfield RD, Scumpia PO, 
Cuenca AG, Warner E, Wallet SM, Wallet MA et al: Sepsis induces early alterations in 
innate immunity that impact mortality to secondary infection. The Journal of 
Immunology 2011, 186(1):195-202. 
References	
	
	
	 Page 268 
521. Vachino G, Chang X-J, Veldman GM, Kumar R, Sako D, Fouser LA, Berndt MC, 
Cumming DA: P-selectin glycoprotein ligand-1 is the major counter-receptor for P-
selectin on stimulated T-cells and is widely distributed in non-functional form on 
many lymphocytic cells. Journal of Biological Chemistry 1995, 270(37):21966-21974. 
522. Iannacone M, Sitia G, Narvaiza I, Ruggeri ZM, Guidotti LG: Antiplatelet drug therapy 
moderates immune-mediated liver disease and inhibits viral clearance in mice 
infected with a replication-deficient Adenovirus. Clinical and Vaccine Immunology 
2007, 14(11):1532-1535. 
523. Casewell MW, Hill RL: The carrier state: Methicillin-Resistant Staphylococcus 
aureus. The Journal of Antimicrobial Chemotherapy 1986, 18 Suppl A:1-12. 
524. Noble WC, Valkenburg HA, Wolters CHL: Carriage of Staphylococcus aureus in 
random samples of a normal population. Epidemiology & Infection 1967, 65(4):567-
573. 
525. Boyce JM: Increasing prevalence of Methicillin-Resistant Staphylococcus aureus in 
the United States. Infection Control and Hospital Epidemiology 1990, 11(12):639-642. 
526. de Araujo GL, Coelho LR, de Carvalho CB, Maciel RM, Coronado AZ, Rozenbaum R, 
Ferreira-Carvalho BT, Sá Figueiredo AM, Teixeira LA: Commensal isolates of 
methicillin-resistant Staphylococcus epidermidis are also well equipped to produce 
biofilm on polystyrene surfaces. Journal of Antimicrobial Chemotherapy 2006, 
57(5):855-864. 
527. Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F: The intercellular adhesion 
(ica) locus is present in Staphylococcus aureus and is required for biofilm formation. 
Infection and Immunity 1999, 67(10):5427-5433. 
528. Singhal D, Foreman A, Bardy J-J, Wormald P-J: Staphylococcus aureus biofilms. The 
Laryngoscope 2011, 121(7):1578-1583. 
529. Palma M, Bayer A, Kupferwasser LI, Joska T, Yeaman MR, Cheung A: Salicylic acid 
activates sigma factor B by rsbU-dependent and -independent mechanisms. Journal 
of Bacteriology 2006, 188(16):5896-5903. 
530. Riordan JT, O’Leary JO, Gustafson JE: Contributions of sigB and sarA to distinct 
multiple antimicrobial resistance mechanisms of Staphylococcus aureus. 
International Journal of Antimicrobial Agents 2006, 28(1):54-61. 
531. Rice KC, Firek BA, Nelson JB, Yang S-J, Patton TG, Bayles KW: The Staphylococcus 
aureus cidAB operon: evaluation of its role in regulation of murein hydrolase 
activity and penicillin tolerance. Journal of Bacteriology 2003, 185(8):2635-2643. 
532. Spoering AL, Gilmore MS: Quorum sensing and DNA release in bacterial biofilms. 
Current Opinion in Microbiology 2006, 9(2):133-137. 
533. Allesen-Holm M, Barken KB, Yang L, Klausen M, Webb JS, Kjelleberg S, Molin S, 
Givskov M, Tolker-Nielsen T: A characterization of DNA release in Pseudomonas 
aeruginosa cultures and biofilms. Molecular Microbiology 2006, 59(4):1114-1128. 
534. Das T, Sharma PK, Busscher HJ, van der Mei HC, Krom BP: Role of extracellular DNA 
in initial bacterial adhesion and surface aggregation. Applied and Environmental 
Microbiology 2010, 76(10):3405-3408. 
535. Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management of pulmonary 
infections in cystic fibrosis. American Journal of Respiratory and Critical Care 
Medicine 2003, 168(8):918-951. 
 
References	
	
	
	 Page 269 
536. Thornton RB, Wiertsema SP, Kirkham L-AS, Rigby PJ, Vijayasekaran S, Coates HL, 
Richmond PC: Neutrophil extracellular traps and bacterial biofilms in middle ear 
effusion of children with recurrent acute otitis media – a potential treatment target. 
Public Library of Science One 2013, 8(2):e53837. 
537. Donlan RM, Costerton JW: Biofilms: survival mechanisms of clinically relevant 
microorganisms. Clinical Microbiology Reviews 2002, 15(2):167-193. 
538. Jacqueline C, Caillon J: Impact of bacterial biofilm on the treatment of prosthetic 
joint infections. Journal of Antimicrobial Chemotherapy 2014, 69(suppl 1):i37-i40. 
539. Stewart PS, Costerton JW: Antibiotic resistance of bacteria in biofilms. The Lancet 
2001, 358(9276):135-138. 
540. Da ML, Heroux AK, Pakzad Z, Schiffmacher KF: Salicylic acid attenuates biofilm 
formation but not swarming in Pseudomonas aeruginosa. Journal of Experimental 
Microbiology and Immunology (JEMI) Vol 2010, 14:69-73. 
541. Alem MAS, Douglas LJ: Effects of aspirin and other nonsteroidal anti-inflammatory 
drugs on biofilms and planktonic cells of Candida albicans. Antimicrobial Agents and 
Chemotherapy 2004, 48(1):41-47. 
542. Sendamangalam V, Choi OK, Kim D, Seo Y: The anti-biofouling effect of polyphenols 
against Streptococcus mutans. Biofouling 2010, 27(1):13-19. 
543. Chow S, Gu K, Jiang L, Nassour A: Salicylic acid affects swimming, twitching and 
swarming motility in Pseudomonas aeruginosa, resulting in decreased biofilm 
formation. Journal of Experimental Microbiology and Immunology 2011, 15:7. 
544. Bacalso M, Xu T, Yeung K, Zheng D: Biofilm formation of Pseudomonas aeruginosa 
PA14 required lasi and was stimulated by the Pseudomonas quinolone signal 
although Salicylic acid inhibition is independent of the pqs pathway. Journal of 
Experimental Microbiology and Immunology 2011, 15:84-89. 
545. Carvalho AP, Gursky LC, Rosa RT, Rymovicz AUM, Campelo PMS, Grégio AMT, 
Koga-Ito CY, Samaranayake LP, Rosa EAR: Non-steroidal anti-inflammatory drugs 
may modulate the protease activity of Candida albicans. Microbial Pathogenesis 2010, 
49(6):315-322. 
546. Stepanović S, Vukovi D, Je M, Ranin L: Influence of acetylsalicylic acid (aspirin) on 
biofilm production by Candida Species. Journal of Chemotherapy 2004, 16(2):134-138. 
547. Heilmann C, Gerke C, Perdreau-Remington F, Götz F: Characterization of Tn917 
insertion mutants of Staphylococcus epidermidis affected in biofilm formation. 
Infection and Immunity 1996, 64(1):277-282. 
548. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist 
programmers. Bioinformatics Methods and Protocols 1999:365-386. 
549. Pfaffl MW: A new mathematical model for relative quantification in real-time RT–
PCR. Nucleic Acids Research 2001, 29(9):e45. 
550. Kugelberg E, Norström T, Petersen TK, Duvold T, Andersson DI, Hughes D: 
Establishment of a superficial skin infection model in mice by using Staphylococcus 
aureus and Streptococcus pyogenes. Antimicrobial Agents and Chemotherapy 2005, 
49(8):3435-3441. 
551. Seidl K, Goerke C, Wolz C, Mack D, Berger-Bächi B, Bischoff M: Staphylococcus 
aureus CcpA affects biofilm formation. Infection and Immunity 2008, 76(5):2044-2050. 
552. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP: Secular trend of hospital-
acquired Candidemia among Intensive Care Unit patients in the United States 
during 1989–1999. Clinical Infectious Diseases 2002, 35(5):627-630. 
References	
	
	
	 Page 270 
553. Kreisel KM, Stine OC, Johnson JK, Perencevich EN, Shardell MD, Lesse AJ, Gordin 
FM, Climo MW, Roghmann M-C: USA300 methicillin-resistant Staphylococcus 
aureus bacteremia and the risk of severe sepsis: is USA300 Methicillin-Resistant 
Staphylococcus aureus associated with more severe infections? Diagnostic 
Microbiology and Infectious Disease 2011, 70(3):285-290. 
554. Rozalska B, Burow A, Ljungh A, Rudnicka W: The influence of long-lasting 
implantation on the function of phagocytes towards staphylococci. Acta 
Microbiologica Polonica 1994, 44(3-4):243-254. 
555. Fedtke I, Götz F, Peschel A: Bacterial evasion of innate host defenses–the 
Staphylococcus aureus lesson. International Journal of Medical Microbiology 2004, 
294(2):189-194. 
556. Williams I, Venables WA, Lloyd D, Paul F, Critchley I: The effects of adherence to 
silicone surfaces on antibiotic susceptibility in Staphylococcus aureus. Microbiology 
1997, 143(7):2407-2413. 
557. Ceri H, Olson M, Stremick C, Read R, Morck D, Buret A: The Calgary biofilm device: 
new technology for rapid determination of antibiotic susceptibilities of bacterial 
biofilms. Journal of Clinical Microbiology 1999, 37(6):1771-1776. 
558. Bandara MBK, Zhu H, Sankaridurg PR, Willcox MDP: Salicylic acid reduces the 
production of several potential virulence factors of Pseudomonas aeruginosa 
associated with microbial keratitis. Investigative Ophthalmology & Visual Science 
2006, 47(10):4453-4460. 
559. Yang L, Rybtke MT, Jakobsen TH, Hentzer M, Bjarnsholt T, Givskov M, Tolker-Nielsen 
T: Computer-aided identification of recognized drugs as Pseudomonas aeruginosa 
quorum-sensing inhibitors. Antimicrobial Agents and Chemotherapy 2009, 53(6):2432-
2443. 
560. Gad GFM, Aziz AAA, Ibrahem RA: In-vitro adhesion of Staphylococcus spp. to certain 
orthopedic biomaterials and expression of adhesion genes. Journal of Applied 
Pharmaceutical Science 2012, 02(06):145-149. 
561. Arens S, Schlegel U, Printzen G, Ziegler W, Perren S, Hansis M: Influence of materials 
for fixation implants on local infection an experimental study of steel versus 
titanium dcp in rabbits. Journal of Bone & Joint Surgery, British Volume 1996, 
78(4):647-651. 
562. Ahearn DG, Grace DT, Jennings MJ, Borazjani RN, Boles KJ, Rose LJ, Simmons RB, 
Ahanotu EN: Effects of hydrogel/silver coatings on in vitro adhesion to catheters of 
bacteria associated with urinary tract infections. Curr Microbiol 2000, 41(2):120-125. 
563. Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R: Influence of aspirin on 
development and treatment of experimental Staphylococcus aureus endocarditis. 
Antimicrobial Agents and Chemotherapy 1995, 39(8):1748-1751. 
564. Polonio RE, Mermel LA, Paquette GE, Sperry JF: Eradication of biofilm-forming 
Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and 
vancomycin. Antimicrobial Agents and Chemotherapy 2001, 45(11):3262-3266. 
565. Eisen DP, McBryde ES: An association between aspirin use in human cases of 
infective endocarditis and reduced systemic embolism is shown in meta-analysis of 
observational studies. Journal of Infectious Diseases 2015, 212(4):673-674. 
566. Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD: Does aspirin 
have a role in venous thromboembolism prophylaxis in total knee arthroplasty 
patients? The Journal of Arthroplasty 2010, 25(7):1053-1060. 
References	
	
	
	 Page 271 
567. Liu M, Saeki K, Matsunobu T, Okuno T, Koga T, Sugimoto Y, Yokoyama C, Nakamizo 
S, Kabashima K, Narumiya S et al: 12-hydroxyheptadecatrienoic acid promotes 
epidermal wound healing by accelerating keratinocyte migration via the BLT2 
receptor. The Journal of Experimental Medicine 2014, 211(6):1063-1078. 
568. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN: Cutting edge: 
Humanized nano-proresolving medicines mimic inflammation-resolution and 
enhance wound healing. The Journal of Immunology 2011, 186(10):5543-5547. 
569. Dittmer I, Sharp D, McNulty C, Williams A, Banks R: A prospective study of central 
venous hemodialysis catheter colonization and peripheral bacteremia. Clinical 
Nephrology 1999, 51(1):34-39. 
570. Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, Stryjewski 
ME, Reller LB, Schulman KA, Corey GR: Clinical outcomes and costs due to 
Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. 
Infection Control 2005, 26(06):534-539. 
571. Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, 
Caparon MG, Hultgren SJ: Combinatorial small-molecule therapy prevents 
uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. 
Antimicrobial Agents and Chemotherapy 2012, 56(9):4738-4745. 
572. Guiton PS, Hung CS, Hancock LE, Caparon MG, Hultgren SJ: Enterococcal biofilm 
formation and virulence in an optimized murine model of foreign body-associated 
urinary tract infections. Infection and Immunity 2010, 78(10):4166-4175. 
573. Bernthal NM, Stavrakis AI, Billi F, Cho JS, Kremen TJ, Simon SI, Cheung AL, Finerman 
GA, Lieberman JR, Adams JS et al: A mouse model of post-arthroplasty 
Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial 
implant coatings. Public Library of Science One 2010, 5(9):e12580. 
574. Campoccia D, Montanaro L, Arciola CR: The significance of infection related to 
orthopedic devices and issues of antibiotic resistance. Biomaterials 2006, 27(11):2331-
2339. 
575. Toner P, McAuley D, Shyamsundar M: Aspirin as a potential treatment in sepsis or 
acute respiratory distress syndrome. Critical Care 2015, 19(1):1-9. 
576. Serhan CN, Hamberg M, Samuelsson B: Lipoxins: novel series of biologically active 
compounds formed from arachidonic acid in human leukocytes. Proceedings of the 
National Academy of Sciences 1984, 81(17):5335-5339. 
577. Claria J, Lee MH, Serhan CN: Aspirin-triggered lipoxins (15-epi-LX) are generated 
by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are 
potent inhibitors of cell proliferation. Molecular Medicine 1996, 2(5):583-596. 
578. Keel M, Ungethüm U, Steckholzer U, Niederer E, Hartung T, Trentz O, Ertel W: 
Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of 
neutrophil apoptosis during severe sepsis. Blood 1997, 90(9):3356-3363. 
579. Muller L, Gorter K, Hak E, Goudzwaard W, Schellevis F, Hoepelman A, Rutten G: 
Increased risk of common infections in patients with type 1 and type 2 diabetes 
mellitus. Clinical Infectious Diseases 2005, 41(3):281-288. 
580. Doi K, Leelahavanichkul A, Hu X, Sidransky KL, Qin Y, Eisner C, Schnermann J, Yuen 
PST, Star RA: Pre-existing renal disease promotes sepsis-induced acute kidney injury 
and worsens sepsis outcome via multiple pathways. Kidney International 2008, 
74(8):1017-1025. 
References	
	
	
	 Page 272 
581. Scott E, Ho H, Yu M, Chapital A, Koss W, Takanishi Jr D: Pre-existing cardiac disease, 
troponin I elevation and mortality in patients with severe sepsis and septic shock. 
Anaesthesia and Intensive Care 2008, 36(1):51. 
582. Betjes MG: Prevention of catheter-related bloodstream infection in patients on 
hemodialysis. Nature Reviews Nephrology 2011, 7(5):257-265. 
583. O’Horo JC, Maki DG, Krupp AE, Safdar N: Arterial catheters as a source of 
bloodstream infection: a systematic review and meta-analysis*. Critical Care 
Medicine 2014, 42(6):1334-1339. 
584. Trautner BW, Darouiche RO: Role of biofilm in catheter-associated urinary tract 
infection. American Journal of Infection Control 2004, 32(3):177-183. 
585. Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic 
attack (UK-TIA) aspirin trial: final results. Journal of Neurology, Neurosurgery & 
Psychiatry 1991, 54(12):1044-1054. 
586. Aguejouf O, Eizayaga F, Desplat V, Belon P, Doutremepuich C: Prothrombotic and 
hemorrhagic effects of aspirin. Clinical and Applied Thrombosis/Hemostasis 2009, 
15(5):523-528. 
 
 
 
 
	
	
	
	
	
	
		
 
	
8.  Appendices 
 
Appendix 1	
 
Page 274 
	
	
	
Appendix 1	
 
Page 275 
	
	
	
	
	
	
Appendix 2	
	
	
Page 276 
	
	
	
Appendix 2	
	
	
Page 277 
	
	
	 	
	
Appendix 3	
	
	
Page 278 
	
	 	
Appendix 3	
	
	
Page 279 
	
